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Cytoplasmic and transmembrane protein tyrosine phosphatases (PTPs) provide the 
enzymatic counterbalance to protein tyrosine kinase activity. PTP sigma (PTPa) is an 
adhesion molecule-like receptor PTP (RPTP) that is expressed on the growth cones of 
developing axons. PTPa binds ligands located in the basement membrane (heparan 
sulphate proteoglycans: agrin and collagen 18) and developing muscle (Nucleolin). 
Disruption of ligand-PTPa interactions affects axon guidance, although neither the role of 
PTPa in neurons nor the effect of ligand binding on PTPa activity is well understood. 
Further characterisation of PTPa function remains difficult in the absence of an 
understanding of PTPa biochemistry that would allow a functional assay to measure the 
effects of an experimental manipulation on PTPa function.
PTPa was shown to be dimeric using a combination of disulphide cross-linking and 
co-immunoprecipitation techniques. This dimeric form of PTPa was principally cell surface 
localised according to its accessibility to trypsinisation. However, neither co- 
immunoprecipitation nor glutathione S-transferase (GST) pull-down techniques allowed 
the identification of proteins that interact with wild type or recombinant substrate-trapping 
PTPa.
Secondly, H20 2  treatment of PTPa-expressing cells induced the formation of 
reduction-sensitive, high molecular weight species. In contrast to the formation of PTPa 
dimers under the same conditions, this did not require the tyrosine phosphatase domain 
catalytic site cysteines. It may be possible to utilise the formation of high molecular weight 
species on non-reducing SDS-PAGE analysis as a proxy measure of PTPa oligomerisation. 
Moreover, unlike co-immunoprecipitation it can be used on wild type and even 
endogenously expressed proteins.
Finally, the type Ha RPTP family consists of PTPa, PTPS and LAR. To allow the 
simultaneous disruption of type Ha RPTPs, chicken LAR was cloned from embryonic 
chick whole body mRNA and characterised.
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14Chapter 1: Introduction
All cellular organisms have the ability to detect and respond to extracellular stimuli 
and to fluctuations in their intracellular environment. This ability to receive stimuli and to 
generate appropriate responses to them may be termed homeostasis. Organisms can 
respond to environmental fluctuations by altering protein activity or location or by 
changing the profile of genes that they express. The major mechanisms used to regulate 
protein function are allosteric regulation and reversible protein phosphorylation. O f these, 
protein phosphorylation has perhaps evolved to be the most prominent and is a feature of 
all three domains of life: Archaea, Bacteria and Eucarya (Kennelly and Potts, 1999). The 
reasons for this are simple. Addition of a protein phosphorylation site in principle has only 
a low cost to the gene or organism concerned —  the addition of a single or at most a few 
amino acid residues. However, the chemical properties of the phosphate group give a single 
phosphate group the power to disrupt protein structure significantly. This effect is most 
pronounced when the phosphorylation site is otherwise neutrally charged (e.g. serine, 
threonine and tyrosine at physiological pH). Moreover, phosphate groups readily form salt 
bridges with arginine residues, resulting in novel tertiary or quaternary protein structures 
(Johnson and Lewis, 2001).
1.1: Protein Tyrosine phosphorylation
The key role of protein phosphorylation in cellular processes means that the 
enzymes that mediate it must be tightly regulated (Levitzki and Gazit, 1995; Hunter, 2000; 
Alonso et al., 2004). A number of different protein phosphorylation systems exist in the 
three domains of life. These differ in the target amino acid and in catalytic mechanisms.
The enzymes that catalyse protein phosphorylation and dephosphorylation are known as 
kinase and phosphatase enzymes, respectively. Although it was thought initially that some 
phosphorylation schema were confined to Eucarya and others found only in Bacteria or 
Archaea, it is now recognised that these enzyme families are relatively evenly distributed 
among all forms of life (Kennelly and Potts, 1996; Kennelly and Potts, 1999).
This thesis will be primarily concerned with tyrosine phosphorylation. Indeed, the 
work described in this thesis is part of an ongoing effort to understand the function of a 
single eucaryotic protein tyrosine phosphatase (PTP), PTPa. Tyrosine phosphorylation 
together with serine/threonine phosphorylation represent the most important forms of 
protein phosphorylation seen in Eucarya. Although too large a subject to be dealt with
15adequately here, a broad distinction may be drawn between these different kinds of protein 
phosphorylation (Barritt, 1992; Cohen, 2000; Krauss, 2001). In general, serine/threonine 
phosphorylation affects enzyme activity by causing changes in protein structure and the 
basal levels of serine/threonine phosphorylation are quite high. Phosphoserine and 
phosphothreonine binding domains that mediate protein-protein interactions are a 
relatively recent discovery (Yaffe and Elia, 2001; Yaffe and Smerdon, 2004). In contrast, 
tyrosine phosphorylation is much less common. Indeed, tyrosine phosphorylation accounts 
for less than 0.05% of the normal cellular phosphoproteome (pSer 92%, pThr 8%), 
although this may increase 6-fold in transformed cells (Hunter and Sefton, 1980). In 
contrast to serine/threonine phosphorylation, the main effect of tyrosine phosphorylation 
is not on enzyme activity although most tyrosine kinases require activation loop tyrosine 
phosphorylation for full activity (Hubbard and Till, 2000). Instead, tyrosine 
phosphorylation creates binding sites for adaptor or scaffold proteins that recognise 
phosphotyrosine using She- or Dok-like phosphotyrosine binding domains (PTBs) (Uhlik 
et al., 2005). In addition to mediating protein-protein interactions, the recognition of 
phosphotyrosine residues by PTBs in the same protein molecule can lead to profound 
alterations in tertiary structure that regulate enzyme activity (Xu et al., 1997).
1.1.1: Tyrosine phosphatase classification
The remainder of this introduction will focus on the class I or classical PTPs, in
particular on the type Ha family of classical receptor PTPs (RPTPs), of which PTPa is a
member. However, the other families of tyrosine phosphatase enzymes will be briefly
introduced and the reader is referred to recent reviews for more information on these
proteins. Enzymes that can specifically dephosphorylate tyrosine residues may currently be
divided into several phylogenetic and mechanistic categories (Alonso et al., 2004). The class
I family of tyrosine phosphatases comprises classical cysteine-based tyrosine phosphatases
and will be covered in more detail subsequently. The single vertebrate class II tyrosine
phosphatase, low molecular weight PTP (LMPTP), is structurally related to bacterial
arsenate reductases; its function is not clearly understood. The bacterial class II tyrosine
phosphatases dephosphorylate autokinases involved in capsule synthesis. LMPTP can
dephosphorylate a number of protein kinases. Homologues of this protein are highly
conserved across all the domains of life (Alonso et al., 2004) and mutations in LMPTP are
associated with many pathological conditions including atopy (Bottini et al., 2002). There
are three vertebrate class III tyrosine phosphatases, CDC25A/B/C, which evolved from a
bacterial rhodanese-like enzyme. These cell cycle regulating proteins dephosphorylate the
16adjacent inhibitory tyrosine and threonine sites on cyclin dependent kinase (CDK)/cyclin 
kinase complexes resulting in cell cycle progression (Boutros et al., 2006). A fourth family 
of proteins has recendy been shown to have tyrosine phosphatase activity. Class IV 
tyrosine phosphatases utilise a catalytic aspartate residue and exhibit a different catalytic 
mechanism from the cysteine-based class I-III proteins. The founder members of this sub­
family are the 4 Eyes absent genes (Tootle et al., 2003; Rayapureddi et al., 2003; Li et al.,
2003), which have been identified in a number of human genetic syndromes (Vincent et al., 
1997; Abdelhak et al., 1997; Azuma et al., 2000; Rayapureddi et al., 2003). In contrast, class 
I to III tyrosine phosphatases all use a cysteine-based catalytic strategy and share a 
common active site structure (CX5 R) despite using different protein folds to generate this 
structure. Finally, histidine based acid phosphatases have also been shown to have 
physiological phosphotyrosine phosphatase activity (Meng and Lin, 1998; Fleisig et al.,
2004). The catalytic mechanism of classical PTPs will be discussed in detail below.
1.1.2: Classical cysteine-based PTPs
The class I family of tyrosine phosphatases includes the classical tyrosine 
phosphatases and the VHl-like dual specificity phosphatases (DSPs) (Alonso et al., 2003). 
VHl-like DSPs form a diverse group of enzymes and may be divided into a number of 
sub-families. Confusingly, not all VHl-like DSPs actually have dual specificity. Mitogen- 
activated-protein-kinase (MAPK) phosphatases dephosphorylate threonine and tyrosine 
residues in the pTXpY motif of the activation loop of MAPKs (Farooq and Zhou, 2004). 
Slingshot phosphatases dephosphorylate an inhibitory phosphoserine on cofilin (Ohta et 
al., 2003; Huang et al., 2006). Phosphatase-found-in-regenerating-liver (PRL) PTPs are less 
well understood but may affect Rho family GTPases through a tyrosine phosphatase 
activity (Fiordalisi et al., 2006). CDC14 phosphatases have serine or threonine phosphatase 
activity and stabilise the CKI-1  cip/kip cyclin E inhibitor and cause cell cycle arrest (Saito 
et al., 2004; Koreth and van den Heuvel S., 2005). The myotubularin-related and PTEN 
phosphatases dephosphorylate inositol phospholipids and are implicated in a number of 
human genetic diseases (Wishart and Dixon, 2002; Laporte et al., 2003; Pendaries et al., 
2003; Begley and Dixon, 2005). The remaining VHl-like DSPs are grouped together to 
form a heterogenous sub-family of “atypical” DSPs, some of which have mRNA 
5’triphosphatase activity (Martins and Shuman, 2002; Changela et al., 2005). The atypical 
VHl-like DSPs generally lack the protein domains characteristic of other tyrosine 
phosphatases. It has been postulated that the atypical DSPs may be regulated using a
17similar system to the combinatorial subunit principle utilised by serine/threonine 
phosphatases (Alonso et al., 2004).
1.1.3: Catalytic mechanism of classical PTPs
Cysteine-based tyrosine phosphatases catalyse the hydrolysis of the tyrosine 
phosphate monoester via a dissociative mechanism. Their catalytic mechanism has been the 
subject of extensive recent reviews and the reader is directed to these for further detail 
(Denu and Dixon, 1998; Barford et al., 1998; Kolmodin and Aqvist, 2001; Zhang, 2002; 
Zhang, 2003). However, there follows a brief overview of the PTP catalytic mechanism to 
allow the reader to understand some of the experimental approaches used in this thesis, 
particularly the use of “substrate-trapping mutations” (7.2.2, 7.2.3) and tyrosine 
phosphatase inhibitors. Throughout this thesis, sites involved in tyrosine phosphatase 
catalysis will be referred to by their position in the archetypal PTP1B tyrosine phosphatase 
domain. For instance, the PTP1B catalytic P-loop cysteine is located at amino acid 215. 
However, at their first introduction, mutations in PTPa that affect residues involved in 
tyrosine phosphatase catalysis will also be referred to by their location within the chick 
PTPal protein (cDNA: Genbank accession number L32780)(Stoker, 1994). All other PTPa 
mutations will be referred to by their location within chicken PTPal only.
Cysteine based tyrosine phosphatases are marked by the active site motif, CX5R, 
which constitutes the P-loop. In all but CDC25 PTPs, this conserved sequence may be 
extended to CX5 R(S/T). The P-loop forms the base of a fold in the phosphatase domain 
surface and is orientated such that the guanidium group of the P-loop arginine (R221) and 
the amide side groups of the P-loop backbone project into the cavity of this fold. This 
creates a positively charged pocket to receive the negatively charged phosphate group. 
Phosphate binding in the active site pocket is further stabilised by an adjacent a-helix 
dipole moment and the active site arginine. The depth of active site pocket is variable, 
being deeper in tyrosine-specific enzymes and shallower in those that can also 
accommodate the smaller serine or threonine groups (Jia et al., 1995). Although, tyrosine 
phosphatases were initially considered relatively non-specific with regard to their choice of 
substrate, in recent years this concept has been overturned. Numerous examples of PTP 
specificity have now been discovered and the complex structural and regulatory basis for 
this specificity is under investigation (Tonks and Neel, 2001).
18The catalytic mechanism of these enzymes is quite different from that of classical 
serine/threonine phosphatases; they form a covalent phosphoenzyme intermediate (Guan 
and Dixon, 1991; Cho et al., 1992) and they do not require metal ions as cofactors. The 
reaction is nucleophilic and can be divided into two stages: formation and breakdown of 
the phosphoenzyme intermediate. The catalytic cysteine has a low pKa (4.6) (Zhang and 
Dixon, 1993) and hence is present in the thiolate form at physiological pH. This is achieved 
by interactions with the P-loop histidine (H214), with a second adjacent oc-helix dipole 
moment, with main chain amide residues and via the formation of a hydrogen bond with 
the P-loop hydroxyl group (S/T222 —  where present) (Zhang and Dixon, 1993; Denu and 
Dixon, 1998). In the first step, the active site cysteine acts as a nucleophile, attacking the 
phosphorus centre of the tyrosine phosphate group to form the phosphoryl-cysteine 
intermediate (PTP-Cys-P03 ) leading to release of the dephosphorylated substrate. Any 
mutation in the catalytic cysteine residue removes all catalytic activity although the resulting 
protein may still be able to bind substrates (Streuli et al., 1989; Streuli et al., 1990; Guan and 
Dixon, 1991).
The p-loop is surrounded by several other loops that contribute to catalysis and 
substrate recognition. The most important of these in catalysis is the WPD loop. This 
forms a mobile loop between two hinge regions that contains at its centre a highly 
conserved tryptophan, proline, aspartate sequence (W179, PI 80, D181). Following 
substrate binding the WPD tip of this loop moves over the substrate positioning D181 
adjacent to the substrate (Jia et al., 1995). In the first stage of phosphatase catalysis D181 
acts as a general acid donating a proton to the leaving group phenolic oxygen. This assists 
expulsion of the leaving group (Zhang et al., 1994b; Hengge et al., 1995). In the second 
stage of phosphatase catalysis D181 acts as a general base and extracts a hydrogen from a 
chelated water molecule, which is thus activated to act as the nucleophile in the second 
stage reaction (Wu and Zhang, 1996; Denu et al., 1996; Lohse et al., 1997). The water 
molecule is positioned by interactions with Q262 (Sarmiento et al., 1998; Zhao et al., 1998). 
The phosphoryl-cysteine intermediate is then hydrolysed by the activated water resulting in 
the restoration of the enzyme with the production of free inorganic phosphate.
As remarked above, mutations in the conserved P-loop cysteine destroy 
phosphatase activity but not substrate binding. Therefore, PTPs containing mutations at 
this site can be used to affinity purify PTP substrates. Owing to the two step catalytic 
mechanism of PTPs, a number of other mutations have been identified that remove 
catalytic activity or interfere with hydrolysis of the phosphoenzyme intermediate without
19having significant effects on substrate binding. Collectively, proteins containing such 
mutations are known as “substrate-trapping” mutants and they have been used to identify a 
large number of potential PTP substrates (Blanchetot et al., 2005). This has been achieved 
primarily using co-immunoprecipitation and pull-down techniques. However, substrate- 
trapping mutants have also been used successfully in far-Westem analysis and to identify 
PTP inhibitors.
The majority of studies have used one of two substrate trapping mutations, the 
C215S mutation in the P-loop (Sun et al., 1993; Furukawa et al., 1994; Jia et al., 1995) or the 
D181A mutation in the WPD loop (Flint et al., 1997). In addition, a number of other 
mutations have been useful in substrate trapping experiments although these have been less 
widely used (Q262A (Pannifer et al., 1998), S/T222A(Zhang et al., 1995; Agazie and 
Hayman, 2003; Merritt et al., 2006), C215D (Romsicki et al., 2003) and Y676F (PTPH1 
nomenclature —  in combination with D181A) (Zhang et al., 1999)). Finally, several studies 
have used combinations of these two mutations. In particular, the C215S/D181A (Agazie 
and Hayman, 2003) and the D181A/Q262A (Xie et al., 2002; Kontaridis et al., 2004) 
combinations have been widely used. Each trapping mutant has its own advantages and 
disadvantages. Indeed some mutations that work effectively in certain PTPs are not 
effective in others (Agazie and Hayman, 2003). However, the D181A mutation (alone or in 
combination with the Q262A mutation) is generally considered to be the most effective of 
the substrate trapping mutations (Garton et al., 1996; Aoki and Matsuda, 2000; Xie et al., 
2002; Kolli et al., 2004). In addition to a gready decreased catalytic rate, this mutant has a 
decreased  when compared to wild type protein. This is thought to be due to the loss of 
the potential electrostatic repulsion between the WPD loop aspartate and the incoming 
negatively charged phosphate group. In addition, there are general concerns that are a 
feature across the group. The most significant of these are the effects that such mutations 
have on overall protein structure, particularly with respect to substrate specificity and the 
interactions of these proteins with tyrosine phosphatase inhibitors, which will be 
considered subsequendy. Although the substrate trapping mutants as a whole retain a low 
K^, there is the possibility that these mutations may affect substrate binding. Indeed, 
although the C215S mutation retains the ability to recognise phosphotyrosine (Guan and 
Dixon, 1991), structural and kinetic analysis revealed differences between wild type PTP1B 
and the C215S mutant (Scapin et al., 2001). This resulted in the generation of the 
alternative C215D mutant which more closely resembled wild type protein but had a 7000- 
fold lower Kcat at physiological pH and may be of use in future substrate trapping
20experiments (Romsicki et al., 2003). A final cautionary point can be made about the use of 
substrate trapping mutants with RPTPs. Although successfully used in RPTPs, the majority 
of substrate trapping experiments used intracellular PTPs. This is especially true of work 
carried out in vivo (Blanchetot et al., 2005).
This thesis uses several non-specific protein tyrosine phosphatase inhibitors to 
increase cellular phosphotyrosine levels. A general understanding of the mechanism of 
action of these agents is useful in discussing both the desired and unwanted effects that 
they have on RPTPs. Non-specific tyrosine phosphatase inhibitors may be divided into 
cysteine oxidising agents (e.g. peroxide) (Denu and Tanner, 1998) and those that compete 
with tyrosine phosphate for access to the active site (e.g. vanadate) (Trudel et al., 1991; 
Huyer et al., 1997). Pervanadate mediates its effects primarily through active site oxidation 
although it may retain some ability to compete with substrate for active site binding. In 
general, competitive inhibitors have a less marked effect on cellular phosphotyrosine levels 
and have the potential to interfere directly with the trapping of phosphatase substrates. On 
the other hand, oxidising inhibitors alter the conformation of the active site and so have 
the potential to perturb substrate binding. Original studies that showed that oxidising 
inhibitors could have reversible (e.g. cysteine to sulphenic acid (SOH) or irreversible effects 
(e.g. cysteine (SH) to sulphonic acid (S03H)) (Huyer et al., 1997; Denu and Tanner, 1998). 
The reversibility of oxidation has been suggested to be enzymatic as well as spontaneous. 
Recently, however it has been shown that PTPs are able to form a reversible cyclic 
structure (sulphenyl-amide) when exposed to oxidising agents that protects them from 
further oxidation and is also likely to block substrate binding (Salmeen et al., 2003). It 
therefore follows that substrate trapping mutants of PTPs, which lack the active site 
cysteine (e.g. C215S/D), should be relatively immune to the structural effects of oxidising 
PTP inhibitors. However in two domain RPTPs (Most RPTPs, for examples see 1.1.5), it is 
unclear whether the inhibitory effect of cysteine oxidising agents is mediated by or reflects 
changes in the membrane-proximal (Dl), or membrane-distal (D2) tyrosine phosphatase 
domain or indeed both (Blanchetot et al., 2002a; Persson et al., 2004). Despite these 
concerns, the cellular level of tyrosine phosphorylation is so low that it is essential to 
artificially boost it in substrate trapping experiments (Blanchetot et al., 2005). In general, 
this may be achieved either with tyrosine phosphatase inhibition or with tyrosine kinase 
activation. Recently, novel inhibitors have been developed that are specific for individual 
PTPs (Puius et al., 1997; Reviewed in Zhang, 2003). These have considerable promise as 
both experimental tools and potentially in the future, as therapeutic agents.
217. 1.4: The role of classical PTPs in human disease
The discovery of protein tyrosine kinases in 1980 was followed by a rapid 
recognition of the importance of tyrosine phosphorylation and tyrosine kinases in many 
physiological and pathological systems (Hunter and Sefton, 1980; Strawn and Shawver, 
1998; Manning et al., 2002; Ostman et al., 2006; Vivekanand and Rebay, 2006). Initially 
there was an expectation that tyrosine phosphatases would very rapidly be identified as 
important players in human genetic diseases, particularly in oncogenesis where they might 
act as tumour supressor genes opposing tyrosine kinase oncogenes. However, nearly two 
decades after the identification of the first tyrosine phosphatase (Tonks et al., 1988; 
Charbonneau et al., 1989) this early promise has not yet been fulfilled. It is worth 
considering that the first PTP (Tonks et al., 1988; Charbonneau et al., 1989) was identified 
almost a decade after the first tyrosine kinase (Hunter and Sefton, 1980) and kinase-specific 
therapeutics have only recently reached the clinic (Giles et al., 2005; Tokunaga et al., 2006; 
Ventura and Nebreda, 2006; Larkin and Eisen, 2006). Therefore, the importance of PTPs 
in human disease has yet to be fully appreciated and manipulation of phosphatase activity 
may in the future yield promising therapeutic options. An understanding of the 
biochemistry of these proteins will no doubt help in this undertaking.
Mutations in a small number of PTPs have been shown to cause or be associated
with human diseases including congenital and acquired conditions. The first identified
mutation in a class I PTP shown to cause a congenital human disease was in a member of
the cytoplasmic myotubularin inositol phospholipid phosphatase family (MTM1) (Laporte
et al., 1996). Mutations in related genes cause phenotypically similar autosomal recessive
Charcot-Marie-Tooth disease type 4B1  (MTMR2) and 4B2 (MTMR13/Sbf2) (Bolino et al.,
2000; Azzedine et al., 2003; Senderek et al., 2003). It is thought that the similar phenotype
of mutations in the active MTMR2 and inactive MTMR13 phosphatases may be conferred
by virtue of deregulation of the activity of MTMR2. Interestingly, the wild-type MTMR13
is an inactive pseudophosphatase, which both interacts physically with dimeric MTMR2,
increasing MTMR2 catalytic activity and competitively inhibits MTMR2 binding to lipid
vesicles. This is suggestive of potential roles for the inactive membrane-distal D2 domains
in type II RPTPs. In addition, Laforin, the protein product of the EPM2A gene is mutated
in some cases of progressive myoclonic epilepsy of Lafora (Minassian et al., 1998). Finally,
mutations in CD45 are one cause of X-linked severe combined immunodeficiency (SCID)
(Cale et al., 1997; Kung et al., 2000). Interestingly, mice deficient for CD45 were known to
have a SCID phenotype over 5 years before the first human CD45 mutations were
22identified (Kishihara et al., 1993; Kung et al., 2000). Several human genetic syndromes are 
associated with PTP mutations. These include Noonan syndrome and LEOPARD 
syndrome (Shp2/PTPN11) (Tartaglia et al., 2001; Digilio et al., 2002). Mutations in the 
recently identified type IV PTP Eya (Eyes absent) family are responsible for several 
developmental syndromes (Abdelhak et al., 1997; Wayne et al., 2001; Schonberger et al.,
2005).
In addition, disruption of PTP function has been implicated in many acquired 
conditions including autoimmune diseases, type II Diabetes Mellitus and cancer (Asante- 
Appiah and Kennedy, 2003; Stoker, 2005). PTP-associated autoimmune diseases include 
type I Diabetes Mellitus (IA2/PTPRN, IA2R/ PTPRN-2, PTPN22/PTPN8) (Rabin et al., 
1994; Morahan et al., 1998; Bottini et al., 2004), Systemic Lupus Erythematosis (PTPN22) 
(Kyogoku et al., 2004), Rheumatoid Arthritis (PTPN22) (Begovich et al., 2004; Carlton et 
al., 2005), Graves thyroiditis (PTPN22) (Smyth et al., 2004) and Multiple Sclerosis (CD45) 
(Jacobsen et al., 2000). PTPN22 in particular appears to play a prominent role in several 
autoimmune diseases (Criswell et al., 2005). Although it was expected that PTPs would be 
implicated in many cancers, no cancer syndrome has yet been associated with a PTP, 
although patients with PTPN22-related Noonan syndrome have an elevated incidence of 
certain cancers (Tartaglia et al., 2003). Although abnormalities in PTP expression are often 
detected in malignancies, it is difficult to know whether these mutations are significant or 
reflect genomic instability in neoplastic cells. The role of PTPs as both tumour supressor 
genes and oncogenes has recently been reviewed and is a rapidly developing area (Ostman 
et al., 2006). For example, DEP1, LAR, PTPy, PTPx, PTPN3, PTPN 13 or PTPN 14 are 
mutated in a quarter of colorectal cancers (Ruivenkamp et al., 2002; Wang et al., 2004). 
PTPt mutations were the most frequently found and were associated with decreased 
phosphatase activity, suggesting a role for these PTPs as tumour suppressor genes (Wang 
et al., 2004). In contrast, activating PTPN11 mutations are oncogenic and the H.pylori CagA 
antigen, which is associated with gastric carcinoma, activates Shp2 (Tartaglia et al., 2001; 
Higashi et al., 2004; Bentires-Alj et al., 2004). A range of other pathogens and toxins have 
co-opted PTPs to mediate their effects and PTP polymorphisms may affect the effects of 
these agents (Krasnoperov et al., 2002; Fujikawa et al., 2003; Peek, Jr., 2003).
1.1.5: Classification of classical PTPs
The classification of PTPs has been an evolving subject. However, now that all of 
the classical PTPs in the human genome are thought to have been identified, this
23classification is unlikely to change significantly. The most recent phylogenetic and structural 
PTP classification will be followed in this thesis (Andersen et al., 2004). This developed 
from an original, purely structural RPTP classification with little need for modification 
(Fischer et al., 1991; Brady-Kalnay and Tonks, 1995).
Classical tyrosine phosphatases are conventionally divided into receptor and non­
receptor subtypes although several receptor sub-types contain members or isoforms that 
lack a transmembrane domain. There are nine non-receptor sub-types and eight receptor 
subtypes. As PTPa is a receptor protein tyrosine phosphatase (RPTP), non-receptor PTPs 
will not be discussed in any further detail. For a classification of these enzymes, the reader 
is referred to the literature (Andersen et al., 2001b; Andersen et al., 2004).
The receptor protein tyrosine phosphatase subtype is divided into eight sub-groups 
based on their domain architecture and phylogenetic relationship (Brady-Kalnay and 
Tonks, 1995; Andersen et al., 2001b). There follows, a brief description of the domain 
architecture of the eight RPTP families together with representative vertebrate examples of 
each family. In addition, several invertebrate RPTPs are mentioned, as these will be 
referred to subsequently. The type I sub-group contain CD45 proteins, whose extracellular 
domain contains spectrin-like repeats in addition to fibronectin type III domains. PTPa is a 
type II RPTP and this sub-group will be described in more detail below. The extracellular 
domain of type 3 RPTPs (e.g. PTP^) contains only fibronectin type III domains. The 
Drosophila (melanogaster) genes DPTP4E and DPTP10D and the Caenorhabditis elegans 
(C.elegamj gene F44G4.8 are also members of the type III family. The Drosophila genes 
DPTP99A and DPTP52F and the C.elegans gene K04D7.04 are usually classified in the type 
III family. However, they exhibit significant differences from other type III RPTPs both in 
domain structure and in genomic organisation (Schindelholz et al., 2001). Type IV RPTPs 
(e.g. PTPa/e) possess a very short, highly glycosylated extracellular domain. Both the type 
III and IV RPTP families include several non-receptor RPTP members. The extracellular 
domain of type V RPTPs (e.g. PTPy/Q includes a large carbonic anhydrase-like domain. 
The type VI sub-group contains only the chicken CD45 orthologue. Type VII RPTPs (e.g. 
PCPTP1, STEP) contains both transmembrane and intracellular proteins. Finally, type IIX 
RPTPs (e.g. IA2/IA2p) are believed to be catalytically inactive proteins whose extracellular 
domain contains a RDGS adhesion recognition motif. Type I-II and type IV-VI RPTPs 
contain two intracellular tyrosine phosphatase domains, of which only D1 usually exhibits 
significant phosphatase activity due to the presence of a number of critical point mutations
in D2 domains (Lim et al., 1998; Nam et al., 1999; Buist et al., 1999; Lim et al., 1999;
24Krueger et al., 2003). However, it is becoming apparent that despite this, D2 domains play 
an important role in RPTP function. This includes effects on protein stability, D1  substrate 
specificity and overall RPTP regulation. In addition, D2 domains participate in key protein- 
protein interactions (Streuli et al., 1990; Wang and Pallen, 1991; Johnson et al., 1992; 
Debant et al., 1996; Wu et al., 1997; Kashio et al., 1998; Felberg and Johnson, 1998; Buist 
et al., 2000; Felberg and Johnson, 2000; Tsujikawa et al., 2001; Krueger et al., 2003; Persson 
et al., 2004; Wang and Johnson, 2005). In some systems, the residual activity of D2 
domains may have a functional role (Garrity et al., 1999). All RPTPs with tandem 
phosphatase domains cluster together on phylogenetic analysis and all D2 domains form a 
separate off-shoot supporting the hypothesis that 2 phosphatase domain RPTPs resulted 
from the early intragenic duplication of a phosphatase domain followed by gene 
duplication (Hooft van Huijsduijnen, 1998; Andersen et al., 2001b). Type III (In general), 
VII and IIX RPTPs contain only a single intracellular tyrosine phosphatase domain; in type 
IIX RPTPs this is thought to be catalytically inactive (Lu et al., 1994; Drake et al., 2003). 
Indeed, these and other inactive PTP domains may function as atypical phosphotyrosine 
binding domains or via inhibitory interactions with other PTPs (Wishart and Dixon, 1998; 
Gross et al., 2002).
The type II RPTP subfamily contains proteins that cluster into two groups based 
on the absence (Type IIA) or presence (Type IIB) of an amino-terminal MAM domain 
(Meprin, A2, PTP^x). Otherwise, the extracellular domains of type IIA and IIB RPTPs are 
characterised by a number of immunoglobulin and fibronectin type III domains. 
Unfortunately, it is not unusual for RPTPs from different species to follow different and 
often inconsistent nomenclatures. Therefore, the synonymous names for each of the type 
II RPTPs are appended in parentheses below, after the name that is in most common use 
and which will be used throughout this thesis. The type IIA RPTP family contains 3 
members in vertebrate species: PTPS, PTPa (CRYPa, LAR-PTP2, PTP-PS, PTP-P1, 
mPTPNU3, PTPT9a, PTPT9b) and LAR (RPTPf). The type IIB RPTP family contains 
four members: PTPk, PTPa (PCP2, PTPomicron, PTPpi, PTPi, PTPRO, PTPpsi but not 
chick VTVX (CD45 orthologue)), PTPp and PTPp (PTP-SL, PCPTP, PTPBR7, PC 12- 
PTP1). The Drosophila gene DLAR and the C.elegans gene C09D8.1 are considered type Ha 
RPTPs. However, the structure of the DLAR gene shows no similarities to those of 
vertebrate type Ha RPTPs (O'Grady et al., 1994; Krueger et al., 1996). Therefore, it is 
unlikely that DLAR and human LAR are functional orthologues. Rather, DLAR and LAR 
are more likely to represent the independent development of cell adhesion molecule-like
25RPTPs in the fly and vertebrate genomes from a common ancestral pool of domain types. 
The Drosophila gent DPTP69D and the C.elegans gene CLR-1 are often considered to be 
type Ha RPTPs despite differing from other type Ha RPTPs in domain structure and 
genomic organisation (Schindelholz et al., 2001). Flybase refers to DLAR as LAR and 
DPTP69D etc as PTP69D. However, to avoid confusion between vertebrate and 
invertebrate PTPs, the D prefix will be retained throughout this thesis.
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Figure 1.1: Classification of receptor protein tyrosine phosphatases
Modified from a published figure taken from the PTP web resource 
http://science.novonordisk.com/ptp/index.asp (Andersen et al., 2001b)
Schematic representation of PTP classification. Representative human examples of each 
family are included. In addition, several fly and C.elegans PTPs have been included as they 
will be included in subsequent discussions of PTP function. Those PTPs in brackets (e.g. 
CLR-1) are included in the most appropriate family although they may not have the 
canonical features of the family in which they are included. The 11 remaining C.elegans 
PTPs contain domains that evolved after separation of the lineage that gave rise to C.elegans 
from that which gave rise to vertebrates and insects
271.2: Type II RPTPs
The PTPa gene is located on mouse chromosome 17 and human chromosome 
19pl3.3 (Yan et al., 1993; Wagner et al., 1994). Allelic forms have been reported in mouse 
(Yan et al., 1993), however there is little evidence for any association of PTPa alleles with 
human disease. In contrast, although PTP8 is also not known to be associated with human 
disease, mutations in LAR have been associated with human disease (Jirik et al., 1992; 
Harder et al., 1995; Wang et al., 2004; Miscio et al., 2004). All three type Ila RPTPs have 
been disrupted in mouse models (Schaapveld et al., 1997; Elchebly et al., 1999; Wallace et 
al., 1999; Uetani et al., 2000). The phenotypes of these mutants and their implications for 
PTP function will be discusssed later (1.2.2). The general structure of the major PTPa 
isoforms includes an extracellular domain containing a number of immunoglobulin (Ig) and 
fibronectin type III (FN3) domains and an intracellular domain containing one or two 
tyrosine phosphatase domains. As such, the domain architecture of PTPa resembles that of 
several proteins known to be involved in cell-cell recognition and communication, which 
have been described as type I and type II members of the Ig superfamily (Vogel et al., 
2003).
1.2.1: mRNy4 Expression
The type Ila RPTPs are conventionally thought to produce 2 major isoforms, one 
short (~6kb) and one long (~8kb) (Streuli et al., 1988; Yan et al., 1993; Mizuno et al., 1993; 
Walton et al., 1993; Sahin and Hockfield, 1993; Pan et al., 1993; Kaneko et al., 1993). The 
short isoform (e.g. CRYPal; human PTPa isoforms 3, 4; LAR-PTP B) corresponds to a 
transmembrane protein containing three amino-terminal Ig domains, followed by four FN3 
domains and two intracellular tyrosine phosphatase domains. The longer isoform (e.g. 
CRYPa2; human PTPa isoforms 1, 2; LAR-PTP A) includes an additional 4 FN3 domains 
between the 3rd and 4th FN3 domains of the shorter isoform (Mizuno et al., 1993; Stoker, 
1994; Wagner et al., 1994; O'Grady et al., 1994; Mizuno et al., 1994). Antibodies directed 
against PTPa have confirmed the presence of two major PTPa protein species in tissues 
expressing both isoforms (Stoker et al., 1995a; Stoker et al., 1995b; Stepanek et al., 2005).
The expression pattern of PTPa has been mapped by Northern and in situ analysis 
of mRNA expression and by immunological detection of PTPa protein. In addition, it has 
recently become possible to analyse the expression pattern of PTPa using a transgenic 
mouse line in which a (3-galactosidase ({3-Gal) gene has been inserted into the PTPa locus
28(Wallace et al., 1999; Meathrel et al., 2002). (3-Gal detection in these animals has broadly 
confirmed studies that detect PTPa mRNA or protein direcdy. PTPa is quite widely 
expressed, but is one of few RPTPs to be preferentially expressed in neural tissue (Sahin et 
al., 1995). However, in addition to the two major PTPa isoforms described above, a wide 
range of other species has been reported (Pan et al., 1993; Stoker, 1994; Rotin et al., 1994; 
Ogata et al., 1994; Zhang et al., 1994a). These are likely to represent alternatively spliced 
isoforms of PTPa. Indeed, many RPTPs are known to produce multiple alternatively 
spliced isoforms including CD45. Alternative splicing of CD45 has significant implications 
for CD45 function (Xu and Weiss, 2002; Hermiston et al., 2003). Unfortunately, it is 
unlikely that the probes used in previous experiments will have detected all PTPa isoforms 
and only a limited number of studies have explicidy discriminated between even the two 
major species. This is potentially of great significance for instance, mRNA for the recently 
described LAR FN5C isoform is as abundant as that for the full length isoform but was 
not detected in previous studies due to probe design (Yang et al., 2003). These outstanding 
issues must be borne in mind when considering the currently available studies of PTPa 
isoforms and expression pattern.
1.2.1.1: Isoforms generated by mRNv4 alternative splicing
The alternative splicing of PTPa has not been studied in any detail. However, a 
large number of alternatively spliced isoforms have been reported for the remaining type 
Ila RPTPs. There is evidence that the expression of these isoforms is developmentally and 
spatially regulated (Pan et al., 1993; Longo et al., 1993; Stoker, 1994; Rotin et al., 1994; 
Ogata et al., 1994; Mizuno et al., 1994; Wang et al., 1995; Sahin et al., 1995; Zhang and 
Longo, 1995; Pulido et al., 1995b; Honkaniemi et al., 1998; Zhang et al., 1998; Ledig et al., 
1999b; Chilton and Stoker, 2000; Zhang et al., 2003; Yang et al., 2003). Where this has been 
examined, homologous isoforms are found for all three genes (Stoker, 1994; O'Grady et al., 
1994; Zhang and Longo, 1995; Pulido et al., 1995a). In addition, comparison of the 
structure and sequence of these genes suggests that findings in one gene are likely to be 
conserved across the family (O'Grady et al., 1994). These genes produce isoforms from 
two major kinds of alternative splicing events.
Firstly, the gene structure of the type Ila RPTPs means that domain and exon 
boundaries largely coincide (O'Grady et al., 1994). Therefore, individual domains can be 
precisely excised to produce alternative isoforms with different numbers of Ig, FN3 or 
PTP domains (Mizuno et al., 1993; Pan et al., 1993; Stoker, 1994; Zhang and Longo, 1995;
29Pulido et al., 1995a). Examples include the short and long major isoforms described above. 
In addition, soluble isoforms lacking the PTP domains and isoforms consisting only of Ig 
or FN3 domains have also been reported (Stoker, 1994; Yang et al., 2003). Although 
ligand-binding differences have been reported for the two major PTPa isoforms (Haj et al., 
1999; Chilton, 2000; Sajnani-Perez et al., 2003), the functional significance of many of these 
isoforms is unknown. In addition, the two isoforms of the C.elegans type Ila RPTP, PTP-3, 
have distinct roles in axon guidance and synaptogenesis (Ackley et al., 2005). Computer 
predictions (2.6.3) suggest that the major alternatively spliced isoforms of CRYPa do not 
differ in potential tyrosine sulphation sites (Kehoe and Bertozzi, 2000). However, CRYPa2 
has twice the predicted N-glycosylation (4 vs 2) and O-glycosylation (2 vs 1) sites found in 
CRYPal  (Yan et al., 1993; Stoker, 1994). Experimental studies will be required to 
determine whether these predicted differences are real. However, given the importance of 
differential glycosylation in CD45 function, this difference in the glycosylation potential of 
PTPa isoforms is of interest (Xu and Weiss, 2002).
Secondly, a number of small alternatively spliced exons have been reported for 
PTPS and LAR, which add short peptide sequences rather than whole domains. Pulido et 
al reported 3 small PTPS mini-exons (me): meA introduces 9 amino acids within the 2nd Ig 
domain, meB introduces 4 amino acids between the 2nd and 3rd Ig domains; finally, meC 
introduces 9 amino acids into the 5th FN3 domain and is identical to LASE-c (See below) 
(O'Grady et al., 1994; Pulido et al., 1995a). Several alternatively spliced forms of LAR have 
been reported (LAR alternatively spliced element —  LASE) (O'Grady et al., 1994; Zhang 
and Longo, 1995). The LASE-a exon introduces 11 amino acids just upstream of the 
juxtamembrane wedge. The LASE-a coding sequence includes a juxtamembrane cysteine 
residue which may contribute to disulphide bond formation between native RPTP 
monomers (Chapter 4; van der Wijk et al., 2004). This exon also contains two conserved 
serine residues that play a key regulatory role in PTPa (Tracy et al., 1995; Stetak et al., 
2001). LASE-b introduces four amino acids just after the transmembrane domain. LASE-c 
is equivalent to PTPS meC and equivalent isoforms are found in LAR, PTPa and PTPS 
(O'Grady et al., 1994; Zhang and Longo, 1995). The LASE-c/meC insert has been shown 
to mask a laminin-nidogen binding site in the fifth FN3 domain and it is also included in a 
homophilically binding isoform that supports neurite outgrowth (O'Grady et al., 1998; 
Yang et al., 2003; Yang et al., 2005). In contrast to the other small alternatively spiced 
exons, LASE-d and LASE-e are associated with major architectural changes. The LASE-d 
exon introduces a stop codon between FN3 domain number 5 and 6, resulting in a
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Ila RPTPs might have developed the ability to generate secreted forms both from 
proteolysis of transmembrane proteins and alternative splicing (Streuli et al., 1992). LASE-e 
has been identified in association with the LASE-c and LASE-d exons. Isoforms including 
the LASE-e exon contain a novel start codon just upstream of the LASE-c insert in FN3 
domain 5. The association with LASE-d results in a small (11 kilodalton (kDa)) secreted 
protein (LARFN5C) mainly comprised of the C-terminal portion of FN3 domain 5. This 
secreted motif contains a homophilic binding site that is able to mediate LARFN5C 
tetramerisation and also binding to full-length forms of LAR. Despite its effects on the 
intact domain, the presence of the LASE-c exon does not disrupt the neurite outgrowth 
promoting effect or the homophilic binding site of the c-terminal region of FN3 domain 5. 
(Yang et al., 2003; Yang et al., 2005). Due to their similar properties, it is likely that the 
laminin-nidogen binding site will prove to be closely related to the FN5C homophilic 
adhesion site. The CRYPal and -a2 cDNAs are LASE-a, d, e and meA, B negative and 
LASE-b positive. The Longer CRYPa2 cDNA is LASE-c/meC negative (Stoker, 1994; 
O'Grady et al., 1994; Zhang and Longo, 1995; Pulido et al., 1995a; Yang et al., 2003). 
Therefore, they lack the currently identified homophilic and ECM binding sites reported 
above.
The presence of currently undescribed PTPa isoforms should be bome in mind 
when studying the reported PTPa expression data. However, several points can be made 
with the available data on the major large (3 Ig, 8, FN3, 2 PTP) and small (3 Ig, 4 FN3, 2 
PTP) isoforms. PTPa is expressed from an early developmental stage (Hara et al., 2003). It 
is tempting to speculate that type II RPTPs might have a conserved role in early vertebrate 
and invertebrate development (Fitzpatrick et al., 1995; Bateman et al., 2001; Frydman and 
Spradling, 2001; Harrington et al., 2002; Chin-Sang et al., 2002a; Hinton et al., 2003). In 
addition, PTPa expression can be detected in the visceral endoderm and yolk sac of early 
embryos (Sousa-Nunes et al., 2003).
1.2.1.2: Expression patterns
Northern analysis shows that whilst the long isoform is expressed in many tissues, 
expression of the short isoform is limited to neural tissue (Yan et al., 1993; Walton et al., 
1993; Sahin and Hockfield, 1993; Stoker, 1994; Rotin et al., 1994; Zhang et al., 1994a; 
Wang et al., 1995; Sahin et al., 1995; Kim et al., 1996; Ranjan and Hudson, 1996; 
Schaapveld et al., 1998; Haj et al., 1999; Elchebly et al., 1999; Ledig et al., 1999b; Chilton
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PTPa expression is low in the mature animal except in discrete regions of the central 
nervous system. However, many tissues express PTPa at high levels during development 
for example, the central and peripheral nervous system, many neural crest derived tissues, 
endodermal derivatives such as the liver and mesodermal derivatives including muscle 
(smooth, cardiac and skeletal) (Yan et al., 1993; Walton et al., 1993; Sahin and Hockfield, 
1993; Stoker, 1994; Rotin et al., 1994; Zhang et al., 1994a; Sahin et al., 1995; Norris et al., 
1997; Ostenson et al., 2002; Lajus and Lang, 2006). Several studies report conflicting data 
regarding the expression of PTPa in different tissues. This may be attributable to 
differences in the choice of probes with differing abilities to recognise PTPa isoforms. 
Finally, the timing of PTPa expression during development varies between species. This is 
likely to reflect differences in the developmental ages of experimental model species at 
parturition.
In non-neural tissue, which expresses only the larger PTPa isoform, expression is 
upregulated in actively proliferating and differentiating epithelial cells but reduced in 
quiescent cells (Rotin et al., 1994; Kim et al., 1996). This is reminiscent of the effect of 
increasing cell-cell contact on PTPa expression (Celler et al., 1995). In contrast, PTPa 
expression peaks twice during neural development. During embryonic development, PTPa 
expression in most neural tissue changes from a situation where the larger major isoform 
predominates to one where the shorter isoform is the more common (Yan et al., 1993; 
Sahin and Hockfield, 1993; Stoker, 1994; Wang et al., 1995). The larger isoform is 
expressed most strongly in the proliferating neuroepithelium whereas the shorter isoform is 
found predominandy in migrating and differentiating mantle zone cells. Finally, towards 
the end of embryonic development, PTPa expression changes again from the relatively 
widespread developmental expression pattern to a picture more reminiscent of the adult 
with localised areas of high signal (Stoker, 1994; Wang et al., 1995; Sahin et al., 1995).
In the adult organism, PTPa expression is significantly lower than in the developing 
embryo. Expression in non-neuronal tissues is minimal. In neural tissues, both neurons and 
myelinating oligodendrocytes and Schwann cells express PTPa. However, both the long 
and in particular the short isoform are expressed strongly in discrete areas within the 
central nervous system although the overall level is lower than during embryonic 
development. The highest levels are seen in the hippocampus,
rhinencephalon/paleopallium and cerebellum. In the hippocampus, PTPa is expressed in 
the granule cells of the dentate gyrus and in the cells to which they project, the pyramidal
32cells of the hippocampus proper. PTPa is expressed in olfactory neuroepithelium, in mitral 
and granule cells in the olfactory bulb and in the olfactory cortex. Expression is also 
maintained in the pyramidal cells and internal granule layer of the cerebellum (Walton et al., 
1993; Sahin and Hockfield, 1993; Pan et al., 1993; Rotin et al., 1994; Wagner et al., 1994; 
Ogata et al., 1994; Zhang et al., 1994a; Wang et al., 1995; Sahin et al., 1995; Kim et al.,
1996; Norris et al., 1997; Haworth et al., 1998; Ostenson et al., 2002; Meathrel et al., 2002; 
McLean et al., 2002; Thompson et al., 2003; Batt et al., 2003). The areas that continue to 
express PTPa in the adult brain share several interesting characteristics. The olfactory and 
gustatory neuroepithelium are the only neuronal tissues that are known to be continually 
regenerated throughout life (Beidler and Smallman, 1965; Graziadei and Graziadei, 1979). 
The lifespan of individual olfactory receptor neurons is on the order of 20-30 days 
(Samanen and Forbes, 1984). New cells are continually produced that elaborate an axon, 
which fasciculates with the olfactory nerve before passing through an olfactory ensheathing 
cell sheath, to form a synapse at the appropriate site in the olfactory bulb (Doucette et al., 
1983). Similarly, the subventricular zone-olfactory bulb system and the granule cell layer of 
the dentate gyrus are the only regions of the mammalian central nervous system that 
continue to exhibit neurogenesis in the adult animal (Altman and Das, 1965; Altman, 1969; 
Pencea et al., 2001; Kempermann, 2002). In addition, the hippocampus is an area known to 
show high levels of synaptic plasticity, while neurogenesis in the adult hippocampus may 
play a role in memory processing (Martin et al., 2000; Lamprecht and LeDoux, 2004). 
Similarly, cerebellar plasticity may be involved in motor learning (Ito, 2001; De Zeeuw and 
Yeo, 2005).
The expression pattern of PTPa has been most extensively described in the 
developing visual pathway and spinal cord of the chick embryo. Where examined, the 
pattern of PTPa expression in the chick is matched in the mouse visual pathway (Sapieha 
et al., 2005). For a number of reasons, the visual pathway is among the most well described 
models of axon guidance (Mey and Thanos, 2000; Thanos and Mey, 2001). In particular, 
the generation and maintenance of the retinotopic map throughout the visual pathway has 
been extensively described both anatomically and molecularly (Mey and Thanos, 2000; 
Thanos and Mey, 2001).
Neuroepithelial development (primary neurogenesis) has 4 stages: proliferation of 
neuroblasts, followed by their vertical migration, the formation of processes and synapse 
formation and finally, programmed cell death and process pruning (Gilbert, 1997). The 
development of the chick retinotectal system will be described in more detail below.
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proliferating to form a laminated structure comprising the seven major retinal cell types 
(Sadler, 1995; Gilbert, 1997; Masland, 2004). Although the birthdates of retinal cell types 
overlap, retinal ganglion cells (RGCs) are among the first cells to be produced and migrate 
furthest, being followed by the cells of the more external retinal layers (Young, 1985; Prada 
et al., 1991; Hu and Easter, 1999). RGCs then elaborate axons that run along the vitreal 
basement membrane towards the optic cup. In the chick, the first RGC axons reach the 
tectum at E6. The RGC dendritic arbor develops about a week after the axon reaches the 
tectum in parallel with the differentiation of the cells of the inner nuclear layer.
The neural retina differs from other neural tissues in the pattern of PTPa isoforms 
it expresses. At all developmental stages, the long form of PTPa predominates in the retina 
in contrast to the shorter isoform that is more common in other neural tissues (Stoker, 
1994; Stoker et al., 1995b). Early in development, PTPa is expressed in the proliferative 
zone and widely in migrating neuroblasts in the mande zone or inner neuroblastic layer. 
However, as retinal lamination proceeds, it becomes apparent that PTPa expression is 
highest in post-mitotic neurons of the RGC and inner nuclear layers (INL). However, 
isoform specific studies indicate that initially, RGCs only express the short PTPa isoform. 
RGC expression of the longer isoform is upregulated after RGC axons reach the tectum. 
Although both isoforms are expressed in the developing INL, the short isoform is 
particularly strongly expressed in cells with the characteristics of amacrine cells. In the 
mature retina, a similar pattern of expression is seen, however the level of expression is 
lower (Stoker, 1994; Haj et al., 1999; Ledig et al., 1999b; Johnson and Holt, 2000; Sapieha 
et al., 2005). In early retinal development in contrast, PTPa protein is predominantly found 
in the layer of RGC axons adjacent to the developing vitreous. There is also some weak 
staining of processes that span the inner plexiform layer. As development proceeds, PTPa 
is also found in the area of the developing vitreal basement membrane and the staining of 
inner plexiform processes becomes more marked. In late development, PTPa protein levels 
may be reduced but show the same pattern of localisation (Stoker et al., 1995b; Ledig et al., 
1999b). Finally, RGC axons are not myelinated until late in development. The 
oligodendrocytes of the mature optic and other nerves express PTPa (McLean et al., 2002; 
Sapieha et al., 2005). In summary, PTPa protein is located on the axons of retinal cells as 
they extend processes to contact other neurons and changes in isoform expression are 
associated with the progress of neurite extension.
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with 15 histologically defined layers containing at least 20 cell types (Huber and Crosby, 
1933; Mey and Thanos, 2000). Briefly, the proliferating tectal neuroepithelium undergoes 2 
phases of neuroblast migration. The first wave of migrating cells produces the stratum 
griseum centrale (SGC) and the stratum griseumperiventriculare (SGP). The large SGC cells are 
the major tectal efferents. These cells elaborate axons that form the circumferentially 
running tectobulbar tract of the stratum album centrale (SAC) that runs over the SGC. The 
second wave of neuroblast migration occurs in parallel with the arrival of retinal axons at 
the anterior tectal pole. These cells migrate above the SAC and subsequently form the 
multilaminar stratum griseum et  fibrosum superficial (SGFS) region in such a way that RGC 
axons are never in direct contact with the SAC axon bundles. Unusually, this second wave 
of migration generates the deeper SGFS layers before the superficial SGFS layers, in the 
reverse manner to that seen in most other developing neuroepithelia. RGC axons do not 
immediately enter the tectum, but rather course along its surface to a topologically 
appropriate location. The arrival of new axons occurs in such a way that they always run on 
top of their predecessors such that growth cones remain in contact with the radial glia 
endfeet in the pial basement membrane. Almost a week after they arrived at the anterior 
tectum, the first RGC axons enter the tectum and pass into the SGFS layers to form 
defined terminal arbors of a predictable size and shape. Axons exhibit multiple course 
corrections and their trajectories and fasciculation becomes more refined with time.
Expression of PTPa in the chick optic tectum may be divided into two areas. The 
long isoform is expressed from the earliest stages in the ventricular zone whilst these cells 
are still proliferating. In contrast, the short isoform is expressed in differentiated 
neuroblasts as these appear and form the definitive cellular layers of the tectum (Stoker, 
1994; Haj et al., 1999). As in the retina, PTPa protein is predominantly found in fibre 
rather than cellular layers. In early development, before the RGC axons arrive, PTPa signal 
is prominent only in the presumptive tectobulbar tract that will later form the SAC. Later 
in development, PTPa is detectable in the more superficial plexiform SGFS layers, into 
which the RGC axons will migrate. As reported above, RGC axons express PTPa. PTPa 
maintains this pattern of expression albeit at a lower level in the mature tectum (Stoker et 
al., 1995b; Ledig et al., 1999b). In the tectum therefore, PTPa is expressed in the tectofugal 
fibre tracts and also in some of the areas targeted by ingrowing RGC axons.
The development of spinal motor neurons in the ventral horn of the chick lumbar 
spinal cord has been extensively reviewed elsewhere. Briefly, a combination of dorsoventral
35and regionalising signals specify the generation of motor neurons expressing members of 
the 1JM  (Linll-Isll-Mec3) homeodomain transcription family (Price and Briscoe, 2004).
In the chick, motor neurons are bom between Hamilton-Hamburger (HH) stage 15 and 
stage 23 having previously been specified with regard to their targets (Hollyday and 
Hamburger, 1977; Matise and Lance-Jones, 1996).
As in the tectum, in early spinal cord development, PTPa is expressed in the 
proliferating cells of the ventricular zone. As development proceeds, PTPa expression is 
extended to all the ventral hom motor neurons. In addition, a significant proportion of 
cells scattered through the spinal cord express the short isoform of PTPa at levels that are 
demonstrably lower than are those seen in proliferating ventricular zone cells or motor 
neurons. Isoform-specific studies confirmed that as in the tectum, proliferating ventricular 
zone cells express the long isoform of PTPa and the differentiating cells that elaborate long 
axons, in this case motor neurons, express the short form. In addition, PTPa is expressed 
on axons within the fibre tracts of the ventral commissure and the dorsal funiliculus (Sahin 
and Hockfield, 1993; Stoker, 1994; Stoker et al., 1995a; Chilton and Stoker, 2000).
In summary, PTPs are expressed in a wide range of developing tissues, particularly 
in the nervous system. In the adult brain, PTPa is restricted to areas that exhibit ongoing 
neurogenesis or plasticity. In addition, the expression of particular isoforms is 
developmentally regulated such that the large and short PTPa isoforms are associated with 
proliferating and differentiating cells respectively. Finally, it is intriguing that PTPa is often 
expressed both on growth cones and on their targets. For instance, PTPa is expressed on 
RGC and motor neuron axons and in their targets, the optic tectum and muscle 
respectively (Stoker, 1994; Stoker et al., 1995b; Schaapveld et al., 1998; Ledig et al., 1999b; 
Chilton and Stoker, 2000; Johnson and Holt, 2000). This mimics the pattern of DLAR 
expression on Drosophila photoreceptor axons and motor axons and on their targets, the 
optic lobe lamina and medulla and peripheral muscle (Clandinin et al., 2001; Fox and Zinn,
2005)  and may therefore represent a common feature of type Ila RPTP function.
1.2.2: Functional studies of type Ila RPTPs
The expression pattern of PTPa in the developing and adult brain strongly suggests 
that continued expression of the short PTPa isoform in the adult brain is limited to regions 
known to exhibit significant plasticity or in the case of the olfactory neuroepithelium, 
ongoing proliferation. In addition, the domain structure of PTPa is reminiscent of many
36cell adhesion and axon guidance molecules. Axon guidance is mediated by a combination 
of multiple partially redundant long- and short-range guidance cues, which act at a large 
number of axon guidance choice points. These cues affect the rate or direction of growth 
cone migration and the formation or separation of axon fascicles by individual growth 
cones (Tessier-Lavigne and Goodman, 1996; Desai et al., 1996). PTPa is a transmembrane 
protein that undergoes ectodomain shedding and so is well suited to acting as a contact or 
diffusible axon guidance molecule. Studies have shown that tyrosine phosphorylation plays 
an important role in the developmental migration of axon growth cones to their 
appropriate targets and the targeted regeneration of severed axons (Desai et al., 1997b). 
Furthermore, immunological studies confirmed that PTPa protein is indeed expressed in 
migrating axon growth cones like type Ila RPTPs in other species (Stoker et al., 1995a; 
Biswas et al., 2002). Studies in Drosophila have confirmed that RPTPs including the type Ila 
RPTP DLAR are involved in the guidance of photoreceptor (Garrity et al., 1999; Newsome 
et al., 2000a; Maurel-Zaffran et al., 2001; Clandinin et al., 2001), motor neuron (Desai et al., 
1996; Krueger et al., 1996; Desai et al., 1997a; Sun et al., 2001; Schindelholz et al., 2001) 
and commissural axon growth cones (Sun et al., 2000a). These studies have described a 
range of axon guidance phenotypes including stall, parallel bypass and fusion bypass and 
have shown that individual RPTPs can act together or in opposition at specific choice 
points in the path of a growing axon (Desai et al., 1997a; Sun et al., 2001). Similarly, type 
Ila RPTPs are involved in axon guidance, neuroblast migration and the formation of an 
orchestrated pattern of parallel neurite processes through mutual repulsion and sibling 
avoidance in the roundworm, C.elegans, and the medicinal leech, Hirudo medicinalis (Gershon 
et al., 1998a; Gershon et al., 1998b; Baker and Macagno, 2000a; Baker et al., 2000b; Baker 
and Macagno, 2000b; Harrington et al., 2002; Chin-Sang et al., 2002b; Chang et al., 2004; 
Ackley et al., 2005). However, a number of questions remain concerning RPTP function in 
axon guidance. It is unclear why when many of these proteins are expressed on the 
majority of axons, only a subset of axons are affected in mutants. Similarly, it is unclear 
whether the RPTPs act primarily as ligands or receptors and whether the phosphatase 
activity of these proteins is essential for their function. Finally, it is not certain whether 
these proteins affect axon guidance through effects on the rate of neurite outgrowth, 
growth cone direction or fasciculation.
Mice in which the PTPa locus has been targeted and disrupted by insertion of a 
recombinant cassette (PTPa knockouts) exhibit significant perinatal mortality and 
abnormalities in physical and behavioural development (Elchebly et al., 1999; Wallace et al.,
371999). However, there was phenotypic variability between the two PTPa knockout lines 
and many of the developmental abnormalities appeared to correct with age if pups were 
supported through the neonatal period (Elchebly et al., 1999; Wallace et al., 1999; Batt et 
al., 2002; Meathrel et al., 2002). It was elegantly demonstrated that neonatal survival could 
be drastically improved with neonatal growth hormone (GH) supplementation of PTPa -/- 
pups (Batt et al., 2002). As expected given the correction of many aspects of the PTPa -/- 
phenotype with age, GH supplementation also reverses several of the histopathological 
features of the PTPa -/- phenotype including the abnormalities of the pituitary and 
endocrine pancreas (Batt et al., 2002). It is unclear whether other aspects of the PTPa 
phenotype respond to GH supplementation in this way. In summary, it appears that the 
phenotype of the PTPa -/- mice reflects developmental delays in several important 
structures including the pituitary and endocrine pancreas. However, although the two 
PTPa knockout lines have similar phenotypes, there are significant differences between 
them. The remaining type IIA RPTPs have been disrupted in a similar way (Skames et al., 
1995; Schaapveld et al., 1997; Uetani et al., 2000). Unfortunately, there is evidence that 
these lines can express residual forms of the disrupted gene (Yeo et al., 1997; Yang et al., 
2003). It may be noted that the approach used to generate the Elchebly line would suggest 
that residual PTPa activity would most likely be in the form of extracellular domain 
protein. In contrast, the targeting strategy adopted to create the Wallace line implies that 
residual PTPa activity would be in the form of catalytic domain protein. These differences 
may account for discrepancies in the phenotypes of the two PTPa knockout mice as may 
differences in the genetic background of the two lines.
All three type Ila RPTPs have been disrupted using gene targeting approaches 
(Skames et al., 1995; Schaapveld et al., 1997; Elchebly et al., 1999; Wallace et al., 1999; 
Uetani et al., 2000). Although each type Ila RPTP knockout has a distinct phenotype, there 
are suggestions from their phenotypes that in some tissues, these genes may play similar 
roles and in others that they may counteract each other. Like PTPa -/- mice, LAR -/- mice 
display abnormal peripheral nerve regeneration (Johnson et al., 2001; McLean et al., 2002; 
Thompson et al., 2003; Lorber et al., 2004; Lorber et al., 2005; Sapieha et al., 2005; 
Kirkham et al., 2006). In addition, LAR -/- mice exhibit abnormalities in the development 
of lactation and also alterations in septohippocampal innervation that are associated with 
impaired spatial learning (Schaapveld et al., 1997; Yeo et al., 1997; Van Lieshout et al.,
2001). Like PTPa -/- mice, PTPS -/- mice show growth retardation and increased neonatal 
mortality. The increased neonatal mortality seen in the PTPS -/- pups is due to delays in
38neuromuscular maturation. However, like LAR -/- mice PTPS -/- also exhibit impaired 
hippocampal long term potentiation (LTP), which is associated with impaired spatial 
learning in these animals (Uetani et al., 2000). The expression pattern of PTPa and PTPS 
overlap in many areas, whereas the expression pattern of LAR is more often reciprocal to 
that ofPTPS/o. In particular, PTPa and PTPS are both highly expressed in the developing 
nervous system whereas LAR is only expressed at low levels in this area (Yan et al., 1993; 
Mizuno et al., 1993; Longo et al., 1993; Rotin et al., 1994; Katsura et al., 1995; Sommer et 
al., 1997; Schaapveld et al., 1998). In addition, RNA interference studies suggested that 
PTPa and PTPS have overlapping functions in the guidance of specific motor axons and 
synaptogenesis (Dunah et al., 2005; Stepanek et al., 2005). Therefore, PTPa and PTPS -/- 
mice were intercrossed to determine whether PTPa and PTPS exhibit a degree of 
functional redundancy during nervous system development. The most striking findings in 
double mutant mice (PTPa -/-; PTPS -/-) are significant abnormalities in phrenic nerve 
development (Uetani et al., 2006). It is unclear at this stage whether this phenotype reflects 
a primary neuronal or muscular defect. Double mutant motor neurons extend to the 
periphery normally but then retract having failed to interact appropriately with their muscle 
target. Motor neurons are then lost, probably due to a lack of peripheral target-derived 
trophic support (Sendtner et al., 2000). A similar final phenotype is seen with DLAR, 
DPTP69D or N-cadherin mutant photoreceptors which terminate early in the R8 layer of 
the optic lobe lamina (Newsome et al., 2000a; Maurel-Zaffran et al., 2001; Clandinin et al., 
2001; Lee et al., 2001). However, the double mutant phenotype is also associated with 
impaired myotube development, which may alternatively imply that the double mutant 
phenotype reflects a primary muscle defect. Indeed, PTPa and PTPS are both expressed in 
muscle (Schaapveld et al., 1998; Sajnani-Perez et al., 2003). In addition several mice, which 
are deficient in molecules that have been implicated in PTPa function have significant 
muscle phenotypes (Debant et al., 1996; Gautam et al., 1996; Bateman et al., 2000; O'Brien 
et al., 2000).
In addition to its role in neural development, PTPa -/- animals revealed a 
continuing role for PTPa in mature neurons. Nerve injury and culture models show that 
the rate of neurite outgrowth is increased from PTPa -/- neurons when compared to wild 
type neurons and that this is associated with more rapid functional recovery (McLean et al., 
2002; Thompson et al., 2003; Sapieha et al., 2005; Kirkham et al., 2006). These studies 
suggest that PTPa functions to reduce the rate of axon extension from wild type cells. 
Moreover, overexpression of a putative dominant negative PTPa protein in cultured RGCs
39increases neurite outgrowth (Johnson et al., 2001). However, although PTPa-/- axons 
regenerate more quickly, they also exhibit more pathfinding errors (McLean et al., 2002). 
This may reflect a role for the regulation of growth cone velocity in the correct 
interpretation of axon guidance cues. However, it is unclear whether PTPa acts as a general 
inhibitor to neurite outgrowth or whether it interprets inhibitory gradients of other 
molecules. Interestingly, early findings suggested that PTPa mRNA is increased after nerve 
injury. This would be compatible with PTPa playing an important role in the regeneration 
of accurate connections. More recent studies have failed to show any change in PTPa 
protein levels (Haworth et al., 1998; Thompson et al., 2003; Sapieha et al., 2005). However 
these protein studies compared PTPa levels in the cell body, and so it remains possible that 
after nerve injury PTPa protein is upregulated on the axon and growth cones of the 
regenerating cells. Indeed, the related RPTP LAR enhances neurite initiation and is 
increased after nerve injury and factors that increase the rate of recovery are associated 
with reduced LAR levels (Lorber et al., 2004; Lorber et al., 2005).
Several studies have interfered with PTPa-ligand interactions. In the intact 
retinotectal projection overexpression of a VSV-tagged PTPa extracellular domain protein 
produced significant pathfinding errors (Rashid-Doubell et al., 2002). This protein was 
expressed in a mosaic fashion in the tectum where it bound to the tectal outer limiting 
basement membrane, which forms the substrate for ingrowing RGC axons, potentially 
blocking PTPa ligands that are located in this region (Haj et al., 1999; Mey and Thanos,
2000). The abnormal axons predominantly fail to reach their correct location suggesting 
that the PTPa-ligand interaction supports RGC axon extension. Similarly, perturbing the 
interaction of PTPa with basement membrane heparin sulphate ligands reduces neurite 
outgrowth in culture (Ledig et al., 1999a; Mueller et al., 2000). In contrast, it has been 
suggested that PTP8-ligand interactions might reduce neurite outgrowth (Johnson et al.,
2001). However, it is unclear what the effect on PTP phosphatase activity as distinct from 
“PTP function” is in each case. The DLAR ligands, syndecan (Sdc) and dally-like protein 
(Dip) act antagonistically to regulate the activity of DLAR in synaptogenesis but not axon 
guidance (Fox and Zinn, 2005; Rawson et al., 2005). However, a unifying hypothesis does 
not require two kinds of antagonistic ligand-mediated effect but rather one ligand, whose 
binding alters PTPa activity and others that compete with the functional ligand for a shared 
PTP binding site but which have no effect on PTPa activity themselves. Given the high 
basal activity of PTPs and the dominance of the inhibitory Dip over Sdc, it is most likely 
that PTPa catalytic activity is inhibited by binding of specific ligands and that other ligands
40compete for PTPa binding but do not affect PTP activity. It is unclear what effect the 
PTPa ligands, agrin, collagen 18 or nucleolin have on PTPa catalytic activity (Aricescu et 
al., 2002; Sajnani-Perez et al., 2003; Alete et al., 2006). However, overexpression of 
catalytically inactive PTPa has a similar phenotype to perturbation of the basement 
membrane heparin sulphate ligand-PTPa interaction (Johnson et al., 2001; Rashid-Doubell 
et al., 2002). Therefore, it can be suggested that this ligand inhibits PTPa catalytic activity.
In addition to acting as a receptor for a variety of extracellular cues, PTPa may also 
have some ligand-like activity. This might explain why some type II RPTP functions 
require the presence and activity of the tyrosine phosphatase domains whereas others only 
require extracellular domain expression (Maurel-Zaffran et al., 2001; Mario and Desai, 
2006). Studies on the Drosophila type Ila RPTP, DLAR, have revealed that it functions in 
both a cell autonomous and non-cell autonomous manner during axon guidance, actin 
polarisation and oskar localisation (Maurel-Zaffran et al., 2001; Bateman et al., 2001; 
Frydman and Spradling, 2001; Krueger et al., 2003). Several approaches have suggested that 
this type of signalling has been retained by vertebrate type II RPTPs (Wang and Bixby, 
1999; Drosopoulos et al., 1999; Sun et al., 2000b). Normal axon regeneration after nerve 
injury requires PTPa expression by the nerve and the nerve sheath down which it 
regenerates. However, regeneration occurs faster in the absence of PTPa (McLean et al.,
2002). Although PTPa inhibits axon regeneration, the ectodomains of type II RPTPs 
support neurite outgrowth (Wang and Bixby, 1999; Drosopoulos et al., 1999; Sun et al., 
2000b; Yang et al., 2003; Sajnani et al., 2005; Yang et al., 2005). It is unclear whether the 
non-cell autonomous effects of type Ila RPTPs reflect authentic reverse or bidirectional 
signalling as described for the Eph/Ephrin and the PTP^-contactin interactions, or a 
ligand-like activity of the shed RPTP ectodomain on an as-yet undescribed receptor (Peles 
et al., 1995; Holland et al., 1996; Mellitzer et al., 2000). Moreover, it has not been 
determined whether the receptor for the non-cell autonomous effects of PTPa is an 
isoform of PTPa itself as appears to be the case for other type Ila RPTPs (Baker et al., 
2000b; Yang et al., 2003; Yang et al., 2005). However, PTPa -/- axons exhibit path-finding 
defects that are ameliorated by PTPa expression in wild type nerve sheaths, suggesting that 
another receptor may mediate the non-cell autonomous effects of PTPa in this system.
1.2.3: Interactions of type Ila RPTPs
Finally, a number of studies have attempted to identify the pathways with which 
PTPa and related RPTPs interact in order to bring about the cellular functions described
41above. A limited number of these studies have looked at PTPa direcdy. However, it is 
likely that inferences can be made based on the findings of studies that examined PTPS, 
LAR or invertebrate type Ila RPTPs. To date, only one type Ila RPTP signalling cascade 
has been described in detail. Binding of the soluble IAR FN5C isoform to LAR on target 
cells can promote neurite outgrowth (Yang et al., 2003). This is associated with 
transactivation of the cell surface receptor TrkB. Therefore, the effects of IAR FN5C 
binding are augmented by neurotrophin administration. TrkB transactivation is likely to 
account for the subsequent activation of phospholipase-Cy and phosphoinositide-3-kinase, 
which in turn activate protein kinase C and B, respectively. Focal adhesion kinase (FAK) is 
also activated, coupling LAR-induced neurite outgrowth to the regulation of cell-cell 
adhesion by integrins. Interestingly, FAK may be direcdy activated by the LAR-interacting 
protein, TRIO (Medley et al., 2003). Src is also activated in LAR FN5C-induced neurite 
outgrowth potentially by direct dephosphorylation of the inhibitory Y509 tyrosine residue 
by LAR (Tsujikawa et al., 2002). Finally, LAR FN5C binding is likely to induce 
transcriptional changes since mitogen activated protein (MAP) kinase and cyclic AMP 
response element binding protein (CREB) pathways are activated by LAR FN5C binding 
(Krauss, 2001; Yang et al., 2005). Lower resolution studies have revealed that type Ila 
RPTPs interact with a wide variety of cell signalling systems. These relationships include 
interactions with canonical axon guidance molecules, cytoplasmic and receptor tyrosine 
kinases, and with the cytoskeleton through interactions with Rac-family GTPases via 
proteins such as TRIO and through direct interactions with cell adhesion molecules. 
Finally, a novel family of proteins, the liprins, were first characterised through their 
interaction with type Ila RPTPs.
1.2.3.1: Classical axon guidance molecules
Whilst PTPa has not been direcdy linked to any of the classical axon guidance
molecules, the related RPTPs CLR-1, PTPA, DPTP10D DPTP69D and PTPRO have
been linked to the ephrin, netrin and slit axon guidance pathways (Tessier-Lavigne and
Goodman, 1996; Sun et al., 2000a; Yu and Bargmann, 2001; Harrington et al., 2002;
Dickson, 2002; Chin-Sang et al., 2002c; Huber et al., 2003; Chang et al., 2004; Chilton,
2006; Shintani et al., 2006). PTPRO may function in axon guidance through competition
with PTPa and PTP8, which potentially places these RPTPs in an Eph related pathway
(Stepanek et al., 2005). Although RPTPs have not yet been shown to interact with
semaphorins in axon guidance, CD45 interacts with the immune cell semaphorin, CD100
(Elhabazi et al., 2003). It has not yet proven possible to delineate the level at which PTPs
42act in these pathways, although they may function to regulate the sensitivity of pathways to 
ligand binding or to allow the specific ativation of some receptor stimulated behaviours and 
not others (Haugh et al., 2004; Chang et al., 2004; Shintani et al., 2006). Alternatively, in 
some systems, RPTP regulated pathways act in parallel to these well described pathways 
(Dalpe et al., 2005).
1.2.3.2: Receptor and cytoplasmic tyrosine kinase pathways
RPTPs modulate growth factor signalling in response to several stimuli (Kulas et 
al., 1995; Li et al., 1996; Kulas et al., 1996; Phung et al., 1997; Mooney et al., 1997; Kokel et 
al., 1998; Suarez et al., 1999; Wang et al., 2000; Graness et al., 2000; Qiao et al., 2001; Xu et 
al., 2005; Machide et al., 2006). It has been proposed that a major function of PTPs might 
be to set the threshold and gain of phosphotyrosine signalling, controlling the response of 
signalling pathways to activation by different amounts of ligand or in different cellular 
environments (Weiss et al., 1997; Weng et al., 1998; Weng et al., 1999; Tisi et al., 2000; Lei 
et al., 2002). There is evidence in the case of LAR, that excessive PTP-mediated inhibition 
of receptor signalling may be of clinical relevance, causing insulin resistance (Ahmad et al., 
1995; Ahmad et al., 1997; Ahmad and Goldstein, 1997; Ren et al., 1998; Cheung et al.,
2000; Zabolotny et al., 2001; Tagami et al., 2002; Frederiksen et al., 2003; Miscio et al., 
2004; Mander et al., 2005). PTPs may mediate these effects in a number of ways including 
dephosphorylation of the RTK tyrosine residues required for full activation or recruitment 
of downstream effectors or by dephophosphorylation of key components of signalling 
cascades downstream of receptor activation (Wang et al., 2000; Cheung et al., 2000; 
Zabolotny et al., 2001; Mander et al., 2005; Machide et al., 2006). Finally, RPTPs can have 
effects on the dimerisation of receptor tyrosine kinases presumably by forming 
heterodimers with kinase proteins (Qiao et al., 2001).
Many ligand regulated cell-signalling pathways do not contain a receptor tyrosine 
kinase but mediate their effects through activation of cytoplasmic tyrosine kinases such as 
Src, Abl, Lck and Fyn. The interaction of cytoplasmic tyrosine kinases with RPTPs 
including RPTPa and CD45 is well described (Zheng et al., 1992; den Hertog et al., 1993; 
Bhandari et al., 1998; Ponniah et al., 1999; Su et al., 1999; Zheng et al., 2000; Brandt et al., 
2003; Pallen, 2003; Shrivastava et al., 2004; Maksumova et al., 2005). So far, there is less 
evidence for direct interactions of vertebrate type Ila RPTPs with cytoplasmic tyrosine 
kinases (Tsujikawa et al., 2002). However, the Ableson (Abl) cytoplasmic tyrosine kinase 
and DLAR counteract each other in Drosophila motor neuron axon guidance possibly
43through the regulation of the F-actin assembly dynamics (Kaufmann et al., 1998; Wills et 
al., 1999a; Wills et al., 1999b; Witke, 2004). Ena regulates actin polymerisation, promoting 
lamellipodial protrusion  and is potentially both a LAR and Abl substrate, it is tempting to 
speculate that this is mediated by Abl and DLAR having direcdy opposing effects at a 
single site (Comer et al., 1998; Wills et al., 1999a; Biswas et al., 2002; Sutherland and Way, 
2002; Bear et al., 2002; Krause et al., 2003; Gitai et al., 2003). The functional significance of 
Ena phosphorylation is uncertain, although it may affect its interactions with other proteins 
resulting in reduced Ena activity and increased actin branching (Kaufmann et al., 1998; 
Comer et al., 1998; Sutherland and Way, 2002; Krause et al., 2003). In some systems, it 
appears as though DPTP69D may play a similar and DPTP99A an opposing role (Desai et 
al., 1997a; Wills et al., 1999a).
1.2.3.3: TRIO proteins and the Rxis-related small GTPase family
Changes in the actin cytoskeleton are an integral part of neurite outgrowth and 
axon guidance. Actin-based cell motility is regulated in part by small Ras-related GTPases, 
including Rac, RhoA and cdc42 (Hall, 1993; Nobes and Hall, 1995; Luo et al., 1997; 
Etienne-Manneville and Hall, 2002; Jaffe and Hall, 2005; Hall, 2005). Ras family GTPases 
have intrinsic GTPase activity and cycling between the active GTP-bound form and the 
inactive GDP bound form is regulated by guanine nucleotide exchange factors (GEFs) and 
GTPase activating proteins (GAPs) (Quilliam et al., 1995; Rossman et al., 2005). A link 
between type Ila RPTPs and Ras-family GTPases is suggested by the similar phenotypes 
that are seen following disruption of the actin cytoskeleton and in DLAR or Ras-family 
GTPase mutants (Kaufmann et al., 1998). In addition, DLAR mutations interact with Racl 
mutations and PTPS interacts with the actin-binding protein, MIM-B (Bateman et al., 2001; 
Woodings et al., 2003). TRIO was first identified as a LAR D2-interacting protein and is 
the archetypal member of a large protein family that includes TRIO-homologues in 
Drosophila (DTRIO) and C.elegans (UNC-73) as well as paralogues including the kalirins 
(Debant et al., 1996; Alam et al., 1996; Alam et al., 1997; Steven et al., 1998; Kawai et al., 
1999; Ratovitski et al., 1999; Bateman et al., 2000; Awasaki et al., 2000; Liebl et al., 2000; 
Newsome et al., 2000b; Bateman and Van Vactor, 2001; Alam et al., 2001; Daggett et al., 
2004; Tse et al, 2005).
TRIO contains four spectrin-like repeats, two guanine nucleotide exchange factor 
(GEF) domains (Dbl-homology (Diffuse B-cell lymphoma oncogene product; DH)-type), 
two SH3 domains, two Ig domains and a serine-threonine kinase domains (Debant et al.,
441996). UNC-73 and DTRIO differ in structure from TRIO, most significantly lacking the 
LAR interacting domain although the significance of these differences is unclear as DLAR 
and DTRIO still interact at a genetic level (Debant et al., 1996; Bateman et al., 2000; 
Awasaki et al., 2000; Liebl et al., 2000; Newsome et al., 2000b; Maurel-Zaffran et al., 2001). 
The function of the non-GEF domains remains unclear although the Ig domains may 
function to bind and position GTPases and the serine-threonine kinase domain may 
autophosphorylate TRIO, which may regulate TRIO function (Kawai et al., 1999; Medley 
et al., 2000; Penzes et al., 2003). In addition, TRIO has the ability to activate downstream 
signalling proteins directly without a requirement for GEF activity (Bellanger et al., 2000; 
Seipel et al., 2001). Alternatively spliced isoforms may also play a role in the regulation of 
TRIO family members, as exemplified by isoforms of kalirin (Mains et al., 1999; Penzes et 
al., 2001; Estrach et al., 2002; May et al., 2002; Xin et al., 2004; Chakrabarti et al., 2005; 
Rabiner et al., 2005; Steven et al., 2005; McPherson et al., 2005; Portales-Casamar et al.,
2006).
DH domains such as those found in TRIO preferentially bind specific members of 
the Ras GTPase superfamily. In general, Racl activation leads to lamellipodia formation 
and RhoA activation to growth cone retraction (Luo et al., 1997). It is not clear whether 
TRIO function requires the activity of both GEF domains (Steven et al., 1998; Bateman et 
al., 2000; Awasaki et al., 2000; Newsome et al., 2000b; Spencer et al., 2001; Hakeda-Suzuki 
et al., 2002). However, both the isolated amino-terminal TRIO GEF domain (GEF1) and 
GEF2 are catalytically active, GEF1 activating the Mig2 or Mig-2-like (Mti) GTPase and 
RhoG/Racl with subsequent RhoG-dependent activation of Racl and cdc42hs whereas 
GEF2 activates RhoA (Debant et al., 1996; Zipkin et al., 1997; Bellanger et al., 1998; 
Gauthier-Rouviere et al., 1998; Blangy et al., 2000; Honigberg and Kenyon, 2000;
Newsome et al., 2000b; Wu et al., 2002; Kishore and Sundaram, 2002; Struckhoff and 
Lundquist, 2003; Dalpe et al., 2005). Thus, TRIO is ideally situated to function as a key 
regulator of GTPase activity in specific developmental processes including a subset of axon 
guidance decisions (Wu et al., 2002).
The function of TRIO proteins is unknown. Their multi-domain structure suggests 
a role as scaffolding proteins. This suggestion is supported by the severity and widespread 
nature of the defects seen in TRIO mutants, particularly UNC-73 mutants, which suggest 
that TRIO is not part of a single pathway but rather a focal point linking several pathways 
to the Ras GTPase activation (Bateman and Van Vactor, 2001). These might include PAK, 
Abl, Ena, reactive oxygen species (ROS) production and signalling and the netrin, robo,
45integrin and semaphorin signalling pathways (Bashaw and Goodman, 1999; Wills et al., 
1999b; Liebl et al., 2000; Bashaw et al., 2000; Newsome et al., 2000b; Sigal et al., 2003; 
deBakker et al., 2004; Forsthoefel et al., 2005; Schiller et al., 2005; Mizrahi et al., 2005; 
Henson, 2005; Lee et al., 2005; Dalpe et al., 2005).
Animals lacking TRIO have significant abnormalities in the development of the 
nervous system and also in secondary myogenesis, a phenotype that bears comparison with 
that of PTPo/PTPS double mutants (O'Brien et al., 2000; Uetani et al., 2006). Mutations in 
the C.elegans TRIO homologue, UNC-73, produce an uncoordinated phenotype and exhibit 
a number of abnormalities in axon guidance (Hedgecock et al., 1987; Desai et al., 1988; 
Siddiqui, 1990; Siddiqui and Culotti, 1991; Mclntire et al., 1992; Wightman et al., 1997; 
Morck et al., 2003), cell migration (Hedgecock et al., 1987; Desai et al., 1988; Chen et al.,
1997)  and asymmetric cell division (Way et al., 1992), this last possibly through an effect on 
cell polarisation (Run et al., 1996; Honigberg and Kenyon, 2000; Kishore and Sundaram,
2002). DTRIO mutations result in defects in wing development, dorsal closure and axon 
guidance abnormalities (Bateman et al., 2000; Awasaki et al., 2000; Liebl et al., 2000; 
Newsome et al., 2000b). The role of DTRIO in the adult mushroom body organs may be 
related to the adult expression of PTPa and PTPS in the adult vertebrate hippocampus and 
cerebellum (1.2.1.2). Finally, although DTRIO has only been shown to interact with 
DLAR, the photoreceptor phenotype of the DTRIO mutant resembles that of DPTP69D 
mutants, suggesting that DTRIO may interact with other type Ila RPTPs (Garrity et al., 
1999).
1.2.3.4: Cell adhesion molecules
The role of PTPs in cell-cell and cell-matrix adhesion has recently been reviewed 
(Burridge et al., 2006; Sallee et al., 2006). In particular, type II RPTPs interact with cell 
adhesion molecules including integrins, cadherins and catenins (Matsunaga et al., 1988; 
Bixby and Zhang, 1990; Riehl et al., 1996; Stone and Sakaguchi, 1996; Aicher et al., 1997; 
Bateman et al., 2001). DLAR and the P-catenin/N-cadherin system cooperate in axon 
guidance, opposing Abl function (Iwai et al., 1997; Loureiro and Peifer, 1998; Wills et al., 
1999a; Maurel-Zaffran et al., 2001; Clandinin et al., 2001; Lee et al., 2001). However, type 
Ila RPTP-cadherin interactions are poorly understood. In contrast, type lib RPTPs 
regulate signalling pathways downstream of cadherins that include PKC8 and cdc42 
(Brady-Kalnay et al., 1998; Burden-Gulley and Brady-Kalnay, 1999; Mourton et al., 2001; 
Rosdahl et al., 2002; Rosdahl et al., 2003; Ensslen and Brady-Kalnay, 2004). PTPp controls
46cdc42 via IQGAP1, which may play a similar role in PTPp function to that occupied by the 
Ras-family GEF, TRIO, in type Ila RPTP function (Phillips-Mason et al., 2006). In 
addition, RPTP/cadherin interactions affect RPTP function, probably through effects on 
the sub-cellular distribution or expression level of (3-catenin/Armadillo, which is a potential 
type II RPTP substrate (Brady-Kalnay et al., 1995; Kypta et al., 1996; Fuchs et al., 1996; 
Burden-Gulley and Brady-Kalnay, 1999; Muller et al., 1999; Symons et al., 2002; 
Chattopadhyay et al., 2003; Lilien and Balsamo, 2005; Brembeck et al., 2006). Type II 
RPTPs may also affect the nuclear functions of (Tcatenin (Anders et al., 2006).
1.2.3.5: PAK-interactingprotein. 1  (LIP. 1)-relatedproteins (Uprins)
The Liprin family consists of a- and (Tliprins, which are characterised by amino-
terminal coiled-coil, which mediate protein-protein interactions including subtype-specific
homodimerisation (i.e. a-Hprin:a-Hprin/(THprin:(Tliprin), and carboxyl-terminal sterile a
motif (SAM) domains, which mediate subtype specific heterodimerisation (i,e, a-liprin/(3-
liprin) and the a-liprin-type IIA RPTP (LAR) interaction (Serra-Pages et al., 1995; Pulido et
al., 1995b; Serra-Pages et al., 1998; Wyszynski et al., 2002; Kriajevska et al., 2002; Schoch et
al., 2002; Shin et al., 2003; Ko et al., 2003b; Hofmeyer et al., 2006). Dominant negative
liprin splice variants affect liprin interactions and liprin activity may be regulated by
ubiquitination or phosphorylation (Serra-Pages et al., 1995; Wyszynski et al., 2002;
Kriajevska et al., 2002; Im et al., 2003; van Roessel et al., 2004; Teng and Tang, 2005;
Hofmeyer et al., 2006). Phosphorylation is particularly intriguing because liprin
phosphorylation affects its interaction with type Ila RPTPs and the major source of liprin
phosphorylation might be an intrinsic serine kinase activity of the liprin proteins
themselves (Serra-Pages et al., 2005). The function and regulation of liprins remains poorly
understood although they appear to act as scaffolding or adaptor proteins (Wyszynski et al.,
2002; Schoch et al., 2002; Wang et al., 2002b; Shin et al., 2003; Kim et al., 2003; Ko et al.,
2003a; Ko et al., 2003b; Olsen et al., 2005). Moreover, the LAR/liprin interaction
represents only a small part of liprin function, which includes roles in axon guidance,
synaptic zone assembly, and other aspects of neurotransmission (Desai et al., 1996;
Krueger et al., 1996; Kaufmann et al., 1998; Garrity et al., 1999; Zhen and Jin, 1999; Wills
et al., 1999a; Newsome et al., 2000a; Maurel-Zaffran et al., 2001; Clandinin et al., 2001;
Bateman et al., 2001; Frydman and Spradling, 2001; Lee et al., 2001; Wyszynski et al., 2002;
Kaufmann et al., 2002; Ackley et al., 2005; Choe et al., 2006; Hofmeyer et al., 2006).
Therefore, the significance of the LAR/liprin interaction is unclear (Baran and Jin, 2002). It
was suggested that liprins might function to localise LAR proteins however, liprins, LAR,
47and potential LAR ligands function cooperatively to determine their mutual localisation 
(Serra-Pages et al., 1995; Serra-Pages et al., 1998; Ackley et al., 2003; Ko et al., 2003a; Ko et 
al., 2003b; Ackley et al., 2005; Hofmeyer et al., 2006). A single explanation reconciling the 
many effects of liprin proteins might be found in the involvement of liprins in anterograde 
transport. It has been suggested that liprins might act as kinesin cargo receptors for a 
number of protein complexes (Ahmari et al., 2000; Shin et al., 2003; Miller et al., 2005; 
Olsen et al., 2005). Such cargoes are not passively freighted but synergise with their cargo 
receptor and other cargoes to derive an appropriate sub-cellular localisation, as is seen in 
the LAR-liprin system (Setou et al., 2002; Dunah et al., 2005).
1.3: RPTP regulation
It was apparent from the discovery of tyrosine kinases that a system must exist to 
dephosphorylate their substrates. However for technical and philosophical reasons it took 
almost ten years after the identification of the first tyrosine kinase before the first tyrosine 
phosphatase was identified and sequenced (Hunter and Sefton, 1980; Tonks et al., 1988; 
Tonks and Neel, 2001). With the exception of catalytically inactive tyrosine phosphatases 
(Wishart et al., 1995; Wishart and Dixon, 1998) and those PTPs that act on substrates other 
than tyrosine phosphate (Martins and Shuman, 2002; Ohta et al., 2003; Laporte et al., 2003; 
Koreth and van den Heuvel S., 2005), the principle function of PTPs may be assumed to 
be to counteract the activity of tyrosine kinases. It is clear that tyrosine dephosphorylation 
can have both positive and negative effects on cell signalling, dependent on the effects of 
individual tyrosine phosphorylation events on protein function, and that many tyrosine 
phosphatases are well equipped to function in signalling cascades independently of tyrosine 
kinases (Marx, 1991).
The regulation of tyrosine phosphatase activity remains unclear and this thesis 
includes experiments designed to improve our understanding of this area. In principle, it 
must he somewhere between two extremes. Firstly, a small number of constitutively active, 
broad specificity enzymes might act to mop up any unprotected tyrosine phosphate 
residues, thereby rapidly terminating any tyrosine kinase activity that is not prolonged or 
supported in some way. Such a model would be suggested by the high basal activity level of 
tyrosine phosphatases (Streuli et al., 1989; Guan et al., 1990), their broad substrate 
specificity in vitro (Zhang, 2002), the ability of related PTPs to compensate for the 
disruption of individual PTPs (Sun et al., 2000a; Schindelholz et al., 2001; Stepanek et al., 
2005; Uetani et al., 2006) and the extremely low level of tyrosine phosphate seen in cells
48(Hunter and Sefton, 1980). Whilst enzymes that require activation (i.e. tyrosine kinases) can 
be maintained in the same cellular environment as their substrates, it is likely that highly 
active enzymes (i.e. tyrosine phosphatases) must be kept separate from their substrates until 
their activity is needed. Therefore tyrosine phosphatase activity might require regulatory 
factors to colocalise enzyme and substrate as is seen with the serine/threonine 
phosphatases (Faux and Scott, 1996a; Faux and Scott, 1996b). Alternatively, a larger 
number of enzymes might be activated to dephosphorylate individual tyrosine phosphate 
residues in a specific manner. This would be similar to the regulation of tyrosine kinases. 
Indeed, the number of tyrosine phosphatases (107) in the human genome is similar to that 
of tyrosine kinases( 90), suggesting that there may be a phosphatase for every kinase 
although the substrate profile of individual tyrosine phosphatases and kinases do not 
appear to match exactly (Manning et al., 2002; Alonso et al., 2004). Such a model would 
require tyrosine phosphatases to exhibit significant substrate specificity, at least in vivo. 
Despite their lack of specificity in vitro^ PTPs do appear to exhibit some degree of substrate 
specificity in living cells (Sarmiento et al., 2000; Zhang, 2002; Vetter and Zhang, 2002). It 
may be that the various classes of tyrosine phosphatase are regulated and function in 
different ways.
The function of RPTPs is made more complex than that of their cytoplasmic 
cousins by their ability to directly sense and respond to extracellular cues. As described 
elsewhere, RPTPs may function in a number of ways (Johnson and Van Vactor, 2003). 
Some RPTPs may not possess functional ligands in the classical sense —  soluble or 
transmembrane proteins that bind to the receptor and alter its activity. Instead, the RPTP 
extracellular domains may function to control their inclusion in higher order protein 
complexes. Alternatively, RPTPs may have cognate ligands that affect tyrosine phosphatase 
activity (increase or decrease). It may not be reasonable to propose a single regulatory 
schema for all RPTPs.
The functional activity of RPTPs is likely to be regulated in two ways: firstly, at the 
level of the specific activity of the tyrosine phosphatase enzyme and secondly by altering 
the relative localisation of RPTPs and their substrates. Although the regulation of RPTPs is 
an area of active research, several modes of regulation may be distinguished as being 
important. It is likely that many RPTPs recognise extracellular ligands, which may affect 
RPTP activity or function. In addition, the activity of many proteins is affected by 
regulatory mechanisms including oligomerisation, the enzyme-catalysed attachment of 
chemical groups to specific amino acid side chains of the RPTP peptide backbone (Post-
49translational modification) and post-translational cleavage. Finally, it has recently become 
clear that the cysteine-based catalytic mechanism of RPTPs makes them peculiarly 
susceptible to the effects of reactive oxygen species (ROS).
1.3.1: Regulation o/PTPs by sub  cellular localisation
The role of localisation in PTP regulation is an emerging field. However, there is 
evidence that the regulated colocalisation of substrate and enzyme may play an equally 
important role in PTP as in serine-threonine phosphatase regulation. Numerous PTPs 
exhibit distinct patterns of subcellular distribution, which are brought about by a diversity 
of targeting mechanisms, and in some cases PTP localisation is regulated such that PTPs 
shuttle between different sites in response to stimuli (Frangioni et al., 1992; Flores et al., 
1994; Tillmann et al., 1994; Lorenzen et al., 1995; Wang et al., 1996; Cossette et al., 1996; 
Kamatkar et al., 1996; Aicher et al., 1997; Jena et al., 1997; Tiganis et al., 1997; Tenev et al., 
2000; Gjorloff-Wingren et al., 2000; Xu et al., 2001; Craggs and Kellie, 2001; Uchida et al., 
2002; Yang et al., 2002; Wang et al., 2002a; Bompard et al., 2003; Herrmann et al., 2003; 
Seifert et al., 2003; Ianzano et al., 2004; Chirivi et al., 2004; Del Vecchio and Tonks, 2005; 
van Ham et al., 2005; Gupta and Swarup, 2006; Hernandez et al., 2006). However, specific 
effects of PTP localisation have so far only been elucidated in a minority of cases. 
Localisation of the Yersiniapestis (Plague) tyrosine phosphatase is an important aspect of the 
pathogenesis of this disease (Persson et al., 1999). In addition, type II RPTPs generally 
localise to areas of cell-cell contact, where they interact with components of the actin 
cytoskeleton or cell-cell adhesions. This area will be covered below when the regulation of 
RPTPs by post-translational cleavage and the interaction of RPTPs with other proteins are 
considered (1.2.3.4^1.3.5). The type IV RPTPs, PTPa and PTPs, are regulated by post- 
translational cleavage and alternative splicing, which may also be mediated by the 
differential localisation of the cleaved or alternatively spliced proteins (Gil-Henn et al., 
2000; Gil-Henn et al., 2001; Andersen et al., 2001a; Kraut et al., 2002). Finally, one of the 
most exciting areas of research on RPTP localisation is in the effects of localisation on the 
role of CD45 in T Cell receptor (TCR) signalling.
The archetypal RPTP, CD45, plays a key role in immune cell signalling. Up 
to 5-10% of the surface of lymphocytes is coated in CD45 molecules and both T and B 
cells deficient in CD45 exhibit abnormalities in signalling downstream of their respective 
antigen receptors. The defect in T cell signalling is the more pronounced and the role of 
CD45 in TCR signalling is more clearly understood than its role in B cell signalling
50(Alexander, 2000). The major substrates of CD45 are Src-family tyrosine kinases 
downstream of the TCR. The regulation of these tyrosine kinases by CD45 is complex as 
CD45 has both positive (through dephosphorylation of the C-terminal inhibitory tyrosine) 
and negative (through dephosphorylation of the autophosphorylation site) effects on 
tyrosine kinase activity (Thomas and Brown, 1999; Baker et al., 2000a). TCR signalling 
induces the formation of an immune synapse at the T Cell/antigen presenting cell junction 
(Bromley et al., 2001). Following T cell receptor activation, lipid rafts migrate to the 
synapse concentrating the components of the TCR signalling system (Montixi et al., 1998; 
Viola et al., 1999; Kabouridis, 2006). Lipid rafts are sphingolipid- and cholesterol-rich 
microdomains of the cell membrane to which a number of signalling proteins are 
specifically targeted and which play an important role in physiological and pathological 
processes including axon guidance (Dykstra et al., 2003; Edidin, 2003; Simons and Vaz, 
2004; Lagerholm et al., 2005; Kamiguchi, 2006). Interestingly, Src tyrosine kinases and other 
components of T cell receptor signalling cascade segregate to lipid rafts whereas CD45 is 
usually excluded from these regions of the membrane (Rodgers and Rose, 1996; Xavier et 
al., 1998). However, a proportion of CD45 molecules move between lipid rafts and the 
remainder of the cell membrane (Johnson et al., 2000; Edmonds and Ostergaard, 2002; 
Freiberg et al., 2002; Zhang et al., 2005). A model has been suggested where low levels of 
raft-associated CD45 negatively regulate basal levels of TCR signalling, possibly preventing 
the effects of inappropriate TCR activation. In contrast, CD45 excluded from lipid rafts 
plays a positive role in downstream signalling through ERK kinases potentiating the effects 
of appropriate TCR activation (Miceli et al., 2001; Hermiston et al., 2003). Preliminary data 
suggests that PTPa may also localise to lipid rafts (A. Stoker, unpublished data).
1.3.2: Regulation of RPTPs by ligand binding
The structure of many RPTP extracellular domains immediately suggests that these
proteins might act as transmembrane receptors for extracellular ligands, which might
regulate RPTP tyrosine phosphatase activity (Charbonneau et al., 1988). Epidermal growth
factor (EGF) negatively regulates the activity of an EGF receptor extracellular domain-
CD45 phosphatase domain chimera, proving that in principle, ligands have the potential to
regulate RPTP activity and that ligands are likely to inhibit PTP catalytic activity (Desai et
al., 1993). However, the in vivo function of CD45 is rescued by a chimaera lacking the
endogenous CD45 extracellular domain (Hovis et al., 1993). Thus, the function of RPTP
extracellular domains remains unclear. It must be noted however, that CD45 is expressed at
extremely high levels by nucleated blood cells, covering up to 10% of the cell surface (Cited
51in Thomas, 1989). Therefore, CD45 regulation may not need the influence of the 
extracellular domain to regulate CD45 localisation or protein-protein interactions. 
Furthermore, the number of proteins known to interact with RPTP extracellular domains is 
small and even fewer have been shown to have an effect on RPTP function or activity. The 
lack of an assayable RPTP function or identified substrates for many RPTPs has made it 
extremely difficult to evaluate these putative ligands. Indeed for the majority of the RPTP 
family, “it is mainly an article of faith that such physiologically relevant ligands really exist” 
(Bixby, 2001). Several different types of ligand-RPTP interactions will be discussed below.
Firstly, most reminiscent of a canonical ligand-receptor interaction, several RPTPs 
including PTPa bind proteins expressed on other cells or in the extracellular environment 
(in trans). Extracellular domain ligands have been reported for PTPa, PTP£ (PTPRZ),
CD45 and DEP1  (see below for references). In addition, a putative IA2 ligand has been 
located in pancreatic islets however, it has not been characterised further (Chiang and 
Flanagan, 1996). At least two kinds of candidate PTPa ligands have been identified, a 
heparan sulphate proteoglycan (HSPG) in basement membranes and the protein, nucleolin, 
in developing muscle (Aricescu et al., 2002; Sajnani-Perez et al., 2003; Alete et al., 2006). In 
addition, PTPa has been identified as one of a number of candidate targets for a 
component of Black Widow venom (Krasnoperov et al., 2002). There is no appropriate 
functional PTPa assay currently available to determine the effect of these candidate ligands 
on PTPa. Therefore, it remains to be determined whether these two potential PTPa ligands 
represent authentic ligands, affecting PTPa function or activity or whether they play a 
different role, for example as a co-receptor as is seen for HSPGs in other signalling systems 
(Lin, 2004). The Drosophila type Ha RPTP, DLAR, also recognises HSPGs and vertebrate 
LAR recognition of the laminin-nidogen complex promotes neurite outgrowth, suggesting 
that the recognition of extracellular matrix components including HSPGs may be a 
common feature of this RPTP family (O'Grady et al., 1998; Fox and Zinn, 2005; Johnson 
et al., 2006). The effects of the laminin-nidogen complex on LAR function are also 
unknown. However, the closely related Drosophila HSPGs, Syndecan and Dally-like Protein, 
appear to either increase or decrease DLAR activity respectively (Fox and Zinn, 2005; 
Johnson et al., 2006). Similarly, an undefined extracellular matrix ligand has been reported 
to increase DEP1  (PTPRJ) phosphatase activity (Sorby et al., 2001). It may be possible to 
predict the effect of PTPa ligands from studies on other RPTPs.
In contrast to the situation for PTPa, both substrates and ligands have been 
identified for PTPa, PTP£ and CD45. PTPa is inhibited by an undefined ligand in serum
52(Blanchetot and den Hertog, 2000a). However, the effect of ligand binding on PTPa 
dimerisation was not determined. PTP£ ligands fall into two distinct categories. A number 
of Fibronectin-type 3 domain-containing Ig super-family cell adhesion molecules and 
extracellular matrix components bind to PTP£ through interactions that require the N- 
linked glycosylation of PTP£ but not its chondroitin sulphate sidechains, which may in fact 
inhibit binding of FN3 domain-containing ligands (Bamea et al., 1994; Milev et al., 1994; 
Grumet et al., 1994; Milev et al., 1995; Peles et al., 1995; Milev et al., 1996; Milev et al.,
1997; Milev et al., 1998a; Revest et al., 1999; Garwood et al., 2003). The PTP£ interaction 
with these proteins may initiate bidirectional signalling (Peles et al., 1995; Revest et al.,
1999). However, the effect of these interactions on PTP£ function is not known. In 
contrast, the interaction of PTP£ with heparin-binding proteins such as pleiotrophin, 
midkine, Fibroblast Growth Factor-2 or amphoterin may require the chondroitin sulphate 
sidechains (Maeda et al., 1996; Maeda and Noda, 1998; Milev et al., 1998a; Milev et al., 
1998b; Maeda et al., 1999; Maeda et al., 2003; Sakaguchi et al., 2003). Moreover, 
pleiotrophin-PTP^ binding inhibits the intrinsic tyrosine phosphatase activity of this RPTP 
towards its substrates including the JVr-family tyrosine kinase, Fjn, and the key 
developmental and cell signalling molecule, (3-catenin (Meng et al., 2000; Kawachi et al., 
2001; Fukada et al., 2005; Pariser et al., 2005a; Pariser et al., 2005b). Significantly, inhibition 
of PTP£ phosphatase activity by pleiotrophin is associated with PTP£ clustering and a 
similar effect is seen by systems that artificially dimerise PTP£ in response to ligands 
(Fukada et al., 2006).
Several lectins including galectin-1  (galectin), are candidate CD45 ligands (Walzel et 
al., 1999; Rachmilewite et al., 2003). Galectin exists in an equilibrium between a monomeric 
and dimeric form in vivo, and multiple galectin molecules are able to bind to CD45 in a 
carbohydrate-dependent fashion (Cho and Cummings, 1995; Symons et al., 2000). 
However, although treatment of T cells with galectin induces apoptosis (Perillo et al.,
1995), this effect is not mediated by the galectin-CD45 interaction but through binding of 
galectin to other cell membrane proteins including CD3, CD4 CD7 and CD42 (Fajka-Boja 
et al., 2002). In fact, the galectin-CD45 interaction serves to regulate the susceptibility of T 
cells to apoptosis induced by galectin treatment rather than to induce apoptosis per se. The 
effects of the galectin-CD45 interaction are complex and depend on the glycosylation 
status of CD45 (1.3.3). However, the resistance of O-linked glycosylation deficient cells to 
galectin induced cell death requires CD45 catalytic activity, suggesting that galectin binding 
to normal cells inhibits CD45 catalytic activity (Nguyen et al., 2001). Moreover in
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decreased CD45 tyrosine phosphatase activity (Walzel et al., 1999; Fouilht et al., 2000b) and 
decreased Lyn tyrosine kinase activity (a CD45 substrate) (Katagiri et al., 1999; Fouilht et 
al., 2000a; Fouillit et al., 2000b). In contrast, in cells that are resistant to galectin-induced 
cell death, there is decreased CD45 clustering and a requirement for higher levels of CD45 
phosphatase activity (Nguyen et al., 2001). As galectin is potentially a divalent ligand, an 
obvious possibility is that galectin treatment causes receptor dimerisation, which is 
associated with tyrosine phosphatase inhibition as in the PTP£ system. This has been 
shown for the PP14-CD45 interaction (Rachmilewitz et al., 2003).
Secondly, several RPTPs exhibit homophilic binding. Although PTPa has not been 
shown to interact homophilically, the remaining two members of the vertebrate type Ha 
RPTP family (PTPS, LAR), all studied type lib RPTPs (PTPp, PTPx) and the related leech 
type Ila RPTP, HmLAR2, all interact homophilically (Brady-Kalnay et al., 1993; Gebbink 
et al., 1993b; Brady-Kalnay and Tonks, 1994; Sap et al., 1994; Zondag et al., 1995; Wang 
and Bixby, 1999; Baker et al., 2000b; Yang et al., 2003; Cismasiu et al., 2004; Yang et al., 
2005; Aricescu et al., 2006). It is therefore likely that PTPa also interacts in this fashion. 
Although in the case of type lib RPTPs, these interactions can occur both between PTPp 
molecules on opposing cells (in trans) and between PTPp molecules in the same cell 
membrane (in as)(Cismasiu et al., 2004; Aricescu et al., 2006). As these interactions involve 
the PTP[i MAM domain, the homophilic interactions exhibited by LAR and PTPS must 
utilise an overlapping or distinct mechanism. It is of note that the homophilic interaction 
of LAR protein requires the presence of a small alternatively spliced exon. Although this 
exon is conserved in the PTPa and PTPS genes, it was not present in the PTPa isoforms in 
which homophilic adhesion has been assayed and it is unclear whether it is required for 
PTPS mediated homophilic adhesion (O'Grady et al., 1994). Although homophilic 
interactions between RPTPs have clear functional consequences at the level of cell 
behaviour (Wang and Bixby, 1999; Yang et al., 2003) it is not yet possible to state what 
effect they have on the function or activity of the RPTP involved . However, there are 
suggestions that homophilic interactions between LAR molecules might stimulate LAR 
tyrosine phosphatase activity (Yang et al., 2005).
Finally, the binding of transmembrane ligands by RPTPs expressed on the same 
cell (in as) has been reported. However, at the present time this has only been described for 
PTPa and the function of the interaction is unclear (Zeng et al., 1999). However, there is 
the intriguing possibility that the ligand, contactin, might function to link PTPa function to
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in cis and the other in trans, it might function to link RPTP function in neighbouring cells. 
Such ligands remain potentially undetectable with many of the methods used to identify 
RPTP ligands and as such represent an interesting future area of research.
1.3.3: Post-translational modification
Proteins may exhibit a number of different post-translational covalent 
modifications. These include glycosylation and phosphorylation. The regulation of RPTPs 
by reversible oxidation will be considered separately as unlike the modifications considered 
here, it is not mediated by the enzyme-catalysed transfer of a chemical group to the RPTP 
peptide chain but rather the direct effects of a diffusible chemical on the peptide chain 
itself. Other covalent protein modifications play a role in cell signalling and protein 
function (e.g. ubiquitylation (Hershko and Ciechanover, 1998; Voges et al., 1999;
Welchman et al., 2005), prenylation and palmitoylation (Huang and El Husseini, 2005)), but 
the role of these modifications in RPTP function remains to be determined.
Many proteins involved in embryonic development exhibit enzyme-catalysed 
glycosylation, predominantly on asparagine (N-linked) or serine and threonine (O-linked) 
residues (Vliegenthart and Casset, 1998; Ten Hagen et al., 2003; Haltiwanger and Lowe, 
2004; Weerapana and Imperiali, 2006). In general, glycosylation serves to create unique 
carbohydrate epitopes that participate in ligand-receptor interactions or to alter the general 
properties of a protein such as its charge, protease sensitivity or solubility (Varki, 1993).
The primary sequences of many RPTPs contain potential glycosylation sites. PTPa is 
predicted to contain 1 O-linked and 2 N-linked glycosylation sites.These predictions have 
been empirically verified in a number of proteins (Daum et al., 1991; Yu et al., 1992; Daum 
et al., 1994; Sorio et al., 1995; Hermel et al., 1999). In most cases, it is unclear what effect 
glycosylation has on RPTP function. However, RPTP glycosylation has been shown to 
affect the susceptibility of PTPx to proteolytic cleavage (1.3.5), which may be associated 
with the acquisition of metastatic potential by malignant cells (Kim et al., 2006). In 
addition, the binding of physiological ligands and toxins are independently affected by 
PTP{3/£ glycosylation (Milev et al., 1995; Yahiro et al., 2004). The most well understood 
effect of glycosylation on RPTP function is seen in the prototypical RPTP, CD45. It has 
long been appreciated that CD45 isoforms exhibit differential glycosylation thanks to the 
inclusion of exons containing additional glycosylation sites (Jackson and Barclay, 1989; 
Pulido and Sanchez-Madrid, 1990; Pulido et al., 1994). These differences have significant
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cell function in HIV-infected cells, leukaemogenesis, antigen-presenting cell function and 
immune senescence (Deans et al., 1991; Lefebvre et al., 1994; Ohta et al., 1994; Craig et al., 
1994; McKenney et al., 1995; Dang et al., 1996; Wood et al., 1998; Bleesing et al., 2003; 
Garcia et al., 2005). O- and N-linked glycosylation affect the susceptibility of T cells to 
galectin and both are required for the induction of cell death by galectin treatment (Galvan 
et al., 2000; Nguyen et al., 2001; Amano et al., 2003). In addition to differing in the number 
of glycosylation sites, CD45 isoforms differ in their degree of sialylation. Increased CD45 
sialylation reduces galectin binding and CD45 clustering, abrogating the inhibitory effect of 
galectin on CD45 tyrosine phosphatase activity resulting in reduced galectin-induced cell 
death. A clinical correlate of this may be the reduced CD45 sialylation seen in HIV infected 
thymocytes, which is associated with increased exposure of O-linked CD45 glycans and 
increased susceptibility to cell death (Lanteri et al., 2003). It was suggested that the effects 
of glycosylation and sialylation on CD45 activity might reflect an effect on CD45 
dimerisation, which has been shown to inhibit CD45 phosphatase activity (1.3.4) (Xu and 
Weiss, 2002; Doman et al., 2002). This effect might be mediated by direct blockade of the 
binding site for a dimerising ligand, masking of a CD45 dimerisation motif or the affect of 
the additional sugar residues on the extracellular domain electric charge. The significant 
effects of glycosylation on CD45 function and the widespread presence of glycosylation in 
the RPTP family make it possible that this may represent a widespread form of RPTP 
regulation.
Although many PTPs are regulated by phosphorylation, it is difficult at present to 
generalise about the role of conserved potential phosphorylation sites or empirically 
described phosphorylation events across the family (Su et al., 1994; Ostman and Bohmer,
2001). However, two phosphorylation events show that phosphorylation is likely to play a 
key role in PTP regulation. Firstly, the C-terminal PTPa Tyr789 residue is a binding site for 
the Grb2 adaptor protein and facilitates dephosphorylation of the inhibitory c-terminal 
tyrosine of JVr-family tyrosine kinases via a phosphotyrosine displacement mechanism (den 
Hertog et al., 1994; Zheng et al., 2000). The role of Tyr789 is modulated by reactive oxygen 
species (1.3.6) and by Protein Kinase C phosphorylation of PTPa at several serine residues 
(SI 80, S204) (Zheng et al., 2002). Src-family kinases play important roles in cell function, 
many PTPs dephosphorylate Src or its close relatives and a C-terminal tyrosine is a 
common feature of many RPTPs including those of the type Ha family (Roskoski, Jr.,
2005). Secondly, as mentioned above PTPa is constitutively phosphorylated upon two
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phosphorylation of these residues may play an important role in RPTPa function (Stetak et 
al., 2001; Zheng et al., 2002). Moreover, these residues are contained in an alternatively 
spliced exon (1.2) in the type Ha RPTP family, implying that phosphorylation of 
juxtamembrane serine residues may be important across the RPTP family (Zhang and 
Longo, 1995).
1.3.4: RPTP oligomerisation
Receptor dimerisation is a major feature of the regulation of many transmembrane 
protein families. Paradigmatically, receptor tyrosine kinases are activated by ligand induced 
dimerisation, which facilitates the conformational change required to allow subunit 
transphosphorylation and kinase activation (Schlessinger, 1986; Schlessinger, 1988; 
Lemmon and Schlessinger, 1994; Schlessinger, 2002). In addition, G-protein coupled 
receptors (GPCR) form homo- and heterodimers both as an integral part of signal 
transduction and to allow cross-talk between different GPCR pathways (Milligan, 2004; 
Milligan et al., 2004; Kubo and Tateyama, 2005; Fotiadis et al., 2006).
Dimerisation is also a feature of RPTP regulation. The transmembrane domains of 
many RPTPs dimerise in micelles, a common feature of dimerising transmembrane 
proteins (Chin et al., 2005). Studies support a role for ligand binding in the inhibition of 
CD45, RPTPa and possibly PTPp, mediated through formation of a receptor dimer in 
which the active site of each subunit is occupied by a conserved juxtamembrane wedge 
from the other subunit (Desai et al., 1993; Bilwes et al., 1996; Weiss and Schlessinger, 1998; 
Feiken et al., 2000). In addition to ligand binding, there is evidence that other systems may 
regulate RPTP dimerisation including post translational modification (Xu and Weiss, 2002) 
and reactive oxygen species (1.3.6). As is seen with receptor tyrosine kinases, the 
orientation of the dimer is critical for normal signal transduction (Burke et al., 1997; Burke 
and Stem, 1998; Jiang et al., 1999; Jiang and Hunter, 1999). The inhibitory role of the 
juxtamembrane wedge appears to be important in vivo for CD45 (Majeti et al., 1998; Majeti 
et al., 2000; Hermiston et al., 2005). However, this dimeric structure may be related to the 
selection of a specific region of RPTP sequence for crystalisation (Felberg and Johnson,
1998). Indeed, an alternative dimer configuration is seen with the PTPp D1  domain that is 
related to crystalisation conditions (Hoffmann et al., 1997; Eswaran et al., 2006). In 
addition, the juxtamembrane wedge sequence is not present in all RPTPs and the single 
phosphatase domain crystal structure which first suggested this model is not seen in all
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some RPTPs reduces activity rather than increasing it in accordance with the model 
proposed by Majeti et al 1998 (Wang and Pallen, 1992; Gebbink et al., 1993a). Indeed, 
extant crystal structures of tandem phosphatase domains suggest that they may be unable 
to form the requisite homodimeric structure to inhibit phosphatase activity in this way 
(Nam et al., 1999; Nam et al., 2005). Despite this, wedge domain peptides successfully 
inhibit the activity of RPTPs including those that appear to be unable to form the necessary 
dimeric crystals (Xie et al., 2006). A role for dimerisation in RTP function is supported by 
other studies although the structure of the dimer has not been determined in all cases 
(Takeda et al., 1992; Jiang et al., 2000; Blanchetot and den Hertog, 2000a; Tertoolen et al., 
2001; Gross et al., 2002; Blanchetot et al., 2002a; Toledano-Katchalski et al., 2003; Takeda 
et al., 2004; Walchli et al., 2005). In summary, it appears that dimerisation is an important 
regulatory mechanism in many RPTPs, although the exact mechanism of dimerisation 
remains unclear.
A number of alternative mechanisms of tyrosine phosphatase dimerisation have 
been reported, which are unlikely to play a significant role in RPTP regulation (Tabemero 
et al., 1999; Akerud et al., 2002; Bemado et al., 2003). In addition, several type II RPTPs 
form homo-oligomeric complexes mediated by both as and trans interactions as described 
above (Brady-Kalnay et al., 1993; Gebbink et al., 1993b; Brady-Kalnay and Tonks, 1994; 
Sap et al., 1994; Zondag et al., 1995; Wang and Bixby, 1999; Yang et al., 2003; Cismasiu et 
al., 2004; Yang et al., 2005; Aricescu et al., 2006). Furthermore, heterophilic interactions 
have been reported between the D1  and D2 tyrosine phosphatase domains of a number of 
different RPTPs. The specificity of this interaction is affected by the juxtamembrane wedge 
region, which may represent the physiological function of the wedge region, and is 
inhibited by an intramolecular interaction between the D1-D2 spacer region and the C- 
terminal region of D2 (Wallace et al., 1998; Felberg and Johnson, 1998; Feiken et al., 2000; 
Hayami-Noumi et al., 2000; Felberg and Johnson, 2000; Blanchetot and den Hertog,
2000b; Gross et al., 2002; Blanchetot et al., 2002a; Blanchetot et al., 2002b; Toledano- 
Katchalski et al., 2003). This spacer/c-terminal interaction may produce a locked 
conformation of the D2 domain, unable to interact with other PTP domains, that is 
analogous to the locked conformation of the Src-family tyrosine kinases (Xu et al., 1997; 
Blanchetot et al., 2002a; Hantschel et al., 2003; Nagar et al., 2003; Harrison, 2003). Finally, 
it has been suggested that reactive oxygen species may play a role in the regulation of RPTP 
activity through an effect on dimerisation (1.3.6).
581.3.5: Post-translational cleavage
A striking feature of members of the type II RPTP family is that they undergo 
sequential post-translational cleavage events. Four distinct kinds of type II RPTP cleavage 
events have been described. The cleavage of signal peptides by signal peptidase during 
translocation into the endoplasmic reticulum will not be considered here (Paetzel et al., 
2002).
Type II RPTPs possess a conserved dibasic recognition site for cleavage by 
subtilisin-like protein convertases (PC) that is located approximately 100 amino acids from 
the plasma membrane, in the membrane proximal FN3 domain (Streuli et al., 1992; Jiang et 
al., 1993; Yan et al., 1993; Serra-Pages et al., 1994; Pulido et al., 1995a; Campan et al., 1996; 
Cheng et al., 1997). PCs cleave a wide range of peptide substrates, playing an important 
role in development, normal physiology and in the pathogenesis of infective, degenerative 
and malignant disease (Seidah et al., 1994; Thomas, 2002; Seidah and Prat, 2002; Rockwell 
et al., 2002). The PCs exhibit differing subcellular distributions exemplified by that of furin, 
which cycles between the trans-Golgi network (TGN), endosomal compartments and cell 
surface with furin cleavage being either a TGN or a post-TGN event (Seidah et al., 1994; 
Molloy et al., 1994; Yischer and Wagner, 1994; Molloy et al., 1999; Chen et al., 2001; Band 
et al., 2001; Thomas, 2002; Seidah and Prat, 2002). Specifically, the cleavage of PTPx is 
mediated by fiirin, and that of PTPp, by PC5 (Campan et al., 1996; Anders et al., 2006).
The enzyme(s) responsible for LAR, PTPS, PTPa, PTPk and PTPp cleavage remains 
unidentified. The precise role of PC mediated cleavage in type II RPTP function is unclear. 
However, as with other PC substrates, cleavage of type II RPTPs at this site is not required 
for membrane expression and heterodimeric forms containing both cleaved and uncleaved 
protein have been reported (Streuli et al., 1992; Jung et al., 1993; Serra-Pages et al., 1994; 
Pulido et al., 1995a; Bush et al., 2001). Indeed, although furin-mediated cleavage of Notch 
is required for the subsequent release of the Notch intracellular domain by y-secretase (De 
Strooper et al., 1999; Weinmaster, 2000), uncleaved Notch is not an artefactual finding. 
Rather, it regulates a distinct signalling pathway in response to binding of the Notch ligand, 
Delta (Bush et al., 2001). The regulation of PC-mediated PTPp cleavage by cell density 
suggests that cleaved and uncleaved type II RPTPs may similarly have distinct functions 
(Campan et al., 1996). It is unknown what effect PC-mediated cleavage has on the ligand 
binding or signalling properties of type Ha RPTPs. However, PC-mediated cleavage is not 
required for the ectodomain shedding that is associated with the second form of type Ha 
RPTP cleavage (Serra-Pages et al., 1994).
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is associated with shedding of the extracellular domain portion and in some cases with 
internalisation of the intracellular domain (Serra-Pages et al., 1994; Aicher et al., 1997). 
Cleavage at this site is increased in response to cell density and treatment with phorbol 
ester, calcium ionophores or anti-RPTP antibody and is associated with an increase in 
specific PTP activity (Aicher et al., 1997; Anders et al., 2006). It can be hypothesised that 
this increase may reflect the removal of an inhibitory dimeric structure forced upon the 
intact protein by an interaction with an extracellular ligand. Many transmembrane proteins 
including Notch are subject to cleavage by members of the matrix metalloprotease or “a 
distintegrin and metalloprotease” (ADAM) family (Brou et al., 2000; Lieber et al., 2002; 
McFarlane, 2003; White, 2003; Seals and Courtneidge, 2003; Huovila et al., 2005; Malemud, 
2006). Cleavage is associated with shedding of the extracellular domain with the remaining 
intracellular portion of the protein being subject to degradation, often via cleavage and 
release from the membrane by a protease that cleaves within the lipid bilayer (e.g. y- 
secretase). However, it is not clear whether cleavage by ADAMs is sufficient for 
ectodomain shedding or whether additional conformational effects are required. 
Specifically, ADAM-10 is responsible for cleavage of PTPx and TACE/ADAM-17 is 
suggested to mediate LAR cleavage (Ruhe et al., 2006; Anders et al., 2006). The enzymes 
responsible for the cleavage of other type II RPTPs at this site have not yet been identified.
A third cleavage event has recently been identified for at least some type II RPTPs. 
Mediated by y-secretase, it releases the RPTP intracellular domain from the membrane 
either for transport to the nucleus where it dephosphorylates (Tcatenin affecting (3-catenin 
regulated transcription or for degradation by the 26S proteasome. Cleavage at this third site 
requires antecedent cleavage by a sheddase (Anders et al., 2006). Thus in the future, RPTPs 
may follow tyrosine kinase receptors and be identified as unlikely mediators of nuclear 
signalling (Ni et al., 2001; Lin et al., 2001).
Finally, the type III RPTPs, PTPa and PTPs are cleaved by calpain within the 
juxtamembrane region. This releases a soluble intracellular domain fragment with an 
apparently reduced tyrosine phosphatase activity (Gil-Henn et al., 2000; Gil-Henn et al.,
2001). However, the function of this event in type III RPTP function and its relevance to 
RPTP processing in general remains to be elucidated.
601.3.6: Regulation by reactive oxygen species (ROS)
The effect of certain oxidising agents on the catalytic cysteine of classical tyrosine 
phosphatases has long been used to inhibit cellular tyrosine phosphatase activity (Huyer et 
al., 1997; Denu and Tanner, 1998). Recendy it has become apparent that hydrogen 
peroxide (H-,0,) in particular is not just a pharmacological tool but a major cell signalling 
molecule in its own right, playing an important role in the signalling induced by growth 
factor binding to receptor tyrosine kinases (Sundaresan et al., 1995; Bae et al., 1997; Meng 
et al., 2002). Other signals also have the potential ability to regulate PTP activity by ROS 
production (Barford, 2004; den Hertog et al., 2005). The major effects of ROS signalling 
appear to be mediated through redox modification of cysteine residues (Barford, 2004; 
Rhee, 2006; Biswas et al., 2006). The production of ROS in these signalling cascades is 
incompletely understood, but probably utilises the same catalytic machinery as the 
oxidative burst in phagocytic cells through the NADPH oxidase (Nox) complex. Nox 
generates superoxide, which can be converted into H20 2 by superoxide dismutase 
(Sundaresan et al., 1995; Irani and Goldschmidt-Clermont, 1998; den Hertog et al., 2005; 
Rhee, 2006).
Tyrosine phosphatases are likely to be the major target of ROS signalling and they 
specifically regulate distinct aspects of ROS signalling (Hao et al., 2006a); PTP catalysis 
requires a critical cysteine to be maintained in a reduced state (Zhang and Dixon, 1993; Xu 
et al., 2002; den Hertog et al., 2005). However, H20 2 also has direct effects on protein 
tyrosine kinases (Giannoni et al., 2005). Oxidation of the PTP catalytic cysteine to 
sulphenic acid is reversible, whereas further oxidation is less so. It has recently been shown 
that at least some PTPs are able to protect their catalytic cysteine from irreversible damage 
by oxidation. The catalytic cysteine may be protected by the formation of homodimeric 
intramolecular disulphide bonds (Caselli et al., 1998; Lee et al., 1998; Savitsky and Finkel,
2002)  or the formation of a ring-form sulfenyl-amide (Salmeen et al., 2003; van Montfort et 
al., 2003). Although both mechanisms temporarily inhibit phosphatase activity, they are 
readily reversible to the thiolate ion. It is not known whether RPTPs utilise either of these 
protective strategies. However, in vitro oxidation of PTPa results in the formation of 
sulphonic acid at the D2 catalytic cysteine but not at the equivalent D1 residue (Persson et 
al., 2004). This suggests that the D1 cysteine might be less susceptible to oxidation than the 
D2 cysteine, perhaps because of the tertiary and quaternary structure of PTPa or through 
utilisation of one of these strategies.
61Although H20 2  has the potential to cause oxidation of the catalytic cysteine leading 
to decreased phosphatase activity, it is possible that it in fact has its effects on RPTP 
function through a quite different mechanism that is just beginning to be elucidated. The 
membrane distal, D2, domain of PTPa is more susceptible to in vitro oxidation than the 
membrane proximal D1 domain. H20 2  treatment inhibits PTPa phosphatase activity, 
which is associated with the stabilisation of preformed PTPa dimers and the association of 
PTPa with potential downstream effectors (Blanchetot et al., 2002a; Hao et al., 2006a; Hao 
et al., 2006b). Interestingly, H20 2 treatment also inhibits the intramolecular D2 spacer/c- 
terminal interaction whilst stimulating an intermolecular D2-D2 interaction. This suggests 
that the spacer/c-terminal interaction may function to maintain PTPa in an active dimeric 
state and prevent the intermolecular interaction of D2 domains in the PTPa dimer 
(Blanchetot et al., 2002a). These effects are associated with a conformational change both 
in the structure of isolated D2 domains and in the structure of the extracellular region of 
PTPa dimers. The conformational effect on PTPa D2 domains is conserved in D2 
domains from the type Ila RPTP, LAR, and thus is likely to be generally applicable to all 
two-phosphatase domain RPTPs (Blanchetot et al., 2002b). A similar effect can be 
produced by altering the axis of dimerisation of constitutively dimeric PTPa (Jiang et al., 
1999; van der Wijk et al., 2003). Surprisingly, these effects do not require a functional D1 
catalytic cysteine, but appear to be mediated by cysteine residues in D2 (Buist et al., 2000; 
Blanchetot et al., 2002a; van der Wijk et al., 2003).
In addition, H20 , treatment induces the formation of disulphide crosslinked forms 
of PTPa (van der Wijk et al., 2004). This effect requires the presence of the D2 catalytic 
cysteine but it is unclear whether this residue is the site of reciprocal disulphide bond 
formation between dimer subunits. Disulphide bonded dimers are not formed in dimers 
consisting of a full-length PTPa molecule and an isolated D2 domain (Blanchetot et al., 
2002a). Indeed, the data presented could reflect a requirement for the D2 catalytic domain 
in sensing ROS and inducing a conformational change in PTPa dimer structure, disulphide 
bond formation being mediated by other cysteine residues. In the absence of the D2 
catalytic cysteine, the conformation of the PTPa dimer might not place the responsible 
cysteines close enough together for disulphide bond formation. As dimeric receptors 
commonly exist in equilibrium between “tense” and “relaxed” conformations, even in the 
absence of ligand stimulation, this might also explain why even in the insensitive D2 
catalytic cysteine mutants, a small amount of PTPa would be found in the appropriate 
conformation for disulphide bond formation.
62These results suggest that the major effect of H20 2  on RPTP activity might not be 
mediated through oxidation of the catalytic cysteine as previously assumed but through 
indirect effects on protein structure via a Redox-sensitive switch incorporating the D2 
catalytic cysteine.
1.4: Thesis Aims
The aim of this thesis is to investigate the mechanism of action and function of 
type Ha RPTPs, in particular PTPa. A number of approaches were taken to identify the 
role of receptor oligomerisation in PTPa function, to evaluate the effects of 
pharmacological agents including the putative PTPa ligand, heparin sulphate, on PTPa 
function and to identify additional PTPa— interacting proteins, with a particular emphasis 
on potential substrates. One aim of this work was to establish an assay that could be used 
to assess PTPa activity in response to experimental manipulations. Finally, a major focus of 
the research of this laboratory is studying the role of RPTPs in chick embryonic axon 
guidance. Although successful attempts have been made to perturb PTPa function, these 
have so far produced subde phenotypes. In fly models of axon guidance, it has often been 
necessary to disrupt the function of several PTP family members to produce a phenotype. 
The chick homologues of PTPa and PTPS have been cloned. Therefore, the isolation of 
the chick homologue of LAR was attempted. This would complete the family of three 
chick type Ha RPTPs and allow disruption of all three type Ha RPTPs, alone or in 
combination.
63Chapter 2: Materials and Methods 
2.1: Materials and equipment
Laboratory reagents and molecular biology enzymes were obtained from a number of 
suppliers (Sigma-Aldrich, UK; Invitrogen, UK; VWR International, UK; Bioline, UK; 
Promega, UK; New England Biolabs, UK or Roche, UK). The source of reagents did not 
appear to be a critical factor for any experiment unless otherwise specified. Agarose gel 
electrophoresis equipment was purchased from Thistle Scientific Ltd, UK. DNA markers 
were obtained from Bioline, UK. Protein gel electrophoresis, semi-dry transfer and gel- 
drying equipment were obtained from BioRad, UK. Protein markers were obtained from 
BioRad, UK. All chemicals were dissolved in MiliQ-grade (Milipore, UK) purified water 
(ddH20), adjusted to the appropriate pH using HC1 or NaOH and autoclaved at 120°C for 
15 minutes or filter-sterilised (0.22pm) unless otherwise stated. Where pH values are 
indicated these are at 25°C unless otherwise specified. Routine techniques were performed 
according to standard sources unless otherwise specified (Harlow and Lane, 1988; 
Sambrook et al., 1989; Ausubel et al., 1999; Freshney, 2000).
2.1.1: Antibodies
Antibody working dilutions were determined empirically for each application and batch of 
antibody. The following antibodies were used:
c-Myc tag: Clone 9E10; monoclonal mouse IgGt antibody raised against amino acids 408- 
439 of the human p62cm yc protein fused to KLH (Evan et al., 1985) (Sigma-Aldrich, UK) or 
clone 4A6, protein G purified mouse monoclonal IgG raised against amino acids 410-420 
of human p62cM yc (Upstate, UK).
FLAG tag: Clone M2; affinity purified mouse monoclonal IgGt.
GFP: Living colours anti-Green Fluorescent Protein. Affinity purified mixture of rabbit 
polyclonal IgG raised against Aequorea victoria GFP peptides (Cloritech, UK).
GST: Polyclonal goat (Amersham-Pharmacia, UK).
HA tag: Clone HA-7; monoclonal mouse IgGj antibody raised against amino acids 98-106 
of human influenza virus haemagglutinin fused to KLH (Sigma-Aldrich, UK) or clone 
3F10; affinity-purified monoclonal rat antibody raised against amino acids 76-111 of X47 
haemagglutinin 1  fused to KLH (Roche, UK).
IG2: Anti-chick PTPa, raised against a GST-fusion containing the first 2 PTPa Ig domains 
(Stoker et al., 1995a).
64Phosphotyrosine: Clone 4gl0; His-tag purified monoclonal mouse IgG2bx antibody raised 
against phospho-tyramine-KLH (Upstate, UK).
2.1.2: Common solutions
Tris-buffered saline (TBS) —  150mM NaCl, 25mM Tris.HCl pH 7.50 
TBST -  TBS + 0.2% Tween-20
Phosphate buffered saline (PBS) —  130mM NaCl, 15mM Na2H P 04,15mm NaH2P 0 4 pH 
7.50 (Not for use in tissue culture)
25xSSC -  0.75M NaCl, 0.375M Na Citrate dihydrate, pH 7.00
2.2: Molecular Biology
2.2.1: Preparation and analysis of DNA 
2.2.1.1: DNA purification
Where appropriate, DNA was purified by extraction with phenol-choloroform as decribed 
previously by equilibration of DNA (<lpg/ pi) in Tris-EDTA buffer (lOmM Tris.HCl;
ImM ethylenediaminetetraacetic acid (EDTA), pH 8.00 —  TE) with buffered
phenol/chloroform/isoamylalcohol (25:24:l (v/v/v); pH 8.00) (Sambrook et al., 1989; Ausubel
et al., 1999).
2.2.1.2: DNAprecipitation
DNA precipitation from aqueous solutions was performed as described previously using 
3M sodium acetate pH 5.20 (Routine applications) or 4M ammonium acetate pH 4.80 
(Removal of unincorporated nucleosides/oligonucleotides) (Sambrook et al., 1989; Ausubel 
et al., 1999).
2.2.1.3: Precipitation using an inert carrier
When the DNA concentration was low (<lpg/ml) or contained small DNA molecules
(<500bp), precipitation efficiency was increased using the inert carrier, linear
polyacrylamide (LPA) (Gaillard and Strauss, 1990). Briefly, 5% acrylamide (without
bisacrylamide) was dissolved in 40mM Tris.HCl pH 7.80, 20mM sodium acetate, ImM
EDTA. Linear polymerisation was initiated with 0.1% ammonium persulphate and 0.1%
65NjNjN’jN'-Tettamethylethylenedkmine (TEMED). After 30 minutes, linear polyacrylamide 
was precipitated with 2.5 volumes of 100%  ethanol and centrifugation for 5 minutes at 13k 
rpm. The resulting pellet was redissolved in 20 volumes ddH20  on a shaking platform 
overnight. The 2.5pg/pi LPA solution is stable at 4°C and 4-8pl LPA (10-20pg) was used 
per precipitation.
2.2.1.4: DNA purification with silica
DNA was extracted from agarose gel slices and from solution using a silica suspension 
(glass milk) as previously described (Vogelstein and Gillespie, 1979; Boyle and Lew, 1995). 
Silica (5g) was suspended in 50ml phosphate buffered saline (137 mM NaCl, 2.7 mM KC1, 
10 mM Na2H P04, 1.76 mM KH2P 0 4 —  PBS). The silica was allowed to settle for 2 hours 
and the supernatant was then discarded. This step was repeated twice and the final silica 
pellet was resuspended in 50ml 3M sodium iodide (lOOmg/ml) and stored at 4°C. The 
binding capacity of the final solution is approximately 0.5pg/ pi. The agarose gel slice or 
solution containing DNA was incubated at 55°C for 5 minutes in three volumes of 6M 
sodium iodide with lOpl of silica suspension. The sample was then incubated on ice for 10 
minutes. The silica was then pelleted and the supernatant discarded. The pellet was 
resuspended three times in wash buffer (10 mM Tris.HCl, pH 7.05, 50 mM NaCl, 2.5 mM 
EDTA, 50% ethanol) and recovered by centrifugation. A final wash was carried out in 70% 
ethanol. The pellet was air-dried and incubated in lOpl prewarmed TE at 55°C for 10 
minutes. The silica was then pelleted and the supernatant containing the DNA carefully 
transferred to a clean tube.
2.2.1.5: Preparation of oligonucleotide linkers
Complementary oligonucleotide linkers (2nmol each) were annealed immediately prior to 
use by heating to 90°C for 5 minutes in New England Biolabs Buffer 1  (lx —  lOmM Bis- 
Tris Propane.HCl pH 7.00, 20mM MgCl2, ImM dithiothreitol) containing lOmM MgCl0in 
a hot block, which was then allowed to cool gradually to room temperature.
2.2.1.6: DNA electrophoresis
DNA was analysed by electrophoresis using horizontal agarose gels in Tris-Acetate
electrophoresis buffer (40mM Tris acetate, 2mM EDTA). DNA samples were mixed with
lOx loading buffer (20% Ficoll 400, 0.1M EDTA pH 8.00,1% SDS, 0.25% bromophenol
blue/xylene cyanole/orange G) to permit sample loading.
662.2.2: Enzymatic manipulation of DNA. 
2.2.2.1: Restriction digestion, Filling-in, Dephosphorylation
DNA for modification was diluted in ddH ,0 or precipitated and resuspended in lOmM 
Tris.HCl pH 8.00 as required. All digestions were carried out in the presence of 0.1 mg/ml 
bovine serum albumin (BSA). All reactions were performed according to the 
manufacturer’s instructions using established techniques (Sambrook et al., 1989; Ausubel et 
al., 1999).
2.2.2.2: Ligation
Ligations were performed using lOng vector, an appropriate amount of insert (See below) 
and 1-3U T4 DNA ligase in ligation buffer (lx: 66mM Tris pH 7.60, lOmM MgCL,, lOmM 
DTT, ImM ATP, 7.5% Polyethylene glycol (PEG) 6000). Molecules with cohesive ends 
were incubated together overnight at a molar ratio of 3:1 at 18°C. Molecules with blunt 
ends or single adenine overhangs (i.e. PCR products from non-proofreading polymerases) 
were incubated overnight at a 1:1 molar ratio at 4°C. The relative amounts of insert and 
vector were chosen to keep the total DNA concentration below 5ng/ pi. Routinely 1 pi of 
the ligation reaction was transformed into competent bacteria.
2.2.2.3: Tailing PCR products  for insertion into T-vectors
PCR products produced with a TaqAike polymerase produce often have single, template- 
independent 3’ deoxyadenosine base overhangs (Clark, 1988). However, unless freshly 
generated, purified PCR products were retailed with deoxyadenosine prior to AT cloning 
using 5U Taq polymerase for 2 hours at 75°C in lxTaq buffer (Manufacturer supplied) 
containing 2mM Mg2S04 and ImM deoxyadenosine triphosphate (dATP) (Ausubel et al., 
1999). The tailed PCR product was then gel purified and cloned into the commercial 
pGEM T vector series or the pT-Not vector (Gift from N. Dear) (Franz and Dear, 1998).
2.2.3: Polymerase chain reaction techniques
Oligonucleotide primers were ordered from Thermoelectron GmBH, Ulm, Germany. 
Polymerase chain reactions were carried out using thermal cyclers from MJ Research Ltd, 
UK. Primer sequences are given in the text with relevant restriction sites underlined for 
clarity.
672.2.3.1: Polymerase chain reaction (PCR)
PCR (Saiki et al., 1985) using either conventional or degenerate oligonucleotide primers 
were carried out as follows. Reactions (50pl total volume) were assembled on ice and 
comprised lOOpmol each primer, lpg vector template, 200pM each dNTP, lx T ^  buffer 
(Manufacturer supplied), 1.5mM MgCl, (Most reactions) and 0.75U Taq polymerase. Where 
fidelity was a concern, 2.5U Pfu polymerase was used with the appropriate buffer and 2mM 
MgS04 instead. All other reaction constituents were unchanged. 1M (final) Betaine was 
frequently added to PCR reactions to improve the efficiency of difficult amplifications.
Cycle parameters were optimised for each reaction but were broadly as follows: initial 
denaturation 94°C 1 minute; 25-35 cycles of 96°C 10 seconds, ((Primer Tm)-5°C) 15 
seconds, 72°C 1 minute/kb expected product; reactions finished with a final extension of 
10 minutes. When using Pfu polymerase, extension was at 68°C not 72°C and the extension 
time was 2min/kb product with a final extension twice the length of the main extension 
step (at least 20min). Proteinase K digestion was used occasionally to improve the cloning 
efficiency of PCR products (Crowe et al., 1991). Completed PCR reactions (50pl) were 
diluted to 200pi with ddH,0, SDS (0.5%(w /v) final) and EDTA (5mM final). Digestion were 
performed using 20pg Proteinase K at 55°C for 30 minutes. The DNA was then recovered 
by phenol-chloroform extraction and ethanol precipitation.
2.2.3.2: Site-directed mutagenesis
A site-directed mutagenesis method was developed that was essentially similar to one 
subsequently published (West and Wilson, 2002). Standard Pfu-based PCR with primers 
250-350bp apart, one of which contained the desired mutation, was used to generate a PCR 
product containing the desired mutation. Following purification with agarose gel 
electrophoresis and silica extraction, half of the purified PCR product acted as a 
megaprimer in a second Pfu-based PCR reaction. Agarose gel electrophoretic analysis of 
1/10th of the second PCR product confirmed whole plasmid amplification and 10U Dpril 
added directly to the remaining product selectively digested methylated template DNA 
leaving only mutated product (37°C 2 hours). Transformation of an appropriate amount of 
the digested PCR product into competent Escherichia coli (E.coli), recovered colonies 
containing the mutant DNA. Restriction analysis (where appropriate) and 
dideoxynucleotide chain terminator DNA sequencing (2.2.3.4) of coding sequences 
confirmed the presence of the desired mutation only.
682.2.3.3: Ijong-accurate polymerase chain reaction (LAPCR)
The chicken LAR cDNA was amplified from RNA using the following long-accurate-PCR 
(LAPCR) conditions (16:1  Taq: Pfu ratio; W. Bames, personal communication). Each 
reaction was carried out in a final volume of 50pl containing the following components: 
lOOpmol each primer; 0.2mM dNTPs; lx T ^  buffer (16mM (NH4 )2S 04; 67mM Tris-HCl, 
pH 8.80; 0.01% Tween-20);1.5mM MgCl2; 1.3M Betaine; 1.3% Dimethyl sulphoxide; lpl 
RT reaction; 5U Taq\ 0.3125U Pfu. PCR was carried out for 35 cycles using the following 
profile: 1 minute denaturation at 94°C; 35 cycles of 94°C for 10 seconds, 62.7°C for 10 
seconds, 68°C for 7 minutes; final extension at 68°C for 15 minutes. Reactions were not 
overlaid with mineral oil, thin-walled PCR tubes were used and the machine lid was heated 
to 96°C.
2.2.3.4: DNA sequencing
DNA was sequenced using the dideoxynucleotide method (Sanger et al., 1977) with the 
DYEnamic ET dye terminator system (Amersham, UK) and a Megabace 500 automated 
DNA sequencer according to the manufacturer’s instructions. Plasmid DNA and primers 
for sequencing were prepared in ddH20 . Reactions (2pl Megabace sequencing mix, 6pl 
Better Buffer (Microzone, UK), 3.6pmol oligonucleotide primer, 150fmol DNA template) 
were cycled 30 times (95°C 20 seconds; 50°C 15 seconds; 60°C 1 minute) before 
precipitation with 2pl 7.5M ammonium acetate and 55ptl absolute ethanol followed by 
centrifugation at 13k rpm for 15 minutes at room temperature. The resulting pellet was 
washed with 200pl 70% ethanol and air-dried. Samples were resolublised in lOpl loading 
buffer (Manufacturer supplied) immediately before use. Sequence runs were performed 
using the long sequence preprogrammed protocol.
2.2.4: Escherichia coli methods
Several bacterial strains were used for the work contained in this thesis. Most work was 
carried out using the E.coli strains: DH5a-FT (Invitrogen, UK), XL1 or XL10-Blue 
(Stratagene, UK). GST protein expression was carried out in the E.coli strain BL21. 
Standard molecular biology techniques were used unless otherwise specified (Sambrook et 
al., 1989; Ausubel et al., 1999).
69Genotypes: DH5oc-FT: F' 80dlacZ(lacZYA-argF) U169 deoRrecAl endAl hsdR17 (rK-, 
mK+) phoA supE44 - thi-1 gyrA96 relA l/F' proAB+ lacIqZM15 TnlO (tetr); XLl-Blue: 
recA1 endAl gyrA96 thi-1 hsdK17 supE44 relA1 lac [F' proAB lacIqZAMI5 Tn/0 (Tetr)]; 
XLIO-Gold: TetrD(mcrA) 183 ~D(mcrCB-hsdSMR-mrr)173 endAl supE44 thi-1 recA1 gyrA96 
relA1 lac Hte [F' proAB lacIqZDMI5 Tn/0 (Tetr) Amy Camr]; BL21: F-, ompT, hsd&fc^-m^- 
), dcm, gal, (DE3) tonA
2.2.4.1: E.co/ipropagation: Media and antibiotics
Lysogeny broth (LB) —  Miller’s formulation (Bertani, 1951; Miller, 1972): For one litre: lOg 
tryptone, lOg NaCl, 5g yeast extract. (Agar plates +15g agar/1).
LB top agar: For 100ml: lg tryptone, lg NaCl, 0.5g yeast extract, 0.7g agar.
Super-optimal Broth (SOB)/Super-optimal broth catabolite repression (SOC) (Hanahan, 
1983): For one litre SOB: 20g tryptone, 5g yeast extract, 10 mM NaCl, 2.5 mM KC1,10 
mM MgCl2, 10 mM MgS04. Add Mg2+ salts before use, after autoclaving. SOC : Prepare 
SOB. Add 20mM glucose with Mg2+  salts.
Antibiotics (Working concentrations): Ampicillin (50-1 OOpg/ml); Tetracycline (12pg/ml); 
Kanamycin (30pg/ml); Chloramphenicol (20pg/ml)
2.2.4.2: Preparation of competent E.coli
Competent E.coli were prepared as previously described (Inoue et al., 1990). 
Untransformed E.coli were plated overnight at 37°C and ten to twelve colonies were used 
to innoculate 250 rnL SOB medium in a 2-liter flask. The culture was grown to an A600 of 
0.6 at room temperature with vigorous shaking (200-250 rpm). The culture was then 
transferred to a prechilled 500 mL centrifuge bottle on ice and allowed to rest for 10 
minutes. The bacteria were recovered by centrifugation at 2500 x g for ten minutes at 4°C. 
and resuspended in 80 mL ice-cold transformation buffer (TB: 10 mM Pipes, 55 mM 
MnCl2, 15 mM CaCl2  and 250 mM KC1; pH adjusted to 6.70 with KOH before addition of 
MnCl,; TB was sterilised by filtration). The bacteria were then allowed to rest on ice for ten 
minutes and spun down as above. The pellet was resuspended in 20 mL ice-cold TB and 
dimethylsulphoxide (DMSO) was added (7%v/v final). The suspension was then incubated
70on ice for ten minutes, aliquoted into single use 200fil aliquots and snap frozen in liquid 
nitrogen for long-term storage at -80°C.
2.2.4.3: Transformation of competent E.coli with plasmid DNA
Bacterial transformation was performed as previously described (Inoue et al., 1990). 
Competent cells were thawed at room temperature and transferred into a prechilled 15ml 
polypropylene tube (Falcon 2059) on ice. 1-5 pi of plasmid were added to the competent 
cells and they were incubated on ice for 30 minutes. They were then heat-pulsed without 
agitation at 42°C for 30 seconds and replaced on ice for a further 5 minutes. After 0.8ml of 
SOC was added, the tubes were securely capped and placed horizontally in an incubator at 
37°C and shaken vigorously for one hour. An appropriate amount of the mixture was 
plated onto selective LB plates. Plates were incubated overnight at 37°C.
Blue white screening was used where the cloning strategy permitted. Before plating 
transformed bacteria, 50pl 20mg/ml 5-bromo-4-chloro-3-indoyl-galactoside (X-gal) in N ,N  
dimethyl formamide was spread onto each 10cm2  agar plate and allowed to air dry. 
Isopropyl-1 -thio-(3-D-galactoside (IPTG) was used to induce (S-galactosidase expression in 
E.coli strains expressing the omega fragment of (3-galactosidase (XL-1/10 (JacZf). It was 
not required in strains that did not express the omega fragment (DH5a-FT {lacZM.15)). 
After application of X-Gal, 30pl lOOmM IPTG was spread onto each 10cm2 agar plate and 
allowed to air dry. Bacteria were then plated in the normal way.
2.2.4.4: Preparation of  frozen E.coli stocks
lml from an overnight culture was supplemented with 1ml 7%(v/v) DMSO. The culture was 
transferred to a cryotube and frozen rapidly by immersion in liquid nitrogen. Frozen stocks 
were stored at -80°C for an indefinite period together with an accompanying DNA pellet.
2.2.4.5: Extraction of DNA from transformed E.Coli
Small, low quality and larger-scale, high quality methods of DNA preparation were 
routinely used to produce DNA for rapid analysis or transfection and sequencing 
respectively. Commercial alkaline lysis DNA preparation kits (Qiagen, UK; Amersham,
UK) were used when problems were encountered with these techniques. All of these 
protocols use modifications of the alkaline lysis method (Bimboim and Doly, 1979). In
71addition, in the high quality DNA preparation, polethylene glycol (PEG) is used to 
precipitate DNA (Lis and Schleif, 1975).
Minipreps were prepared from 1.5ml overnight cultures of transformed E.coli (Zhou et al., 
1990; Xiang et al., 1994). The supernatant was removed after 1 minute centrifugation at 13k 
rpm and the pellet resuspended in the remaining 30-50|il of media. 300pl TENS solution 
(TE with 0.1M NaOH, 0.5% SDS; made fresh) was added and the sample was mixed gently 
by inversion before incubation at room temperature for 5 minutes. TENS solution was 
neutralised by addition of 150pl 3M sodium acetate pH 5.20. The resulting suspension was 
mixed gently by inversion and cleared by centrifugation at 13k rpm for 5 minutes. The 
supernatant containing plasmid DNA was transferred to a fresh tube and precipitated by 
addition of 900pi ice-cold ethanol followed by gentle mixing and centrifugation for 5 
minutes at 13k rpm. The pellet was washed in 70% ethanol and the pellet was recovered 
after a final centrifugation for 2 minutes at 13k rpm. The pellet was air-dried and 
resuspended in 40pl TE warmed to 70°C. 4pl DNA solution was used per restriction digest 
or 1 pi of a 1:100 dilution was used as template in PCR reactions. RNA present in the final 
product was removed with 5pl RNAse A solution (0.5mg/ml) added for the final 15 
minutes of each restriction digest.
High quality DNA preps were performed as follows. Overnight E.coli cultures were 
pelleted by centrifugation at 3600 rpm for 5 minutes. The supernatant was discarded and 
the pellet resuspended in GTE buffer (0.2ml/10ml culture; 50mM glucose, 25mM Tris.HCl 
pH 8.00, lOmM EDTA). Cells were lysed by addition of lysis buffer (0.3ml/10ml culture; 
0.2M NaOH, 1% SDS). The resulting solution was mixed rapidly by inversion until the 
solution cleared and incubated on ice for 5 minutes. Lysis buffer was neutralised by 
addition of 3M potassium acetate pH 4.80 (0.3ml/10ml culture). The resulting suspension 
was mixed rapidly by inversion until the solution became less viscous and a fine white 
precipitate formed. The solution was then incubated on ice for 5 minutes. Cellular debris 
was removed by centrifugation at 3600 rpm for 15 minutes. The supernatant was 
transferred to a clean tube and residual RNA was removed by treatment with 0.5mg/ml 
RNAse A solution (32pl/10ml culture) at 37°C for 20 minutes. The sample was then 
extracted twice with chloroform (400pl/10ml culture). The DNA was precipitated by 
addition of an equal volume of isopropanol and immediate centrifugation at 13k rpm at 
room temperature. The resulting DNA pellet was washed in 70% ethanol and resuspended 
in ddH20  (32[il/10ml culture). DNA was precipitated a second time by addition of 4M 
NaCl (8|jd/10ml culture) and 13% PEG8000 (40pl/10ml culture). The sample was
72incubated on ice for 20 minutes and then precipitated DNA was pelleted by centrifugation 
at 13k rpm for 15 minutes at 4°C. The supernatant was decanted and the pellet was washed 
twice with 70% ethanol. The pellet was recovered following a final centrifugation of 5 
minutes at 13k rpm at room temperature. The pellet was air-dried and resuspended in an 
appropriate amount of TE or ddH20.
2.2.4.6: Screening colonies  for  plasmid si% e differences indicating insert  presence
Colonies from ligations were rapidly screened for inserts using a modified method (Law 
and Crickmore, 1997; Beuken et al., 1998). 150pl from an overnight culture was pelleted by 
centrifugation for 20 seconds. The pellet was resuspended in 40|il prewarmed lysis buffer 
(10% sucrose, 0.25% SDS, lOOmM NaOH, 60mM KC1, 0.025% bromophenol blue) and 
incubated at 37°C for 5 minutes. The solution was placed on ice for 5 minutes and debris 
was pelleted by centrifugation at 13k rpm for 1 minute. 20pl was loaded onto an agarose 
gel. Plasmid DNA obtained in this way can be further analysed by restriction digests if the 
remaining sample is first phenol-chloroform extracted and precipitated.
2.2.4.7: Libraiy screening
Membrane replicas were made from library plates of E.Coii transformed with a plasmid 
library containing embryonic chick cDNAs (R. Aricescu). The replicas were then prepared 
for screening. Filters (Hybond N+, Amersham-Pharmacia, UK) were incubated serially for 
two minutes each in Solution 1  (0.2M NaOH, 1% SDS, Solution 2 (0.5M NaOH, 1.5M 
NaCl) and solution 3 (1.5M NaCl. 0.5M Tris pH 7.50). Bacterial debris was then rubbed off 
the plates in Wash solution (2xSSC, 0.1% SDS) and filters were rinsed in 5xSSC (10 
minutes). Filters were then air-dried on paper towels and the DNA was crosslinked to the 
filter using the automatic setting on a Stratalinker UV crosslinker (Stratagene, UK).
Membranes were soaked in 0.25M Na2P 0 4  pH 7.20 for followed by pre-hybridisation for 1 
hour at 65°C in Hybridisation buffer (0.25M Na2P04 pH 7.20, 7% SDS, ImM EDTA, 
100pg/ml Poly-A RNA). A chicken LAR EST was identified in a chick bursal library 
(http://pheasant.gsf.de/DEPARTMENT/dt40.html) by comparison to species 
homologues. A plasmid containing this cDNA (Clone: dkfz426_27il0rl) was generously 
provided by J.M. Buerstedde. The insert was excised and labelled using the Brightstar 
Psoralen-Biotin Nonisotopic labelling kit (Ambion, UK) according to the manufacturer’s 
instructions.
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incubation at 90°C for ten minutes. Denatured probe (lOng/ml final) was added to fresh 
pre-warmed (65°C) Hybridisation buffer that was then added to the filters, which were 
then incubated overnight at 65°C. Following overnight hybridisation, filters were rinsed in 
2xSSC, 1%SDS at room temperature (2x5 minutes) and then washed in O.lxSSC, 1%SDS 
at 65°C (2x15 minutes). Finally, filters were washed at room temperature in lxSSC (2x5 
minutes).
Bound probe was then detected as follows. Filters were washed in blocking solution 
(PBS+0.2% Casein, 0.5% SDS; 2x5 minutes), followed by incubation in blocking solution 
(lxl5min). The filters were then incubated with streptavidin-alkaline phosphatase diluted 
1:10,000 in blocking solution for 1 hour. Unbound antibody was removed by washes in 
blocking solution (lx5min) then wash solution (PBS+0.5% SDS; 3x5min). This was 
followed by incubation in assay buffer (2x2min). Finally, the filters were detected by a five 
minute incubation in assay buffer (20mM Tris pH 9.80, ImM MgCL) containing a 1:50 
dilution of CDP-Star (Stock solution: 12.5mM; Applied Biosystems, UK). Detection of 
chemiluminescent signal from detected library replica filters was performed in the same 
way as for Western blotting (2.5.4.2). Exposures lasting 20 and 100 minutes were made.
2.2.4.8: Induction of GST  fusion protein expression
Bacteria transformed with pGEX vectors encoding inducible GST fusion proteins were 
induced to express PTPa proteins by the addition of IPTG (final concentration: 0.1 mM) to 
cultures (OD600=0.6). Induced cultures were harvested after incubation for 4h at 25°C and 
lysed by boiling in an appropriate volume of lxLaemmli buffer containing 5% (5- 
Mercaptoethanol.
2.2.5: RNA methods
Where appropriate, solutions used for RNA analysis were treated with 
diethylpyrocarbonate (DEPC —  0.2%) (Ausubel et al., 1999).
2.2.5.1: RNA isolation
RNA was extracted from whole chick embryos (Embryonic day 7) using Tri2ol 
reagent (Invitrogen, UK) according to the manufacturer’s instructions. This is a 
modification of the original guanidium thiocyanate technique (Chomczynski and Sacchi,
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RNA integrity was confirmed using chicken glyceraldehyde-phosphate-dehydrogenase 
primers (F —  gatggtgaaagtcggagtca; R —  gacacccatcacaaacatgg; P. O’Neill, personal 
communication).
22.5.2: Reverse transcription
Reverse transcription (RT) reactions were performed using ImProm-II (Promega, UK) or 
Transcriptor (Roche, UK) reverse transcriptase (RT). The following conditions were used 
to amplify the LAR cDNAs. lpl RNA (lOOmg/ml), lpl ohgo dT1 7  adaptor 
(gactcgagtcgacatcgatttttttttttttttttvn), 2\d lOmM dNTP mix, lx RT buffer (supplied with 
enzyme). Reactions were heated to 65°C for 5 minutes to denature the RNA and then 
placed on ice for 5 minutes. 0.5pl RNAse inhibitor (10U) and 0.5pl RT (5U) were added 
and the reactions were incubated at 55°C for 30 minutes.
2.3: Vectors
A number of DNA constructs were made during the work described in this thesis. These 
are described here and vector maps are appended (Appendix 2: Plasmid vector maps). 
Where vectors were not generated by the author of this thesis, this is clearly indicated. The 
numbering of PTPa residues is based on the Genbank CRYPal cDNA sequence, 
accession number L32780 and its 1,499 amino acid open reading frame (Stoker, 1994). For 
historical reasons, catalytic site mutations are referred to both by analogy to the equivalent 
sites in the single PTP1B catalytic domain and by their position within PTPa; all other 
mutations are identified by virtue of their PTPa location.
2.3.1 :pCRYPa1
All of the PTPa constructs generated during this thesis were derived from the chick PTPa 
coding sequence in the vector pCRYPal. This vector was generated by Dr Andrew Stoker 
and has previously been described. It comprises chick PTPal cloned into the commercial 
cloning vector pT7/T3al8 (Invitrogen, UK) (Stoker, 1994). This vector also contains a 
large (ca. 2000 bp), so-far incompletely sequenced 3’ untranslated region from chick PTPa.
752.3.2: pBGA1
Eukaryotic cells transfected with this vector were used to generate PTPa RAP probe 
without the 3xFLAG tag for comparison with the protein generated by the p3xFLAG- 
CMV25-PTPg-EC-AP construct (Below). The construction of this vector has previously 
been described (Haj et al., 1999; Chilton, 2000) and encodes wild type PTPa including the 
endogenous signal peptide and the complete extracellular domain (bp: 112-2274; aa: 1-721).
2.3.3: p3xFLAG-CMV25  -PTPa-E C
The PTPa extracellular domain, lacking the endogenous signal peptide (bp: 196-2682 
inclusive; aa: 29-829), was amplified by PCR with primers that inserted unique 5’-Nod and 
y~XbaI sites (F: atatgcggccgcggaaagtccccctgtgttc; R: attctagagggcccaatgacccagat). The PCR 
product was digested with Notl and Xbal and inserted into Notl/Xbal digested p3xFLAG- 
CMV25-Myc (Sigma) to produce p3xFLAG-CMV25-PTPa-EC. Transfection of 
mammalian cells with this construct results in the secretion of an amino-terminal 3xFLAG 
tagged PTPa extracellular domain into the tissue culture medium. Membrane expression of 
proteins carried by the p3xFLAG-CMV25 backbone is driven by the preprotrypsin signal 
peptide.
2.3.4: p3xFLAG-CMV25-PTPo-EC-AP
In order to evaluate the effect of the 3xFLAG tag on PTPa ligand binding, the p3xFLAG- 
CMV25-PTPn-EC-AP vector was constructed by cloning the BgHI-Xbal fragment from 
pBGAl into similarly digested p3xFLAG-CMV25-PTPa-EC. Eukaryotic cells transfected 
with this vector were used to generate PTPa RAP probe with the 3xFLAG tag for 
comparison with the protein generated by the pBGAl construct. The p3xFLAG-CMV25- 
PTPa-EC-AP vector encodes the complete extracellular domain of wild type PTPa minus 
the endogenous signal peptide (bp: 195-2275; aa: 29-721) with an amino-terminal 3xFLAG 
tag and a carboxyl-terminal alkaline phosphatase moiety.
2.3.5: p3xFLAG-CMV25-PTPo- UTR
A BgHI/Xbal fragment (bp 1265 —  4613, plus approximately 1300bp of unsequenced,
endogenous PTPa 3’-untranslated region (UTR)) was obtained from the pCRYPal vector
(Stoker, 1994). This fragment was inserted into BgHI/Xbal digested p3xFLAG-CMV25-
PTPa-EC to produce p3xFLAG-CMV25-PTPa-UTR. Transfection of mammalian cells
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amino-terminal 3xFLAG tag.
2.3.6: p3xFLAG-CMV25-PTPo-Myc
The carboxy-terminal region of PTPa (bp: 3651-4608; aa: 1232-1499) was amplified by 
PCR (F —  gaactacatggtacagacagaagaccagtacagc; R - cctctagatgttgcatagtgatcaaaacttccc). The 
reverse primer introduced a unique Xbal site. The PCR product was digested with EcoRI 
and Xbal and inserted into EcoRI/Xbal-digested pCMV25-PTPa-UTR to create p3xFlag- 
CMV25-PTPa-Myc. Transfection of this construct into mammalian cells results in the 
expression of full-length PTPa (aa 29-1499) with an amino-terminal 3xFLAG tag and a 
carboxy-terminal Myc tag.
2.3.7: p3xFLAG-CMV25-Mjc-5 ’+3 ’ Xhol
The 3xFLAG-PTPa-Myc cassette was made excisable by insertion of two Xhol-containing 
linkers, one each into the p3xFLAG-CMV25-Myc SacI (5’) and BamHI (3’) sites. The Notl- 
Xbal fragment from p3xFLAG-CMV25-PTPs-Myc was then inserted to create the final 
vector (5’ Xhol F —  tcgctcgagtcttagct; 5’ Xhol R —  aagactcgagcgaagct; 3’ Xhol F —  
gatcgtactcgagcta; 3’ Xhol R —  gatctagctcgagtac). The intermediate constructs p3xFLAG- 
CMV25-PTPa-Myc-5’X M  and P3xFLAG-CMV25-PTPa-Myc-3’X M  were kept and used 
in other cloning steps.
2.3.8: p3xFLAG-CMV25-PTPa-3xMyc
p3xFLAG-CMV25-PTPa-3xMyc was derived from p3xFLAG-CMV25-PTPa-Myc by 
insertion of a linker containing an additional two Myc tags into X^J-digested vector. 
Insertion of this linker destroyed one of the two resulting Xbal sites to recreate a single 
Xbal site, located between the PTPa sequence and the tag sequence (F —  
ctagagaacaaaaactaataagtgaagaagacctagagcagaagctgatcagcgaggaggacctga; R —  
ctagtcaggtcctcctcgctgatcagcttctgctctaggtcttcttcacttattagtttttgttct).
2.3.9: p3xFLAG-CMV25-PTPo-HA
This vector was derived from the p3xFLAG-CMV-Myc-3X7w/ vector by linker insertion 
(HA F —  ggatctagatacccctacgacgtgcccgactacgcctgactcgagagc: HA R —  
gctctcgagtcaggcgtagtcgggcacgtcgtaggggtatctagatcc) and replacement of the single Myc tag
77with an HA tag. The p3xFLAG-CMV25-Myc-3XM vector and the annealed linkers were 
digested with Xbal and Xhol. Linker insertion replaced the Myc tag with an HA tag in 
frame with the PTPa insert and recreated both the 5’ Xbal site and the 3’ Xhol site. 
Transfection of mammalian cells with this vector results in the expression of full-length 
PTPa with an amino-terminal 3xFLAG tag and a carboxy-terminal HA tag.
2.3.10: pCI-Neo-PTPa-HA
This vector was created by sub-cloning the BstEII/3’ Xhol PTPa fragment from 
p3xFLAG-CMV25-PTPa-HA-5’+3’X/>o7 and inserting it into the BstEII/L^/7-digested pCI 
Neo-PTPa vector (A.Stoker, unpublished). The pCI-Neo-PTPa vector contains the entire 
Xbal flanked PTPa fragment from the pCRYPal vector cloned into the pCI-Neo 
mammalian expression vector (Promega, UK). pCI-Neo-PTPa-HA therefore contains full- 
length PTPa (bp: 112 —  4606 inclusive; aa: 1-1499 inclusive) including the endogenous 
PTPa signal peptide but not the preprotrypsin leader used in all of the other mammalian 
expression vectors in this thesis. Transfection of mammalian cells with this vector results in 
the expression of full-length PTPa without an amino-terminal tag, but with a carboxy- 
terminal HA tag.
2.3.11: pHE vectors —  C-terminally His6 tagged  protein expression
Eukaryotic expression vectors containing various extracellular domain deletions of PTPa 
were created using the pHL vector for dimerisation experiments using dynamic light 
scattering. The vectors pHL and pHL-FNA3 were provided by Dr Radu Aricescu. The 
construction of the pHL backbone which contains 6 tandem Histidine (His6 ) residues has 
previously been described (Aricescu et al., 2006). pHL-FNA2 and pHL-FNA4 drive the 
expression of carboxyl-terminally His6-tagged truncated PTPa extracellular domain 
proteins lacking sequences after the second or fourth FN3 domain. The PTPa extracellular 
deletions were based upon those previously characterised by John Chilton (Chilton, 2000). 
pHL-FNA3-AP adds an alkaline phosphatase moiety (lacking the endogenous AP signal 
peptide —  CAP) to the truncated PTPa extracellular domain product produced by pHL- 
FNA3. Finally, pHL-SAP encodes a soluble form of the alkaline phosphatase domain 
alone.
The alkaline phosphatase inserts for pHL-SAP and pHL-FNA3-AP (CAP) were amplified 
by PCR (SAP F —  cgcggaattcgacccaagcttcctgcatgctgctg; CAP F —
78cgcggtaccatcatcccagttgaggaggagaacc; SAP/CAP R -  cgcggtaccacccgggtgcgcggcgtcggtg) 
from pAP-Tag4 (SAP) or pBGal  (CAP) to introduce either two Kpnl sites (CAP) or unique 
5’ EcoRI and 3’ Kpnl sites at each end of the product (SAP). The SAP insert was cloned into 
EcoRI/Kpnl digested pHL and the CAP insert was cloned into Kpnl-digested pHL-FNA3.
The PTPa extracellular domain from the signal peptide to the desired deletion sites was 
amplified (FNA2/ 4 F —  cgcggaattcaagcttgcatgcctgcaggtcgact; FNA2 R —  
cgcgggtaccaacctggatggggtcagaaagaggc; FNA4 R -  cgcgggtaccgacgataactggcgagctctccggg) 
from the pBAG series of extracellular domain deletions (Chilton, 2000) to create unique 
EcoRI and Kpnl sites at the 5’ and 3’ ends of the products, respectively. The resulting 
appropriately digested inserts were cloned into EcoRI/Kpnl digested pHL (R. Aricescu).
2.3.12: pGEXKT-PTPaD 1+D2
Bacterial expression vectors containing either wild type PTPa or PTPa containing substrate 
trapping mutations (D181A, Q262A, Dbl, C215S, C215D) fused to glutathione-S- 
transferase (GST) were created using the pGEX-KT vector (Hakes and Dixon, 1992). 
Induction of E.coli transformed with this vector results in the production of a fusion 
protein where the PTPa portion is carboxy-terminal to the GST moiety, separated from it 
by a thrombin site and a 6 residue glycine-rich linker, which facilitates thrombin cleavage. 
The PTPa intracellular domain (bp: 2743-4701; aa: 928-1499) was amplified by PCR using 
primers that created 5’ and 3’ BamHI sites (F —  ggtcaggatccccagacagcaaacggaaagatt; R —  
ggtcaggatccttatgttgcatagtgatcaaaact).
2.3.13: Chicken cDNA libraries
Plasmid libraries containing cDNA derived from embryonic chick RNA were previously 
created in the laboratory (Aricescu, 2002).
2.3.14: Isolation of chicken EAR cDNA
Two chicken LAR clones were generated independently (pGEM T-easy LAR clone 1 
(pLAR-1) and pGEM T-easy LAR clone 2 (pLAR-2)) by ligation of RT-PCR products 
(LAR IF  —  gtttgatgatgggtcgggat; LAR 1 R —  ccggccgctgcgtccgcaaag; LAR 2 F —  
gtttgatgatgggtcgggatc; LAR 2 R -  ctgcgtccgcaaagtcttcac), amplified from an E7 mRNA- 
enriched template (Oligotex: Qiagen, UK or mini-oligo(dT), 5 Prime Inc, Boulder USA), 
into the pGEM-T-easy vector (Promega).
792.4: Cell Biology
HEK 293T, and Cos-7 cells were obtained from the American Tissue Culture Collection 
(ATCC). PCI 2 cells were a gift of Dr Jonathan Ham, Media and sera were sourced from 
Sigma-Aldrich, UK. Plasticware was obtained from Techno Plastic Products (TPP) AP, 
Switzerland. Dulbecco’s PBS solution A (DPBSA), which is Ca/Mg2+ free, and complete 
Dulbecco’s PBS (DPBS), which contains both divalent cations, were purchased from 
Sigma. Single batch foetal bovine serum was obtained from Sigma-Aldrich.
2.4.1: Cellpropagation
All cell lines were routinely maintained in Dulbecco’s modified eagle media (DMEM; High 
glucose) without antibiotics, supplemented with 10% heat inactivated FBS at 37°C, 5%
C 02. However, for H20 2  treatments and related experiments, HEK-293T cells were grown 
in FI0 or FI2 media as described in the text and cells were serum starved overnight before 
treatment. Cells were passaged every 2-3 days using Trypsin/EDTA solution (Sigma- 
Aldrich, UK) and seeded at a density of lxlO3  cells/ml (Gibco recommendations —  15cm2  
plate: 20ml/2xl06  cells; 10cm2 plate: 10ml media/lxlO6  cells; 6-well plate: 2ml 
media/2xl0:>  cells; 12-well plate: 1ml media/lxlO6  cells; 24-well plate: 0.5ml media/5xl04  
cells). The progress of trypsinisation was monitored and terminated by the addition of 
complete growth medium.
2.4.2: Transfection
HEK-293T cells were transfected using two different methods and cells were harvested 48- 
72 hours post transfection. No significant difference was detected between cells transfected 
in either way for any parameter including transfection efficiency and PTPa expression level 
and cleavage pattern (Data not shown). PC6-3 cells were transfected using Effectene 
(Qiagen, UK) according to the manufacturer’s instructions.
2.4.2.1: Calcium Phosphate transfection
An optimised calcium phosphate transfection method was used (Jordan et al., 1996; Jordan
and Wurm, 2004). Cells were plated on the day before transfection as described above.
Cells were transfected with a total of 1 OOpil of transfection mix per 1ml of growth medium.
DNA (2.5pig/ml medium) was diluted into solution A (250mM CaCl2 ). An equal volume of
solution B (1.4mM Sodium phosphate, 140mM sodium chloride, 50mM Hepes, pH 7.05)
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transfection mix was added to the cells and the plates were returned to the incubator. After 
4 hours the media was removed and replaced with 10% glycerol in DPBSA. After 1 minute 
glycerol shock, the glycerol solution was replaced with normal growth medium. The 
glycerol shock step was omitted for HEK-293T cells.
2.4.2.2: Polyethyleneimine transfection
Polyethyleneimine (PEI; 25kDa branched form, Aldrich 40,872-7) was diluted to lm g/ml 
in ddH20  and used to transfect cells as previously described (Durocher et al., 2002). The 
resulting solution was adjusted to pH 7.40 with dilute HC1 and passed through a 0.22pm 
filter to sterilise it. The solution was stored as aliquots at -20C. Cells to be transfected were 
plated at 1x10s cells/ml the day before transfection. Immediately before transfection, the 
media on the cells was replaced with a half volume of fresh media. The DNA to be 
transfected was diluted in 1/10th media volume serum-free media. For HEK-293T cells in 
this lab the optimal amount of DNA was 16pg/ml transfection solution and the optimal 
DNA(H g ):PEI((lg ) ratio was 8:9. PEI was added to the DNA and mixed well by vortexing for 
10 seconds. The DNA-PEI solution was allowed to rest for 10 minutes at room 
temperature to allow complex formation. The DNA-PEI mixture was then added to the 
cells, which were then returned to the incubator. After 3 hours, the media on the cells was 
made up to the normal volume again.
2.4.3: Polyethyleneimine coating cover-slips
Cells for immunofluorescent analysis were plated onto coverslips before transfection. To 
optimise adherence, the cover slips were treated with polyethyleneimine (Personal 
communication, L. Ensor). All stages were carried out under sterile conditions. 
Polyethyleneimine (Sigma P3143 50%A q ) was diluted to 5% in water and stored at -20°C 
until required. Prior to use the frozen stock was diluted to 0.05% in 0.15M boric acid. 
Coverslips were coated overnight in 0.05% PEI, washed twice in ddH20  and air-dried 
leaning at an angle on the side of a Petri dish. The Petri dish containing the coated 
coverslips was then sterilised for 5 minutes in a UV crosslinker (Stratalinker, Stratagene, 
UK)
812.4.4: Immunofluorescence
Cells for immunofluorescent analysis were cultured on polyethyleneimine-coated coverslips 
placed into the well of a 6-well plate. After removing the growth media, the coverslips were 
rinsed three times in cold DPBSA before being fixed for 30 minutes in cold 4% PFA. 
Following fixation, all steps were carried out at room temperature unless otherwise 
specified and wash steps were carried out on a gendy rocking platform. Fix was removed 
by a 5 minute wash in PBS followed by quenching in 2% glycine in PBS for 5 minutes. The 
glycine solution was removed with a further 5 minute wash in PBS. The fixed cells were 
permeabilised by incubation for 5 minutes in 0.1% TX100, 0.05% SDS in PBS. Excess 
detergent was removed with 2 washes of 5 minutes each in PBS. The coverslips were then 
incubated with aHA (1:1000) and a FLAG (1:1000) for 45min at 37°C on parafilm. 
Coverslips were then returned to the 6-well plates and unbound antibody was removed by 
6 washes in PBS. A second incubation step was performed as above using the appropriate 
a-Rat TRITC conjugated and a Mouse-FITC conjugated antibodies (Both 1:1000; Dako, 
UK). The cells were washed again as above and the coverslips mounted with Fluorsave 
(Calbiochem, UK). Immunofluorescence was observed using an Axioskop 2+ microscope 
with Axiovision software and with exposure times of 1200ms and 2000ms for FITC and 
Texas Red channels, respectively.
2.4.5: Trypsin treatment of  intact monolayers
Trypsin treatment of intact monolayers was performed as previously decribed (Olson et al.,
1988). All aspirations were performed gendy using a wide bore pipette and an automatic 
pipettor on the lowest setting. Cells were washed twice with PBS at room temperature 
before incubation for ten minutes in 5 ml room temperature Trypsin solution (0.5 mg/ml 
L-l-tosylamido-2-phenylethyl chloromethylketone-trypsin (Sigma, UK) in DPBS; prepared 
fresh from powder). After ten minutes, the trypsin solution was gently aspirated without 
disturbing the plate and replaced with 8 ml ice-cold inhibitor solution (1.5 mg/ml soybean 
trypsin inhibitor (Sigma), 1% (w/v) bovine serum albumin in DPBSA; prepared fresh from 
powder). This was then gendy aspirated without disturbing the plate and the cells were 
washed with ice-cold DPBS. Cells were lysed in the conventional manner.
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Receptor affinity probe experiments were performed as previously described using secreted 
alkaline phosphatase (SEAP) fusion proteins (Haj et al., 1999; Flanagan and Cheng, 2000; 
Flanagan et al., 2000). Conditioned media from pBGAl/pCMV25-PTPa-EC-AP 
transfected HEK-293T cells was removed between 3 days to 2 weeks after transfection, 
supplemented with 1M Hepes pH 7.00 (Final: lOmM) and sodium azide (0.1%(w /v) final) 
and filtered to sterilise the media and remove cells and debris.
The SEAP activity in lOOpl conditioned media was determined following heat inactivation 
of endogenous AP (5 minutes, 65°C) at 37°C using an equal volume of SEAP buffer (21% 
diethanolamine, ImM MgCh). The AP substrate p-Nitrophenylphosphate (pNPP) (lOpil) 
was added and AP activity measured at 405nm (ImU SEAP activity =+0.04 U/minute 
A^j, SEAP specific activity = 2U/ pg protein (Aricescu, 2002)).
RAP assays on sections or fixed cells were performed as follows. Fresh-frozen cryosections 
were washed in wash buffer (0.035% w/v sodium bicarbonate; 20 mM HEPES; 0.05% 
w/v BSA; pH 7.00) before fixation in 100% methanol at -20°C for 90 seconds. Slides were 
then briefly washed in wash buffer and excess liquid was removed. The section was 
covered in AP probe media and incubated at room temperature for 75 minutes. Unbound 
fusion protein was removed by washing in TBST (5x5min). Bound probe was fixed to the 
section by a 90 seconds incubation in 4% paraformaldehyde. Slides were again washed and 
endogenous AP activity was inactivated by incubation at 65°C for 30 minutes. Alkaline 
phosphatase activity was then detected using NBT/BCIP (Roche, UK) as recommended by 
the manufacturer. RAP assays on living cells were performed in the same way except that 
cells were incubated in conditioned media for 8 hours.
2.4.7: Homophilic binding —  SDS-PAGE assay
PTPa homophilic binding was assessed by SDS-PAGE as previously described (Cismasiu 
et al., 2004). PTPa- and mock-transfected cells were prepared for the homophilic binding 
assay . The medium was removed, and prepared as for a RAP probe conditioned medium.
It was saved at 4°C for future analysis. The cells were then washed three times in DPBSA 
and conditioned media was added. The cells were then incubated in conditioned medium 
for 8 hours at 37°C. The media was again set aside and cells were washed twice in ice cold
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compared using SDS-PAGE analysis.
2.4.8: Microscopy
Coverslips were analysed following staining and mounting on an Axioskop 2 with 
Axiovision software (Zeiss) at 400x magnification using phase and immunofluorescence 
optics. The exposure time was 1.2 seconds for the FITC channel and 2 seconds for the 
TRITC channel.
2.4.9: Time post transfection assay
HEK-293T cells were plated in 6cm2  plates and transfected as described above. All steps 
were carried out using a single preparation of cells or transfection mix that was used on 
each plate in turn. Cells were harvested as described below at 2, 4, 8, 16, 32 and 64 hours 
after removal of the transfection mix and lysates were analysed by SDS-PAGE and western 
immunoblotting.
2.4.10: Cell density experiment
A single 10cm" dish of HEK-293T cells (~2xl03  cells/ml) was transfected with calcium 
phosphate as described. Following removal of the calcium phosphate precipitate, cells were 
allowed to rest for 4 hours. Cells were then gently returned to a single cell suspension by 
trituration without using trypsin before being replated into the wells of a 6 well plate at the 
following densities: 1.6xl04, 3.12xl04, 6.25xl04,1.25xl03, 2.5xl03, 5xl03  cells/ml. Cells 
were then allowed to express the transfected protein for a further 64 hours before 
harvesting. Lysates were analysed by SDS-PAGE and western immunoblotting
2.4.11: Treatment of cells with BS3
Chemical crosslinking was performed by washing cells twice in ice-cold PBS before 
incubation with ImM BS3  (Pierce, UK) in ice-cold DPBS for 60 minutes with gentle 
agitation. Crosslinking was quenched by washing cells in TBS for 15 minutes. Cells were 
then lysed nomally.
842.4.12: Treatment of cells with Phorbol-12  -myristate-13 -acetate (TPA)
Phorbol-12-myristate-l 3-acetate (TPA) was obtained from Calbiochem Phorbol-12- 
myristate-13-acetate (TPA) was obtained from Calbiochem, dissolved in DMSO (Final 
TPA concentration: ImM) and stored at -20°C until required. TPA was added to cells at 
the indicated concentration, which were then replaced in the incubator for 30 minutes.
2.4.13: Treatment of  HEK-293T cells withpervanadate
Pervanadate was prepared as previously described (Lyons, 2003). 1.84g sodium 
orthovanadate (Na2 V 04 ) was dissolved in 45ml ddH ,0 and activated as follows. The pH 
was adjusted to pH 10.00 with 1M NaOH or 1M HC1 as appropriate. The solution was 
then boiled until colourless and the pH adjusted back to pH 10.00. This was repeated until 
the pH remained stable and colourless after boiling. The volume was returned to 50ml with 
ddH20 . This 200mM stock was defrosted immediately before use at 100°C and vortexed to 
redissolve any crystals. Working solution was prepared by adding 150pl 200mM activated 
orthovanadate to 789pi PBS. Hydrogen peroxide (H-jO,) (30% stock) was diluted 1:10 in 
PBS (3% final) and stored at 4°C for up to a month. To produce a pervanadate solution 
(30mM), 61 pi 3% H20 2 was added to the diluted sodium orthovanadate and mixed well. 
The mixture was incubated at room temperature in the dark for 15 minutes to allow 
pervanadate formation. The stock solution was diluted to 1 mM in culture media and the 
resulting ImM solution was diluted 1:10 into the media on the cells (Final concentration 
lOOpM). Cells were returned to the incubator for 30 minutes before being harvested as 
described.
2.4.14: Treatment of cells with H20 2
HEK-293T cells for H20 2 treatment were cultured in Ham’s F10 media with 10% FBS. To 
remove residual serum, cells were washed twice in F10 media without serum. Finally, cells 
were treated with the indicated amount of H20 2  freshly diluted in Ham’s F10 media for the 
indicated period of time. Cells were harvested in the normal manner.
2.4.15: Treatment of cells with serum
HEK-293T cells were grown in Dulbecco’s Modified Eagle Media supplemented with 10% 
FBS. The day before the experiment, conventional growth media was refreshed or replaced
85with fresh DMEM lacking any serum and the cells were cultured overnight. On the day of 
the experiment, the overnight media was replaced with DMEM containing 10% FBS as 
indicated and the culture dish was replaced in the incubator for the indicated length of 
time. Cells were harvested as described above.
2.5: Protein analysis
Protein concentrations were determined using Bradford reagent in the micro-assay 
protocol (Sigma, UK).
2.5.1: Harvesting and lysis ofHEK-293T cells to obtain protein samples
Following treatment and harvesting of the tissue culture supernatant if appropriate, HEK- 
293T cells were washed briefly twice in ice-cold DPBS. Cells were then lysed by the 
addition of an appropriate volume of lysis buffer (1ml/10cm diameter plate). Samples were 
left in lysis buffer on ice for 30 minutes with frequent mixing by inversion. Insoluble 
material was set aside following a 30 minute centrifugation at 13,000 rpm in a refrigerated 
centrifuge at 4°C. Samples were stored at -20°C until required. Unless otherwise indicated, 
cells were lysed in the following lysis buffer: 150mM NaCl, 20mM Tris-HCl pH 7.40, 2mM 
EDTA, 1% Nonidet P-40, 7pg/ml Pepstatin A, 1.5 mg/ml Aprotinin, 2mM PMSF). In 
indicated experiments a cysteinyl modifying agent (Iodoacetamide 20mM) was added. In 
experiments where phosphotyrosine levels were analysed, phosphatase inhibitors were 
added with the protease inhibitors (lOmM NaF, 2mM activated sodium orthovanadate).
2.5.2: Deglycosylation of  proteins with PNGase F
Peptide N-glycosidase F (PNGase F —  Sigma-Aldrich, UK) treatment was carried out as 
follows. Briefly, protein samples in conventional lysis buffer were denatured at 100°C for 
10 minutes in glycoprotein denaturing buffer (0.1% SDS, 1% (3-mercaptoethanol, 50mM 
sodium phosphate pH 7.50). The sample was cooled to room temperature and non-ionic 
detergent was added (Nonidet-P40, 1% final). The denatured protein was then incubated in 
a water bath at 37°C for 10 minutes before 500u PNGase F was added. Digestion was 
allowed to proceed for 3 hours. Samples were analysed by SDS-PAGE as described below.
862.5.3: Sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE)
Sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE) was performed 
as originally described (Laemmli, 1970). Stacking gels (0.125 M Tris.HCl, pH 6.80; 0.1% 
SDS) contained 3% total acrylamide ((I); Stock: 30% 37.5:1 total acrylamide:bisacrylamide 
(BioRad, UK)); the percentage of the resolving gel (0.375 M Tris.HCl, pH 8.80; 0.1% SDS) 
varied according to the size of the protein of interest (e.g. Disulphide crosslinked full 
length PTPa —  6% T resolving gel). Gels were polymerised using TEMED (Final: 0.04- 
0.1%(v/v)) and APS (Final: 1%). Electrophoresis was carried out in electrode buffer (0.025 M 
Tris, 0.192 M glycine, 0.1% SDS; pH~8.30). Samples (lOpg total protein) were completely 
denatured by incubation for 5 minutes at 100°C in sample buffer (2x: 0.125 M Tris.HCl pH 
6.80, 4% SDS, 20% glycerol, 10% fTmercaptoethanol, 0.001% bromophenol blue). 
Electrophoresis was carried out with a current of 10mA per gel until the marker left the gel. 
Protein size was determined by comparison to the migration of Precision Plus Protein 
prestained standards (BioRad, UK).
2.5.3.1: Two-dimensional Non-reducing/ Reducing SDS-PAGE
Samples (lOpg total protein) were analysed as described above except that reducing agents 
were omitted from the sample buffer and an alternative protein ladder that lacked reducing 
agents was used (SeeBlue Prestained standard, Invitrogen, UK). A schematic showing the 
process can be found below (4.3.4). The gel was removed from the electrophoresis cassette 
and following zinc staining, protein-containing lanes were excised and destained. The 
resulting sample lanes were incubated in lx Laemmli buffer (62.5 mM Tris-HCl pH 6.80, 
2% SDS, 10% glycerol, 0.001% bromophenol blue, 50mM N-Ethylmaleimide) with or 
without 5%(v/v) 2-Mercaptoethanol for 5 minutes at 100°C. The excised strips were then 
washed thoroughly for 2x5 minutes in 1%SDS, 10% glycerol, 62.5mM Tris-HCl pH 6.80, 
20mM Iodoacetamide to remove reducing agents and placed in an electrophoresis cassette. 
A 6%T resolving gel followed by a 3%T stacking gel was poured below or around the gel 
slice, respectively. An extra spacer was used to form a single well at the side of the gel for 
protein markers. The gel was then analysed in the usual manner.
2.5.3.2: SDS-PAGE analysis - Neutral silver stain
Silver staining visualisation was performed as previously described (Shevchenko et al.,
1996). Briefly, the gel was fixed overnight (50% methanol, 5% acetic acid). The gel was
87then washed for 10 minutes with 50% methanol and for 30 minutes in ddH20 . The gel was 
sensitised for 1 minute in 0.03% sodium thiosulphate and then rinsed three times for 5 
minutes each in ddH0O. The gel was then incubated in 0.1% silver nitrate for 20 minutes. 
The gel was then rinsed twice in ddH20 for 1 minute before development (0.04% 
formaldehyde, 2% sodium carbonate). Development was stopped by addition of 5% acetic 
acid. If necessary, gels were destained as required in Farmer’s Reducer (12.4g/l sodium 
thiosulphate, 0.28g/l potassium ferricyanide). Gels were stored in water or dried using a 
Model 583 gel dryer on the automatic 2 hour step programme (BioRad, UK). To prevent 
thick or high percentage gel cracking, gels were incubated for 1 hour in 35% ethanol, 2% 
glycerol prior to drying (Amersham Pharmacia website - Gel Drying Troubleshooting).
2.5.3.3: SDS-PA.GE analysis - Brilliant blue stain
Alternatively, SDS-PAGE gels were stained with brilliant blue (Alete, 2003). Gels were 
incubated in fix (50% Methanol, 10% Acetic acid) for 30 minutes and then incubated in 
staining solution (50% Methanol, 10% Acetic acid, 0.1% Brilliant Blue G-250; filtered 
through 3MM paper) for 30 minutes. Gels were washed in water and destained overnight in 
destain (12% Methanol, 7% Acetic acid) until the required intensity of staining was 
achieved. Gels were stored in ddH20  or dried as described above.
2.5.3.4: SDS-PA.GE analysis 3- Zinc staining
Proteins were stained using a modification of a published method (Femandez-Patron et al.,
1992). Briefly, gels were removed from the gel cassette and rinsed in ddH ,0 for 5 minutes. 
Then the gels were sensitised in 1% sodium carbonate for 15 minutes. Gels were incubated 
in imidazole solution (200mM imidazole, 0.1% SDS) for 30 minutes and then rinsed in 
ddH20  for 1 minute. Finally, gels were developed in lOOmM zinc acetate solution (0.45pm 
filtered) until they reached the desired opacity. Development was terminated by rinsing the 
gels in ddH20  three times for 5 minutes each time. Gels were destained in 50mM EDTA, 
pH 8 .00 prior to protein transfer or 2D electrophoresis.
2.5.4: Western blotting
Proteins separated by SDS-PAGE analysis were transferred to Immobilon-P (Pore size: 
0.45pm) polyvinylidene fluoride (PVDF) membranes (Milipore, UK) using a modification 
of the original protocol (Towbin et al., 1979). Gels were equilibrated in ice-cold transfer 
buffer (25mM Tris.HCl, 192mM Glycine, 20% methanol (pH~8.30)). 6 pieces of 3MMpaper (Whatman, UK) and one piece of PVDF membrane pre-trimmed to the size of the 
gel were prepared by incubation in ice-cold transfer buffer. The PVDF membrane was first 
wetted in methanol. A cassette was assembled on the cathode plate of a Trans-Blot II 
semidry electrophoretic transfer apparatus (BioRad, UK) according to the manufacturer’s 
instructions. Up to two gels at a time were transferred for 30 minutes at room temperature 
using 20V constant voltage. After transfer, to enhance protein retention and reduce 
background noise, membranes bearing the proteins from transferred gels were washed in 
ddH20  for 5 minutes and then submerged in methanol and allowed to air dry (Milipore 
Immobilon-P technical literature). Membranes were rewet in methanol followed by a five 
minute wash in ddH20  prior to subsequent analysis.
2.5.4.1: Analysis ofproteins on membranes 1 - Ponceau stain
Proteins transferred to PVDF were stained for 1 minute using Ponceau S/Ponceau red 
(lOx Stock solution (2% ponceau red, 30% trichloroacetic acid, 30% sulfosalicylic acid); 
Dilute 1:10 in 1% acetic acid prior to use). The membrane was then rinsed in ddH20  until 
the desired contrast was reached. The membrane was destained using frequent changes of 
ddH20 . If necessary the final traces of red stain were removed with a wash in 0.1 M NaOH.
2.5.4.2: Analysis of  proteins on membranes 2 - Immunological detection
Non-specific antibody binding was blocked by incubation of the membrane for 1 hour at 
room temperature in Tris-buffered saline with Tween (TBST) containing either 10% (w /v) 
non-proprietary dried, skimmed milk powder (all primary antibodies other than anti- 
phosphotyrosine) or 3% bovine serum albumin (anti-phosphotyrosine). Membranes were 
rinsed for 5 minutes in TBST and then detected by incubations of one hour each in the 
appropriate blocking buffer with primary antibody and subsequently with horseradish 
peroxidase (HRP)-conjugated species-specific secondary antibody. Following each antibody 
incubation step, unbound antibody was removed by a series of five 5-minute washes in 
TBST.
Bound HRP-labelled species-specific secondary was detected using the ECL-Plus system 
(Amersham) according to the manufacturer’s instructions using cassettes with intensifying 
screens and blue-sensitive autoradiography film (Kodak X-Omat Blue; Kodak, UK). 
Exposed film was either developed automatically using a Compact X4 film processor 
(Xograph Imaging Systems, UK) or manually using the X4 developing reagents.
892.5.4.3: Analysis of  proteins on membranes 3 - Stripping western blots
Membranes blocked with skimmed milk were stripped to allow a second or third antibody 
probing in the following manner (Suck and Krupinska, 1996). Blots were rinsed for 5 
minutes in ddH20  and then incubated for 5 minutes in 0.2M NaOH. This was followed by 
a 5 minute wash in ddH20 . The membrane was then re-blocked and processed as 
described above.
2.5.5: Kate-^onal centrifugation
5-20% glycerol gradients were prepared in 4.8ml polyallomer (Beckman, UK) tubes using 
the underlayering technique and allowing the formed step gradients to diffuse overnight at 
4°C. The glycerol solutions were prepared in the gradient buffer (ImM EDTA, 2mM 
MgS04, 0.1% Triton X-100, 20mM Hepes-NaOH pH 8.00, 7pg/ml Pepstatin A, 1.5|ig/ml 
Aprotinin, 2|ig/ml PMSF). Unfortunately, it was not technically possible to confirm that 
the gradient formed was linear, although this might be achieved by measuring the refractive 
index of blank fractions. 100pi protein sample in Triton lysis buffer (1% Triton X-100, 
20mM Tris pH 8.00,150mM NaCl, 7pg/ml Pepstatin A, 1.5pg/ml Aprotinin, 2pg/ml 
PMSF) was gendy applied to the top of the gradient and the samples were centrifuged at 
43k rpm in a Beckman Ultracentrifuge using a SW41Ti rotor for 17 hours. Samples 
(~250pl) were collected from the bottom of the tube using a 27G needle and analysed by 
SDS-PAGE.
2.5.6: Immunoprecipitation
All steps were carried out on a rotating platform at 4°C unless otherwise specified. Protein 
A /G  (Coupled to agarose; Fast-flow, 2mg/ml as 50% slurry; Upstate, UK) was prepared by 
addition of BSA (Final: 5%(w /v)) to block non-specific binding. Protein A /G  was blocked 
overnight. Protein lysates (adjusted to 2pg/ pi) were cleared by incubation for 1 hour with 
50pl Protein A/G. The agarose beads were removed by centrifugation (20s, 13k rpm), 20pl 
precleared lysate was set aside for use as a lysate control. Precleared lysates (400pg) were 
incubated overnight with 2.5pg specific or control antibodies. The next day, 60pl protein 
A /G  was added and the sample incubated for an additional 2 hours. The 
immunoprecipitate was collected by centrifugation for 30s at 13k rpm and washed five 
times by vigorous resuspension in lysis buffer followed by centrifugation as above. Finally,
90immunoprecipitates were eluted from the beads by denaturation in 50(jil 2xLaemmli buffer 
at 100°C for 5 minutes followed by centrifugation as above. The supernatant was removed 
and 15jjtl was analysed by SDS-PAGE.
2.6: Bioinformatics
DNA and protein analysis was performed using the programs BioEdit, Chromas, and 
pDraw32, which the authors have generously made freely available to download 
(http: / /www.mbio.ncsu.edu/BioEdit/bioedit.html:  http: / / www.acaclone.com/: 
http: / /www.technelvsium.com.au/chromas.html) (Hall, 1999; Tippmann, 2004).
2.6.1: Transmembrane domain prediction
Transmembrane peptides were predicted using the THMM server as described 
(Sonnhammer et al., 1998; Krogh et al., 2001; Moller et al., 2001).
2.6.2: Molecular weight  prediction
The tool, Compute pI/Mw, from the Expasy site (http://ca.expasy.org/tools/) was used 
to predict the molecular weight of the peptide backbone of all PTPa species (Gasteiger E 
et al., 2005). Molecular weights were computed using average amino acid molecular weights 
rather than monoisotopic weights.
2.6.3: Protein 0  -/ N-glycosylation prediction
Protein N- and O- glycosylation was predicted using the NetOGlyc and NetNGlyc tools 
(http://www.cbs.dtu.dk/services/NetNGlvc/ and ~/NetOGlyc/ (Gupta et al., 2002; 
Julenius et al., 2005).
2.6.4: Tyrosine sulphation prediction
Tyrosine sulphation prediction was performed using Sulphinator 
(http.7 /www.expasy.org/tools/sulfinator/) (Monigatti et al., 2002).
2.6.5: Hjdrophobicity analysis
Hydrophobicity analysis was performed using the method of Kyte & Doolittle (Kyte and 
Doolittle, 1982) in the BioEdit package.
912.6.6: Helical wheelplots
Helical wheel plots were generated using the Java applet at 
http: / /cti.itc. virginia.edu / ~ cmg /Demo / wheel/wheelApp.html.
2.6.7: Chicken EST database searches
During the course of the work described in this thesis three chicken EST databases were 
generated that were useful in the cloning of chicken LAR http:/ /www.chick.umist.ac.uk/: 
http://www.chickest.udel.edu/: http://pheasant.gsf.de/DEPARTMENT/dt40.html 
(Boardman et al., 2002; Carre et al., 2006).
92Chapter 3: Overexpression studies of PTPcr
The core chapters of this thesis examine the role that dimerisation plays in PTPa 
function (Chapter 4, Chapter 5). In order to carry out these experiments it was necessary to 
create a number of constructs that may be used to drive the expression of tagged PTPa in 
transfected cells. In this chapter the expression of recombinant tagged PTPa using these 
expression constructs is characterised. It was found that a number of PTPa species are 
produced in transfected cells including full-length PTPa and a range of fragments resulting 
from cleavage at specific sites. A modified nomenclature is proposed for PTPa processing. 
The sub-cellular localisation of the various PTPa species was examined using 
immunofluorescent and biochemical approaches. Full-length PTPa was found to be 
expressed on the surface of transfected cells whereas at least a significant proportion of the 
cleavage products were found within the cell.
3.1: Expression of wild type PTPa
Transfection of HEK-293T cells with vectors encoding chick PTPa with an amino- 
terminal 3xFLAG tag resulted in the detection of three FLAG-reactive PTPa species 
(Figure 3.1Bi). These had apparent molecular weights of approximately 160 kDa, 90kDa 
and 80kDa respectively. The relative level of the largest species when compared to the two 
smaller species varied between experiments. However, the smallest of the three species 
(Mw~80kDa) was always present at a higher level than the intermediately si2ed species 
(Mw~90kDa).
The carboxyl-terminal single Myc tag contained in the p3xFLAG-CMV25-Myc 
vector was not detectable in lysates in which the 3xFLAG epitope tag was successfully 
detected (Figure 3.1Bii). Therefore, two approaches were used to allow the detection of a 
carboxyl terminal epitope. Firsdy, the single Myc tag was direcdy replaced with a single HA 
tag. Secondly, the single Myc tag was lengthened to a 3xMyc tag by insertion of an 
oligonucleotide linker. In addition, it may be noted that the single Myc-tagged protein was 
detectable using a different monoclonal antibody (Clone 4A6; Upstate, UK) said to be less 
sensitive to the tag location than the 9E10 clone (Sigma-Aldrich, UK) used in this thesis 
(Data not shown). In cells that overexpress appropriately tagged PTPa, three peptide 
species can be detected using antibodies directed against the carboxy-terminal HA or 
3xMyc tag (Figure 3.1Bii,iii). These have apparent molecular weights of approximately 
160kDa, 85kDa and 75kDa respectively. In agreement with the data obtained using
93antibodies directed against the amino-terminal tag, whilst the relative abundance of the 
largest species relative to the two smaller species varied between transfections, there was 
always a significant difference in the relative level of the two smaller species. In all 
experiments, the larger fragment (Mw~85kDa) was reproducibly more abundant than the 
smaller (Mw~75kDa).
Transfection of a rat phaeochromocytoma-derived cell line (PC6-3) results in the 
production of the same PTPa species that are seen in transfected HEK-293T cells (Figure 
3.1 C). As expected, transfection of this cell line resulted in a significantly lower transfection 
efficiency and a noticeably lower level of recombinant protein expression than transfection 
of the HEK-293T cell line (Data not shown). The extracellular and full-length species from 
the PC6-3 cell line appeared to run very slightly smaller than those from E1EK-293T cells 
(Data not shown). There was no detectable difference in the si2e of the larger intracellular 
domain fragment. The smaller intracellular domain fragment was undetectable under the 
same conditions used to detect it in HEK-293T cells. This is likely to be due to low 
expression levels rather than qualitative differences in PTPa processing.
Cells that overexpress PTPa shed an extracellular domain fragment into the tissue 
culture media. The media from cells transfected with PTPa was removed and cell debris 
was removed by passage through a 0.22pm filter. Analysis by SDS-PAGE and subsequent 
immunoblotting revealed the presence in the media of a PTPa species that was 
immunoreactive for both the FLAG (Figure 3.1 B iv) and IG2 antibodies (Data not shown) 
(Stoker et al., 1995a). Careful examination of the apparent molecular weight of this shed 
species revealed that the band was different in si2e from both the intermediate and smallest 
bands seen in cell lysates (Band 2) (Figure 3.1 B). The band migrated with an apparent 
molecular weight very slightly larger than that of the smallest FLAG positive species 
(~82kDa).
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95Figure 3.1: Overexpression of 3xFLAG- and HA-tagged PTPa
A.  Schematic diagram of PTPa proteins to show tag locations and expected cleavage 
products.
B.  Expression of 3xFLAG- and HA-tagged PTPa in HEK 293T cells. Cells were 
transfected using calcium phosphate. Lysates or conditioned cell culture media (iv. lane 
1) were analysed using reducing SDS-PAGE. Western blots were probed with antibody 
against the amino-terminal 3xFLAG tag (Panel i.), the carboxyl-terminal Myc or 3xMyc 
tag (Panel ii.), the carboxyl-terminal HA tag (Panel iii.) and the amino-terminal 
3xFLAG tag (Panel iv.).
C.  Expression of 3xFLAG- and HA-Tagged PTPa in PC6-3 neuronal cell line. PC6-3 cells 
were transfected with PTPa by J. Nixon using Effectene (Qiagen, UK). Lysates were 
analysed using reducing SDS-PAGE and Western blots were probed with antibody 
against the amino-terminal 3xFLAG tag (Left panel) or the carboxyl-terminal HA tag 
(Right panel).
Band 1.  Full-length PTPa 1 (FL1 6 6 )
Band 2.  Extracellular domain from
Band 3.  Phosphatase domain from
Band 4.  Extracellular domain from
Band 5.  Phosphatase domain from
amino terminal cleavage (E8 1 ) 
amino-terminal cleavage (P85) 
carboxy-terminal cleavage (E9 0 ) 
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96Previous work on chick PTPa has utilised the IG2 antibody, which was raised 
against a bacterially expressed GST fusion containing the first 2 PTPa Ig2 domains (Stoker 
et al., 1995a). This antibody has not previously been shown to detect full-length chick 
PTPa. In addition, only a single smaller extracellular domain species has been detected 
rather than the two that are detectable with the FLAG antibody. The detection profile of 
these 2 antibodies was therefore compared. Under reducing conditions, it proved very 
difficult to detect overexpressed PTPa with the IG2 antibody, despite the known high level 
of PTPa in these cells (Figure 3.2 B). Indeed detection of any PTPa expression at all under 
reducing conditions required significantly extended exposure times. Moreover, even under 
these conditions, it did not prove possible to detect full-length PTPa and only small 
amounts of the intermediately si2ed fragment were detectable despite the abundance of 
both of these species in the lysate (c.f. Figure 3.IB, Figure 3.2B). Subsequent work 
described in this thesis makes abundant use of non-reducing SDS-PAGE. As an aside to 
this work, it was noted that when used to immunoblot non-reducing SDS-PAGE gels, the 
IG2 antibody is able to detect all three PTPa species that contain the extracellular domain 
(Figure 3.2 C). However, although the relative abundance of the intermediately sized 
species normalises under these conditions, the relative abundance of the full-length species 
is still noticeably under detected.
Although its interpretation is complicated, the IG2 antibody allows comparison of 
endogenously expressed PTPa with that produced in HEK-293T cells. Using the IG2 
antibody on lysates made from embryonic chick tissues, two species are detected with 
apparent molecular weights of approximately 75 and 130 kilodaltons (kDa) respectively 
(Figure 3.2D). These are believed to represent the extracellular fragments of the short, 
PTPal, and long, PTPa2, isoforms respectively. However, there is no direct agreement 
between the size of the endogenous PTPal band and the two extracellular domain 
fragments as expressed in HEK-293T cells. The endogenous band is slightly smaller than 
those seen when PTPa is overexpressed (Figure 3.2D). However, the difference is larger 
than that which would be expected from the inclusion of the 3xFLAG tag.
It is possible that the reduced size of the extracellular domain fragments seen when 
PTPa was expressed endogenously or in neuronal cells reflects a difference in post- 
translational modification between these different types of cell. The magnitude of the 
difference is in the order of 5-10kDa. A possible mechanism for this difference might be 
differential glycosylation. Indeed it is likely that PTPa is glycosylated on several residues 
(Stoker, 1994). Therefore, PTPa overexpressed in HEK-293T cells was digested with
97PNGase F, which removes N-Iinked sugar residues from asparagine residues in the peptide 
backbone. This resulted in a small decrease in the molecular weight of all PTPa species 
containing extracellular domain constituents (Figure 3.2E). Following digestion with 
PNGase F, the smallest PTPa extracellular domain species migrated with an apparent 
molecular weight approximately lOkDa less than following mock digestion. Similarly, the 
intermediate fragment migrated approximately 5-8kDa faster. It was difficult to determine 
whether the full-length protein also migrated faster following PNGase F treatment and 
there was no discemable effect on intracellular domain fragment size (Data not shown).
The effect of degylycosylation on PTPa size suggested that it does not exhibit extensive 
glycosylation. This is in keeping with the small number of predicted glycosylation sites 
(1.2.1).
It was noted above that the proportion of PTPa found in the full-length or cleaved 
form varied significantly between experiments. Experience suggested that some of this 
variability was due to the amount of time between transfection and cell harvesting. 
Harvesting cells at set time-points post-transfection showed that the appearance of PTPa 
species followed a predictable pattern (Figure 3.3C). FL1 66 appeared first, at approximately 
16 hours post transfection. In contrast, E90 and E8 1  were only detectable from 
approximately 32 hours post-transfection. Moreover, Egl appeared earlier than E90. It might 
be suggested that the observed effects of time post-transfection on cleavage pattern might 
reflect differences in the relative exposure of lanes containing little PTPa and lanes 
containing large amount of PTPa. However, comparison of equivalently exposed lanes 
(Figure 3.3C Panel i lane 4; panel iii lane 5) reveals that this is not the case. The pattern of 
PTPa cleavage therefore appears to change during the course of this experiment. One 
possible explanation for this difference is that the HEK-293T cells continued to proliferate 
throughout the experiment increasing cell density, another might be that the transfection 
method inhibits protein expression and that this effect diminished with time. However, as 
the cleavage pattern of RPTPs may be affected by cell density (Campan et al., 1996), a 
complimentary experiment was designed to determine the effects of cell density on PTPa 
expression level and cleavage pattern.
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99Figure 3.2: Analysis of IG2 antibody detection pattern and PTPa glycosylation
A.  Schematic diagram of PTPa proteins to show tag locations and expected cleavage 
products.
B., C. Detection of overexpressed 3xFLAG-PTPa-HE using IG2 antibody under reducing 
(B) and non-reducing (C) conditions using the same lysate shown in Figure 3.1 B-C. 
Samples were analysed in parallel with identical exposure times (Standard exposure =  1 
minute; long exposure = 1 hour).
D.  Non-reducing detection of endogenous PTPa expression in lysates from embryonic 
chick tissue.
E.  Glycosylation status of PTPa peptides. HEK-293T cells were transfected with 
3xFLAG-PTPa-HA. Lysates were treated with PNGase F (+) or mock digested (-). 
The effects of PNGase F digestion were analysed by SDS-PAGE and western 
immunoblotting using antibodies against the amino-terminal 3xFLAG tag
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Deglycosylated band 4
Deglycosylated band 2Cells at a range of cell densities were harvested 64 hours after transfection, 
representing the final time point in the time-course experiment, at which all three FLAG- 
positive species were detectable. At low cell densities only FL166 was detectable whereas 
only above normal cell densities (2.5x103  cells/ml) were all three species detectable (Figure 
3.3B). However, comparison of equivalendy exposed lanes suggested that the apparent 
effect of cell density on PTPa cleavage may be due to the relative exposure of each lane 
(Figure 3.3B Panel i lane 4; panel iii lane 6). It must be noted that in addition to cellular 
proliferation, the HEK-293T cell line would also exhibit plasmid amplification . It is not 
clear whether the degree of plasmid amplification was consistent in cells at all densities. 
Finally, in the time-course and cell density experiments, the total amount of PTPa 
increased in proportion to increasing time post-transfection or increasing cell density, 
respectively. Equal amounts of total protein (Bradford Assay) were loaded into each lane. 
However, it is clear from the Brilliant blue stained gels (Figure 3.3 B panel ii, C panel ii) 
that wells contained variable amounts of lysate and that this was balanced by differences in 
the contribution of bovine serum albumin (BSA) to the sample. Despite these problems 
however, the observed differences in total protein level (at most 5-fold) appeared not to 
account for all the increase in PTPa levels (> 10-fold).
3.2: Sub-cellular localisation of PTPa
The finding that both full-length and cleaved PTPa could be detected using SDS- 
PAGE raised the concern that the full-length PTPa was an artefact. This might be due to 
the accumulation of overexpressed protein that is not appropriately modified by the PTPa 
cleavage apparatus. For example, this might reflect the formation of insoluble aggregates 
containing overexpressed protein or the saturation of cellular processing systems by 
overexpressed protein resulting in the upstream accumulation of immature full-length 
PTPa. Under this second model, the additional intermediate band detected might represent 
an “escape” processing pathway utilised only when PTPa levels exceed that which can be 
contained within the normal processing pathways. Therefore, the localisation of PTPa 
within transfected cells was assessed using two different techniques. Firstly, the localisation 
of PTPa in fixed cells was assessed using immunofluorescence and then the accessibility of 
PTPa to extracellular trypsin was assessed using living PTPa-transfected cells.
101A. Schematic diagram of PTPa cleavage fragments
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-75Figure 3.3: Effects of cell density and duration since transfection on PTPa cleavage pattern
A.  Schematic diagram of PTPa proteins to show tag locations and expected cleavage 
products.
B.  Effect of increasing cell density on PTPa cleavage pattern. HEK-293T cells were 
transfected with PTPa and then split into plates at a range of cell densities. Cells were 
harvested 64 hours after transfection and the PTPa cleavage pattern was analysed by 
SDS-PAGE and western immunoblotting using antibodies against the amino-terminal 
3xFLAG tag(Panel i). A shorter exposure is also shown to allow comparison of 
equivalent exposures (Panel iii). Gels were also analysed by Brilliant Blue staining to 
show total protein content (Panel ii).
C.  Effect of increasing time since transfection on PTPa cleavage pattern. HEK-293T cells 
were transfected and then allowed to express PTPa for periods of time ranging from 2 
hours to 64 hours after removal of the transfection mix. Cells were harvested and the 
PTPa cleavage pattern was analysed by SDS-PAGE and western immunoblotting using 
antibodies against the amino-terminal 3xFLAG tag (Panel i). A shorter exposure is also 
shown to allow comparison of equivalent exposures (Panel iii). Gels were also analysed 
by Brilliant Blue staining to show total protein content (Panel ii).
10|ig total protein was loaded for each sample.
Band 1. Full-length PTPa 1(FL1 6 6 )
Band 2. Extracellular domain from amino terminal cleavage (E8 1 )
Band 3. Phosphatase domain from amino-terminal cleavage (P8 5 )
Band 4. Extracellular domain from carboxy-terminal cleavage (E9 0 )
Band 5. Phosphatase domain from carboxy-terminal cleavage (P7 5 )
BSA Bovine serum albumin from the cell culture media
1033.2.1: Immunofluorescent analysis of wild type PTPa protein
Under the conditions used, neither the anti-FLAG nor the anti-HA antibody 
exhibited significant levels of background staining on untransfected cells (Figure 3.4B, C).
In addition, there was no significant background seen when cells were detected with 
control serum and specific secondary antibodies (Data not shown).
Using the anti-FLAG antibody, which detects the amino-terminal tag, cell surface 
labelling was observed (Figure 3.4E, Arrows Figure 3.5D, G). In addition, in some cells a 
filamentous pattern of fluorescence was seen in association with the presence of discrete 
subcellular rings of signal (Arrow and arrowheads Figure 3.5A). This pattern may represent 
an optical section including cell-matrix adhesions at the cell base. There was evidence of an 
increase in signal intensity in areas of cell-cell contact (Figure 3.5G). However, this effect 
was not uniformly seen and was not clearly associated with contact either between two 
PTPa expressing cells or between one cell expressing PTPa and one that did not. Finally in 
some cells, FIAG-positive processes were seen (Figure 3.5K-M).
Immunofluorescent detection of the carboxy-terminal HA tag produced a similar 
picture of membrane localisation, although filamentous staining was not seen and the ring 
staining seen with the FLAG antibody was less clear using the HA antibody (Figure 3.4F, 
Figure 3.5B, E, H). However, two additional staining patterns were seen with the HA 
antibody. Firstly, the apparent depth of the pericellular staining was greater using the 
carboxyl-terminal HA tag than that seen using the amino-terminal FLAG tag. Secondly, in 
some cells a ring of perinuclear signal was seen (Figure 3.5B, C —  Open arrowheads).
Staining using the two tags generally agreed as can be seen by artificially overlaying 
the FLAG signal (green) over the HA signal (red). Areas of overlap were seen by the merge 
colour, yellow (Figure 3.4G, Figure 3.5C, F, I). However, as previously noted, the HA 
signal forms a less distinct perinuclear ring than the FLAG signal.
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105Figure 3.4: Immunofluorescent localisation of overexpressed PTPa —  1
A-C.  Control untransfected cells.
A —  Phase contrast; B —  anti-FLAG detection; C —  anti-HA detection 
D-G  Wild type PTPa-transfected cells,
D —  Phase contrast; E —  anti-FLAG detection; F —  anti-HA detection; G —  Merge of HA 
and FLAG signal
HEK 293T cells were grown on polyethyleneimine-coated coverslips and either mock- 
transfected or transfected with wild type PTPa using the calcium phosphate method. Cells 
were washed and fixed 72 hours after transfection. The PTPa construct used contained an 
amino-terminal FLAG tag, and a carboxyl-terminal HA tag. The FLAG epitope was 
detected with FITC-labelled secondary antibody (green) and the HA epitope was detected 
with Cy3-labelled secondary antibody (red). Scale bars (10pm) are included in each image. 
All images were obtained at 400x magnification using Axiovision software on an Axioskop 
II microscope (Zeiss).
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107Figure 3.5: Immunofluorescent localisation of overexpressed PTPa —  2
HEK 293T cells were grown on polyethyleneimine-coated coverslips and transfected using 
the calcium phosphate method with wild type PTPa bearing an amino-terminal FLAG tag 
and a carboxyl-terminal HA tag. The FLAG epitope was detected with FITC-labelled 
secondary antibody (A, D, G —  green) and the HA epitope was detected with Cy3-labelled 
secondary antibody (B, E, H —  red). Scale bars (10pm) are included in each image. All 
images were obtained at 400x magnification and merged images (C, F, I) were produced 
using Axiovision LE software (Rel. 4.5) on an Axioskop II microscope (Carl Zeiss).
A-C: Arrowheads indicate filamentous intracellular FLAG signal. Arrows indicate oval 
bodies surrounded by FLAG signal
D-F: Arrows indicate cell membrane signal
G-I: Arrows indicate membrane-localised FLAG signal, arrowheads indicate perinuclear 
HA signal
J-M: Arrow heads indicate cytoplasmic process with FLAG signal
1083.2.2: Analysis of cell surface exposure of PTPa peptides by limited trypsin digestion
The presence of PTPa protein at the cell surface was also assessed using limited 
trypsin digestion, which exposes living cells expressing the protein of interest to a dilute 
solution of trypsin. Theoretically, only peptide chains outside the protection of the plasma 
membrane are sensitive to digestion. Intracellular peptide chains are relatively protected 
from digestion.
Control experiments using the intracellular green fluorescent protein were initially 
discouraging as this intracellular protein was subject to significant amounts of digestion. 
This can be seen both from anti-GFP immunoblotting and from comparison of the total 
protein content of treated and untreated lysates using Brilliant Blue staining (Figure 3.6A). 
This was due to loss of cells following trypsinisation. Unfortunately, HEK-293T cells are 
easily detached form culture-ware even in the absence of trypsin. However, experience of 
the technique resulted in the ability to trypsinise cells under conditions where only a 
minority of cells were lost and so the total protein content was not significantly affected 
(Figure 3.6C). Moreover as exemplified by the results with PTPa, under these conditions, 
specific bands were either unaffected or disappeared entirely following trypsinisation.
Limited cell surface trypsinisation of PTPa-transfected cells resulted in the specific 
disappearance of full-length PTPa, with the specific preservation of the level of the 
smallest PTPa species detected by the FLAG antibody (Figure 3.6B). The low level of the 
intermediately sized fragment in many transfections made it difficult to form a clear picture 
of the effect of trypsinisation on this species. However, in some experiments it appeared to 
be unaffected by digests that completely removed full length PTPa and so it is likely that 
this band was also relatively protected from trypsin when compared to the full-length 
protein.
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110Figure 3.6: Subcellular localisation of PTPa using limited cell surface trypsinisation
A.  Control cell surface trypsinisation. Cells transfected with green fluorescent protein 
(GFP) were digested with trypsin. The control sample represents a lysate of cells that 
were not treated in any way. Lysates were analysed by reducing SDS-PAGE and 
western immunoblotting using an antibody against GFP. SDS-PAGE gels were also 
analysed by brilliant blue staining to demonstrate the reduction in total protein content. 
The BSA band resulting from the trypsin inhibitor solution is clearly visible in digested 
samples.
B.  Cell surface trypsinisation of PTPa expressing cells. Anti-FLAG immunoblots. Two 
independent experiments are shown. Mock and + trypsin samples were prepared in 
parallel; the mock sample digestion solution lacked trypsin only.
C.  Cell surface trypsinisation of PTPa-expressing cells. Total protein detected using 
brilliant blue stain. Equal volumes of lysate were used; samples were not normalised for 
protein content. The lanes shown represent non-adjacent samples on the same gel. The 
gel was processed intact and the lanes subsequently excised for ease of comparison.
The BSA band produced by the trypsin inhibitor solution is clearly visible as are several 
bands from the lysates themselves
1113.3: Discussion
This chapter introduces the PTPa expression constructs that will be used 
throughout the remainder of this thesis. Although the expression of chicken PTPa has 
previously been described using antibodies to the extracellular domain (Stoker et al.,
1995a), this represents the first description of chicken PTPa expression using a 
combination of antibodies recognising both the extracellular and the intracellular domains. 
The findings presented confirm previous work on rat and human PTPa (Aicher et al.,
1997). On SDS-PAGE analysis, lysates from PTPa-expressing cells contained a number of 
PTPa species that represented full-length PTPa and several PTPa-derived cleavage 
fragments. To simplify the discussion of PTPa processing, a modified nomenclature will be 
proposed for PTPa processing and the resulting PTPa cleavage fragments. The identity of 
each species seen on SDS-PAGE analysis was predicted with reference to previous studies 
on type II RPTPs. O f the PTPa-derived species reported here, full-length chicken PTPa 
was present at higher than expected levels and a novel extracellular cleavage fragment (E9 0 ) 
was described. The discussion of these findings raises several issues that are of significance 
in the field. Several lines of evidence are presented that suggest that the current model of 
type Ha RPTP processing is incomplete.
The post-translational processing of type Ha RPTPs is complicated, generating at
least five PTPa peptides from a combination of at least two cleavage events. In this thesis,
it will be necessary to discuss the various PTPa species and varying combinations of
cleavage events in an unambiguous manner. An extension of the existing nomenclature is
suggested to allow the unambiguous discussion of both previously described species and of
novel species. (Yu et al., 1992; Streuli et al., 1992). Conventionally, the two post-
translational cleavage events affecting type Ha RPTPs are referred to as primary and
secondary cleavage, acknowledging their perceived temporal relationship. However, this
thesis will show that secondary cleavage can occur independently of primary cleavage.
Therefore, it is clearer to refer to these two cleavage events by their spatial location, that is
amino- (Primary) and carboxyl-terminal (Secondary) cleavage. Secondly, previous studies
have referred to single extracellular (E) and phosphatase (P) fragments generated by post-
translational cleavage (Streuli et al., 1992; Aicher et al., 1997). In this thesis, a number of
PTPa cleavage fragments will be introduced. To distinguish between species it is proposed
that their approximate molecular weight be added to their E /P fragment designation. Thus,
full-length protein will be referred to as FL16 6  and the extracellular domain products of
amino- and carboxyl-terminal cleavage as E8 1  and E^, respectively. In the absence of
112confirmation that the shed extracellular domain form is identical to either of the cell 
associated forms, shed protein will be referred to as Es. The phosphatase domain fragments 
resulting from amino- and carboxyl-terminal cleavage will be referred to as P8 5  and P75, 
respectively. This nomenclature was summarised in pictorial form above (Figure 3.1 A) and 
will be used for the remainder of this thesis.
PTPa-expressing HEK-293T cell lysates contain IG2 /FLAG/HA positive PTPa- 
derived species with apparent molecular weights of ~ 160/90/80 kDa (FLAG/IG2 
detection) and — 160/85/75 (HA detection) (Figure 3.1, Figure 3.2)(Stoker et al., 1995a).
The ~ 160 kDa band, which is recognised by all 3 antibodies, is likely to represent full- 
length PTPa (Predicted Mr~ 165.7 kDa. Regarding the smaller species, type II RPTPs 
undergo proteolytic cleavage at several sites (reviewed above, 1.3.5). Based upon previous 
studies, the ~80 kDa FLAG/IG2-positive, and the ~85 and ~75 kDa HA-positive species 
are likely to represent the extracellular domain product of amino-terminal cleavage (E81) 
and the intracellular domain products of amino- (P85) and carboxyl-terminal (P7 5 ) cleavage, 
respectively (Streuli et al., 1992; Pulido et al., 1995a; Aicher et al., 1997). Although 
previously unrecognised, carboxyl-terminal cleavage occurring in the absence of amino- 
terminal cleavage would generate P7 5  and an extracellular domain fragment with the same 
characteristics as the remaining ~90kDa FLAG/IG2 detectable species (E9 0 ). It must be 
noted that the presence of the E90 species in cell lysates implies that carboxyl-terminal 
cleavage is not sufficient for ectodomain shedding. Previous studies have shown that 
amino-terminal cleavage is not necessary for ectodomain shedding (Serra-Pages et al.,
1994). The presence of the E^, and significant amounts of FL16 6  were unexpected from 
previous studies, which had predicted that lysates would contain mainly E8 1  and P8 5  (Streuli 
et al., 1992; Stoker et al., 1995a; Aicher et al., 1997). Each of these two unusual findings will 
be explored in more detail below.
PTPa-expressing cells also secrete a soluble form of the PTPa extracellular domain 
(Es) (Figure 3.IB) (Aicher et al., 1997). The identity of the shed band and the mechanism 
and purpose of type Ha PTPa extracellular domain shedding are not fully understood 
(Serra-Pages et al., 1994; Aicher et al., 1997). Studies of chick PTPa in tissue and 
transfected cells have reported only a single extracellular domain species in cell lysates 
(Stoker et al., 1995a). In contrast, chick tissue lysates contain 2 extracellular domain species, 
that represent the cleaved extracellular domains of short (PTPal) and long (PTPa2) PTPa 
isoforms (Stoker et al., 1995a; Stoker et al., 1995b). It is thought that this single PTPal - 
derived extracellular domain species seen in tissue and cell lysates represents the PTPal E8 1
113molecule. A case may be made from the literature that this species might represent the E8 1  
or E90 species or an accumulation of cell bound Es (Aicher et al., 1997; Krasnoperov et al., 
2002). However, functional interactions have been demonstrated for both E9 () and E8 1  
forms, suggesting that they are both physiological forms of the protein (Krasnoperov et al., 
2002). In addition, the level of cell-associated E90 is of the same order of magnitude as the 
E8 1  band, implying that the majority would have to bind back onto an unknown receptor 
on the cell surface. As will be shown later, whilst cell-binding experiments suggest that 
PTPa extracellular domains can bind to HEK-293T cells, they do not support an effect of 
this magnitude (7.1.2).
In this study, SDS-PAGE analysis revealed that Es was slightly different in size 
from both the ~90kDa and the ~80kDa FLAG-positive species and also from PTPa 
species seen in the developing chick. Unfortunately, this study is one of very few to 
compare directly the size of shed ectodomain with those of the cell-associated proteins and 
in previous studies it can be difficult to identify single PTPa cleavage fragments in lysates 
due to the small size difference between E8 1  and E90 and the presence of multiple PTPa 
isoforms. Furthermore, previous studies have not shown a consistent relationship between 
the sizes of the various forms of type Ha RPTPs and some studies report shedding of both 
the large and small extracellular domain fragments (Serra-Pages et al., 1994; Pulido et al., 
1995a). There are several possible explanations for the differences between the sizes of Es 
and other PTPa species reported here and elsewhere. Firstly, the difference seen may 
reflect differences in buffer conditions. Alternatively, it is possible that there is a real 
difference in size between these species. This may be due to differences in post- 
translational modification or indeed cleavage at different sites. Cleavage at a novel site 
might be mediated by a different enzyme as has recently been described in PTPx and PTPp 
(Anders et al., 2006) or may reflect the sliding specificity of the enzyme responsible for 
classical carboxyl-terminal cleavage; it is able to recognise any of a number of overlapping 
cleavage sites (Serra-Pages et al., 1994). Whatever the explanation, these data suggest that 
caution must be exercised in identifying PTPa cleavage fragments and in interpreting data 
comparing PTPa from different expression systems. This is especially true of any 
conclusions that may be drawn regarding PTPa function. PTPa expressed in HEK-293T 
cells may not be behaving in the same way as endogenously expressed PTPa.
This chapter represents the first report of full-length chicken PTPa in cell lysates, 
although full-length forms of PTPa and other type II RPTPs have previously been 
reported in other species (Streuli et al., 1992; Mizuno et al., 1993; Brady-Kalnay and Tonks,
1141994; Rotin et al., 1994; Stoker et al., 1995a; Stoker et al, 1995b; Kypta et al., 1996; Fuchs 
et al., 1996; Cheng et al., 1997; Krasnoperov et al., 2002; Ostenson et al., 2002; Ruhe et al., 
2006; Lajus and Lang, 2006). In many but not all previous studies, full-length PTPa has 
only been reported in lysates from transfected and therefore PTP-overexpressing cells 
(Figure 3.1)(Streuli et al., 1992; Serra-Pages et al., 1994; Aicher et al., 1997; Krasnoperov et 
al., 2002) whereas lysates from tissues that express PTPa endogenously often only contain 
the cleaved form of the receptor (Stoker et al., 1995a). However, it was shown above that 
on reducing SDS-PAGE analysis, only cleaved protein is detectable with the IG2 antibody 
using standard detection conditions. In contrast, on non-reducing SDS-PAGE analysis, the 
overall signal obtained is significantly greater and full-length PTPa can be detected, 
although its level still appears to be reduced relative to cleaved protein when compared to 
the picture seen with the FLAG antibody (Figure 3.1, Figure 3.2). Therefore, in comparison 
with the epitope tag antibodies used in this thesis, the IG2 antibody appears preferentially 
to recognise cleaved rather than full-length protein. Although the mechanism for such 
preferences is unclear, they have been previously reported for type Ha RPTP antibodies 
(Aicher et al., 1997; note lack of full length form in immunoblots using extracellular 
domain antibodies compared to immunoprecipitates made with carboxyl-terminal 
antibody). As previous studies on chick PTPa have used the IG2 and RP1 antibodies it is 
possible that tissue and transfected QT6 lysates might contain other PTPa species that 
remain undetectable with the IG2 antibody (Stoker et al., 1995a; Stoker et al., 1995b). 
However, analysis of tissue lysates under non-reducing conditions failed to identify any 
full-length PTPa (Figure 3.2), although the overall detection level was still low. Therefore, 
although previous studies may not have been equipped to detect full-length PTPa for 
technical reasons, it appears that there may be genuine differences between this and 
previous studies.
The hypotheses used to explain the presence of full length PTPa in some studies 
might essentially be reduced to the proposition that some expression systems lack adequate 
levels of the appropriate enzyme pathways to process PTPa in the normal manner. 
Therefore, it has been argued that the detection of full length protein represents an 
artefactual accumulation of immature protein (Streuli et al., 1992; Aicher et al., 1997).
Based on a careful re-examination of previous studies and using the data presented in this 
chapter it will be argued below that full-length PTPa is not an artefact of overexpression 
but rather a mature cell surface receptor. It will be shown that there are several possible 
reasons for the discrepancy between studies that do not demonstrate full-length PTPa and
115those that do. Firsdy, not all cells transfected with type Ha RPTPs produce detectable 
levels of full-length protein (Stoker et al., 1995b). This is not solely down to the reduced 
expression level obtained in some expression systems as PTPa-transfected PC6-3 neuronal 
cells showed a similar pattern to that seen in transfected HEK-293T cells (Figure 3.1) 
despite expressing significandy lower levels of PTPa (Data not shown). Although it is not 
known whether PC6-3 cells express PTPa, their parental cell line (PCI2) does and 
therefore it is likely that PC6-3 cells possess the requisite processing machinery (Wagner et 
al., 1994; O'Grady et al., 1994; Lajus and Lang, 2006). Secondly, in time course studies 
(Figure 3.3C), full-length PTPa was the first form to appear. There was no detectable 
period of low expression preceding this during which PTPa was cleaved in a 
“physiological” manner. However, “physiological” cleavage may have occurred at PTPa 
levels below the detection threshold of this assay. Finally and perhaps conclusively, not 
only do untransfected PCI2 and insulinoma cell lines express detectable levels of full- 
length PTPa, full-length PTPa can be detected in pancreatic tissue lysates from wild type 
animals (Ostenson et al., 2002; Lajus and Lang, 2006). It may be stated that the presence of 
full-length type II RPTPs in tissue lysates from wild type animals precludes the notion that 
this form is simply an artefact of overexpression systems. Therefore, the key issue is not 
the presence of full-length protein in some studies, but rather what affects the cleavage of 
type Ha RPTPs.
Although the presence of full-length PTPa is not simply an artefact of 
overexpression, it might not reflect the mature functional form of the receptor (Streuli et 
al., 1992). Unfortunately, our understanding of type Ha RPTP function does not currently 
allow us to determine which receptor forms are competent to bind ligand and respond 
appropriately. However, several features of a transmembrane receptor may be absent in 
immature proteins including mature glycosylation and cell surface localisation.
In this study, both extracellular PTPa cleavage fragments were glycosylated but the 
resolution of the SDS-PAGE system used made it difficult to form any conclusion 
regarding the glycosylation state of full-length PTPa (Figure 3.2). However, previous 
studies have concluded that the full-length form of type II RPTPs is glycosylated although 
its glycosylation state may be less mature than that of the cleaved form (Yu et al., 1992; 
Streuli et al., 1992). A number of experimental approaches might be used to refine this 
question.
116Immunofluorescence studies showed a predominandy cell surface pattern of PTPa 
localisation (Figure 3.4, Figure 3.5). In addition, it was noted that a number of PTPa- 
expressing cells appeared to be undergoing detachment and possibly entering apoptosis. 
Previous studies have suggested a role for LAR and PTPji in programmed cell death (Weng 
et al., 1998; Weng et al., 1999; Tisi et al., 2000; Ensslen et al., 2003). Detailed studies of cell 
death were not performed during this thesis but remain an interesting avenue to explore as 
cell death might be a factor in the difficulties encountered in establishing stable 
transfectants (Unpublished observations, Dr A. Stoker; stable PTPa transfectants have 
been previously reported (Suarez et al., 1999)). The finding that PTPa is predominandy 
membrane-localised despite the significant proportion of uncleaved protein agreed with 
previous studies showing that mutations, which block PTPa cleavage, do not affect surface 
expression (Serra-Pages et al., 1994). Unfortunately, it was not technically possible to 
distinguish between full length PTPa and the PTPa cleavage products using 
immunofluorescence. However, given the significant proportion of the total amount of 
cellular PTPa found in the full-length form, there was no suggestion that a similarly large 
proportion of PTPa staining was confined to an intracellular compartment. The relative 
subcellular localisation of the PTPa species was therefore analysed further biochemically 
using limited trypsinisation of intact, living cells. Cells expressing PTPa were incubated in a 
dilute trypsin solution. This has previously been shown to trim cell surface proteins whilst 
leaving intracellular proteins unchanged (Olson et al., 1988; Brady-Kalnay and Tonks,
1993). Interestingly, full-length PTPa was sensitive to digestion with extracellular trypsin 
whereas cleaved PTPa was relatively protected (Figure 3.6). Several possible explanations 
exist for the relative resistance of E90/81 to trypsin. Firsdy, biochemical differences, perhaps 
in the post-translational modifications of the different PTPa species, may protect E81/90 but 
not FL1 6 6  from trypsin digestion. On the other hand, there may be a tyrpsin-sensitive site 
close to the plasma membrane. Alternatively, E90/81 PTPa might be protected from trypsin 
by its inclusion in a larger protease resistant complex. Finally, trypsin cleavage may result in 
the rapid internalisation of the extracellular domain. However, although these possibilities 
might mask individual trypsin cleavage sites, it is unlikely that they would have the effect of 
entirely protecting E81/90 from digestion. Therefore, there is likely to be a difference in the 
subcellular localisation of E81/90 and FL166.
There are several variations in the relative subcellular localisation of E81/90 and FL16 6  
that might result in the picture described above. Firsdy, the presence of multiple subcellular 
populations of each form of PTPa. Secondly, if trypsinisation causes cell lysis, then mature
117membrane localised E81/90 but not intracellular full length protein might be protected from 
trypsinisation by inclusion in “outside-in” micelles. Indeed, in this model the E81/90 species 
might in fact result from trimming of micellar full length protein. However, in these 
models one might expect a greater reduction both in total protein content and in the E81/90 
content than that seen. Therefore, it is likely that cleaved PTPa is indeed cell surface 
localised and E81/90 intracellularly localised. Further work might usefully examine whether 
the HA-tagged intracellular domain cleavage fragments, P85/75, are likewise protected from 
trypsinisation. As intracellular proteins, their level should not be reduced by trypsin 
treatment if the cell membrane remains intact. Indeed, their effective level may go up as 
similar fragments will be produced by trypsinisation of cell surface FL166. Finally, if E81/90 is 
present at the cell surface in the form of E /P subunit heterodimers it may also be possible 
to detect the loss of the short extracellular domain peptide present in P85, which might 
function as an indirect measure of the amount of E /P subunit heterodimers located at the 
cell surface.
In contrast to the data discussed above, previous studies have reported that full- 
length PTPa has an intracellular distribution whereas E81/90 represents the mature cell- 
surface form of the receptor (Yu et al., 1992; Streuli et al., 1992; Stoker et al., 1995b). 
Previous studies have used surface labelling methods, which highlight membrane proteins 
in contrast to trypsinisation, which selectively digests membrane proteins. However, the 
two approaches should give comparable results with one notable exception. The labelling 
methods will irreversibly label all proteins that reach the cell surface during the course of 
the assay. However, this label will then persist whether or not the protein is cleaved and 
whether or not it remains on the cell surface. As cleaved PTPa must necessarily be 
generated from full length PTPa, the presence of label on cleaved PTPa does not 
necessarily prove that the cleaved form is present on the cell surface. In contrast, proteins 
marked by trypsinisation do not persist in the same way and the digestion of full length 
protein means that it must at some stage in its lifetime be localised to the plasma 
membrane. In addition, the selection of immunoprecipitation or detection antibodies may 
have contributed to discrepancies between studies. However, it is of interest that no 
previous study has determined what proportion of each PTPa species is detected at the cell 
surface although one study commented that type II RPTP surface labelling is inefficient, 
implying that only a fraction of these proteins might be present at the cell surface (Gebbink 
et al., 1995; Krasnoperov et al., 2002). Moreover, although Streuli et al detected full-length 
LAR after a 15 minute labelling period, the relative level of this species when compared to
118the cleaved form meant that it was not detectable in cells labelled for 4-6 hours, which 
must necessarily contain some protein in this form (Streuli et al., 1992). In systems where 
little or no full-length protein is seen, only cleaved protein is seen on the cell surface 
(Streuli et al., 1992; Stoker et al., 1995b). In contrast, in systems where a small proportion 
of full-length protein is seen, a small proportion of cell surface full-length protein is seen 
(Yu et al., 1992). The present study has the highest level of full-length protein of these 
studies and correspondingly has the highest level of cell surface full-length protein. By 
extension if cleaved protein is located intracellularly, in cells expressing predominandy 
cleaved protein, most PTPa must be intracellularly located. This resembles the situation 
seen with the leech type Ha RPTP, HMLAR2 (Gershon et al., 1998a). Moreover, this thesis 
represents the first study to compare the total amount of RPTP detected with that located 
at the cell membrane. The next question that must be answered is what affects the cleavage 
rate of full-length PTPa in different expression systems?
The regulation of type lib RPTP cleavage has been extensively studied. Although 
less well understood, the amino-terminal cleavage of type Ha RPTPs appears to be 
regulated in the same way. However, despite the similarities between these two cleavage 
events, the field does not normally consider them analogous. There is little evidence for 
this position. Both cleavage events occur at a conserved furin-like cleavage site in the final 
fibronectin type III repeat (Streuli et al., 1992; Jiang et al., 1993; Serra-Pages et al., 1994; 
Pulido et al., 1995a; Campan et al., 1996; Fuchs et al., 1996; Cheng et al., 1997; Anders et 
al., 2006). The expression level of several RPTPs including the type Ha and lib RPTPs is 
regulated by cell density and is associated with changes in cellular proliferation rate (Streuli 
et al., 1992; Ostman et al., 1994; Celler et al., 1995; Gebbink et al., 1995; Campan et al., 
1996; Fuchs et al., 1996; Li et al., 1996; Bianchi et al., 1999; Xu et al., 2005). In both protein 
families, the cleaved form is generally more abundant than the uncleaved form and there is 
evidence that both full-length and cleaved protein reach the cell surface, although the 
majority of cellular type lib RPTP is located intracellularly in low density cells (Gebbink et 
al., 1995; Phillips-Mason et al., 2006). Strikingly, surface expression of type lib RPTPs is 
restricted to focal adhesions where they interact with cadherins and [3-catenin (Brady- 
Kalnay et al., 1995; Gebbink et al., 1995; Fuchs et al., 1996; Brady-Kalnay et al., 1998; 
Bianchi et al., 1999; Mourton et al., 2001; Schnekenburger et al., 2005; Del Vecchio and 
Tonks, 2005). These interactions may be important mediators of the effects of cell density 
on type lib RPTP level (Taniguchi et al., 1999; Chattopadhyay et al., 2003). The level of 
type Ha and lib RPTPs increases in confluent cells due to changes in protein stability,
119although it is unclear whether this effect is due to cell-cell contact per se, possibly through 
cadherin engagement, or due to cell cycle arrest. Type Ha RPTP mRNA also increases in 
contact-inhibited cells (Celler et al., 1995; Gebbink et al., 1995; Symons et al., 2002). The 
increase in type II RPTP levels in confluent cells may function to specifically block the 
induction of proliferation by growth factor signaling in contact inhibited cells (Machide et 
al, 2006).
The post-translational cleavage of type II RPTPs has also been reported to be 
affected by cell density. This effect is associated with an increase in the levels of the 
protease responsible (Campan et al, 1996). In addition, there is a suggestion that the 
turnover rate is reduced in confluent when compared to sparse cultures. The turnover rate 
of type II RPTPs is high as would be expected for a protein that behaved in this way (Yu et 
al, 1992; Streuli et al, 1992). In this thesis it was shown that PTPa protein levels were 
stabilised in confluent when compared to sparse cultures (Figure 3.3B). However, the 
steady state pattern of PTPa cleavage fragments with FL166, E90 and E8 1  was only reached 
after 64 hours, despite the rapid half-life reported for these proteins (Yu et al, 1992; Streuli 
et al, 1992). However, previous studies showed that type II RPTP protein levels stabilise 
over at least 36 hours after induction (Gebbink et al, 1993b; Wang et al, 2000). The 
increase in PTPa level may therefore reflect the fact that these proteins appear to stabilise 
their own expression or be stabilised by increasing cell contacts. Finally, a detailed 
examination of the data failed to show any clear effect of cell confluency on PTPa 
cleavage. However, interpretation of these gels was complicated by a number of factors. 
The most important being the difficulty encountered loading equivalent amounts of cell 
lysate into each lane. Unfortunately, the variable contribution of media-derived bovine 
serum albumin (BSA) to different lysates prevented the direct comparison of equivalent 
amounts of cell lysate. In addition, it was difficult to determine whether apparent 
differences in the pattern of PTPa species seen reflected real differences or artefacts of 
different relative exposure levels in samples with different amounts of PTPa. Alternative 
experimental approaches might minimise the effects of cell proliferation or separate 
transcriptional and post-translational levels of regulation. This would allow the accurate 
determination of the effects of cell density on PTPa expression level and cleavage patterns.
In summary, the experiments presented in this chapter confirmed that PTPa is 
expressed initially as a large precursor protein (FL1 6 6 ), which is subsequendy cleaved at two 
sites. Amino-terminal cleavage generates E8 1  and P85 fragments. Carboxyl-terminal cleavage 
generates E90 and P7 5  fragments. Sequential amino- and carboxyl-terminal cleavage
120generates E81, P7 5  and a juxtamembrane fragment. Neither cleavage event alone is sufficient 
for shedding of the extracellular domain. It was shown that the majority of cellular PTP is 
found in the cleaved form and that this is mainly intracellular. In contrast full-length 
protein is located mainly at the cell surface.
121Chapter 4: Disulphide cross-linking of PTPq oligomers
The regulation of receptor tyrosine kinase activity is well understood whereas very 
little is known about RPTP regulation. The reasons for this discrepancy are complex but a 
major factor is that inappropriate or prolonged RTK activation is associated with a range of 
human and animal conditions whereas RPTP inactivation has in general a much less 
conspicuous effect. It has therefore been easier to examine the function and regulation of 
RTKs than RPTPs. Classically, inactive RTKs are monomeric and the binding of specific 
ligands stimulates dimerisation and receptor activation (Yarden and Schlessinger, 1987; 
Lemmon and Schlessinger, 1994). However, more recent data suggests that like the insulin 
receptor and some cytokine receptors, which signal through activation of associated 
cytoplasmic tyrosine kinases, many RTKs form inactive dimers in the absence of any 
ligand. In these cases, ligand binding possibly stabilises or stimulates an active dimeric 
conformation in which each subunit is able to transphosphorylate the other resulting in an 
active RTK dimer (Schlessinger, 1988; Herr et al., 1997; Livnah et al., 1999; Luo et al.,
1999; Moriki et al., 2001; Yu et al., 2002; Li et al., 2005).
RPTPs are similar in many ways to RTKs. Both enzyme families consist of 
extracellular receptor-like domains and intracellular catalytic domains that catalyse 
phosphate group transfer at the plasma membrane. For this reason, it is assumed that 
RPTPs counter-balance RTK activity and it would not be surprising if similar control 
mechanisms existed to regulate their activity. However, despite these initial similarities 
there are many areas of difference. In contrast to RTKs, RPTPs isolated from cell 
membranes are constitutively active (Streuli et al., 1989; Guan et al., 1990). The low 
phosphotyrosine level seen in unstimulated cells thus may reflect a low unstimulated level 
of RTK activity and a high basal level of RPTP activity (Hunter and Sefton, 1980). Like 
some RTKs, RPTPs can exist in dimeric form (Bilwes et al., 1996; Jiang et al., 2000; 
Tertoolen et al., 2001; Xu and Weiss, 2002). However, it is unclear what proportion is 
dimeric at the cell membrane. Previous research has revealed RPTP dimers using cross- 
linking techniques and cellular treatments. In contrast to RTKs, high levels of RPTP 
dimerisation are associated with RPTP inhibition not activation possibly through steric 
occlusion of each monomer’s active site by a corresponding juxtamembrane wedge domain 
on the other subunit (Desai et al., 1993; Bilwes et al., 1996; Majeti et al., 1998; Jiang et al., 
1999; Xu and Weiss, 2002). However, the physiological role of this mechanism is unclear. 
This wedge motif is not present in all RPTPs. Furthermore, two catalytic domain RPTPs
122are stericaUy unable to adopt a dimeric conformation opposing the wedge and catalytic 
domains (Nam et al., 1999; Nam et al., 2005). Therefore, although dimerisation plays a key 
role in RTK function, the role and even the existence of dimerisation in physiological 
RPTP function remains unclear.
This chapter describes for the first time, the isolation of a full length RPTP dimer 
in unstimulated cells. A large-template, site-directed mutagenesis system was developed and 
used to introduce ectopic cysteine residues into the chick PTPa cDNA. The introduction 
of these residues allowed the formation of intramolecular disulphide bonds that cross- 
linked PTPa dimers in mammalian cells.
4.1: Introduction of cysteine substitutions by large template site- 
directed mutagenesis
Disulphide cross-linking is a method that introduces cysteine residues into one or 
more proteins of interest in order to induce ectopic disulphide bond formation. This allows 
the scientist to address a variety of structural and biochemical questions. The degree of 
disulphide bond formation between any two specific cysteine residues provides 
information on their proximity in the native tertiary or quaternary structure and on the 
flexibility of the local structure (Falke and Koshland, Jr., 1987; Falke et al., 1988; Lynch and 
Koshland, Jr., 1991; Pakula and Simon, 1992). In comparison to biochemical crosslinking 
agents, disulphide crosslinking occurs at specific selected sites only, identifies closer 
interactions (due to shorter crosslink length) and can occur under physiological conditions, 
as it usually does not require chemical treatment. Furthermore, cysteine substitution is 
minimally disruptive to native structure, allowing the examination of sensitive biological 
responses such as the effects of ligand binding on receptor dimerisation, conformation and 
activity (Milligan and Koshland, Jr., 1988; Cao et al., 1992; Sorokin et al., 1994; Jiang et al., 
1999).
Disulphide cross-linking requires the introduction of several point mutations at a 
range of sites in the PTPa cDNA. However, the shorter of the two major PTPa transcripts 
is approximately 4.5 kb in length. Constructs containing it are too large for conventional 
whole-plasmid, site-directed mutagenesis (e.g. Quikchange, Stratagene). Although 
mutagenesis reactions using a 4kb template produced many mutant PTPa colonies, use of 
the 12kb full-length PTPa expression vector did not produce any colonies. Moreover, in 
contrast to the reaction employing the shorter template, the full-length template reaction
123did not produce detectable amplification product. (Figure 4.1 A, lane 3 and 2).
Conventional, exponential PCR amplification reactions generated detectable products using 
templates of this size. Varying the DNA polymerase, the cycle number or the reaction mix 
components did not improve mutagenesis efficiency using the larger template (Data not 
shown). This suggested that some factor peculiar to the site-directed mutagenesis reaction 
was responsible for the failure of these reactions rather than the length of the PCR reaction 
per se.
Alternative mutagenesis strategies were considered. However, all required suitably 
located, unique restriction enzyme recognition sites in the PTPa sequence. The length of 
the PTPa expression construct means that these are not often available. Therefore, the use 
of these methods with PTPa often requires partial digests and several cloning steps. This 
project required the introduction of a number of different mutations into a variety of PTPa 
sites. Using conventional mutagenesis and sub-cloning techniques this would have meant 
many, possibly technically difficult steps for each mutation. It is likely that a method of this 
kind would have significantly delayed progress from molecular biology experiments making 
the mutant constructs to in vivo experiments testing the effect of the mutations. Therefore, 
a large-template, whole-plasmid mutagenesis system was developed and used to introduce 
the cysteine substitutions.
4.1.1: Development of  a large template site-directed mutagenesis method
Most of the important variables in whole plasmid amplification are the same as 
those in conventional polymerase chain reactions. However, there are specific features of 
site-directed mutagenesis reactions that make them less efficient than conventional 
polymerase chain reactions.
Firstly, the complementary mutagenic primers used in site-directed mutagenesis 
reactions make primer-dimer formation more favourable than primer-template binding. 
The likelihood of productive primer-template binding can be favoured in several ways. The 
use of long primers minimises the relative effect of the mutation on primer-template 
binding affinity. However, excessively long primers again favour primer-dimer formation 
(Wang and Malcolm, 1999). The template level in site directed mutagenesis reactions is also 
higher than would be expected in a conventional PCR reaction to maximise the likelihood 
of primer-template collisions. In addition, primer template binding is improved by carrying 
out reactions with only a single primer, or using two initial half-reactions utilising only one
124primer each, which are later combined to make a whole 2-primer reaction for the remaining 
cycles (Wang and Malcolm, 1999).
Secondly, mutagenic primers bind more strongly to mutated product than to 
template. However, mutagenic primer can only bind to the extreme 3’ end of the mutated 
product (Figure 4.ID). Therefore such primer-product complexes cannot be extended by 
DNA polymerases. Therefore, site directed mutagenesis reactions exhibit linear rather than 
exponential amplification and this results in a lower yield. In addition, as mutated product 
accumulates it antagonises further productive cycles and so increasing cycle number is not 
useful in these reactions.
A range of different primer and template concentrations were tried together with a 
number of cycle parameters (Data not shown). However, it did not prove possible to 
achieve successful conditions for large template site directed mutagenesis using any of 
these conditions.
Increasing the length of oligonucleotide primers does not improve the efficiency of 
large template mutagenesis (Wang and Malcolm, 1999). However, splice-overlap extension 
PCR commonly uses 2 pairs of perfectly complimentary megaprimers in excess of lOObp 
and 1 pair of flanking oligonucleotide primers to generate products. It may be that the 
exponential nature of these reactions allows them to succeed where site directed 
mutagenesis does not. However, it may be that above a certain length, which it is not 
practical to reach using synthetic oligonucleotides, large primers begin again to work. Such 
megaprimers would be long enough that the decrease in binding affinity due to the 
mutation would be almost undetectable. The optimum size for megaprimers in such 
reactions is about 300bp (Batik and Galinski, 1991; Lai et al., 2003). The Quikchange 
method was easily adapted to use 300bp megaprimers generated by a first stage reaction 
instead of the synthetic mutagenic oligonucleotides conventionally used.
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A.  Failure of standard mutagenesis system using large templates: Agarose gel 
electrophoretic analysis of the products of standard Quikchange (Stratagene) 
mutagenesis reaction. The same primers were used with equimolar amounts of either a 
12kb template (Lane 2) or a 4kb template (Lane 3) with appropriately adjusted reaction 
profiles. L+=Gibco lkb+ Marker (Lane 1). Marker bands are as indicated.
B.  Efficient production of 12kb mutagenesis product using a modified two-stage protocol. 
Equal volumes of PCR reaction pre-enzyme addition (Lanes 2, 4) and after thermal 
cycling (Lanes 3, 5). LI=Bioline Hyperladder I (Lane 1). Marker bands are as indicated.
C.  Production of megaprimer for two stage modified mutagenesis protocol: Agarose gel 
electrophoresis of the short PCR product (Megaprimer —  Lanes 2,3,4) produced in the 
first stage of the modified large template mutagenesis system. LV=Bioline Hyperladder 
V (Lane 1), LI=Hyperladder I (Lane 5) Marker bands are as indicated.
D.  Schematic depiction of whole plasmid PCR method. 1: Complimentary mutagenic 
primers anneal to the (methylated) template of interest. 2: Primer extension generates 
complimentary unmethylated single-stranded, linear DNA containing the desired 
mutation. 3: In subsequent cycles, primer is a better match for product than template 
but is unable to extend the new product as the sequence is broken in a 5,-^3’ direction 
immediately after the site recognised by the primer.
127Large template mutagenesis using PCR generated mutagenic megaprimers 
successfully generated 12kb mutated plasmids. Replacing one of the complementary 
primers with a primer 300bp downstream produced abundant first stage PCR product 
(Figure 4.1 C). The entire megaprimer product was used as a primer in a second stage 
reaction following electrophoresis and gel extraction to remove unwanted DNA species 
(Smith and Klugman, 1997). The second PCR reaction produced a high molecular weight 
band that migrated at the same size as linearised plasmid DNA (Figure 4.IB) and the 
appearance of this linearised plasmid DNA was often associated with a decrease in the 
amount of megaprimer seen following the reaction (Data not shown). The second stage 
PCR product was then digested with Dpnl and transformation of a fraction of this product 
recovered many clones of mutated plasmid DNA. Mutant clones were verified by digestion 
(if applicable) followed by DNA sequencing of the PTPg coding region and test expression 
studies. No undesired mutations were detected in any of the mutants containing the 
mutation of interest.
The method described above is similar to one recendy published for transferring 
mutations between plasmids (West and Wilson, 2002). The only major difference between 
the method described here and that published by West and Wilson is that the method 
described here uses larger template sizes and employs the PCR additive, Betaine. 
Experiments using this method generated more than 20 independent mutations in plasmids 
ranging from 4 to 15kb in size and also allowed the transfer of mutations between 
constructs. Sequence analysis has revealed no additional amplification errors in the coding 
regions of these constructs. However, despite optimisation some primers do not generate 
second-stage, mutated products although they efficiently generate first-stage products. 
Moving the primer binding sites by as little as a couple of nucleotides in either direction 
overcomes this problem (Michael West, personal communication and data not shown).
This method is a robust protocol that can be easily used to generate mutated plasmids of 
over 12kb in size.
4.1.2: Selection of  sites  for cysteine substitution
The selection of suitable sites for cysteine substitution is an essential part of any 
disulphide cross-linking project. Guidelines have previously been established for the 
selection of suitable sites and these will be addressed in detail below with particular 
reference to PTPo (Falke and Koshland, Jr., 1987). Briefly, mutations at such sites need to
128be unlikely to interact with endogenous cysteines, surface exposed and non-disruptive to 
receptor function.
Firsdy, to ensure that substituted cysteines do not interact with endogenous 
unpaired cysteines it is essential to identify the sites of the endogenous cysteine residues. 
Chick PTPg (short form with four Fibronectin type III domains) contains twenty cysteines 
distributed throughout the protein, rather than clustered in a cysteine rich region as seen in 
some other extracellular receptors. Seven cysteine residues are located extracellularly, one in 
the transmembrane domain and twelve intracellularly. The predicted signal peptide includes 
one cysteine residue, which is therefore probably not found in the mature protein. Each of 
the three immunoglobulin domains contains a disulphide bond, which together account for 
the remaining six extracellular cysteine residues. Therefore, all the cysteine residues that are 
present in the extracellular domain of mature PTPa protein are already involved in 
disulphide bonds and hence are unlikely to interact with ectopic cysteine substitutions. The 
remaining twelve cysteines are intracellular. One is located just inside the membrane in a 
position likely to be involved in palmitoylation, which may play a role in the localisation of 
RPTPs to lipid rafts (Pace et al., 1999; Yik and Weigel, 2002; Caselli et al., 2002; Bijlmakers 
and Marsh, 2003). Two more are located close together between the two phosphatase 
domains and there are five in the first and four in the second phosphatase domain 
including the two catalytic site cysteines. However, in mammalian systems the reducing 
intracellular environment and potent intracellular and membrane-associated disulphide 
reductases reduce the likelihood of the formation of stable disulphide bonds in these 
regions. Therefore, it is not appropriate to locate the cysteine substitution sites in the 
intracellular region and the extracellular, juxtamembrane and transmembrane domains were 
analysed further for suitable substitution sites.
Secondly, primary sequence comparison of PTPo with closely related proteins 
identified conserved sequences likely to be important for receptor function. Overall, the 
primary sequences of PTPo orthologues from different species showed a very high degree 
of conservation (Data not shown). This was particularly marked in the transmembrane and 
catalytic domains with the extracellular domain and juxtamembrane regions being less well 
conserved when PTPo was compared with orthologues and particularly paralogues from 
other species. This suggests that the selective pressure against mutations is less in the 
extracellular and juxtamembrane regions than the transmembrane region and so these 
regions are less critical for the function of type II RPTPs.
129Thirdly, residues need to be exposed on the protein surface if they are to be able to 
interact and form disulphide bonds. The structure of the non-catalytic regions of type II 
RPTPs has not yet been determined and so surface exposure can only be predicted based 
on amino acid composition and fold. Transmembrane domains form a-helices such that all 
the amino acid side-groups project outwards. However, PTPa has an endogenous 
transmembrane cysteine residue that is notably conserved in all known PTPa and PTP8 
proteins but absent in all known LAR proteins (Figure 4.2A). This pattern of conservation 
might indicate an association with the different characteristics of PTPa/8 and LAR, which 
would complicate the functional interpretation of the effects of any cysteine substitutions 
in this region. In addition, it might be difficult to distinguish between disulphides 
comprised of one endogenous and one ectopic cysteine and those comprised of two 
ectopic cysteines. Furthermore, the interactions between dimeric receptors are complex but 
often involve transmembrane domain interactions (Weiner et al., 1989; Moriki et al., 2001; 
Constantinescu et al., 2001; Fleishman et al., 2002; Mendrola et al., 2002; Chin et al., 2005; 
Choi et al., 2005; Kjaer et al., 2006). Therefore, because of its possible role in dimer 
interactions the transmembrane domain is not an ideal target for cysteine substitution. The 
juxtamembrane region often continues the alpha-helical structure of the transmembrane 
region. Therefore, the juxtamembrane region was subjected to further analysis to determine 
suitable sites for cysteine substitution.
Lastly, the transmembrane domain has several features that might affect the 
location of cysteine substitutions sites. Hydrophobicity analysis of the juxtamembrane 
region shows that the most charged region is centred on residue 838 and that a second 
highly charged region is located from residues 846-9 (Figure 4.2B). These two regions are 
therefore more likely to be surface exposed than buried and so might provide suitable 
target regions for cysteine substitution. However, the highly hydrophilic group of residues 
(846-9) just outside the predicted transmembrane domain is likely to determine the 
orientation of membrane insertion together with the corresponding positively charged 
cluster on the opposite side of the membrane (von Heijne, 1989; Beltzer et al., 1991). It is 
likely that disruption of this region might have significant effects on protein structure. This 
region also contains a proline rich region (839-43). Proline has particular characteristics that 
often play an important role in protein structure, breaking a-helices. However, as there are 
several prolines the loss of any one proline should be well tolerated. Moreover, the proline- 
rich region is only poorly conserved: RPTPS lacks one proline, LAR lacks two and their 
presence is variable in type lib RPTPs. Therefore, the cysteine substitution sites were
130located in the proline-rich region (839-843) in proximity to the polar region centred on 
residue 838.
Dimerisation per se is not sufficient for RTK activation and has specific effects 
depending on the orientation of the constituent monomers to each other (Burke and Stem, 
1998; Jiang et al., 1999). Therefore, disulphide crosslinking might have different effects on 
PTPa function depending on the orientation imposed on the dimers by each disulphide 
bond. As transmembrane domains and their immediate juxtamembrane surrounds are 
considered a-helical in nature, mutations at every other residue over a range of eight to ten 
amino acids will place a potential disulphide bond site on most of the potential interaction 
faces. If the protein in question dimerises then this ensures that at least some of the 
substitution sites are in an appropriate orientation for disulphide bond formation. 
Furthermore, if multiple cross-links form then the properties of the dimers may vary 
according to the relative orientation of the constituent monomers. Therefore, five cysteine 
substitutions were made at alternate sites in the juxtamembrane region (D837C, P839C, 
P841C, P843C, I845C -  Figure 4.2C).
4.2: Expression of cysteine-substituted PTPa
Although the cysteine substitutions were located in such a way as to reduce the 
likelihood that they would have significant effects on PTPa structure, it is important to 
identify whether they do disrupt any of the known characteristics of PTPa such as its sub- 
cellular localisation and post-translational processing. As discussed above, PTPa undergoes 
post-translational cleavage at two sites resulting in five distinct protein species. (Chapter 3) 
These correspond to mature FL protein (Fl1 6 6 ), the products of amino-terminal cleavage 
(E90, P7 5 ) and the products of carboxy-terminal cleavage (E8 1  P8 5 ). It is impossible to 
determine with the current materials whether either of the small fragments (P75, E81) is the 
product of a single cleavage event or the product of consecutive amino- and carboxy- 
terminal cleavage. To allow the products of cleavage to be followed, tags were incorporated 
in the recombinant PTPa proteins at both the N- (FLAG) and C-termini (HA/Myc). Both 
tags detect full-length protein (FL1 6 6 ).
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Chick  RPTPo:  FSDPIQLDNPDPQPIIDGEEGLIWVIGPVLAWFIICIVIAILLYKNK 
Mouse  RPTPo:  FSDPFQLDNPDPQPIVDGEEGLIWVIGPVLAVVFIICIVIAILLYKNK 
Mouse  RPTPS:  YSDPWSMDLDPQPITDEEEGLIWWGPVLAVVFIICIVIAILLYKRK
Mouse  RPTPf:  SPYSDEIVVQVTPAQQQEEPEMLWVTGPVLAVILII  IVIAILLFKRK
Mouse  RPTPk:  KAAATEEPEVIPDPAKQTDRVVKIAGISAGILVFILLLLWIVIVKKS 
Mouse  RPTPp:  TKGASTQNSNTVEPEKQVDNTVKMAGVIAGLLMFIIILLGVMLTIKRR 
Mouse  RPTPp:  ATKGAVT PKPV PE PEKQT DHTVKI AG VI AG ILLFV11FLGWLVMKKR 
Mouse  RPTPA:  KAACKESKRPLEVSQRSEEMGLILGICAGGLAVLILLLGAIIVIIRKG
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132Figure 4.2: Analysis of PTPa juxtamembrane region
A.  Multiple alignment of chicken PTPa and mouse type II RPTPs (Type Ha —  Top; 
Type lib —  Bottom). Predicted transmembrane helices are highlighted in red 
(Sonnhammer et al., 1998; Krogh et al., 2001). The site of the transmembrane 
cysteine that is conserved in PTPa and PTP8 is marked in dark green and indicated 
with an arrow. The leucine present at this site in LAR is indicated in pale green.
B.  Kyte-Doolittle mean hydrophobicity profile of PTPa juxtamembrane region. The 
transmembrane domain is underlined in red. A window size of 9 amino acids was 
used as this is optimal for evaluating surface exposure (Kyte and Doolitde, 1982). 
The predicted transmembrane helix is highlighted in red. The site of the 
transmembrane cysteine that is conserved in PTPa and PTP8 is marked in dark 
green.
C.  Helical diagrams of PTPa juxtamembrane region. The helices start at the top-centre 
of the right hand diagram. The path of each helix is marked by the central spiral 
and the three diagrams are arranged in the same orientation as each other. Red 
asterisks indicate sites of cysteine substitution. Yellow residues are non-polar, green 
residues are polar but non-charged and pink residues are polar and charged. The 
residues of the predicted transmembrane helix are printed in red characters, and the 
site of the transmembrane cysteine that is conserved in PTPa and PTP8 is printed 
using a dark green characters.
1334.2.1: Immunofluorescent analysis of cysteine-substituted PTPa  proteins
Transfection of HEK-293T cells with plasmids containing each of the cysteine 
substitutions resulted in their expression. The immunofluorescent localisation of wild-type 
PTPa is included again for the purpose of comparison. However, as this has previously 
been discussed in detail, a full description will not be repeated here (3.2.1). No significant 
difference could be detected in the pattern of cysteine substituted PTPa expression when 
compared to wild-type PTPa. Nor was there any obvious difference in the morphology or 
behaviour of cells transfected with any of the PTPa constructs (Figure 4.3).
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137Figure 4.3:Immunofluorescent analysis of cells transfected with N- and C-terminal tagged
PTPa
A-D -  WT; E-H -  D837C; I-L -  P839C; M-P -  P841C; Q-T -  P843C; U-X -  I845C . 
HEK 293T cells were grown on polyethyleneimine-coated coverslips and transfected using 
the calcium phosphate method with vectors encoding the cysteine-substitution PTPa 
sequences. These constructs carry an N-terminal FLAG tag, detected with FITC-labelled 
secondary antibody (green) and a C-terminal HA tag, detected with Cy3-labelled secondary 
antibody (red). Scale bars (10pm) are included in each image. All images were obtained at 
400x magnification using Axiovision software on an Axioskop II microscope (Zeiss).
1384.2.2: 1D SDS-PAGE analysis of cysteine substituted  proteins under reducing conditions
Although sub-cellular localisation of PTPa did not appear to be affected by cysteine 
substitution, it is possible that post-translational processing is. Detergent lysis of 
transfected cells and subsequent SDS-PAGE analysis of these lysates under conventional, 
reducing conditions revealed a range of PTPa peptides. As described above, wild-type 
PTPa expression results in the presence of five peptide fragments corresponding to the 
full-length protein (FL1 6 6 ) and four distinct cleavage products (E90, P75, E8 1  P85). The nature 
and variability of these five PTPa species was discussed above and will not be further 
discussed here (3.1).
On reducing SDS-PAGE analysis, the P839C, P841C, P843C and I845C mutants 
were indistinguishable from wild type protein both in the pattern of cleavage fragments and 
in their relative abundance. Detection with the FLAG (Amino-terminal) tag revealed three 
major bands (FL166, E90 and E8 1 ) of which FL1 66 was the most abundant followed by E8 1  and 
then E90 (Figure 4.4B —  bands 1, 2 and 4). Analysis with the HA (Carboxy-terminal tag) 
again shows three major protein bands (FL166, P85 and P75) with a similar pattern of relative 
abundance (Figure 4.4C). No significant difference was observed in the pattern or level of 
cleavage fragments obtained with wild type, P839C, P841C, P843C and I845C PTPa.
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140Figure 4.4: Comparative SDS-PAGE analysis of wild-type and cysteine-substituted PTPa 
under reducing conditions.
A. Schematic diagram of PTPa proteins to show tag locations and expected cleavage 
products.
Protein lysates (Untransfected, wild type, D837C, P839C, P841C, P843C, P845C) were 
analysed by reducing SDS-PAGE. Figure 4.4 and Figure 4.8 were run in parallel analysing 
the same samples under reducing and non-reducing conditions respectively.
Proteins transferred to a membrane were probed with antibodies against the amino- 
terminal FLAG (B) or carboxy-terminal HA tags (C). Longer exposures show the pattern 
of bands seen with the D837C mutant.
Cleavage of D837C mutant protein produces differently sized extracellular (Band 6 —  E8 37) 
and intracellular (Band 7 —  P837) fragments from other PTPa proteins.
A band (8) is visible at approximately 170kDa in all the cysteine mutant lysates but not in 
the wild type lysates. This band (8) is not seen in HA detections of these samples.
1.  Full-length PTPa 1(FL1 6 6 )
2.  Extracellular domain from amino terminal cleavage (E8 1 )
3.  Phosphatase domain from amino-terminal cleavage (P85)
4.  Extracellular domain from carboxy-terminal cleavage (E90)
5.  Phosphatase domain from carboxy-terminal cleavage (P75)
6.  Extracellular domain fragment from D837C mutant (E837)
7.  Phosphatase domain fragment from D837C mutant (P837)
8.  FLAG positive, HA negative, Mw~170kDa.
141Under the same conditions, the D837C mutant produced a different pattern of 
bands. This distinction was also observed in other cell lines transfected with this construct 
(Data not shown). Firstly, the level of this protein was always lower than wild-type or any 
other mutant (Figure 4.4B-C). Secondly, the decrease in the total PTPa level was associated 
with a decrease in the relative amount of full-length compared to cleaved protein. In 
addition, the cleavage products of the D837C mutant were qualitatively different from 
those of other mutants; in most gels only a single FLAG-labelled and a single HA-labelled 
band were detected. Furthermore, the size of these bands were subtly different from the 
Ecjo/g! and Pg5/75  bands seen with wild type PTPa or the other mutants and so will be 
referred to as E8 37 and P837 to distinguish them from the conventional cleaved PTPa forms. 
Lastly, it was only very rarely possible to detect more than a single band in the region of the 
cleaved PTPa fragments and this was usually in the context of a gel where numerous other 
bands possibly representing, degradation or partial translation products or non-specific 
detection by the FLAG antibody were detected in this region. (Figure 4.6 B,C)
An additional band (Figure 4.4 —  band 8) was detected on longer exposures of the 
amino-terminal detection of cysteine mutant 839C-845C samples. In contrast, this band 
was clear on short exposures of the D837C mutant, possibly because the reduced amounts 
of the full-length form, which is similar in size, do not interfere so much in this mutant. 
This band was not detected in wild type samples nor on HA detections. The nature of this 
band will be discussed further when the pattern of bands seen on non-reducing SDS- 
PAGE is described (4.3).
Type Ha RPTPs such as PTPa are cleaved and shed by cells that express them 
(Streuli et al., 1992; Pulido et al., 1995a; Aicher et al., 1997). The function of this secreted 
extracellular domain is unknown but it may act as a ligand or by binding unknown PTPa 
ligands antagonising their interaction with membrane-bound PTPa. It was not possible to 
detect shed extracellular domain in the D837C mutant whereas the remaining mutants did 
not generate reproducibly different levels of the shed extracellular domain than the wild 
type protein (Figure 4.5). Furthermore, it was not possible to detect disulphide crosslinked 
forms of the shed ectodomains, suggesting that as expected, these species do not contain 
the ectopic cysteine residues.
142A.  Schematic diagram of PTPo cleavage fragments
/L A G   WAG  FI .AG
Band 1. Band 2.i Band 4. I
(F L J 
166 kDa
(E J
81  kDa
1   1  Band 3.
(Pas)
■   85 kDa
90 kDa
Band 5 .
(P7 5 )
75 kDa
HA  HA  HA
B.  FLAG detection of conditioned media 
G  W  7  9  1  3  5
kDa
-250 
-150
-100  ------
.7 5  • •   ■
-50
Figure 4.5: Effect of cysteine substitutions on the amount of soluble extracellular domain 
fragment present in the media of transfected cells.
A. Schematic diagram of PTPo proteins to show tag locations and expected cleavage 
products.
Conditioned media (£FP transfected, arild type, D832C, P832C, P841C, P843C, P84£C) 
from HEK 293T cells was analysed by non-reducing SDS-PAGE. Proteins were 
transferred to a membrane and probed with an antibody directed against the amino- 
terminal FLAG tag.
Band 2.  Shed PTPo extracellular domain (EJ
1434.3: Detection and analysis of disulphide cross-linked PTPo proteins
Comparison of the cysteine mutants with wild-type PTPa revealed only limited 
detectable differences in the processing of the D837C mutant but no difference in its 
localisation when compared to wild type PTPa. On the other hand, no differences at all 
were detected between wild type and the remaining (839-45C) mutants. Following the 
introduction of an unpaired juxtamembrane cysteine, dimeric PTPa should form disulphide 
cross-linked dimers if the cysteines are brought close together in the dimeric structure. 
Disulphide cross-linked dimers of this kind are readily detectable using non-reducing SDS- 
PAGE.
4.3.1: Non-reducing one-dimensional SDS-PA.GE without cysteinyl-modijying reagents
Analysis of the wild type and cysteine substituted PTPa proteins under non­
reducing conditions using the amino-terminal FLAG tag showed that there was no 
difference between the migration of wild type and cysteine substituted PTPa proteins 
(Figure 4.6). There was a difference in the apparent si2e of PTPa species under reducing 
and non-reducing conditions. This is presumably due to the different shape of the species 
as they interact with the pores of the gel. In summary, non-reduced PTPa species run faster 
than reduced proteins. To varying degrees, all of the PTPa proteins ran as four main forms. 
Egl, E90and FL1 6 6  have previously been described but a significant amount of protein was 
detected as a previously unseen form, a high molecular weight smear (f) that migrated at 
considerably greater than 200 kilodaltons. This band was not present under reducing 
conditions and furthermore the disappearance of the high molecular weight smear under 
reducing conditions coincided with an increase in the relative amount of full-length protein 
relative to cleaved extracellular fragment. A similar picture was seen with the chemical 
cross-linker BS3  and no clear dimeric bands were detectable in the region of high molecular 
weight smearing. This suggested that the full-length form of both wild type and cysteine 
substituted PTPa proteins might be forming high molecular weight species compatible 
with disulphide cross-linked dimer formation.
There are a limited number of cysteines in the wild type PTPa sequence that could 
mediate wild type PTPa disulphide bond formation. Intracellular cysteines are unlikely to 
mediate disulphide bond formation due to the relatively reducing nature of the intracellular 
environment. Furthermore, work on PTPa demonstrated the lability of disulphide bonds in 
lysates, presumably to the release of intracellular disulphide bond reductases. There are no
144free extracellular cysteines available for disulphide bond formation, all are involved in 
intramolecular disulphide bond formation within the immunoglobulin domains. The most 
likely candidate is a transmembrane cysteine residue. Transmembrane cysteines are not 
uncommon and are able to form disulphide bonds (Rutledge et al., 1992; Moriki et al., 
2001; Lu et al., 2006). It is striking that the PTPa transmembrane domain cysteine is 
absolutely conserved in PTPa and PTP8 in all species in which it has been characterised. 
However, this cysteine is also strikingly absent from LAR in all species characterised and 
LAR has not been reported to form reduction-sensitive high molecular weight species 
(Streuli et al., 1992). Mutation of the PTPa transmembrane cysteine either to a LAR-like 
sequence (C866L mutation), or to the structurally similar serine (C866S) mutation did not 
have a significant effect on the formation of a high molecular weight smear when PTPa 
peptides were analysed by non-reducing SDS-PAGE (Figure 4.6 D., E.).
145A. Schematic diagram of PTPo cleavage fragments
:LAG 
Band 1.
(FL.J
166 kDa
Band 2.
(b*>
81  kDa
HA
B. Reduced SDS-PAGE 
FLAG detection
UWB7  9  13  5
k D a
D. Reduced SDS-PAGE 
FI ,AG detection
W  L  S
kDa
250-
150-
100-
75-
■ I
•LAG LAG
Band 4.
(E J
90 kDa
Band 3.
(P J
85 kDa I
II
Band 5 
75 kDa
HA  HA
C Non-reduced SDS-PAGE 
FLAG detection
UWB7 9   13 5
k D a
-205
-116
-66
K. Non-Reduced SDS-PAGE 
FT  ,AG detection
W  L  S
kDa
250-
148-
98- t -2
146Figure 4.6 : Comparative SDS-PAGE analysis of wild-type and cysteine-substituted PTPa 
under reducing and non-reducing conditions in the absence of iodoacetamide
A. Schematic diagram of PTPa proteins to show tag locations and expected cleavage 
products.
B., C. Protein lysates (Untransfected, wild type, BS3  D837C, P839C, P841C, P843C,
P845C) were analysed by reducing (B) and non-reducing (C) SDS-PAGE. BS3= Wild-type 
PTPa-transfected cells treated with BS3  chemical crosslinker. Proteins transferred to a 
membrane were probed with antibodies against the amino-terminal FLAG tag.
D., E. Protein lysates (Wild type, C866L, C866S) were analysed by reducing (D) and non­
reducing (E) SDS-PAGE. Proteins transferred to a membrane were probed with antibodies 
against the amino-terminal FLAG tag.
On non-reducing analysis, a smear (f) is seen in all samples, which runs at the top of the gel 
and is clearly distinct from the bottom of the sample wells.
Band 1.  Full-length PTPa 1(FL1 66)
Band 2.  Extracellular domain from amino terminal cleavage (E8 1 )
Band 4.  Extracellular domain from carboxy-terminal cleavage (E9 0 )
1474.3.2: Si%e-fractionation by rate-^onal centrifugation
The finding that wild type and cysteine substituted PTPa were indistinguishable 
under these conditions was surprising. A first explanation might be that PTPa does not 
dimerise and that the smear seen is an artefact of non-reducing analysis probably mediated 
by aggregation of non-blocked cysteine residues during denaturation. However, the 
majority of receptors studied form multimers and the formation of disulphide cross-linked 
dimers by other cysteine-substituted RPTPs make it unlikely that PTPa is an exception to 
this (Jiang et al., 1999). Alternatively, the introduced cysteines might not be located in a 
suitable orientation for disulphide formation. However in the case of most multimeric 
receptors including RPTPs, the transmembrane region is implicated in dimer formation 
and the transmembrane domain of each subunit is usually closely approximated 
(Constantinescu et al., 2001; Chin et al., 2005; Gadd and Clevenger, 2006; Lin et al., 2006). 
If PTPa dimerises the range of juxtamembrane cysteine substitutions should allow at least 
some of the mutated proteins to form disulphide bonds. Lasdy even if the cysteines are in a 
suitable location, endogenous PTPa might compete for dimer formation with the 
exogenously expressed form. This would create mixed dimers unable to form disulphide 
bonds. This also is unlikely given the high level of mutant protein expression. Given that it 
is likely that PTPa dimerises, what is preventing the detection of disulphide cross linked 
PTPa dimers in the juxtamembrane cysteine mutants and what is causing smear formation 
in all the samples making wild type and mutant indistinguishable?
Alternatively, disulphide cross linked dimers may form in the cysteine mutant
experiments but be undetectable under these conditions. Disulphide cross-linked dimers
might be unstable during lysis, storage or analysis. On the other hand, both the
hypothetical full-length PTPa dimer (2xFL166 —  Mw~330kDa) and hypothetical cleavage
fragment/full-length dimers (FL166/E 90, FL166/P 8 5  —  Mw~250kDa) might be too large to
resolve satisfactorily using 6% SDS-PAGE gels. Failure to separate these bands from each
other and the full-length PTPa protein (FL16 6 ) would result in a smear between the FL1 6 6
band and the hypothetical 2xFL16 6  band. Lower percentage gels might resolve the dimers
better but would fail to retain some of the smaller fragments. However, although these
observations explain the presence of a smear rather than discrete bands in the cysteine
mutant lanes, they do not explain why the migration patterns of wild type and the cysteine
mutants look similar. The high molecular weight smears seen in all samples suggest that
disulphide bonds might form as well as break down during electrophoresis or sample
handling. Finally, disulphide bonds might form during sample handling or as the proteins
148concentrate at the stacking-resolving gel interface during electrophoresis. Such bonds must 
be mediated by one of the 20 cysteine residues present in wild type PTPa. These residues 
are a very unlikely site of physiological disulphide bond formation. The extracellular 
cysteines already participate in disulphide bonds; stable disulphide bonds are unusual in the 
reducing intracellular environment and the strikingly conserved transmembrane domain 
cysteine is not required for high molecular weight smear formation under these conditions. 
(Figure 4.6 D., E.). However, any of these residues might form artefactual disulphide bonds 
during sample handling or electrophoresis, which is a likely explanation for the high 
molecular smear seen in the wild type lanes.
Rate-zonal centrifugation of protein samples separates proteins on the basis of their 
size. Larger proteins suffer greater drag forces as they pass down a density gradient. The 
long period of the separation should allow subunit exchange and dimer formation to reach 
an equilibrium. This may yield improved resolution when compared to SDS-PAGE 
analysis. The centrifugation step would also have the effect of diluting the sample rendering 
spurious interaction less likely. Lastly, even if complexes separate during electrophoresis, 
fragments from larger complexes should be found in fractions higher up the centrifuge 
than those from small complexes. This should allow better investigation of the high 
molecular weight smears seen following non-reducing analysis of wild type PTPa.
Protein samples from cells expressing wild type or cysteine-substituted PTPa were 
separated by rate-zonal centrifugation and the resulting fractions were analysed by SDS- 
PAGE. Total protein staining of a proportion of the fractions showed that some degree of 
size separation was achieved by rate-zonal centrifugation. (Figure 4.7 C) Following rate 
zonal centrifugation, only the species previously described (FL166, E90/81) were seen on SDS- 
PAGE analysis of lysates containing wild type PTPa (Figure 4.7 D). On the other hand, 
cysteine substituted mutant (839-845C) PTPa formed two additional bands at 
approximately 250kDA and >300kDa (Figure 4.7 E). These may correspond to the dimeric 
FL16 6  species (2xFL16 6 ) and one or more of the predicted heterodimers. It can be imagined 
that if these bands were condensed into a single lane, then a smear rather than a series of 
discrete bands might be formed. It appears therefore that the cysteine substitutions do 
allow the isolation of dimeric disulphide bonded PTPa species using rate zonal 
centrifugation. However, the technique was labour intensive and exhibited significant 
interexperimental variability as the facilities required to pour reproducible gradients were 
not available. Therefore, it was important to develop an alternative experimental technique 
or to optimise the non-reducing SDS-PAGE analysis of cell lysates.
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150Figure 4.7: Rate-zonal fractionation of wild-type and P841C PTPa
A.  Schematic diagram of PTPa proteins to show tag locations, expected cleavage products 
and the locations of the ectopic cysteines (Red C)
B.  Schematic diagram of PTPa proteins to show the hypothetically possible disulphide 
cross-linked PTPa dimers. (1) 2xFL16 6  —  Mw~330; (2) FL166/P 85 —  Mw~250; (3) 
FL166/E 90 —  Mw~255; (4) 2xE90 —  Mw~180; (5) 2xP85 —  Mw~170.
Cell lysates from HEK-293T cells transfected with wild type or P841C PTPa were 
fractionated by rate zonal centrifugation and analysed by non-reducing SDS-PAGE.
D.  Silver stain analysis of alternate fractions 3-19
E.  Flag (Amino-terminal) detection of alternate fractions 3-17 from wild type lysates
F.  Flag (Amino-terminal) detection of alternate fractions 3-17 from P841C mutant 
lysates. Similar results were seen with the remaining cysteine mutants (839-845C).
Band 1.  Full-length PTPa 1(FL1 6 6 )
Band 2.  Extracellular domain from amino terminal cleavage (E8 1 )
Band 4.  Extracellular domain from carboxy-terminal cleavage (E90)
1514.3.3: Non-reducing one-dimensional SDS-PNGE with cysteinyl-modijying reagents
If the high molecular weight smears were due to artefactual disulphide formation 
post-lysis or if they represented background levels of aggregation after destruction of 
specific disulphide bonded dimers then a clearer picture should be seen if samples are 
prepared in an excess of an irreversible cysteine modifying reagent (e.g. N-ethylmaleimide 
(NEM) or iodoacetamide(IAA)). This would have the effect of blocking all exposed 
cysteine residues not involved in disulphide bond formation and preventing artefactual 
disulphide bond formation. In addition, the enzymes capable of reducing disulphide bonds 
all rely on cysteine residues and so cysteine-modifying agents also irreversibly inactivate 
these enzymes.
Non-reducing analysis of wild type and cysteine substituted PTPa from lysates 
containing either NEM (Data not shown) or IAA clearly show disulphide crosslinking of 
cysteine substituted PTPa proteins. In contrast, very little if any disulphide crosslinked 
wild-type PTPa was detectable (Figure 4.8), suggesting that the high molecular weight 
smear described above does represent artefactual post-lysis disulphide mediated 
aggregation. Analysis of non-reduced lanes containing the cysteine-substituted protein with 
the amino-terminal FLAG antibody reveals, in addition to the four bands (1,2,4 and 6) 
previously described on reducing analysis, three reduction sensitive bands (8, 9 and 10), 
which run at approximately 180 and 300kDa respectively (Figure 4.4; Figure 4.8 ). The 
band that runs at approximately 180kDa (Band 8) was reported above (Section 4.2). This 
band is more prominent on non-reducing analysis than on reducing analysis and its 
appearance is associated with a decrease in the relative amount of the E90 band. Moreover, 
no corresponding band is seen on HA detection of non-reducing gels, suggesting that this 
species contains only FLAG-tagged PTPa ectodomains. Analysis of the same gels with the 
carboxy-terminal antibody shows three new reduction sensitive bands (bands 9,10,11) in 
addition to those (bands 1,3,5) described previously (Figure 4.4; Figure 4.8).
The characteristics of the 300kDa species suggest that they might represent 
disulphide cross-linked dimers of full-length PTPa (i.e. 2xFL1 6 6 ). The features of the 
180kDa species (Band 8) seen on FLAG analysis and the 170kDa band (Band 11) seen on 
HA analysis suggest that these correspond to dimeric forms of the PTPa cleavage 
products, 2xE90 and 2xP85, respectively. On HA detection, it is striking that the P85 band is 
relatively more dimeric than the E90 band and that almost all P85 is present in the dimeric 
state. There is no evidence of a heterodimeric interaction between full-length and cleaved
152PTPa (FL166/E 90 or FL166/I85 dimers), which would result in a band intermediate in size 
between 2xFL1 6 6  and 2xE90/2xP85 of approximately 250 kDa. However, the gel area 
corresponding to the 2xFL1 6 6  appears to contain two bands in many of the samples. The 
additional band is too large to represent the heterodimer referred to above. The nature of 
one of these two bands is unclear but may reflect some heterogeneity in PTPa post- 
translational processing resulting in slight size differences in the dimer. It therefore appears 
that a significant amount of PTPa is present in the dimeric form and that all three of the 
PTPa species (FL166, E90 and P8 5 ) that contain the ectopic cysteines form disulphide bonds. 
However, formal identification of these novel species was not possible using these methods 
and so two-dimensional reducing/non-reducing electrophoresis was used to identify the 
components of each species (4.3.4).
The nature of the bands seen in lysates containing the D837C mutant is interesting 
(Figure 4.4, Figure 4.8). The pattern of D837C bands seen on reducing gel analysis has 
previously been described. Briefly, little full-length protein is seen and generally only the 
products from a single cleavage event are detectable. These cleavage fragments are different 
in size to those normally seen suggesting the use of an alternate cleavage site. On non­
reducing analysis, novel bands are seen at approximately 180kDa and 300kDa with the 
FLAG antibody. This suggests again that the 180kDa species (band 8) contains only 
cleaved PTPa ectodomains. However, no additional bands are seen on HA detection of the 
D837C mutant protein, in keeping with the predicted cleavage point for PTPa, which 
would place the disulphide crosslinking site in the extracellular rather than the intracellular 
fragment predicted to produce the D837C peptides.
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154Figure 4.8 Comparative SDS-PAGE analysis of wild-type and cysteine-substituted PTPa 
under non-reducing conditions in the presence of iodoacetamide
A. Schematic diagram of PTPa proteins to show tag locations, expected cleavage products 
and the locations of the ectopic cysteines (C)
B. Schematic diagram of PTPa proteins to show the hypothetically possible disulphide 
cross-linked PTPa dimers. (1) 2xFL16 6  —  Mw~330; (2) FL166/P 85 —  Mw~250; (3) FL166/E 90 —  
Mw~255; (4) 2xE90 -  Mw~180; (5) 2xP8 5  -  Mw~170.
Protein lysates (Untransfected, wild type, D837C, P839C, P841C, P843C, P845C) were 
analysed by non-reducing SDS-PAGE. Figure 4.4 and Figure 4.8 were run in parallel 
analysing the same samples under reducing and non-reducing conditions respectively. 
Samples from D837C mutants required longer exposures for detection.
Proteins transferred to a membrane were probed with antibodies against the amino- 
terminal FLAG (C) or carboxy-terminal HA tags (D). The right hand panels show reduced 
gels for comparison (Figure 4.4).
A band (8) is visible at approximately 180kDa in all the cysteine mutant lysates but not in 
the wild type lysates. A similar novel band (11 —  approximately 170kDa) is seen in HA 
detections of these samples.
Band 1.  Full-length PTPa 1(FL1 66)
Band 2.  Extracellular domain from amino terminal cleavage (E8 1 )
Band 3.  Phosphatase domain from amino-terminal cleavage (P8 5 )
Band 4.  Extracellular domain from carboxy-terminal cleavage (E9 0 )
Band 5.  Phosphatase domain from carboxy-terminal cleavage (P7 5 )
Band 6.  Extracellular domain fragment from D837C mutant (E83 7 )
Band 7.  Phosphatase domain fragment from D837C mutant (P837)
Band 8.  Putative disulphide crosslinked dimer of band 4 (FLAG positive, HA
negative)
Band 9.  Putative disulphide crosslinked dimer of band 1  (FLAG positive, HA positive)
Band 10.  Putative disulphide crosslinked dimer of band 1  (FLAG positive, HA positive)
Band 11.  Putative disulphide crosslinked dimer of band 3 (FLAG negative, HA
positive)
155Immunofluorescent and SDS-PAGE analysis revealed no difference between wild- 
type and the 839-45C cysteine-substituted PTPa proteins. On the other hand, the D837C 
mutant underwent a distinct form of post-translational processing from all the other 
mutants. The data shown in chapter 3 suggest that, in an HEK-293T overexpression 
system, distinct patterns of subcellular localisation occur between uncleaved PTPa and its 
cleavage products. Therefore, perturbation of the normal cleavage events might alter the 
normal distribution of cleaved and uncleaved protein. As full-length protein and some of 
the cleaved protein species are both labelled with the epitope tag it is not possible to detect 
their localisation independently using immunofluorescence except by comparing 
overlapping patterns of detection with antibodies that detect amino- and carboxy-terminal 
epitopes respectively. In chapter 3, a method was described to determine whether PTPa 
species are located at the cell membrane or inside the cell. Limited cell trypsinisation prior 
to lysis results in the digestion of extracellular but not intracellular protein. Furthermore, 
carrying out this experiment under non-reducing conditions allowed dimeric and 
monomeric PTPa to be followed separately.
Analysis of the cysteine-substituted mutants using limited cell-surface trypsinisation 
likewise revealed no differences between wild-type and 839-845C substituted PTPa (Figure 
4.9). The effect of cell surface trypsinisation on wild type PTPa was discussed in detail 
above and will not be repeated here (3.2.2). Using the FLAG epitope tag, under non­
reducing conditions wild type PTPa produced three major bands, FL166, E8 1  and E90. Under 
non-reducing conditions, the 839-845C PTPa mutants exhibited all the expected bands on 
FLAG detection. High molecular weight bands 9 and 10 are readily detected as is non- 
dimeric full-length PTPa (FL16 6 ). The 180kDa band (8) is detected weakly in all lanes and 
the two cleaved fragments are clearly present. As with wild type PTPa, the Egl fragment of 
the mutant PTPa proteins alone appears to be resistant to trypsin treatment Under the 
same conditions, four bands are detected in cells expressing the D837C mutant: as 
described above. However, following digestion, preservation of E8 1  is also seen in D837C, 
which predominantly expresses an E90-like fragment prior to digestion.
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Figure 4.9 Localisation of wild-type and cysteine substituted PTPa proteins by limited cell 
surface trypsinisation
Non-reducing SDS-PAGE analysis of lysates from HEK-293T cell cultures transiently 
transfected with wild-type or mutant PTPa. Prior to lysis cells were incubated for fifteen 
minutes in digestion buffer with (Right hand lanes) or without trypsin (Left hand lanes). 
Lysates were detected with the FLAG antibody. PTPa species are labelled at the right of 
each gel image (FL1 6 6  and E ^ ) .
Band 1.  Full-length PTPa 1(FL1 6 6 )
Band 2.  Extracellular domain from amino terminal cleavage (E8 1 )
Band 4.  Extracellular domain from carboxy-terminal cleavage (E9 0 )
Band 8.  Putative disulphide crosslinked dimer of band 4 (FLAG positive, HA
negative)
Band 9.  Putative disulphide crosslinked dimer of band 1  (FLAG positive, HA positive)
Band 10.  Putative disulphide crosslinked dimer of band 1  (FLAG positive, HA positive)
1574.3.4: Two dimensional non-reducing! reducing SDS-PAGE
Non-reducing SDS-PAGE analysis of lysates from cells expressing wild type or 
cysteine substituted PTPa shows that cysteine substituted PTPa forms disulphide bonded 
oligomers. However, these high molecular weight bands might also represent non-specific 
aggregates of PTPa due to overexpression or disulphide bonded oligomers of PTPa with 
other proteins. However, under non-reducing conditions, several bands appear at the 
predicted si2es for dimeric PTPa species. In addition, the relative si2e differences between 
the species are not constant. Therefore, if PTPa is forming specific oligomers with other 
proteins then each additional PTPa containing species must interact with a different 
protein. In conclusion, PTPa is most likely to be forming specific disulphide bonded 
homodimers in these experiments.
It is important to resolve which of the possible explanations for the high molecular 
bands is in fact the case. Two-dimensional gel electrophoresis can resolve the components 
of each band. The samples were initially run through an SDS-PAGE system under non­
reducing conditions. The sample lane was then carefully excised and incubated in an 
equilibration buffer in either the presence or absence of reducing agents. Complete 
reduction of the intramolecular disulphide bonds was not possible and improved reduction 
was associated with increased protein diffusion through and out of the gel. Resolution and 
retention were already poor due to diffusion during equilibration and at the gel interfaces. 
The sample lane was then applied to the top of a second gel and run perpendicularly to the 
direction of the first gel. If the equilibration step is non-reducing then the PTPa peptides 
will run at the same rate in the second as in the first gel and so will form spots in a diagonal 
line that runs at approximately 45°. Under reducing conditions, any disulphide crosslinked 
dimers will be broken into their monomeric constituents and so will run faster in the 
second gel than in the first and so will appear below this diagonal line. (Figure 4.10)
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Figure 4.10 Schematic diagram to show two-dimensional gel system
A. Conventional 6% SDS-PAGE gel analysis of PTPa containing lysates. Lanes containing 
samples are excised and incubated in equilibration buffer before being applied to the top of 
second dimension gels at right angles to the direction of migration in the first dimension.
B. Second dimension after non-reducing equilibration —  proteins run at the same rate as in 
the first dimension and so are found on a 45° line (dotted grey).
C. Second dimension after reducing equilibration —  proteins containing intermolecular 
disulphides (Red) dissociate to their constituent monomers and so run off the diagonal.
(L=ladder)
159Two-dimensional SDS-PAGE analysis initially under non-reducing conditions then 
in a perpendicular direction in the presence or absence of reducing agents confirmed that 
PTPa forms specific disulphide bonded dimers. Under two-dimensional electrophoresis 
where both dimensions were non-reducing, the migration pattern is identical to that seen in 
one-dimensional electrophoresis under non-reducing conditions albeit in a diagonal plane 
(Figure 4.11 A, C). Very little protein migrated off the 45° angle that indicates migration at 
the same rate in each of the two dimensions. The system was also validated using 
commercial protein markers to ensure that the process did not affect the migration rate of 
proteins in the second dimension slice (Data not shown). This confirms that the two- 
dimensional technique per se does not affect disulphide bonds.
Wild type and all of the cysteine substitutions except D837C were examined using 
this technique. Wild-type PTPa showed no significant differences when the spot pattern 
obtained under the two conditions was compared (Data not shown). Identical results were 
obtained for each of the remaining mutants (Data not shown). As an example, the 
experiments using P839C will be described in detail. These experiments confirm that the 
novel PTPa species seen on non-reducing analysis of the disulphide crosslinking mutants 
represent dimeric forms of PTPa. Therefore, from this point on these species will be 
referred to by their content (i.e.2xFL1 6 6 ) rather than as a numbered band (i.e. band 9). Using 
the amino-terminal FLAG antibody, the major species seen on non-reducing  non­
reducing analysis are dimeric full-length protein (2xFL16 6 ), dimeric cleaved extracellular 
fragment (2xE9 0 ), full-length protein (FL1 6 6 ) and cleaved extracellular domain (E8 1 ) (Figure 
4.11 A). Following reduction of the first dimension gel slice, these bands are still prominent 
but additional bands are apparent at approximately 160 kilodaltons below the site of the 
2xFL166 spot and at approximately 90 kilodaltons below the 2xE90 spot (Figure 4.1 IB). 
These new spots represent disruption of the disulphide bonded dimeric species and 
confirm the nature of these species. The size of the dimeric species therefore correlates 
with the monomeric content and so the oligomers are likely to be PTPa homooligomers 
rather than heterooligomers with a range of different proteins. Again, no heterodimeric 
FL166-E90 dimers are apparent and there are no spots corresponding to the dissociation of 
these intermediately sized oligomers on non-reducing  reducing two-dimensional 
analysis.
Analysis of two dimensional gels with the carboxy-terminal HA antibody gave 
corresponding results. The major species seen on non-reducing  non-reducing analysis 
were dimeric full-length protein (2xFL1 6 6 ), full-length protein (FL16 6 ) and dimeric cleaved
160intracellular fragment (2xP8 5 ) (Figure 4.11C). On non-reducing ^  reducing analysis, these 
spots were still visible but additional spots appeared running at approximately 160 
kilodaltons below the 2xFL1 6 6  spot and at approximately 85 kilodaltons running beneath 
the 2xP85 spot (Figure 4.1 ID). These correspond to the monomeric constituents following 
dissociation of disulphide bonded dimeric 2xFL1 6 6  and 2xP8 5  respectively. It is worth noting 
that the dimeric extracellular and intracellular cleavage products of PTPa and their 
constituent monomers run respectively larger or smaller than the monomeric full-length 
protein. This suggests that the appearance of these bands is not due to artefactual 
proteolysis of PTPa during the two-dimensional procedure but reflect the expected 
differences in the proteins detected with each tag.
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162Figure 4.11: 2-dimensional non-reducing/reducing SDS-PAGE analysis of P839C PTPa.
Cell lysates were analysed as described by non-reducing SDS-PAGE. The sample lanes 
were excised and incubated in equilibration solution with or without reducing agents as 
described. The equilibrated sample lanes were then turned 90° and cast horizontally into 
the top of a second SDS-PAGE gel and analysed as described.
Monomeric and dimeric PTPa species are labelled at the right of each gel image (FL156, 
E90/81 and P8 5/7 5)" An equal amount of the same batch of lysate (pg total protein) was loaded 
in each lane.
A.  1st dimension —  non-reducing; 2nd dimension —  non-reducing. FLAG (Amino-terminal) 
detection
B.  1st dimension —  non-reducing; 2nd dimension — reducing. FLAG (Amino-terminal) 
detection
C.  1st dimension —  non-reducing; 2nd dimension —  non-reducing. HA (Carboxy-terminal) 
detection
D.  1st dimension —  non-reducing; 2nd dimension — reducing. HA (Carboxy-terminal) 
detection.
1634.4: Discussion
The work presented in this chapter describes the dimerisation of PTPa for the first 
time. A long-range site-directed mutagenesis system was developed and used to introduce 
ectopic cysteine substitutions into the PTPa cDNA. These mutations as a whole had no 
detectable effect on PTPa localisation or cleavage or on the behaviour of the transfected 
cells when compared to wild type PTPa. However, the resolution and heterogeneous 
expression levels of these transient transfection experiments makes any firm conclusion 
impossible. This could be addressed by confocal and SDS-PAGE analysis of stably 
transfected cells expressing PTPa at more physiological levels. In contrast, the mutation 
D837C alters the site and the regulation of PTPa cleavage. If the lysates from cysteine- 
substituted PTPa were analysed by SDS-PAGE under non-reducing conditions, disulphide 
cross-linked dimers were detected. Dimeric species were isolated from all of the PTPa 
fragments containing the cysteine residues: FL166, E90 and P85. Heterodimeric PTPa species 
(e.g. FL166+E90) were not detected. Using two-dimensional electrophoresis, the dimeric full- 
length PTPa species was shown to contain only FL166 subunits and the dimeric cleavage 
fragments, only E90 or P85 subunits.
The large template mutagenesis method developed in this chapter is a 
straightforward method that will often require the purchase of only a single mutagenic 
primer. This mutagenic primer can then be used with any suitable primer already held in 
the laboratory to produce a 300-400bp product. However, the method is still not ideal and 
the number of mutant colonies recovered is still low. It remains to be seen if site-directed 
mutagenesis reactions can be converted into exponential amplification reactions by 
judicious off-setting of the two mutagenic primers either in single-stage or two-stage site 
directed mutagenesis reactions.
The disulphide bonding experiments provide evidence for a model for PTPa 
structure. Dimers of full-length PTPa and of each of the longer cleavage fragments were 
detected on non-reducing SDS-PAGE analysis of lysates containing cysteinyl modifying 
reagents. SDS-PAGE analysis of lysates lacking iodoacetamide or N-Ethylmaleimide only 
showed diffuse high molecular weight smears and these were seen in lysates from cells 
expressing either wild-type and or disulphide crosslinking cysteine mutant PTPa. The 
significance of these high molecular weight smears in these lysates will be discussed in a 
subsequent chapter (Chapter 6). Heterodimers of PTPa full-length protein with cleaved 
protein were not detected and using this system, it is not possible to exclude the formation
164of E^/Pgj heterodimers as these cannot be distinguished from the homodimeric species 
which they are very similar to in size. However, there is no evidence that either of these 
heterodimeric species form.
It is not formally possible at this stage to confirm that the disulphide bonded bands 
seen on non-reducing SDS-PAGE analysis represent PTPa dimers or heterodimers of 
PTPa with other proteins. However, heterodimers of PTPa with other proteins are an 
unlikely explanation as the size difference between the proposed PTPa full-length dimers 
and the PTPa cleavage product dimers is the appropriate size for PTPa homodimers. If 
heterodimers are the explanation, then the 2XEC9Q, 2xIC85 and 2xFL16 6  species would each 
represent dimers of specific PTPa species with distinct interacting partners of different 
molecular weights. Furthermore the region of interaction for the disulphide bond 
formation can be restricted to the fragment of protein between the two cleavage sites. In 
addition, two-dimensional analysis confirms that the 2xFL16 6  species contains only full- 
length protein on reduction and that the 2xEC8 1  species releases only E8 1  on reduction. 
However, the only way to formally confirm that these bands represent homodimeric PTPa 
is to immunoprecipitate differentially tagged disulphide crosslinked PTPa and run two- 
dimensional electrophoresis and co-immunoprecipitation experiments (Chapter 5). Finally, 
these experiments do not unequivocably confirm that these species are dimers rather than 
other higher order multimers of PTPa. However, wild type protein does not form these 
species and each cysteine mutant contains only a single ectopic cysteine that can be 
responsible for the disulphide bonds seen. Therefore, these complexes are almost certainly 
dimeric.
A very high degree of dimerisation was seen in the disulphide cross-linking 
experiments. However, litde inference can be drawn from this finding, as disulphide cross- 
linking would be expected to over-represent the level of dimerisation seen in the cell by 
trapping any dimers that do form. It can be concluded however, that dimerisation is 
unlikely to be associated with degradation of PTPa as there was no difference in level 
between wild type and all of the cysteine substitutions mutants except D837C. The only 
ways to confirm the physiological level of dimerisation are co-immunoprecipitation of 
differentially tagged PTPa or resonant energy transfer techniques using cells expressing 
PTPa at physiological levels. Both of these techniques are better suited to comparison of 
the relative amounts of dimerisation under various conditions. They both tend to 
underestimate the level of dimerisation due to the expected forms of dimer formed (i.e. 
subunits A+B  AA, AB, BA, BB); at most, half of all dimers formed will be detected
165using these techniques. Quantitative fractionation of native PTPa complexes might be able 
to resolve the question but would be technically difficult. It was noted that significant 
amounts of disulphide crosslinked protein remained on reducing SDS-PAGE analysis. This 
may reflect a resistance to reduction or the reformation of disulphide bonds during 
electrophoresis despite the inclusion of cysteinyl modifying reagents in these samples. 
Resistance of the juxtamembrane disulphide bond to reduction is a prominent feature of 
these proteins and probably indicates that the juxtamembrane bond is deeply buried and 
relatively inaccessible to reducing agents. A similar pattern is seen in the relative 
accessibility of the various insulin receptor disulphide bonds to reduction (Massague and 
Czech, 1982). Unfortunately, it is not possible to include reducing agents in the gel 
substance of acrylamide gels, as this would interfere with polymerisation.
Assuming that the novel species detected following disulphide crosslinking do 
represent PTPa dimers, their relevance is still open to debate for the following reasons. 
They may be an artefact of the high levels of overexpression achieved in these experiments 
and protein overexpression has previously been shown to induce aggregation of wild type 
receptors (Di Fiore et al., 1987; Di Marco et al., 1990; Maru et al., 1990; Brandt-Rauf et al., 
1990). However, it is impossible to perform the disulphide cross-linking or co- 
lmmunoprecipitation experiments necessary to answer this question in vivo using 
endogenous levels of PTPa expression. However, stable cell lines expressing endogenous 
levels of PTPa might be created to answer this question. Alternatively, the disulphide 
bonds themselves might be necessary and sufficient for dimerisation. The requirement for 
disulphide bonds in PTPa dimerisation can readily be determined by co- 
immunoprecipitation experiments.
The PTPa species, FL166 and E90 were shown to be predominandy located on the 
cell surface whereas the E8 1  species was predominandy intracellular (Chapter 3). This also 
applied to the dimeric forms of FL16 6  and E90, which were mosdy cell surface located. This 
is in conflict with some of the available literature. Cell-surface labelling suggests that only 
cleaved protein is expressed on the cell surface and pulse chase data suggests that full- 
length PTPa is rapidly cleared and that cleaved protein is rapidly degraded (Streuli et al., 
1992). However, full-length PTPa (and other type II RPTPs) can be detected inside the cell 
both physiologically and following cellular treatments (Aicher et al., 1997). The most 
parsimonious explanation for these contrasting observations is that PTPa is expressed on 
the cell surface in the full-length form (both monomeric and dimeric),which is rapidly 
cleaved at the amino-terminal site. Both monomeric and dimeric forms of the protein
166appear to be susceptible to cleavage with internalisation of the resulting fragment (Chapter 
3). Possibly, previous work only detected cleaved protein on the surface as by the time the 
cells were analysed at the end of labelling most of the labelled protein had been internalised 
following cleavage. Most E8 1  is intracellular therefore amino-terminal cleavage of dimers 
may affect both peptide chains. Alternatively, cleavage of a single subunit in a formed 
dimer may result in the immediate shedding of the cleaved extracellular domain. 
Furthermore, it was not possible to detect heterodimers comprising any cleavage fragment 
disulphide bonded to a full-length PTPa molecule. There are several possible explanations 
for this finding. Firstly, only full-length PTPa may be able to form dimers. The dimeric 
cleavage fragments might represent the continued association of the fragments that result 
from the proteolytic cleavage of a dimeric species. Alternatively, there is some data that 
suggests that the full-length and cleaved PTPa species occupy different parts of the cell and 
so might not be able to interact for this reason. Several stimuli can drive PTPa cleavage 
which is associated with redistribution of PTPa (Aicher et al., 1997). However, the 
relationship between cleavage and redistribution is unclear. It can be noted that as both 
full-length and cleaved PTPa have dimeric forms, it is unlikely that dimerisation per se 
regulates cleavage or conversely, is regulated by cleavage.
The tools used in this thesis do not allow the identification of the results of dimer 
cleavage at the amino-terminal site. No P85-FL166 heterodimers are present as remarked 
above but any dimeric Egl species are undetectable as they lack the cysteine residues 
necessary for disulphide formation. However, dimer cleavage at the carboxy-terminal site 
results in the 2xEC90 staying on the cell surface. Eventually the 2xEC90 form is either 
internalised or shed as long-term treatment with agents that induce cleavage at the carboxy- 
terminal site results in complete extracellular domain internalisation. There is not sufficient 
data available to comment on the localisation of the cleaved intracellular domain fragments 
in either monomeric or dimeric form but previous studies suggest that it is internalised with 
the extracellular domain (Aicher et al., 1997).
Previously published models for type Ha RPTP cleavage suggest that the amino- 
terminal cleavage event occurs approximately 100 amino acids from the cell membrane via 
a subtilisin-like protein convertase (PC) (Streuli et al., 1992; Jiang et al., 1993; Yan et al., 
1993; Serra-Pages et al., 1994; Pulido et al., 1995a; Campan et al., 1996; Cheng et al., 1997). 
The prevailing consensus is that this cleavage event is a constitutive part of type Ha RPTP 
maturation, occurring immediately after a conserved dibasic PC recognition motif. The 
model further suggests that carboxy-terminal cleavage is an inducible-event occurring close
167to the transmembrane domain that is catalysed by a matrix metalloproteinase or “a 
distintegrin and metalloprotease” (ADAM) family protease (Serra-Pages et al., 1994; Aicher 
et al., 1997; Ruhe et al., 2006; Anders et al., 2006). These enzymes appear to have 
significant flexibility as to their recognition sequence (Serra-Pages et al., 1994; McFarlane, 
2003; White, 2003; Huovila et al., 2005; Malemud, 2006). Cleavage at this site following 
amino-terminal cleavage is thought to allow shedding of the E8 1  fragment and is associated 
with a redistribution of the remaining detectable intracellular domain to the inside of the 
cell.
In agreement with the data presented above (Chapter 3), all PTPa proteins except 
the D837C mutation showed significant amounts of cell surface located E90. This can only 
be produced by carboxy-terminal cleavage in the absence of amino-terminal cleavage. This 
suggests that amino-terminal cleavage is not a constitutive part of PTPa maturation nor 
need it occur before carboxy-terminal cleavage. However, it may be suggested that 
expression of full-length and E90 are artefacts of overexpression reflecting the limited 
capacity of the conventional PTPa processing pathway. This subject has been discussed 
above (Chapter 3 and this chapter). Furthermore, an E81-like species was seen in lysates 
from trypsinised cells expressing D837C PTPa, which do not express significant levels of 
an E8 1  species normally. The E81-like species seen might be derived from digestion of either 
the 180kDa band (8) or the limited amounts of full-length D837C PTPa seen with this 
mutant. It was not possible to determine the origin of this species using the techniques 
employed in this chapter.
Of the five mutations, only the D837C mutation has a detectable effect on PTPa 
processing. It is difficult to explain why the D837C mutation, which is located furthest 
from the predicted site of carboxy-terminal cleavage, is the only mutant to affect carboxy- 
terminal cleavage. The D837C mutation increases the cleavage rate of full-length PTPa as 
indicated by the disproportionate decrease in the amount of full-length as compared with 
cleaved D837C PTPa protein. Cleavage of the D837C mutant PTPa protein occurs at a site 
that is slightly amino-terminal to the canonical carboxy-terminal cleavage site. This is 
unlikely to reflect cleavage by the amino-terminal PC enzyme as this site does not contain 
the dibasic consensus site required by such enzymes. This generated a single extracellular 
domain band that was slightly smaller than E90 and a single intracellular domain band that 
was slightly larger than E81. Therefore, the ectopic cleavage site in the D837C mutant 
protein must be located carboxy-terminal of the amino-terminal cleavage site and amino- 
terminal of the carboxy-terminal cleavage site. However, as the P8 37 fragment is not able to
168form disulphide bonded dimers but the E837 fragment can, the cleavage site must be 
between the carboxy-terminal cleavage site (P841/I842) and the D837C mutation. This 
only leaves a small window of 4 amino acids for the cleavage site to move into. This is 
probably too small a change to produce the size shift that is detected from E90/81~^E837 and 
from P8 5/7 5"^P8 3 7 even if cleavage shifts as far amino-terminal as these constraints allow, 
that is if cleavage occurs at 837/838 or 838/839.
An alternative explanation is that the PTPa cleavage site previously identified in 
A431 cells is not the same site that is utilised in HEK-293T cells overexpressing cPTPal 
(Aicher et al., 1997). It must also be noted that this site was identified following cleavage 
induced by TPA, which may not occur at the same site as PTPa carboxyl terminal cleavage 
in the resting state. This is supported by the failure of the mutations P841C and P843C to 
affect cleavage and the lack of any difference in the pattern of disulphide crosslinked 
species produced by the P839C and P845C mutations, which are predicted to be on 
alternate sides of the cleavage site. It must be noted however, that the recognition site for 
carboxyl-terminal cleavage exhibits significant sequence flexibility (Serra-Pages et al., 1994). 
The size shift detected is approximately lkDa in size, and as such represents approximately 
ten amino acids. Assuming that carboxy-terminal cleavage of the wild type protein occurs 
at the same site as in the 839-45C mutants, then carboxy-terminal cleavage must be 
occurring C-terminal to 845C, moving the potential cleavage site significantly closer to the 
membrane, suggesting that intramembrane proteolysis may play a role in PTPa cleavage. 
The D837C mutant in this model might affect PTPa cleavage by a conformational effect 
rather than by direct disruption of the recognition site. Other ways in which this effect 
might be mediated include relocalisation of the mutant protein resulting in cleavage by a 
different protease.
Although the D837C mutant does undergo proteolytic cleavage, the resulting E83 7  
fragment is not shed and the level of PTPa is lower in the D837C mutant than in any other 
PTPa protein. This may be the result of increased cleavage of the full-length form or 
increased stability of the cleaved form with or without changes in PTPa expression levels.
It will be interesting to see if shed D837C mutant protein can be detected following protein 
kinase C activation by induction with phorbol ester (Chapter 6). If the ectopic cleavage 
event merely alters the balance of factors controlling PTPa fate, then boosting the 
endogenous shedding signal might allow shed E837 to be detected. Experiments of this kind 
will reveal the relationship between the two cleavage events, shedding and PTPa function. 
Most importandy, if it is confirmed that the D837C mutant is more rapidly cleaved than
169wild type PTPa but that despite this it is not shed then this might suggest that cleavage is 
not a cell surface phenomenon.
Lastly, there is a relative paucity of the full-length PTPa form when compared to 
the amount of cleaved product in cells expressing the D837C mutant protein. This might 
be due to increased stability and retention of the cleavage products, for example due to a 
decrease in shedding. Alternatively, the stability or the susceptibility of full-length D837C 
protein to proteolytic cleavage may be altered with or without accompanying changes in 
PTPa expression level.
The current model of type II RPTP processing does not fit all the available data.
An alternative hypothesis might be that full-length protein is in fact an active receptor, 
which is localised to the plasma membrane. The apparent difference in protein cleavage 
might not reflect differences in PTPa processing but rather a difference in the eventual fate 
of the cleavage fragments. Several groups have followed type II RPTP processing by pulse- 
chase experiments. No group has dissected the two major events in type II RPTP 
processing, namely cleavage and degradation and widely differing results have been 
obtained in different cell types irrespective of whether expression is endogenous or driven 
by transfection. However, all studies agree that type II RPTPs are cleaved rapidly, typically 
within 30 minutes of translation. The discrepancy occurs over the time for which the 
cleaved PTP remains in the cell. The detection of large amounts of cleavage product in 
many tissues might reflect the detection of free extracellular domains. These might be 
bound either to the cell surface or inside cells. A number of mutations have been identified 
that interfere with PTPa-ligand interactions. It would be relatively straightforward to 
determine the cleavage pattern of full-length PTPa expression constructs containing the 
ligand binding site mutations.
The results in this chapter are similar to those obtained with PTPa and suggest that 
dimerisation is a common feature of the RPTP family although as PTPa has a smaller 
extracellular domain than PTPa, it may not be regulated in the same way (Jiang et al., 1999; 
Jiang et al., 2000; Tertoolen et al., 2001). However, it is difficult to determine what the 
effect of PTPa dimerisation is on catalytic activity. Disulphide cross-linked dimers can be 
separated only by using reducing agents, which themselves have a marked effect on the 
activity of cysteinyl-based tyrosine phosphatases. The non-reducing conditions required to 
maintain the disulphide cross-linked dimers inhibit enzyme activity and the reducing 
conditions required to separate the disulphide cross-linked dimers into monomers increase
170enzyme activity. Therefore, the effect of dimerisation per se on enzyme activity would be 
extremely difficult to determine using the cysteine cross-linked dimers. Moreover, it would 
be difficult to determine whether the effect seen was representative of the physiological 
situation or an artefact derived from the cysteine mutations. Having demonstrated that 
PTPa dimerises, it will be important to determine the effect of PTPa dimerisation on its 
activity and cellular function and to identify factors that affect the proportion or 
orientation of PTPa dimers.
171Chapter 5: Co-immunoprecipitation of PTPq oligomers
In chapter four, PTPa dimerisation was demonstrated using disulphide 
crosslinking, following the introduction of a number of ectopic cysteine residues. However, 
all the PTPa species containing an ectopic cysteine were found to dimerise, which might 
suggest that the cysteine residue itself is inducing this interaction. That is the disulphide 
bridges might cause rather than reflect dimerisation. It is important therefore to determine 
whether dimeric PTPa can be isolated using a different method with PTPa protein that is 
wild type with respect to the cysteine substitutions. In this chapter, the 
coimmunoprecipitation of differentially tagged wild type PTPa is described. The results 
agree with those seen using disulphide crosslinking and strongly support a model for PTPa 
function in which significant amounts of PTPa protein are present in a homo-oligomeric 
form.
5.1: Co-immunoprecipitation using two distinct intracellular tags
Two different PTPa constructs were designed such that each had a different 
carboxy-terminal epitope tag; either an HA tag or a 3xMyc tag (Figure 5.1 A). There was no 
detectable difference in either the localisation or cleavage pattern of these two forms of 
PTPa when compared to the other constructs used in this thesis (Data not shown). 
Cotransfection of HEK-293T cells with these two constructs resulted in the robust 
expression of the two encoded proteins. Approximately equal levels of each protein were 
seen in lysates from single- and double-transfected cells (Figure 5.IB, C —  lanes 1-4).
When lysates from cells expressing one of the differentially tagged proteins were 
immunoprecipitated with an antibody directed against the corresponding tag, PTPa protein 
bearing the second tag was readily recovered (Figure 5.1 B —  lane 8, C —  lane 7). All 
detectable forms of PTPa were recovered, that is FL1 66 (band 1), P85 (band 3) and P75 (band 
5). On the other hand, when lysates from cells expressing only one of the differentially 
tagged PTPa proteins were immunoprecipitated with an antibody directed against the 
converse tag, no PTPa protein was recovered (Figure 5.IB, C —  lanes 5, 6). Moreover, 
when immunoprecipitates from cells expressing both lysates were immunoprecipitated with 
one antibody, this co-immunoprecipitated PTPa protein labelled with the converse tag. Co- 
immunoprecipitation is more readily apparent following anti-HA immunoprecipitation of 
lysates expressing both HA- and 3xMyc tagged lysates. This is due to an unfortunate 
combination of quantitatively poorer immunoprecipitation with the Myc antibody and
172detection with the HA antibody. However, careful examination reveals that all three forms 
of PTPa, FL1 6 6  (band 1), P8 5  (band 3) and P7 5  (band 5), that bear a unique COOH terminal 
tag coimmunoprecipitate following immunoprecipitation of PTPa protein bearing the 
converse tag (Figure 5.1 B —  lane 8, C —  lane 7).
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Blot: HAFigure 5.1: Co-immunoprecipitation of dimeric PTPa using recombinant proteins bearing 
distinct intracellular epitope tags
Cell lysates and immunoprecipitates were analysed by reducing SDS-PAGE. Proteins 
transferred to a membrane were probed with antibodies specific for the carboxy-terminal 
Myc (B) or HA tags (C).
A.  Schematic diagram of PTPa proteins to show tag locations and expected cleavage 
products.
B.  Anti-Myc detection of lysates and immunoprecipitates
C.  Anti-HA detection of lysates and immunoprecipitates
Lanes:
HA Lysate: HA-expressing lysate
3xMyc lysate: Myc-expressing lysate
Co-Lysate: Lysate from co-transfected cells
3xMyc —  HA IP: Anti-HA IP of 3xMyc transfected lysate
Co —  Myc IP: Anti-Myc IP of co-transfected lysate
Bands:
Band 1.  Full-length PTPa 1 (FL1 6 6 )
Band 3.  Phosphatase domain from amino-terminal cleavage (P85)
Band 5.  Phosphatase domain from carboxy-terminal cleavage (P7 5 )
IgH   Reduced IgG heavy chain  (Approx 50kDa)
n.s  Non-specific band detected by anti-HA antibody
1755.2: Co-immunoprecipitation using distinct intracellular and 
extracellular tags
As shown above, first by disulphide crosslinking and then using co- 
immunoprecipitation, PTPa forms oligomeric complexes. Either a range of complexes are 
found some of which contain homooligomeric full-length and others, which contain 
homo-oligomeric P8 5/75 or PTPa forms hetero-oligomeric complexes that contain a mixture 
of full-length and P85/75 PTPa. However, the co-immunoprecipitation technique outlined 
above does not address whether the oligomeric complexes also contain the extracellular 
cleavage products. The disulphide crosslinking experiments described previously predict 
that the PTPa extracellular cleavage fragments will also dimerise.
To identify whether the PTPa oligomers also contain the extracellular cleavage 
fragments, two further PTPa constructs were generated. One construct had a unique 
amino-terminal 3xFLAG tag (pCMV 25 PTPa UTR) and the other a unique carboxy 
terminal HA tag (pCI PTPa HA) (Figure 5.2A). There were no detectable differences with 
respect to cleavage or localisation when compared to other wild type PTPa proteins (Data 
not shown). In addition, both proteins were expressed to high levels in HEK-293T cells 
and the levels of PTPa protein were not significandy different in double- or single­
transfected cells( Figure 5.2 B, C —  lanes 1-4).
When lysates from cells expressing one of the differentially tagged proteins were 
immunoprecipitated with an antibody directed against the corresponding tag, abundant 
PTPa protein was recovered (Figure 5.2B —  lane 6, C —  lane 7). All detectable forms of 
PTPa were recovered, that is FL16 6  (band 1), E90 (band 2) and Egl (band 4). On the other 
hand, when lysates from cells expressing only one of the differentially tagged PTPa 
proteins were immunoprecipitated with an antibody directed against the converse tag, no 
PTPa protein was recovered (Figure 5.2B, C —  lanes 4, 5). Moreover, when 
immunoprecipitates from cells expressing both lysates were immunoprecipitated with one 
antibody, this co-immunoprecipitated PTPa protein labelled with the converse tag. Careful 
examination reveals that all three forms of PTPa, FL1 6 6  (band 1), E90 (band 4) and Egl 
(band 2), P85 (band 3) and P7 5  (band 5) coimmunoprecipitate in this way (Figure 5.2B -  lane 
7, C —  lane 6).
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177Figure 5.2 Co-immunoprecipitation of dimeric PTPa using distinct intracellular and 
extracellular tags
Protein lysates and immunoprecipitates were analysed by reducing SDS-PAGE. Proteins 
transferred to a membrane were probed with antibodies against the amino-terminal FLAG 
(B) or carboxy-terminal HA tags (C).
A.  Schematic diagram of PTPa proteins to show tag locations and expected cleavage 
products.
B.  Anti-FLAG detection of lysates and immunoprecipitates
C.  Anti-HA detection of lysates and immunoprecipitates
Lanes:
Cl Lysate: Cl HA expressing lysate
UTR lysate: a UTR expressing lysate
Co-Lysate: Lysate from co-transfected cells
UTR —  HA IP: Anti-HA IP of a UTR transfected lysate
Co —  FLAG IP: Anti-FLAG IP of co-transfected lysate
Bands
Band 1.  Full-length PTPa 1 (FL1 6 6 )
Band 2.  Extracellular domain  from amino terminal cleavage (E81)
Band 3.  Phosphatase domain  from amino-terminal cleavage (P8 5 )
Band 4.  Extracellular domain  from carboxy-terminal cleavage (E9 0 )
Band 5.  Phosphatase domain  from carboxy-terminal cleavage (P75)
*  Additional PTPa cleavage product
1785.3: Co-immunoprecipitation of disulphide cross-linked PTPa proteins
The identification of reduction sensitive high molecular weight species that contain 
specific PTPa proteins, and the co-immunoprecipitation of differentially tagged PTPa 
suggest that PTPa forms oligomeric complexes in human cells. However, it is still possible 
that the reduction sensitive species represent either homooligomeric PTPa or the 
interaction of PTPa with a range of different proteins. Furthermore, even if it is granted 
that the disulphide crosslinking data and the co-immunoprecipitation data support a model 
where PTPa forms oligomers, the exact nature of the PTPa oligomers remains unclear. 
Firstly, the valency of the oligomers is unclear. Secondly, it is not known whether the same 
oligomeric form contains both the full-length PTPa protein and the cleavage fragments or 
whether oligomers contain only full-length or cleaved protein but never both. Similarly, it is 
unclear whether the detection of both oligomeric intracellular cleavage products and 
oligomeric extracellular cleavage products reflects the existence of distinct protein 
complexes or a single complex consisting of oligomers of the reasssociated Ex/P  complex.
These questions can be addressed by combining the disulphide cross-linking 
experiments with the co-immunoprecipitation experiments. Non-reducing and two 
dimensional analysis of co-immunoprecipitates from cells expressing differentially tagged 
PTPa would show the exact identity of the constituent parts of each high molecular weight 
species. Together with this information, molecular weight and quantitative analysis should 
accurately identify the valency of each PTPa complex and also confirm or disprove the 
existence of full-length/cleaved hetero-oligomeric complexes.
Two constructs were designed such that both contained the P843C substitution 
and each had a different carboxy-terminal epitope tag; either an HA tag or a 3xMyc tag 
(Figure 5.3A). There was no detectable difference in either the localisation or cleavage 
pattern of these two forms of PTPa when compared to the other constructs used in this 
thesis (Data not shown). Cotransfection of HEK-293T cells with these two constructs 
resulted in the robust expression of the two encoded proteins. Approximately equal levels 
of each protein were seen in lysates from single- and double-transfected cells (Figure 5.3B).
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180Figure 5.3: Co-immunoprecipitation of P843C disulphide cross-linked PTPa
Protein lysates and immunoprecipitates were analysed by reducing SDS-PAGE. Proteins 
transferred to a membrane were probed with antibodies against the carboxy-terminal Myc 
(B) or HA tag (C).
A.  Schematic diagram of PTPa proteins to show tag locations and expected cleavage 
products.
B.  Anti-HA and anti Myc detection of reducing SDS-PAGE analysis of lysates
C.  Anti-FLAG detection of lysates and immunoprecipitates
D.  Anti-Myc detection of non-reducing SDS-PAGE analysis of immunoprecipitates 
Lanes:
843 HA lysate: PTPa-P843C-HA expressing lysate 
843 Myc lysate: PTPa-843C-3xMyc expressing lysate 
843 Co-Lysate: Lysate from co-transfected cells
843 Myc —  HA IP: Anti-HA IP of PTPa-P843C-3xMyc transfected lysate 
843 Co —  Myc IP: Anti-Myc IP of co-transfected lysate 
843 Mix —  HA IP: Anti-HA IP of mixed lysate (5.4)
Bands:
Band 1.  Full-length PTPa 1(FL16 6 )
Band 3.  Phosphatase domain from amino-terminal cleavage (P8 5 )
Band 5.  Phosphatase domain from carboxy-terminal cleavage (P75)
Ig(2H+ 2L )  Complete quaternary IgG molecule (Mw~160kDa)
fe i  Non-reduced divalent IgG heavy chains (Mw~l OOkDa)
IgH   Reduced IgG heavy chain (Mw~50kDa)
181Coimmunoprecipitation experiments with these constructs produced the same 
results as are seen with wild type PTPa and no significant increase in the quantitative level 
of co-immunoprecipitating PTPa could be detected (Data not shown). Unfortunately, it 
was not possible to determine whether disulphide crosslinked high molecular weight PTPa 
species containing both HA and 3xMyc-tagged protein also co-immunoprecipitated in 
these experiments. Under non-reducing conditions, a large number of very prominent 
antibody bands were present at a range of sizes. Several bands are seen which presumably 
represent the intact IgG molecule (IgG2H +2L Mw~150kDa) and several products resulting 
from the dissociation of this quaternary protein complex (Figure 5.3C). Unfortunately, the 
antibody bands were similar in size to some of the reduction sensitive PTPa high molecular 
weight bands. In addition, the non-reduced antibodies generated smears that further 
masked the relevant regions of the gel. All attempts to clear antibody fragments from the 
immunoprecipitates using protein G or anti-Mouse immunoglobulins failed (Data not 
shown). This problem might be overcome in the future by using a solid matrix-linked 
affinity system that would allow the antibody bands to be efficiendy separated from the 
proteins of interest.
5.4: Contribution of post-lysis interactions to co-immunoprecipitation
Data shown here and in chapter 4 suggest that PTPa forms oligomeric complexes. 
However, these results may reflect an intrinsic tendency of PTPa to aggregate following 
detergent lysis. The aggregation profile of several transmembrane and membrane- 
associated proteins is affected by detergent lysis (Ludi and Hasselbach, 1984; Hsu and 
Youle, 1998; Musatov et al., 2000). One way of examining this possibility is to mix lysates 
from cells each expressing a differentially tagged form of PTPa and to compare the amount 
of PTPa co-immunoprecipitated from the mixed lysates and co-expressing lysates. PTPa 
protein could be co-immunoprecipitated from mixed lysates. However, the recovery was 
significandy lower than that achieved from lysates that co-expressed both proteins (Figure 
5.4B).
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183Figure 5.4: Contribution of post-lysis interactions to co-immunoprecipitation
Protein lysates and immunoprecipitates were analysed by reducing SDS-PAGE. Proteins 
transferred to a membrane were probed with antibodies against the amino-terminal FLAG 
tag.
A.  Schematic diagram of PTPa proteins to show tag locations and expected cleavage 
products.
B.  Anti-FLAG detection of lysates and immunoprecipitates 
Lanes:
Cl HA: Cl HA expressing lysate 
a UTR: a UTR expressing lysate 
CO: Lysate from co-transfected cells
Mix: Combined lysates from Cl HA and a UTR expressing cells 
a UTR —  HA IP: Anti-HA IP of a UTR transfected lysate 
CO —  FLAG IP: Anti-FLAG IP of co-transfected lysate
Mix —  HA IP: Anti-HA IP of combined lysates from Cl HA and a UTR expressing cells 
Bands
Band 1.  Full-length PTPa 1(FL1 6 6 )
Band 2.  Extracellular domain from amino terminal cleavage (E81)
Band 4.  Extracellular domain from carboxy-terminal  cleavage (E9 0 )
IgH   Reduced IgG heavy chain (Approx 50kDa)
1845.5: Discussion
This chapter confirms that wild type PTPa forms oligomeric complexes as shown 
by co-immunoprecipitation. Prior to this work, it had only been possible to detect these 
interactions following biochemical crosslinking, using mutated or chimaeric proteins 
including disulphide crosslinking mutants, after treatment of RPTP-expressing cells with 
biochemical reagents or indirectly, using energy transfer techniques (Takeda et al., 1992; 
Desai et al., 1993; Jiang et al., 1999; Jiang et al., 2000; Tertoolen et al., 2001; Xu and Weiss, 
2002; Blanchetot et al., 2002a). In the course of the work described in this thesis, dimeric 
RPTPs were reported using similar approaches to those described here (Gross et al., 2002; 
Toledano-Katchalski et al., 2003; Takeda et al., 2004; Walchli et al., 2005). In this chapter, 
PTPa is shown to oligomerise without the use of chemical treatments or changes in the 
native PTPa sequence other than the addition of epitope tags. Co-immunoprecipitation 
experiments identified oligomeric forms containing all five known PTPa peptides (FL166, 
P8 5 /7 5 and E85/75). Thus, the results confirm the data seen with disulphide crosslinking 
mutants and extend it to include those species lacking the ectopic cysteine required for 
disulphide crosslinking. In addition, the demonstration of oligomerisation with co- 
immunoprecipitation of native sequence PTPa confirms that the ectopic disulphide bonds 
do not themselves cause PTPa dimerisation. Unfortunately, technical difficulties hindered 
the co-immunoprecipitation of the disulphide crosslinking PTPa mutants (Chapter 4). In 
the future, combined co-immunoprecipitation/disulphide crosslinking experiments would 
clarify the valency and content of the PTPa complexes.
Co-immunoprecipitation experiments with the HA- and 3xMyc-tagged PTPa 
proteins show that PTPa forms oligomeric structures that include the full-length protein 
and both intracellular domain cleavage products (Figure 5.IB, C). This confirms the results 
seen with disulphide crosslinking and extends the finding that PTPa oligomerises to those 
cleavage fragments that lack an ectopic cysteine (i.e. E 9 0/P 8 5 ) and so were not detectable as 
disulphide-linked oligomers. However, this kind of immunoprecipitation experiment failed 
to address whether E 8 1  is found in oligomeric complexes and whether individual complexes 
contain both extracellular and intracellular cleavage fragments or if these are maintained in 
separate oligomeric complexes. These questions can be addressed by co- 
immunoprecipitation experiments using tags that are located on either side of the cleavage 
sites i.e. one at the amino- and one at the carboxy-terminal end of recombinant PTPa 
proteins.
185Co-immunoprecipitation experiments with PTPa proteins labelled with tags on 
different sides of the cleavage sites showed that PTPa forms oligomeric complexes (Figure 
5.2B, C). All labelled forms of PTPa were seen to co-immunoprecipitate showing that E 8 1  
is indeed found in PTPa oligomers. Furthermore, as the tags were located on either side of 
the cleavage sites several hypotheses present themselves regarding the nature of the 
oligomeric complexes. The co-immunoprecipitation of the cleaved forms is highly 
informative. Co-immunoprecipitation of homo-oligomeric complexes containing only 
extracellular or only intracellular domains was not detectable using this system. Therefore 
mixed oligomers must exist that contain either a full-length PTPa molecule or a re­
associated E /P heterodimer in addition to the cleaved domain that is being 
immunoprecipitated. It is notable that full-length PTPa also co-immunoprecipitates in this 
system and so homooligomers of full-length protein or hetero-oligomers of full-length and 
re-associated E /P  heterodimers must also exist. However, so far it has not been possible to 
identify heterodimers of cleaved and uncleaved PTPa (Figure 4.11). Therefore, it appears 
that only homologous PTPa species can be found in oligomers. It may be noted that such 
selectivity is unlikely to be seen if PTPa aggregation was artefactual. However, it will be 
important to formally determine whether mixed full-length/cleaved PTPa oligomers exist 
as this has important implications for many aspects of the biology of PTPa including PTPa 
cleavage and oligomerisation.
Hypothetical models for PTPa oligomerisation differ principally in the state in 
which PTPa cleavage occurs —  monomeric or dimeric PTPa or both. If monomeric PTPa 
is subject to regulated proteolysis then a number of oligomerisation mechanisms must exist 
that on the one hand permit the association of PTPa molecules with homologous patterns 
of cleavage but on the other hand bar the association of PTPa molecules with heterologous 
cleavage patterns. Alternatively, if cleavage occurs at the oligomeric stage in such a way that 
cleavage of all constituent chains is linked, this might produce a number of PTPa 
complexes each containing different PTPa species. The original oligomerisation 
mechanism would need to be relatively unaffected by proteolysis at the two cleavage sites. 
However, this hypothesis does not need to postulate mechanisms for the subunit 
specificity of the PTPa complexes. If cleavage were to occur at both the monomeric and 
oligomeric stages this would imply the same difficulties as cleavage at the monomeric stage 
and require enzyme mechanisms that can act in potentially quite different environments.
As alluded to above, the nature of these mixed oligomers is unclear. Although it 
may be assumed that these oligomers are in fact dimers, this has not been direcdy
186demonstrated. In addition, it is not known whether a single PTPa complex exists that may 
contain any of the various PTPa peptides or if a number of complexes exist, each of which 
consists of a specific combination of PTPa peptide chains. Firstly, the mechanics of PTPa 
cleavage and re-association are not well understood (Serra-Pages et al., 1994). The re­
associated heterodimeric E /P PTPa complexes might result from reassociation of a single 
cleaved PTPa molecule or by the assignment of cleaved extracellular domains to cleaved 
intracellular domains, irrespective of their molecular origin. Furthermore, it is not known 
whether PTPa is cleaved in the monomeric or oligomeric state and if oligomers are cleaved 
it is not known whether the constituent monomers are cleaved simultaneously or 
sequentially. Secondly, it is unclear whether the heterodimeric E /P PTPa complex is stable 
or dynamic with the exchange of individual PTPa E domains between PTPa P domains 
and their immediate subcellular environment. Although no such exchange of cleavage 
fragments has been reported for any RPTP, if the association of PTPa E domains with 
PTPa P domains is not restricted to those that share a common molecular origin, then 
these co-immunoprecipitation experiments need not suggest the formation of oligomeric 
complexes at all. Lastly, PTPa co-immunoprecipitation might not reflect a direct oligomeric 
relationship at all, but rather the ability of a number of PTPa peptides to associate 
simultaneously with a second protein. However, in the disulphide crosslinking experiments 
(4.3), the residual molecular weights (after subtraction of the appropriate PTPa molecular 
weight) of the two major disulphide crosslinked species were different. Furthermore, the 
two size differences were not directly convertible by simple multiplication. Therefore, if 
cleaved and full-length PTPa are not responsible for the residual molecular weight, a model 
must be described that uses two different proteins, not just a different number of the same 
unknown protein. In summary therefore, it should be emphasised that although alternative 
explanations exist, it is likely that PTPa forms homodimers.
The nature of the PTPa heterodimeric E /P complexes and the PTPa oligomers 
can be addressed by combining the disulphide-crosslinking and co-immunoprecipitation 
experiments. Unfortunately, technical limitations have prevented such a study at the 
present time (5.3). Such a study would be most informative if 2 recombinant PTPa proteins 
were used with a unique tag at each end of each protein; a total of four distinct tags. In 
addition, the interpretation of these experiments would be simplified by the use of a system 
that generates consistent levels of PTPa. Historically, it has been difficult to establish a 
stable cell line expressing just a single PTPa construct. Therefore, it might be desirable to 
avoid the necessity of generating a stable cell line expressing two PTPa constructs
187simultaneously. This might readily be achieved using a dual-cistronic system. The 
establishment of a cell line that stably expresses recombinant PTPa would still be required 
to explore the factors that affect PTPa cleavage. These PTPa overexpression systems will 
necessarily exhibit some differences from cells that express PTPa endogenously. However, 
the ability to distinguish individual PTPa molecules is essential in order to gain a better 
understanding of PTPa cleavage and oligomerisation. The results obtained in these systems 
can then be tested for validity in endogenous systems.
Many questions would be answered by the combined co-immunoprecipitation and 
disulphide cross-linking experiments outlined above. Firstly, co-immunoprecipitation of 
disulphide cross-linked PTPa will formally confirm the nature of the PTPa high molecular 
weight species by demonstrating whether the high molecular weight species contain the 
PTPa species predicted to participate in the formation of each species. Secondly, strong 
ionic detergents such as SDS dissociate the E /P heterodimers (Yu et al., 1992). 
Immunoprecipitation of such lysates (following appropriate dilution of the detergent) 
should identify whether full-length/cleaved protein heterodimers form. This can be 
confirmed by non-reducing/reducing 2-dimensional SDS-PAGE analysis of lysates and 
immunoprecipitates. The presence or absence of full-length/cleaved heterodimers is of 
critical importance. It was shown above that PTPa cleaved subunits can be co- 
immunoprecipitated across the cleavage site. If the absence of full-length/cleaved 
heterodimers is confirmed then this is indirect evidence that the oligomeric E subunits and 
P subunits associate rather than existing independently. This would be an important finding 
with significant implications for PTPa oligomerisation and also the mechanisms of PTPa 
cleavage. Further questions would include localising the PTPa cleavage events to 
subcellular compartments and identifying the enzymes and pathways that regulate PTPa 
cleavage. Understanding these events would facilitate further research on the function of 
type Ha RPTPs as current work is limited by the unpredictable variability of PTPa cleavage 
in any given experiment.
Another notable finding from these co-immunoprecipitation experiments is that a 
significant proportion of cellular PTPa co-immunoprecipitates. This suggests that a large 
part of the cellular PTPa pool is oligomeric, at least under the conditions examined in this 
work. It may be that the high level of multimerisation detected reflects the inherent 
tendency of an overexpressed transmembrane domain protein to aggregate. This has 
previously been reported both within the cell as an artefact of overexpression or later, as an 
artefact of detergent lysis (Ludi and Hasselbach, 1984; Di Fiore et al., 1987; Di Marco et al.,
1881990; Maru et al., 1990; Brandt-Rauf et al., 1990; Hsu and Youle, 1998; Musatov et al., 
2000). However, it has already been shown that a significant amount of the full-length form 
of wild type and mutant PTPa reaches the cell surface (3.2, 4.3.3) whereas non-specific 
membrane protein aggregation is density dependent, occurring most commonly in the 
organelles of the secretory pathway. Moreover, although membrane protein overexpression 
can increase receptor dimerisation, this usually represents an increase above physiological 
basal levels rather than the formation of an interaction that does not otherwise occur. The 
increased local density of receptor in the plasma membrane removes a major limiting 
influence on dimer formation. As a non-specific mechanism, it is also unlikely that 
aggregation would result in the formation of distinct oligomers involving only full-length or 
cleaved protein but not both; such a pattern is seen with the disulphide crosslinking 
experiments (4.3).
As mentioned above, the co-immunoprecipitation experiments can be subjected to 
quantitative as well as qualitative analysis. Unfortunately, several features of the PTPa 
expression system used in this thesis prevent a more exact quantification of the amount of 
PTPa found in the monomeric and oligomeric states. This also limits a comparison of the 
propensity of different PTPa peptides to oligomerise. Firstly, it was difficult to standardise 
both the level of PTPa expression and the pattern of PTPa cleavage between experiments 
(Chapter 3). Furthermore, both singly- and doubly-transfected cells were present in the cell 
populations studied and the level of co-transfection varied between experiments. Similar 
variabilities affected the relative level of the two PTPa proteins in each co-transfected cell. 
Furthermore, technical difficulties hindered the normalisation of co-immunoprecipitation 
efficiency between samples. These include the effects of oligomerisation and cleavage on 
epitope accessibility for co-immunoprecipitation. The effects of conformation on epitope 
accessibility have been clearly demonstrated for the related PTPa (van der Wijk et al., 
2003). Lasdy, the usefulness of such a quantification is of questionable value whilst we are 
ignorant of the valency of the PTPa complexes. The proportion of PTPa that co- 
immunoprecipitates as part of an oligomeric complex depends both on the level of PTPa 
oligomerisation and the complex valency. If the complexes are dimeric, at most only 50% 
of each monomer can be co-immunoprecipitated with antibodies against the other subunit. 
In complexes with higher valencies, this limit rapidly approaches 100% (e.g. Trimer —  75%; 
tetramer - 87.5% etc).
Two points can be made regarding PTPa oligomerisation. Firsdy, a significant 
proportion of cellular PTPa is found in oligomeric complexes. This level is similar to that
189detected with disulphide crosslinking techniques. Although these are not formally 
compared in this work, this suggests that disulphide crosslinking reflects rather than 
mediates PTPa oligomerisation. Secondly, there was some variability in the relative 
proportion of each co-immunoprecipitating species, both with respect to each other and in 
comparison with their relative abundance in the lysates (Figure 5.IB, C). However, there 
was no consistent trend to these differences and as described above the relative abundance 
of each band varied from experiment to experiment both in the lysates and in the resulting 
co-immunoprecipitates. As all detectable tagged species co-immunoprecipitated, the 
observed differences are more likely to represent interexperimental variation rather than 
real differences in the propensity of each species to oligomerise. Indeed, as previously 
discussed, the absolute PTPa level and the PTPa cleavage pattern varied significantly from 
experiment to experiment (Chapter 3).
Lastly, it is worth noting that the PTPa oligomerisation seen is not primarily 
mediated by interactions that occur after cell lysis (Figure 5.4). Such interactions have been 
described for other transmembrane receptors following detergent solubilisation. Some 
PTPa oligomerisation is detected following the combination and subsequent 
immunoprecipitation of lysates from cells each expressing only a single PTPa construct. 
However, the level of association detected in this way is significantly lower than that which 
is detected in lysates from cells co-expressing two differentially-tagged PTPa proteins.
In fact, the low level of oligomerisation detected in combined lysates need not 
represent artefactual PTPa aggregation at all. PTPa molecules may retain the ability to 
interact in solution when solubilised with the mild non-ionic detergents used in this study. 
This interaction may reflect a cis- or /ra/w-dimerisation mechanism similar to that seen in the 
related type lib RPTPs or binding of PTPa to a divalent interacting protein present in the 
lysate. Such possible interactions include reverse signaling mechanisms where PTPa acts as 
a ligand rather than a receptor. Previously well characterised for Ephrins, this type of 
interaction has recendy been suggested for PTPa extracellular domains although the 
receptor involved has not been identified (Holland et al., 1996; Mellitzer et al., 2000;
Sajnani et al., 2005). Finally, the size of detergent micelles and the rate of exchange of 
solubilised PTPa molecules between micelles is unknown.
The experiments reported in this chapter support the data presented in chapter 4 
and suggest that PTPa is largely dimeric. This is in agreement with the situation seen with 
type IV and type lib RPTPs. The data presented here extend the disulphide cross-linking
190data to show that the PTPa species that lack the ectopic cysteine required for disulphide 
crosslinking also form dimers. Therefore, all known PTPa peptides, both cleaved and full- 
length form oligomers. A hypothetical model for PTPa oligomerisation and cleavage was 
presented. Briefly, this model proposes that PTPa is highly oligomeric and that it is the 
oligomers that are subject to cleavage. Cleavage on all the chains in an oligomer is coupled 
such that hetero-oligomers of full-length and cleaved PTPa are undetectable. An 
experimental system that might resolve some of the questions that remain in this area was 
presented and discussed.
191Chapter 6: Effects of chemical mediators on PTPcr
This chapter extends the descriptive work carried out in Chapter 3, confirming 
previous work, which showed that PTPa cleavage and shedding may be induced by protein 
kinase C (PKC) activation (Aicher et al., 1997). However, this chapter also shows that in 
addition to the shed Egl fragment, the E 9 0  fragment is shed in a dose-responsive manner 
following PKC activation by a phorbol ester. In addition, the effects of treatment with the 
tyrosine phosphatase inhibitors, sodium pervanadate and H 20 2, are reported. Pervanadate 
treatment and hence tyrosine phosphatase inhibition has no effect on PTPa expression 
level, cleavage pattern or high molecular weight species formation. However, a cleavage 
fragment shows preferential tyrosine phosphorylation at an unknown site, which suggests 
an as-yet unclear interaction between PTPa phosphorylation and at least one of the two 
proteolytic cleavage events. In contrast, it is shown that H 20 2  induces the formation of 
high molecular weight forms of PTPa. This suggests that H 20 2 has effects on RPTP 
expressing cells that are distinct from pure tyrosine phosphatase inhibition. This is in 
agreement with reports of the formation of high molecular weight species by PTPa and an 
PTPa-LAR chimera in cells treated with H 20 2  (van der Wijk et al., 2004). As H 20 , is 
produced in response to growth factor signaling, the effect of serum on high molecular 
weight species formation was evaluated but no effect was seen on PTPa expression level, 
cleavage pattern or high molecular weight species formation. Lasdy, the effect of heparin 
treatment of PTPa-transfected cells was evaluated. A number of Heparan sulphate 
proteoglycans (including heparin) are known to interact with PTPa (Aricescu et al., 2002). 
However, heparin treatment has no discemable effect on PTPa expression level, cleavage 
pattern or high molecular weight species formation.
6.1: Treatment with the phorbol ester, TPA
Among the most prominent features of PTPa processing are the proteolytic
cleavage events. The effect of these events on PTPa function is not understood and so it
will be important to identify the factors regulating the two PTPa cleavage events and the
effects of each on PTPa function. The carboxy-terminal (secondary) cleavage event can be
stimulated by Protein Kinase C (PKC) activation or calcium ionophore treatment, resulting
in intracellular domain internalisation and soluble extracellular domain shedding (Aicher et
al., 1997). Similar processes are a feature of a number of membrane proteins (Jung and
Dailey, 1990; Pandiella and Massague, 1991; Gandy and Greengard, 1994). However, type
Ha RPTPs are different from many of these proteins in that they have two cleavage sites
192allowing the production of E^/P-^ fragments in addition to E 8 1/P 8 5  fragments (Serra-Pages 
et al., 1994; Aicher et al., 1997). The significance of the additional amino-terminal cleavage 
event is not clear. The current model suggests that PTPa is constitutively cleaved by an 
subtilisin-type protein convertase at its amino-terminal site during or immediately after 
maturation in the endoplasmic reticulum and Golgi network (Streuli et al., 1992; Jiang et al., 
1993; Yan et al., 1993; Serra-Pages et al., 1994; Pulido et al., 1995a; Campan et al., 1996; 
Cheng et al., 1997). Subsequendy, inducible carboxy-terminal cleavage, which is mediated 
by a metalloprotease, is thought to occur at a membrane proximal site and release soluble 
extracellular domain from the reassociated E 8 1-P8 5 heterodimer (Serra-Pages et al., 1994; 
Aicher et al., 1997; Ruhe et al., 2006; Anders et al., 2006). However, as shown above, 
significant amounts of the E^, species can be identified in cell lysates and it does not 
generally accumulate in the media in the same way as the E 8 1  fragment (Chapter 3, 4). 
Furthermore, although a formal description of this larger E form is lacking in many papers, 
it has previously been identified in SDS-PAGE gels of sample from both over- and 
endogenously-expressing type II RPTP systems (Serra-Pages et al., 1994; Pulido et al., 
1995a; Aicher et al., 1997; Suarez et al., 1999; Ostenson et al., 2002). This implies that 
carboxy-terminal cleavage alone is not sufficient for PTPa shedding. Therefore, HEK- 
293T cells transfected with wild-type PTPa were treated with a PKC activator to determine 
whether the increase in carboxy-terminal cleavage previously reported to result in an 
increase in the soluble E 8 1  fragment also results in an increase in the amount of the cell 
associated or soluble E90.
HEK-293T cells transfected with wild type PTPa release significant amounts of the 
Es fragment into the tissue culture media over time (3.1). Following the replacement of 
their media, treatment of these cells with phorbol ester (Phorbol-12-myristate-l 3-acetate 
(TPA)) for five minutes resulted in the rapid appearance of PTPa cleavage fragments in the 
media (Figure 6.1). In independent experiments, a dose-responsive increase in the amount 
of shed E 8 1  was seen. The effect of TP  A reached a plateau in the region of l-5pM but was 
detectable at lOnM. It is of note that E 9 0 is also detected in the media of TPA-treated cells. 
The amount of shed E 9 0  also increases in proportion to the TPA concentration and the 
amount of shed protein again peaks at treatment levels around l-5pM. The amount of shed 
E 9 0 is significandy less than the amount of E81. Following harvesting, media was passed 
through a 0.22pm filter and no full-length PTPa was detected in the media. In addition, 
there was no significant difference in the amount of cellular PTPa that paralleled the 
difference seen in the shed protein. Therefore, it is likely that the E^ seen represents shed
193protein and not artefactual cell-associated protein that has passed through the filter into the 
supernatant. As TPA-induced PTPa cleavage has previously been reported, PKC activation 
was not formally confirmed (Aicher et al., 1997). However, it would be possible to confirm 
PKC activation by showing an increase in the phosphorylation state of known PKC targets 
using phosphospecific antibodies. It was not possible to determine whether TPA treatment 
had an effect on PTPa dimerisadon or high molecular weight species formation due to the 
spatial relationship between the cleavage sites and the disulphide cross-linking sites. In 
addition, the TPA vehicle (Dimethylsulphoxide) has a marked effect on the amount of 
immunoprecipitatable PTPa, possibly through structural effects on the epitope tags (Data 
not shown). In summary therefore, the effect of cleavage and shedding on dimerisation and 
indeed the effect of dimerisation on cleavage and shedding are important unanswered 
questions that need addressing.
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195Figure 6.1: Treatment of PTPa-transfected HEK-293T cells with Phorbol-12-myristate-13- 
acetate (TPA) causes PTPa extracellular domain shedding
After media replacement, FLAG-tagged PTPa transfected HEK-293T were treated for one 
hour with a range of concentrations of phorbol ester (Phorbol-12-myristate-l 3-acetate 
(TPA)) to induce protein kinase C activation. The supernatant was harvested and the cells 
were lysed. The media was passed through a 0.22pm filter to remove cells and debris and 
analysed by SDS-PAGE. PTPa extracellular domain fragments present in the media were 
detected using the FLAG (Amino-terminal) tag. PTPa fragments (E9 0/E 8 1 ) are marked to 
the right of the figure. The autoradiographs were scanned using a BioRad Densitometer 
and the amount of the E^ and E 8 1  species determined separately by densitometry (NIH 
Image). The separate values were also combined to give a total amount of shed extracellular 
domain in each sample.
A.  SDS-PAGE analysis of media from one TPA treatment experiment. TPA was added to 
the concentration indicated except in the DMSO only experiments where the amount 
of DMSO added was equal to the highest amount of vehicle used as the TPA vehicle 
(100nM/10pM -  1%(V /V )).
B.  Densitometric analysis SDS-PAGE gel A.
C.  SDS-PAGE analysis of media from second, independent TPA treatment experiment.
D.  Densitometric analysis of SDS PAGE gel C.
1966.2: Treatment with pervanadate
Activation of the serine/threonine kinase, Protein kinase C (PKC), induces PTPa 
cleavage. In addition to their regulation by serine/threonine kinases, preliminary evidence 
exists to suggest that RPTPs have the ability to autodephosphorylate and so are probably 
also regulated by tyrosine phosphorylation (Aricescu, 2002). Little is known about the 
effects of tyrosine phosphorylation on RPTPs. Several receptor protein families undergo 
proteolytic cleavage in response to tyrosine phosphatase inhibition (Vecchi et al., 1998; 
Codony-Servat et al., 1999). It is not known whether tyrosine phosphorylation affects 
PTPa expression level, cleavage or high molecular weight formation. PTPa-transfected 
cells were treated with the powerful tyrosine phosphatase inhibitor pervanadate to 
determine if PTPa is phosphorylated in vivo and whether this has any effect on PTPa 
expression level or cleavage pattern. Although nominally a cysteine-based tyrosine 
phosphatase inhibitor, by preventing the dephosphorylation of the tyrosine kinase 
activation loop tyrosine pervanadate also stimulates tyrosine kinase activity, resulting in a 
raised cellular phosphotyrosine level.
Pervanadate treatment of PTPa-transfected HEK-293T cells reproducibly and 
significantly increased the overall phosphotyrosine level of the cell lysates (Figure 6.2A). 
However, despite the marked effect on phosphotyrosine levels, PTPa cleavage and 
expression level were unaffected with respect to both the amino- and carboxy-terminal 
cleavage fragments (Figure 6.2B, C). Analysis of PTPa immunoprecipitates from these cell 
lysates revealed that both full-length PTPa and its cleaved intracellular domain fragments 
(P8 5 >  ^75) became phosphorylated following PVD treatment (Figure 6.2D). However, the 
cleaved intracellular domain was significantly more phosphorylated than the full-length 
molecule despite significantly more full-length protein being present in the lysates and 
approximately similar amounts of cleaved and full-length protein immunoprecipitating 
(Figure 6.2C, D, E). The effect of PTP inhibition on high molecular weight species 
formation or dimerisation was not assessed.
197A. RPTPo HA
kDA
Blot: Phosphotyrosine
PVD
B.
RPTPo HA
250-
100-
75-
P\rD
C. RPTPo HA
kDA -n.s.
Blot: HA
PVD
D.
kDA
3  3
70
7 Q r
+  +
IP: HA 
Blot: Phosphotyrosine
ha
+  -  + 
IP: HA 
Silver stain
-E  P 
.p*” PM
*73
PVD
198Figure 6.2: Effects of sodium pervanadate on PTPa cleavage and expression level
Cells transfected with various forms of PTPa (FLAG-(Amino-terminal), HA/Myc-tagged 
(Carboxy-terminal)) were treated with the non-specific tyrosine phosphatase inhibitor, 
sodium pervanadate (PVD). The effects of tyrosine phosphatase inhibition on cellular 
phosphotyrosine, PTPa expression and cleavage and on PTPa phosphorylation were 
determined. PTPa peptides, immunoglobulin bands (Heavy —  IgH  (50kDa), Light —  IgL  
(25kDa)) and non-specific (n.s.) bands are marked to the right of the gels.
A.  Phosphotyrosine (4G10) detection of total lysates from PTPa transfected cells treated 
either with control (-) or ImM PVD (+) for 15minutes.
B.  Amino-terminal (FLAG) detection of total lysates from PTPa transfected cells treated 
either with control (-) or ImM PVD (+) for 15 minutes.
C.  Carboxy-terminal (HA) detections of total lysates from PTPa transfected cells treated 
either with control (-) or ImM PVD (+) for 15minutes.
D.  Phosphotyrosine detection (4G10) of immunoprecipitates (HA) from PTPa-HA or 
PTPa-Myc transfected cells treated with either control (-) or lOOpM PVD (+) for 30 
minutes.
E.  Total protein detection (Neutral silver stain) of immunoprecipitates (HA) from PTPa- 
HA or PTPa-Myc transfected cells treated with either control (-) or lOOpM PVD (+) 
for 15 minutes.
1996.3: Treatment with hydrogen peroxide
A second non-specific, cysteine-based-tyrosine-phosphatase inhibitor, H 20 2, has 
recendy been reported to affect the conformation and possibly oligomeric state of PTPa 
(van der Wijk et al., 2003; van der Wijk et al., 2004). Historically, H 20 2  was thought to act 
as an RPTP inhibitor through oxidation of the active site cysteine (C215S Dl) in the 
membrane proximal phosphatase domain, which is essential for the mechanism of cysteine- 
based RPTPs (Huyer et al., 1997; Denu and Tanner, 1998). This data was largely 
extrapolated from work on the cytoplasmic PTP1B, which has only a single phosphatase 
domain. However, recent data shows that the oxidative effects of H 20 2  are expressed 
largely by oxidation not of the membrane proximal phosphatase domain catalytic cysteine 
but of the active site cysteine in the carboxy-terminal tyrosine phosphatase domain, which 
is not thought to have significant catalytic activity (Persson et al., 2004; Groen et al., 2005). 
Therefore, it appears that H20 2  may mediate at least part of its effect by a novel 
mechanism in addition to oxidation of the catalytically active tyrosine phospatase domain 
active site cysteine. Given the data suggesting that PTPa is inhibited by dimerisation, it is 
interesting to note that PTPa inhibition by H 20 2  is associated with a possible increase in 
PTPa dimerisation (van der Wijk et al., 2004). This is of particular interest as H 20 2  is a 
physiological cellular second messenger produced in response to growth factor stimulation 
and so might play a role in the functional regulation of PTPa (Sundaresan et al., 1995; Bae 
et al., 1997; Meng et al., 2002). The effect of H 20 2  on PTPa dimerisation has been shown 
also to apply to a chimaeric PTPa-LAR fusion protein. Therefore, the effect is either 
mediated purely through the PTPa extracellular domain and HA tag or H 20 2  induced 
dimerisation is a feature of several PTPs. The effect of H 20 2  on PTPa expression level, 
cleavage pattern and high molecular weight species formation was determined by treating 
PTPa-transfected cells with different concentrations of H 20 2.
Initial experiments failed to detect any high molecular weight PTPa species on
treatment with H 20 2  (Figure 6.3E). This is especially remarkable when compared to the
amount of high molecular weight species formation seen in Chapter 4. However, in the
experiments shown in Chapter 4, so much high molecular weight product was detected that
the gels were difficult to interpret. Therefore, the experimental protocol was optimised to
minimise high molecular weight smear formation, except that mediated through the ectopic
cysteine residues. Significandy, during the optimisation of high molecular weight smear
formation (Chapter 4), lysates containing Nonidet P-40 (NP40) but lacking iodoacetamide
produced lower levels of high molecular weight smears than similar lysates including Triton
200X-100 (TX100) (Data not shown but compare Figure 4.6 and Figure 6.4). Although these 
two detergents are similar in many ways, a noticeable difference is that many commercial 
batches of TX100 contain significant levels of H 20 2 (~65mM; 1% lysis buffer = 0.65 mM) 
whereas NP40 (<0.06mM; 1% lysis buffer < 0.00065 mM) has a 100,000-fold lower H 20 2  
concentration (Ashani and Catravas, 1980; Roche datasheets). This hypothesis supported 
the PTPa data and suggested that H 20 2  might induce PTPa to form high molecular weight 
species.
The failure of the tyrosine phosphatase inhibitor, H 20 2, to increase cellular 
phosphotyrosine under these conditions was unexpected. The most likely explanation was 
a technical error, although H 20 2-induced phosphatase inhibition has not previously been 
reported to be a fastidious treatment. The most likely problem was that the way in which 
the H 20 2  was presented might not be optimal. A detailed review of the available literature 
showed that although the optimal conditions for H 20 2-induced tyrosine phosphatase 
inhibition have not been widely discussed, the conditions for H 20 2-induced lipid 
peroxidation have been carefully optimised. Firstly, H 20 2-induced lipid peroxidation 
requires a source of Fe2+ and is inhibited by common media additives including Phenol Red 
and tyrosine (Dugas et al., 2000). The standard growth media for HEK-293T cells, as used 
in these experiments is Dulbecco’s modified essential media (DMEM). DMEM contains 
10% (v/v) foetal calf serum, only an Fe3+ source (Fe —  0.1 mg/L Fe(N 03 )3 ) and high 
concentrations of phenol red (PR —  16 mg/L) and tyrosine (Tyr —  104 mg/L) (American 
Tissue Culture Collection website; Sigma-Aldrich media formulations). Although replacing 
growth media with Dulbecco’s phosphate buffered saline (DPBS) prior to stimulation 
removes contaminating catalyse, tyrosine and Phenol Red, DPBS lacks an Fe2+  source. 
However, HEK29T cells also grow well in other media such as Ham’s nutrient mixes F10 
(PR —  1.3mg/L; Tyr —  2.6mg/L; Fe —  0.8mg/L Fe(S04 )) and FI2 (PR —  1.3mg/L; Tyr —  
7.8mg/L; Fe —  0.8mg/L Fe(S04 )), which both have more suitable components for H 20 2  
treatment. In addition, a careful literature review revealed that possibly for serendipitous 
reasons all published work on RPTPs and H 20 2 used either one of Ham’s nutrient mixes or 
a media containing equal proportions of DMEM and one of the Ham’s mixes (Blanchetot 
et al., 2002a; van der Wijk et al., 2003; van der Wijk et al., 2004; Persson et al., 2004). 
Peroxide treatment of PTPa-transfected cells treated using the revised conditions induced 
small but detectable changes in cellular phosphotyrosine levels (Figure 6.3F).
H 20 2 does not affect the cleavage pattern of PTPa but does decrease PTPa protein 
level in a manner that requires an intact active site cysteine in the membrane distal
201phosphatase domain. Lysates from H ,0 2-treated cells expressing wild type or cysteine 
mutant (C215S Domain 1  (cPTPa aa: 1141), C215S Domain 2 (cPTPa aa: 1432), C866L) 
were examined to determine if H 20 2  affects the cleavage pattern of PTPa. SDS-PAGE 
analysis of PTPa-transfected cell lysates failed to show any effect of H 20 2  on PTPa 
cleavage patterns. However, in a number of duplicate experiments there was a suggestion 
that H 20 2  treatment reduced the overall abundance of PTPa proteins. The effect appeared 
to be least marked in cells expressing the C215SD2 mutation (Figure 6.3A-D).
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203Figure 6.3: Effect of H ,02  treatment on PTPa cleavage and expression level
HEK-293T cells cultured in F10 media with 10% foetal calf serum were transfected with 
wild type or mutant PTPa (C215S domain 1, C215S domain 2, C866L). The cells were 
treated with hydrogen peroxide for 5 minutes at a range of concentrations. Before 
treatment, the serum-containing media was replaced with serum-free media. Cells were 
lysed in a buffer lacking iodoacetamide. The lysates were analysed using reducing SDS- 
PAGE. Western analysis used an antibody directed against the FLAG (amino-terminal) tag. 
PTPa peptides are marked at the right hand edge of the figure. Equal total amounts 
(Bradford assay) of protein were loaded in each lane.
A.  Wild type PTPa
B.  C215S Domain 1 mutant PTPa
C.  C215S Domain 2 mutant PTPa
D.  C866L mutant PTPa
E.  Original H20 2  treatment conditions. Cells were treated for 5 minutes with the indicated 
concentration of H20 2  diluted in serum-free DMEM media. Phosphotyrosine levels 
were detected using an anti-phosphotyrosine antibody.
F.  Improved H20 2 treatment conditions. Cells were treated for 5 minutes with the 
indicated concentration of H20 2  diluted in serum-free F10 media. Phosphotyrosine 
levels were detected using an anti-phosphotyrosine antibody.
204H-,0, treatment causes an increase in the formation of high molecular weight 
species by PTPa, which depends upon endogenous cysteine residues (van der Wijk et al., 
2004). In addition, it was suggested above that H20 2  treatment causes a decrease in the 
total level of PTPa protein, which requires the catalytic cysteine in the membrane distal 
phosphatase domain. Having established suitable conditions for H20 2 treatment of PTPa- 
transfected cells, it became possible to test the hypothesis that H20 2  stimulates the 
formation of high molecular weight species by PTPa-transfected cells. HEK-293T cells 
transfected with wild type, C215SD1, C215SD2 and C866L PTPa were treated with H20 2  
at a range of concentrations. Initially, cells were lysed in buffers lacking the cysteinyl- 
modifying agent, iodoacetamide and PTPa protein species were analysed by non-reducing 
SDS-PAGE. In the absence of iodoacetamide, wild-type PTPa formed reduction sensitive 
high molecular weight smears whereas PTPa proteins containing the C215SD1, C215SD2 
or C866L mutations contained markedly less PTPa protein in this size range (Figure 6.4A- 
D). H20 2 treatment decreased the overall signal level of PTPa species seen on immunoblot 
analysis of non-reduced samples from transfected cells. Again, the effect was least marked 
in lysates from cells expressing the C215SD2 mutation. Therefore, the C215SD1, C215SD2 
and C866L mutations appear to reduce high molecular weight smear formation under these 
conditions. However, in comparison to work on PTPa, it should be noted that it was 
necessary to use higher H20 2  concentrations with PTPa and to overexpose these gels to 
detect PTPa high molecular weight species. Therefore under these conditions, H ,0 2- 
induced high molecular weight species formation was less prominent with PTPa than with 
PTPa (van der Wijk et al., 2004).
The presence of iodoacetamide (IAA) in the lysis buffer decreased high molecular 
weight smear formation in untreated wild type PTPa expressing cells (Chapter 4).
However, the addition of IAA into the lysis buffer for the H20 2 experiments had a 
significant and unexpected effect. In the presence of IAA, wild type and mutant (C215S 
D l, C215S D2 and C866L) PTPa proteins formed significantly greater amounts of high 
molecular weight species, and at a lower H20 2  concentration, than in the absence of IAA. 
Moreover, discrete bands were seen rather than the smears reported previously for wild 
type PTPa (Chapter 4). However, the abundance of these forms was still less than seen 
with PTPa. In addition, the amount of H20 2-induced high molecular weight band clearly 
increased in a dose-responsive manner and the amount of total PTPa appeared to decrease 
reciprocally in both wild type and mutant PTPa (Figure 6.5A-D).
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206Figure 6.4: Effects of H20 2  on migration pattern of PTPa peptides on non-reducing SDS- 
PAGE in the absence of iodoacetamide
HEK-293T cells cultured in F10 media with 10% foetal calf serum were transfected with 
wild type or mutant PTPa (C215S domain 1, C215S domain 2, C866L). The cells were 
treated with hydrogen peroxide for 5 minutes at a range of concentrations. Before 
treatment, the serum-containing media was replaced with serum-free media. Cells were 
lysed in a buffer lacking iodoacetamide. The lysates were analysed using non-reducing SDS- 
PAGE. Western analysis used an antibody directed against the FLAG (amino-terminal) tag. 
PTPa peptides are marked at the right hand edge of the figure. Equal total amounts 
(Bradford assay) of protein were loaded in each lane.
A.  Wild type PTPa
B.  C215S domain 1 PTPa
C.  C215S domain 2 PTPa
D.  C866L PTPa
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208Figure 6.5: H ,02 induces the formation of high molecular weight reduction sensitive 
aggregates from PTPa expressing cells lysed in the presence of iodoacetamide.
HEK-293T cells cultured in F10 media with 10% foetal calf serum were transfected with 
wild type or mutant PTPa (C215S domain 1, C215S domain 2, C866L). The cells were 
treated with hydrogen peroxide for 5 minutes at a range of concentrations. Before 
treatment, the serum-containing media was replaced with serum-free media. Cells were 
lysed in a buffer containing iodoacetamide (20mM). The lysates were analysed using non­
reducing SDS-PAGE. Western analysis used an antibody directed against the FLAG 
(amino-terminal) tag. PTPa peptides are marked at the right hand edge of the figure. Equal 
total amounts (Bradford assay) of protein were loaded in each lane.
A.  Lysates  from cells transfected with wild type PTPa analysed by non-reducing
SDS-PAGE and detected with an antibody directed against the FLAG (amino- 
terminal) tag.
B.  Lysates  from cells transfected with C215S Domain 1 PTPa analysed by non­
reducing SDS-PAGE and detected with an antibody directed against the FLAG 
(amino-terminal) tag.
C.  Lysates  from cells transfected with C215S Domain 2 PTPa analysed by non­
reducing SDS-PAGE and detected with an antibody directed against the FLAG 
(amino-terminal) tag.
D.  Lysates  from cells transfected with C866L PTPa analysed by non-reducing SDS-
PAGE and detected with an antibody directed against the FLAG (amino- 
terminal) tag.
2096.4: Treatment with foetal calf serum
The generation of H20 2  in response to growth factor binding by receptor tyrosine 
kinases is one of the mechanisms by which RTKs activate their downstream pathways 
(Sundaresan et al., 1995; Bae et al., 1997; Meng et al., 2002). As H20 2  treatment causes 
PTPa to form high molecular weight smears, it is of interest to determine whether a local, 
physiological source of H20 2, such as growth factor administration, has the same effect as 
the application of a much lower concentration over the whole cell. However, when wild 
type PTPa-expressing cells were starved of serum overnight, they unexpectedly had a 
higher phosphotyrosine level than cells incubated overnight in serum-containing media 
(Figure 6.6C lanes 1, 2). Indeed, phosphotyrosine levels appeared to decrease in proportion 
to the duration of serum treatment (Figure 6.6C lanes 2-6). In contrast, cells that expressed 
catalytically inactive PTPa (C215S Dl) showed the expected picture; serum starved cells 
had lower phosphotyrosine levels than those incubated in serum overnight (Figure 6.6C, 
lanes 7-8). This effect was not seen with other cysteine mutations in PTPa (C215SD2, 
C866L —  Figure 6.6D), which implies that the catalytic activity of PTPa is responsible for 
the decrease in cellular phosphotyrosine seen in serum treated cells. It may be noted that 
the cellular phosphotyrosine level decreased in proportion to the duration of serum 
treatment in all PTPa-transfected cells. This may reflect a technical aspect of serum 
treatment that produces an apparent early decrease in cellular phosphotyrosine. One 
possible candidate is the contribution of cell associated serum proteins to the total protein 
content of the lysates. It was apparent from these results that although it had a paradoxical 
effect, cells expressing PTPa responded to serum. Therefore, the effect of serum on high 
molecular weight formation was investigated.
Serum did not appear to affect high molecular species formation when PTPa- 
expressing cells were lysed in an iodoacetamide-free buffer (Figure 6.6A-B). However, 
when cells were lysed in iodoacetamide-containing lysis buffer, serum treatment tended to 
increase high molecular weight species formation (Figure 6.7 A-D). Serum-induced high 
molecular weight species formation was not affected by mutations in the catalytic or 
transmembrane cysteines (C215S D l/2, C866L) and was thus qualitatively similar to the 
effect of H20 2. The effect of overnight growth in the presence of 10% serum was 
quantitatively similar to the effect of a 5 minute treatment in ImM H20 2 (Figure 6.7).
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]Figure 6.6: Effect of serum on PTPa high molecular weight forms
HEK-293T cells cultured in F10 media with 10% foetal calf serum were transfected with 
wild type or mutant PTPa (C215S domain 1, C215S domain 2, C866L). Overnight before 
the experiment the medium was replaced with serum- free media or had fresh serum 
containing media replaced. On the day of the experiment, cells were exposed to media 
containing 10% serum for the indicated length of time. Cells were lysed in a buffer lacking 
iodoacetamide. The lysates were analysed using non-reducing (A-B) or reducing SDS- 
PAGE (C-D). Equal total amounts (Bradford assay) of protein were loaded in each lane.
A.  Non-reducing SDS-PAGE analysis of lysates from cells transfected with wild type (left) 
or C215S D1  (right) PTPa detected with anti-FLAG antibody.
B.  Non-reducing SDS-PAGE analysis of lysates from cells transfected with C215S D2 
(left) or C866L (right) PTPa detected with anti-FLAG antibody.
C.  Reducing SDS-PAGE analysis of lysates from cells transfected with wild type (left) or 
C215S D1  (right) PTPa detected with anti-phosphotyrosine antibody.
D.  Reducing SDS-PAGE analysis of lysates from cells transfected with C215S domain 2 
(left) or C866L (right) PTPa detected with anti-phosphotyrosine.
2 126.5: Treatment with heparin
Serum contains an incompletely defined mixture of small molecules and 
proteinaceous growth factors. Thus, it may difficult to define which of these components 
are responsible for the results described above. There has been a great deal of interest in 
the role of heparan sulphate proteoglycans (HSPGs) as potential type Ha RPTP ligands and 
HSPG interactions have been identified for PTPa and DLAR (Aricescu et al., 2002; Fox 
and Zinn, 2005). However, functional interactions have been difficult to prove.
Until this work, the effect of HSPG binding on PTPa activity, cleavage, expression, 
localisation or oligomeric state remained undetermined. Treatment of PTPa expressing 
HEK-293T cells with heparin did not affect PTPa expression level, cleavage pattern or 
high molecular weight species formation (Figure 6.7). However, these experiments were 
prone to artefactual variations in the level of high molecular weight species seen. As noted 
in the figure legend, lane 1 on panel A and lane 1 on panel C (Figure 6.7) contain the same 
sample. However, on one transferred gel there is abundant high molecular weight signal, 
whereas on the other there is little high molecular weight signal. Similarly the apparent 
increase in high molecular weight signal seen between lanes 2 and lanes 6/7 on panel A 
(Figure 6.7) was not a reproducible finding.
There were several explanations for the lack of reproducibility of these 
experiments. Firstly, the total amount of high molecular weight species was always low and 
required prolonged exposure to detect it at all. Secondly, the location of the high molecular 
weight species at the edge of the gel made them susceptible to loss either if electrophoresis 
was not perfecdy uniform between wells or if the stacking gel was not cleanly removed 
prior to transfer. In addition, there was some variability between each sample with regard 
to expression level or cell density. Finally, these large proteins transferred relatively poorly 
and as such were significandy affected by even small problems in the transfer process.
In summary, there was no consistent evidence that heparin affected the formation 
of high molecular weight species by PTPa. However, given the importance of this 
question, it should certainly be reassessed using stably transformed cells and techniques 
including energy transfer and co-immunoprecipitation that are not as susceptible to the 
problems outlined above.
213A. IS @@@000 Heparin
E B  @  0   @  @   0
H A
@
kDa  •
B  0  B  0  @   @ Scrum
■  M M
250-
J L W
150  % mm 1
I
 
l
 
8
 
£ mm ^
C215S 
Domain 2
Wild
type
Wild
type
R
C215S 
Domain 1
kDa
250-
-2xFL.
Heparin
HA
Serum
C. Heparin
H O
@@@000 
@  @ 0  @  @  0 
@   0  @   0  @   @   Serum
-2XP'L . 66
C215S 
Domain 2
Dl
C866L
@@@000  Heparin
@  @ 0   @  @  0   h ,0 ,
B  0 @   0  @   @   Serum
a
166
214Figure 6.7: Effect of heparin on high molecular weight species formation
HEK-293T cells cultured in F10 media with 10% foetal calf serum were transfected with 
wild type or mutant PTPa (C215S domain 1, C215S domain 2, C866L) and lysed in the 
presence of iodoacetamide. Equal total amounts (Bradford assay) of protein were loaded in 
each lane. Treatments were performed as indicated above each lane, in the order listed 
below:
1.  Manipulation of serum levels (serum-starved or FI 0+10% FBS overnight)
2.  Heparin treatment (1 pg/ml for one hour)
3.  H20 , treatment (ImM for 5 minutes)
Cells were lysed in a buffer containing iodoacetamide (20mM). The lysates were analysed 
using non-reducing SDS-PAGE. Western analysis used an antibody directed against the 
FLAG (amino-terminal) tag. PTPa peptides are marked at the right hand edge of the figure.
A.  Lysates from cells transfected with wild-type PTPa
B.  Lysates from cells transfected with C215S Domain 1 PTPa
C.  Lysates from cells transfected with C215S Domain 2 PTPa
D.  Lysates from cells transfected with C866L PTPa
Lane 1  on panel A contains an equal amount of the same sample that was loaded into lane 
1 on panel C. Panels A and B and panels C and D were run on the same gels and 
transferred and detected together.
2156.6: Discussion
In the preceding chapters, this thesis has characterised several key features of PTPa 
when it is overexpressed in human cells, namely the generation of cleavage products and 
oligomerisation. This chapter uses a number of biochemical reagents to determine what 
effect manipulation of specific pathways has on PTPa.
Firstly, protein kinase C activation stimulates PTPa cleavage and shedding as 
previously shown (Figure 6.1) (Aicher et al., 1997). Moreover, it is shown that PTPa 
extracellular domain shedding can occur following carboxy-terminal cleavage alone, in the 
absence of amino-terminal cleavage. It may be suggested that shedding of the E90 fragment 
is a non-physiological response to the presence of large amounts of uncleaved protein. It is 
therefore notable that in some systems, extracellular domain shedding is seen not with wild 
type protein but only with mutations that reduce the level of amino-terminal cleavage 
(Serra-Pages et al., 1994). However, shedding of both extracellular fragments shows a dose 
responsive increase to PKC activation, which might not be expected if the non PKC 
stimulated amino-terminal cleavage event were acting as a limiting factor.
In previous reports, only one PTPa band was shed in response to TPA. However, 
studies on LAR have shown the shedding of two species in response to TPA (Serra-Pages 
et al., 1994; Pulido et al., 1995a). The differences between this and previous studies on 
PTPa may reflect the use of different cell lines or the choice of an alternative time-point 
(40 hours post-transfection) at which to carry out the treatment. It is also possible that 
transfection methods using calcium interfere with ectodomain shedding or the distribution 
of probe between media and cell-bound populations (Aicher et al., 1997). However, in my 
hands, untreated cells analysed at 40 hours shed only the E8 1  form and do not express the 
E90 species (Chapter 3). In previous studies, which only reported the shedding of a single 
PTPa band, it is difficult to be certain whether the shed species represents E90 or E81. Few 
studies have directly compared the size of shed protein with that of cell-associated protein. 
There is indirect evidence that this solitary protein species is the product of carboxy- 
terminal cleavage and not amino-terminal cleavage. Firstly, the resulting intracellular 
domain fragment sequence starts at the carboxy-terminal not the amino-terminal cleavage 
site. Although this would also be the case if the protein had undergone cleavage at both the 
amino- and carboxyl-terminal sites, the molecular weight of the cell-associated extracellular 
domain fragment either decreases in size or stays the same following TPA or calcium 
ionophore treatment. Both of these treatments are associated with ectodomain shedding.
216As only the extracellular domain fragment resulting from carboxy-terminal cleavage can 
become smaller by subsequent cleavage at the amino-terminal site, this might suggest that 
where only one band is seen, it might represent E90 and not E81. Therefore, this is 
significant reason to believe that the extracellular domain of type II RPTPs can be shed 
following cleavage at only the carboxy-terminal site. It is however unclear whether amino- 
terminal cleavage is also required for extracellular domain shedding. It may in the future be 
informative to subject cells expressing the disulphide crosslinking mutants to TPA 
treatment. This may reveal whether the shed ectodomains are dimeric as the larger shed 
fragment should contain the ectopic cysteine residue and hence retain the ability to form 
disulphide crosslinked dimers (4.2.2).
Secondly, the inhibition of cysteine-based tyrosine phosphatases with pervanadate 
has no effect on PTPa cleavage or expression level (Figure 6.2). Pervanadate treatment 
irreversibly inactivates all cysteine-based tyrosine phosphatases, preventing tyrosine 
dephosphorylation. In addition, because many tyrosine kinases are activated by active site 
loop tyrosine phosphorylation, pervanadate significantly increases cellular tyrosine kinase 
activity. PTPa becomes phosphorylated on tyrosine residues in response to pervanadate. 
However, the cleaved PTPa intracellular domain becomes significantly more highly 
phosphorylated than full-length protein. It has not yet been possible to determine whether 
it is only one or both of the intracellular domain fragments that become phosphorylated in 
this way. This suggests a link between phosphorylation state and proteolytic cleavage. As an 
increase in tyrosine phosphorylation does not induce post-translational cleavage, it is likely 
that cleavage makes the intracellular domain more available to protein kinases than the full- 
length protein. The most likely mechanism for this observation is that cleaved protein 
occupies a different cellular compartment than full-length protein. Such a phenomenon has 
previously been documented following PKC activation, however it remains technically 
difficult to distinguish cleavage products from full-length protein within intact cells. 
Alternatively, either cleavage or phosphorylation state may have a conformational effect on 
PTPa affecting the recognition of the various species by the immunoprecipitating or 
detection antibody. Indeed, cleavage-associated conformational changes might in turn 
affect the accessibility of tyrosine residues to kinase-mediated phosphorylation. However, 
in this case the marked difference in phosphorylation state of cleaved and full-length 
protein does not seem to be matched by a similar difference in the amount of each protein 
pulled down by the immunoprecipitating antibody. Therefore, the basis for this 
observation remains undetermined. Nevertheless, it represents a possible method for
217tracking changes in PTPa location and possibly functional state. Finally, pervanadate did 
not have any effect on the formation of high molecular weight species formation by PTPa.
In contrast, treatment with a less potent tyrosine phosphatase inhibitor, H20 2, 
initially failed to have any effect on cellular phosphotyrosine levels (Figure 6.3E). It was 
shown that the experimental conditions for H20 2  treatment were more fastidious than 
those for pervanadate treatment. Under optimised conditions, H20 2  treatment also 
increased cellular phosphotyrosine levels, although as expected this effect was more modest 
than that seen with pervanadate (Figure 6.3F). Although H20 2  did not appear to affect 
PTPa cleavage, H20 2  treatment seemed to be associated with a reduction in overall PTPa 
level that was proportionate to H20 2 concentration. Moreover, H20 2 treatment resulted in 
the appearance of high molecular weight species similar to those reported in Chapter 4 
(Figure 6.3-5). In that chapter, it was concluded that as these species were seen only on 
non-reducing analysis and were affected by cysteinyl modifying reagents they were likely to 
represent disulphide-bonded complexes of PTPa. Formally, such complexes may form 
between PTPa molecules or between individual PTPa molecules and other cysteine- 
containing proteins. The high molecular weight species seen following H20 2 treatment are 
similar in size to the disulphide bonded dimers described in chapter 4, and the formation of 
disulphide-bonded dimers in response to H20 2 has been described for the related PTPa 
(van der Wijk et al., 2004). Therefore, it is likely that the reduction-sensitive high molecular 
weight species represent disulphide bonded PTPa dimers. However, there are distinct 
features of high molecular weight species formation by PTPa depending on the presence 
or absence of iodoacetamide in the lysis buffer.
In the absence of cysteinyl-modifying reagents, H20 2  increased disulphide bond 
formation in wild-type PTPa-expressing cells (Figure 6.4). However, this effect was less 
marked in cells expressing PTPa with any cysteine mutation. In the presence of cysteinyl 
modifying reagents, although H20 2  also increased disulphide bond formation, the high 
molecular weight species had distinct characteristics from those seen in the absence of 
cysteinyl modifying reagents (Figure 6.5). In contrast to the diffusely smeared high 
molecular weight species seen in the absence of cysteinyl-modifying agents, at least two 
clearly distinct bands could be seen in lysates containing cysteinyl-modifying agents. These 
high molecular weight species were seen in lysates from cells expressing wild type PTPa 
and in lysates from cells expressing mutant PTPa (C215S D l/2, C866L). In addition, in 
lysates from cells expressing wild type, C215S D1 or C866L PTPa the total amount of 
detectable PTPa decreases with increasing H20 , concentration. This effect was less
218apparent in lysates expressing PTPa with the C215S D2 mutation. Finally, H20 2  treatment 
appeared to be associated with a reduction in overall PTPa level both in the presence and 
absence of iodoacetamide. It is necessary to consider in turn the formation of disulphide 
bonded high molecular weight species in the presence and absence of cysteinyl modifying 
reagents. In addition, the significance of the reduction in overall PTPa level seen on H20 2  
treatment will be discussed.
The formation of high molecular weight species in the absence of cysteinyl 
modifying reagents is likely to reflect the formation of non-physiological disulphide bonds 
after cell lysis and during denaturation under non-reducing conditions. In untreated cells 
expressing wild type PTPa this effect is blocked by the addition of an excess of a cysteinyl- 
modifying reagent. Use of a chemical such as iodoacetamide in the lysis buffer would have 
two effects. It would not affect any disulphide bonds formed before cell lysis but it would 
significantly reduce post-lysis disulphide bond formation. This would include the 
interaction of previously buried, unpaired cysteine residues that are exposed by protein 
denaturation under non-reducing conditions. In addition, such reagents would inactivate all 
enzymes that rely upon cysteine residues for their catalytic mechanism; this would include 
classical tyrosine phosphatases and cellular cysteine reducing systems. The formation of 
disulphide bonds under these conditions may be considered in two categories. Firstly, 
disulphide bonds may form from the random collision of proteins containing free 
cysteines. Such interactions would produce a smear of disulphide-bonded species.
Although a smear was seen under these conditions, such an effect would also be seen with 
a variety of species that differ in the location of their disulphide bond. Such a situation 
would also result if the disulphide bonds formed were not stable, being reduced either by 
their local environment or by the action of solubilised cysteine-reducing enzymes.
However, disulphide bonds produced by the random collision of molecules in solution 
would not be significantly affected by point mutations in specific cysteine residues unless 
that cysteine residue was responsible for a significant proportion of a protein’s free cysteine 
content. The formation of high molecular weight PTPa-containing species in the absence 
of iodoacetamide was susceptible to point mutations in any of three cysteine residues. 
Given that each of the mutated cysteines must be close enough to interact, mutations at 
these sites might perturb the formation of the dimer. Moreover, all three residues are likely 
to be surface-exposed rather than buried at the centre of a hydrophobic domain and only 
becoming accessible after denaturation. Therefore, it is unlikely that these disulphide- 
bonded interactions reflect the random interactions of denatured proteins in solution.
219Moreover, other researchers have been unable to identify any high molecular weight smears 
in the absence of cysteinyl modifying reagents even using PTPa. PTPa contains a cysteine- 
rich domain that might be expected to contribute to the formation of high molecular 
weight aggregates if this effect really occurs. However, PTPa does not form reduction 
sensitive high molecular weight smears in the absence of cysteinyl modifying reagents (van 
der Wijk et al., 2004). Indeed it is also impossible to produce high molecular weight forms 
with disulphide cross-linking PTPa mutants in the absence of cysteinyl modifying reagents. 
This is attributed to the extreme sensitivity of such bonds to cellular disulphide reductases 
(Jiang et al., 1999). Finally, with regard to the formation of high molecular weight species 
by PTPa, significandy greater amounts of high molecular weight species were seen in 
lysates containing Triton X-100 than in those containing Nonidet P-40. Similarly, pre-lysis 
treatment of cells with H20 2  increased high molecular weight species formation. It 
therefore seems that the underlying mechanism for high molecular weight species 
formation occurs pre-lysis. Therefore, there may be some degree of specificity to the 
aggregation seen in the absence of cysteinyl reducing agents and a more likely hypothesis is 
that disulphide bond formation by PTPa, in the absence of cysteinyl modifying reagents, 
reflects the oxidation of closely approximated cysteines in a preformed dimer.
The formation of disulphide bonds in the presence of cysteinyl modifying reagents 
is likely to represent pre-lysis disulphide bond formation. The increased abundance of 
disulphide bonded forms of PTPa and their increased resolution on non-reducing analysis 
is likely to be due to the inactivation of cellular reducing enzymes. Such enzymes might 
otherwise lead to fluctuations in the total level of disulphide-bonded species and in the 
oligomeric state of individual molecules leading to the diffuse low-level signal seen in the 
absence of iodoacetamide. The use of a high concentration of iodoacetamide in the lysis 
buffer and its continuing presence in the sample buffer used for protein denaturation 
should mask all free cysteines in the sample. Therefore, the disulphide-bonded species seen 
in these experiments must reflect either disulphide bonds that form within the cell or very 
rapidly after lysis. As such, they are likely to have formed between closely apposed proteins. 
Thus, their formation may be an aspect of the physiological regulation of RPTPs. 
Alternatively, their formation may be artefactual reflecting an interaction between 
extremely closely apposed cysteine residues in a favorable local environment. However, 
even if this latter hypothesis were true, it is unlikely that such disulphide bonds would form 
in  vivo, where cellular reducing enzymes would continually reduce them. In either case, it 
can be argued that changes in the level of disulphide bonded species formation might
2 2 0reflect changes in the proportion of dimeric PTPa or in the conformation of PTPa 
monomers in preformed dimers. If high molecular weight smear formation is a measure of 
dimer formation, it may be a more accurate measure of PTPa dimerisation at the moment 
of cell lysis than co-immunoprecipitation. Moreover, it would not be susceptible to any 
effect that dimerisation or oxidative stress might have on epitope accessibility (van der Wijk 
et al., 2003).
It is notable that disulphide bond formation in the presence and absence of 
cysteinyl modifying reagents shows different characteristics than that seen with the related 
PTPa (van der Wijk et al., 2004). Firstly, formation of disulphide-bonded dimers by PTPa 
requires the catalytic cysteine in both catalytic domains. The formation of PTPa disulphide 
bonded dimers does not require the first catalytic site cysteine and some disulphide bond 
formation is seen in mutants lacking the second catalytic domain cysteine. Unfortunately, 
time did not permit the assessment of disulphide bond formation in mutants lacking both 
PTPa active site cysteines. Secondly, only a small proportion of PTPa is found in the 
disulphide bonded dimeric form following H20 2  treatment and long exposures are required 
to detect it. In contrast, PTPa disulphide bonded dimers represent a significant proportion 
of total cell PTPa following H20 2  treatment. These may reflect genuine differences in the 
mechanisms of PTPa and PTPa disulphide bond-mediated dimerisation. Alternatively, 
there may be differences in expression level or in the oligomeric state of the two RPTP 
molecules at rest. These may result in different factors limiting disulphide bond formation 
for each protein.
In addition to inducing high molecular weight species formation, it appeared that 
H20 , treatment led to a decrease in the total PTPa protein level. It must be noted that 
accurate quantification of the magnitude of any effect of H20 2  was complicated by several 
factors. It was not possible to perform these experiments using cell lines stably transfected 
with wild type or mutant PTPa. Therefore, the experiments were performed by splitting 
large plates of PTPa-transfected cells into multi-well plates for H20 2  treatment. However, 
even using this method it was still impossible to obtain completely even expression levels 
and patterns of cleavage across all the wells. Therefore, it will be interesting to repeat these 
experiments using either a cell line that expresses endogenous levels of PTPa or that has 
been stably transfected with PTPa. In addition, there may be localised fluctuations in 
transfer efficiency across a large gel, which may be especially significant when comparing 
relatively small changes in the level of high molecular weight species. However, the 
decrease in total PTPa level seen in response to H20 2, was consistent across multiple
221independent experiments and so is likely to represent a real effect. There are several 
possible explanations for this effect. Most importantly, if H20 2 increases high molecular 
weight species formation, then a proportion of the FL1 66 species will be converted into the 
larger 2xFL16 6  dimers, which transfer less efficiently. However although the decrease in 
total protein level is seen with wild type PTPa and in C215S D1 and C866L mutant PTPa, 
lysates from cells expressing the C215S D2 mutant protein do not show an equivalent 
decrease in total PTPa protein. This mutant also shows reduced levels of high molecular 
weight species formation in response to H20 2 (in the presence of iodoacetamide). This 
residue has previously been shown to be a key mediator of the response of PTPa to H20 2  
(Blanchetot et al., 2002a; van der Wijk et al., 2003; van der Wijk et al., 2004; Persson et al., 
2004; Groen et al., 2005). Therefore, although interpretation of the effect of H20 2  under 
these conditions is complicated, there are suggestions that PTPa behaves in a similar way 
to PTPa.
Treatment of serum starved PTPa-transfected cells with foetal calf serum had no 
effect on PTPa cleavage or expression level. However, when serum-treated cells expressing 
PTPa were lysed in the presence of iodoacetamide, serum was seen to increase high 
molecular weight species formation (Figure 6.6A). Foetal calf serum is a rich source of 
growth factors. Stimulation of growth factor tyrosine kinase receptors is associated with 
local hydrogen peroxide generation, which is believed to potentiate tyrosine kinase 
signaling by inactivating nearby tyrosine phosphatases. Thus the application of H20 2  to 
cells may mimic the effect of H20 2  generation in response to growth factor signaling. 
However, the degree of variability seen in these experiments means that further work is 
necessary before any conclusions are drawn. This may include using defined growth factors 
whose receptors have been shown to interact genetically or biochemically with PTPa.
In addition, treatment of PTPa-transfected cells with foetal calf serum produced a 
unexpected decrease in cellular phosphotyrosine (Figure 6.6B). It is likely that serum 
treatment of untransfected HEK-293T cells will produce an increase in cellular 
phosphotyrosine; this has previously been documented in other cell lines. However, the 
effect of serum on untransfected HEK-293T cells was not determined during these studies. 
The assumption that serum treatment will increase cellular phosphotyrosine in 
untransfected cells is further supported by the response of cells expressing catalytically 
inactive PTPa (C215S Dl) to serum treatment. Cells transfected with C215S D1 PTPa 
show an increase in cellular phosphotyrosine in response to serum treatment. On the other
2 22hand, cells transfected with the C215S D2 or C866L mutant PTPa show a decrease in 
cellular phosphotyrosine in response to serum treatment.
It is not clear why PTPa expression should reverse the normal effect of serum on 
tyrosine phosphorylation. The requirement for PTPa catalytic activity suggests that serum 
treatment has a direct stimulatory effect on PTPa activity. Furthermore, it is apparent that 
the effect of serum on PTPa phosphatase activity does not involve significant changes in 
PTPa cleavage or expression level. Changes in PTPa sub-cellular localisation were not 
assessed and might be responsible for the affect on PTPa phosphatase activity by altering 
the access of the enzyme to a range of substrates, phosphorylated in response to serum 
activation. Alternatively, serum treatment might increase PTPa tyrosine phosphatase 
activity directly either via the induction of PTPa tyrosine phosphorylation on a positive 
regulatory site, or by the recognition of a specific PTPa ligand in serum or by the presence 
in serum of a factor that reduces the binding of a culture-derived inhibitory PTPa ligand. It 
is indeed unclear whether the activity of RPTPs is regulated by ligand binding in a manner 
analogous to RTK activity and the available evidence implies that there may be both 
stimulatory and inhibitory ligands. It is moreover unclear whether the effect of serum on 
RPTP-transfected cells is specific to PTPa, suggesting a PTPa-specific factor such as a 
ligand. Alternatively, the effect seen might reflect a general effect of serum on the activity 
of all RPTPs. This might reflect a generalised activation of available PTPs following the 
widespread RTK activation induced by serum. A picture of this kind might suggest that 
PTPs are positively regulated by their own tyrosine phosphorylation state. Therefore, it will 
be extremely interesting to identify the mechanism responsible for the effect of catalytically 
active PTPa expression on the cellular response to foetal calf serum.
The only known PTPa ligand, heparin, has no effect on PTPa expression level, 
cleavage or high molecular weight species formation (Aricescu et al., 2002) (Figure 6.7). 
Unfortunately, the effect of heparin on cellular phosphotyrosine was not determined.
Other type II RPTPs also interact with HSPGs with a varying effect on tyrosine 
phosphatase activity and it is becoming apparent that regulation with HSPGs might be a 
common feature of type II RPTPs (Fox and Zinn, 2005). The absence of a clear result is 
difficult to interpret. It is possible that treatment of PTPa-expressing cells with heparin has 
no effect. However, it is also possible that an inappropriate concentration of Heparin has 
been used. The dose and incubation time selected does result in changes in retinal ganglion 
cell neurite outgrowth (G.Sajnani personal communication). However, overexpression 
often significantly perturbs cellular signaling pathways and may alter the reaction kinetics.
223Specifically, the higher level of receptor expression in an overexpression system when 
compared to an endogenously expressing cell model may require the use of much higher 
concentrations of ligand in the former before effects are seen. Lasdy, it may be possible 
that heparin is having an affect on PTPa protein in these cells, but that this does not result 
in a phenotypic change that we are able to detect. Alternatively, the media used in these 
experiments may contain sufficient heparin to exert a maximal effect on PTPa without 
addition of exogenous heparin (Wang et al., 2000). Therefore, it will be necessary in future 
to dissect the relationship between heparin and PTPa by using different cell lines, assays 
and treatment parameters. In particular, it will be necessary to examine the effect of 
heparin on the expression level, cleavage pattern and high molecular weight species 
formation in a cell model in which heparin treatment has an effect (Sajnani et al., 2005).
In this chapter, several key characteristics of PTPa were examined using 
biochemical treatments and mutants. The effects of posttranslational cleavage of PTPa at 
different sites were distinguished using techniques that suggest that the canonical model for 
PTPa processing does not completely explain the available data. Moreover, it was shown 
that tyrosine phosphorylation is unlikely to be a factor in PTPa cleavage. However, 
cleavage has significant effects on PTPa tyrosine phosphorylation probably via the 
previously reported changes in PTPa sub-cellular localisation. Such data also suggest that 
the different processed PTPa species may have significandy different functions. 
Furthermore, an effort was made to identify the factors that regulate PTPa dimerisation in 
vivo. Although H20 2  treatment increases PTPa dimerisation, in vivo application of stimuli 
that produce physiological levels of intracellular H20 2 failed to have any affect on PTPa 
dimerisation. However, it does not appear that the only identified PTPa ligands, HSPGs, 
have their as yet undetermined effect by altering the pattern of PTPa dimerisation, 
expression level or cleavage pattern. It is likely that further experiments that more precisely 
determine the molecular function of PTPa will be important in discovering the function 
and regulatory mechanisms of PTPa. In addition, various strategies will allow the 
identification of further PTPa interacting proteins.
224Chapter 7: Analysis of PTPq-Interacting proteins
The work described above focused on the interactions of PTPa with itself. Whilst 
the formation of oligomeric PTPa complexes is likely to be very important for its 
mechanism of action, PTPa function may be better described by identifying the other 
proteins, including substrates and ligands that interact with PTPa. This thesis will separate 
the proteins that interact with PTPa into three categories: ligands, interacting partners and 
substrates. For the sake of clarity, only those proteins that interact with the extracellular 
domain of PTPa will be considered PTPa ligands. In this sense, ligands need not cause a 
detectable change in PTPa function. Similarly, only tyrosine-phosphorylated proteins that 
can be de-phosphorylated by the PTPa phosphatase domain will be considered PTPa 
substrates. Lastly, interacting partners are those proteins that interact with regions other 
than the extracellular domain and that are not subject to PTPa-mediated 
dephosphorylation.
In this chapter, several pieces of work are described that attempt to identify PTPa 
interacting proteins. Firstly, the 3xFLAG epitope used throughout this thesis was shown to 
have a negligible effect on the binding of a PTPa-alkaline phosphatase fusion protein to 
known ligand-bearing tissues. Given the work described in previous chapters, which 
showed that PTPa molecules can form ^-dimers when expressed in the same cell, it was 
important to assess whether PTPa can also form dimers when presented in trans. The 
ability of the PTPa ectodomain to bind homophilically was reassessed using an alternative 
technique (Haj et al., 1999). However, only very small amounts of the PTPa extracellular 
domain bound to PTPa-expressing cells. Thus, in contrast to the type lib RPTPs, PTPa 
may not act as a homophilic adhesion molecule (Brady-Kalnay et al., 1993; Gebbink et al., 
1993b; Brady-Kalnay and Tonks, 1994; Sap et al., 1994; Zondag et al., 1995; Wang and 
Bixby, 1999; Baker et al., 2000b; Yang et al., 2003; Cismasiu et al., 2004; Yang et al., 2005; 
Aricescu et al., 2006). A series of His-tagged PTPa extracellular domain deletion proteins 
was designed to investigate PTPa extracellular domain structure and to identify PTPa 
ligands. Some of these deletions showed detergent-resistant dimerisation in SDS-PAGE, 
suggesting that the PTPa extracellular domain alone retains some ability to dimerise. The 
structure and ligand-binding properties of these proteins remain to be characterised.
Secondly, co-immunoprecipitation techniques using wild type PTPa failed to detect 
any interacting proteins above background. Using PTPa trapping mutations that enrich 
immunoprecipitates for PTPa substrates, low levels of possible PTPa substrates were
225detected as previously reported (Aricescu, 2002). Unfortunately, it was not possible to 
obtain sufficient amounts of these putative substrates to allow their biochemical 
identification. In order to scale up this purification, a number of PTPa intracellular domain 
Glutathione-S-Transferase (GST) fusions were created, both of wild-type PTPa and of 
substrate-trapping PTPa. The expression of these constructs was demonstrated; however, 
time did not permit the isolation of putative PTPa substrates using these proteins.
7.1; Extracellular domain interactions
It has proved difficult to identify functional ligands for any RPTP, including PTPa. 
Although a number of PTPa ligands have been identified, the identification of any effect 
on PTP function has proven elusive. PTPa binds at least two ligands in the developing 
chick and also acts as one of several receptors for the Black widow venom toxin a- 
latrotoxin (Aricescu et al., 2002; Krasnoperov et al., 2002; Sajnani-Perez et al., 2003). One 
of the ligands in developing chick embryos, which is located in basement membranes, is a 
heparan-sulphate proteoglycan (HSPG). In vitro, PTPa binds a number of HSPGs 
including collagen 18 and agrin (Aricescu et al., 2002). Whether PTPa binds a single or a 
range of HSPGs in these tissues is not yet clear. A second PTPa ligand is located in muscle 
and does not involve heparan sulphate chains (Sajnani-Perez et al., 2003). This ligand is 
likely to be a cell-surface form of the nucleolar protein, nucleolin, and the significance of 
this ligand-receptor interaction is currendy being investigated (Alete et al., 2006). It has not 
yet been possible to demonstrate a functional effect of binding of either ligand. In addition, 
PTPa has recendy been shown to act as a substrate for neurite outgrowth of retinal 
ganglion cell axons (Sajnani et al., 2005). This implies that PTPa can act as a ligand as well 
as a receptor. The interaction of PTPa with the neurite expressed protein has similarities to 
the interaction of PTPa with the muscle ligand, being affected by the same amino acid 
mutations and being unaffected by heparinase treatment. It is therefore unclear whether 
this interaction reveals a third class of PTPa ligand or utilises one of the previously 
identified ligands.
Both the type Ha RPTPs, PTP8 and LAR, and the related type lib RPTPs have 
isoforms that exhibit homophilic binding both in cis and in trans (Brady-Kalnay et al., 1993; 
Gebbink et al., 1993b; Brady-Kalnay and Tonks, 1994; Sap et al., 1994; Zondag et al., 1995; 
Wang and Bixby, 1999; Baker et al., 2000b; Yang et al., 2003; Cismasiu et al., 2004; Yang et 
al., 2005; Aricescu et al., 2006). The data shown in previous chapters demonstrated that 
PTPa can interact in cis to form oligomeric complexes. However, it was not possible to
226determine whether PTPa molecules can also interact in trans in mammalian cells. However, 
in co-immunoprecipitation experiments data was obtained that suggested that solubilised 
PTPa also interact weakly in solution after cell lysis, suggesting the possibility of a trans 
binding mechanism. Therefore, PTPa must still be considered a potential ligand for itself. 
Experiments were performed to determine whether PTPa is in fact capable of interacting 
in this way.
7.1.1: Effects ofFEAG epitope on PTPa ligand binding
Much of the work described in this thesis uses 3xFLAG-tagged PTPa proteins.
This epitope tag is located at the extreme amino-terminal end of the protein. The PTPa 
proteins used do not lack any endogenous sequence other than the signal peptide.
However, due to the location of epitope tag, it is possible that it may interfere with ligand 
binding. Indeed a major determinant of the heparan-sulphate binding site is located close 
to the amino-terminus, in the first Ig domain (Aricescu et al., 2002). Therefore, 
experiments were performed to determine whether the addition of the 3xFLAG tag 
interfered with PTPa binding to the known ligands in basement membrane and muscle.
The 3xFLAG tag does not interfere with PTPa ligand binding. Previous work has 
characterised PTPa ligand binding using receptor-alkaline-phosphatase (RAP) fusions (Haj 
et al., 1999; Flanagan and Cheng, 2000; Flanagan et al., 2000; Sajnani-Perez et al., 2003). A 
PTPa-AP fusion protein was created that included the 3xFLAG epitope tag located amino- 
terminal to the PTPal extracellular domain. The binding pattern of this probe (3xFLAG- 
PTPal-EC-AP, 3xFLAG probe; Figure 7.1 E-H) was compared to that of a similar probe 
lacking only the 3xFLAG tag (PTPal-EC-AP, wild type probe; Figure 7.1 A-D).
The 3xFLAG probe exhibited similar binding to that previously described for the 
wild type probe (Haj et al., 1999; Sajnani-Perez et al., 2003); Unpublished data, A. Stoker). 
It should be noted that the binding pattern is weaker than that previously published as 
previous work has predominantly utilised the FNA3 deletion which has the strongest 
binding of all PTPa deletion mutants (Chilton, 2000). In the eye at embryonic day 8 (E8), 
the 3xFLAG probe binds to several outer retinal cell layers with particularly strong binding 
in regions where the retinal inner limiting basement membrane is intact (Arrowheads, 
Figure 7.1 A, E). Within the head, binding is also seen to skeletal muscle fibres (Figure 7.1 
B,F) and to the epithelia of the developing oral and nasal cavity, most particularly to the 
epithelial basement membrane (Figure 7.1 D,H). The pattern of muscle staining has
227previously been described and there is no detectable difference between the binding of the 
3xFLAG probe and the wild type probe (Haj et al., 1999; Sajnani-Perez et al., 2003). In 
addition, PTPa RAP probes show strong binding to the basement membrane in developing 
feather buds and the epidermis of the skin (Figure 7.1 C, G). The pattern of PTPa RAP 
probe binding to feather buds is distinctive both in longitudinal and tranverse section. In 
longitudinal section, staining increases towards the tip of the feather (Figure 7.1 C, G). In 
transverse section, a striking star-shaped pattern of staining is seen (Figure 7.1 C inset, G 
inset). This pattern suggests that a ligand is present between the basilar epidermis and pulp 
epithelium of the developing feather (Yu et al., 2004). The binding of PTPa probes to the 
basement membrane of skin and its derivatives (feathers) has not previously been 
published but is well known within the field (Unpublished data, A. Stoker).
228229Figure 7.1: Effect of 3xFLAG epitope tag on PTPal ligand binding in the RAP assay
Localisation of PTPal ligands at embryonic day 8. RAP assays were carried out using 
PTPa-EC-AP (A-D) or 3xFLAG-PTPal-EC-AP (E-H) on sections of E8 retina (A, E), 
extraocular muscle (B, F), developing feather buds (C, G) and beak (D, H). Insets in C and 
G show cross-sectional profile of RAP binding in feather buds. Sites of ligand interaction 
stain purple/blue. RPE, retinal pigmented epithelium; M, muscle; FB, feather bud; BW, 
body wall; ED, epidermis; Ep, Oropharyngeal epithelial basement membrane. Arrowhead 
indicates regions of basement membrane in the retina (A, E). Magnification was 50x (D, 
H), lOOx (A, E, C, G) and 400x (B, F). Scale bars are included in each figure and represent 
40|im (Panels A, E, C, G), 10pm (Panels B, F) and 80pm (Panels D, H).
2307.1.2: PTPa Homophilic binding assays
Although PTPa is believed to bind HSPGs and nucleolin, other ligands have not 
been identified (Aricescu et al., 2002; Alete et al., 2006). Many adhesion factors and several 
RPTPs exhibit homophilic binding, which can occur either when the protein of interest is 
expressed on different cells (in trans) or when both interacting proteins are present in the 
same membrane (in cis) (Brady-Kalnay et al., 1993; Gebbink et al., 1993b; Brady-Kalnay and 
Tonks, 1994; Sap et al., 1994; Zondag et al., 1995; Wang and Bixby, 1999; Baker et al., 
2000b; Yang et al., 2003; Cismasiu et al., 2004; Yang et al., 2005; Aricescu et al., 2006). 
Overexpression of a soluble  vesicular stomatitis virus (VSV)-tagged PTPa extracellular 
domain throughout the avian retina results in an accumulation of protein only in the region 
of the PTPa retinal basement membrane ligand (Rashid-Doubell et al., 2002). This suggests 
that PTPa does not form trans-dimers or function as a homophilic adhesion molecule. 
However, lysis of samples of embryonic chick tissues yields only cleaved PTPa suggesting 
that in these tissues PTPa is rapidly cleaved and shed from the cell surface. Therefore, 
these assays do not reveal the existence or nature of any interaction between individual 
cleaved PTPa extracellular domains or between the majority cleaved PTPa extracellular 
domains and the minority of uncleaved full-length proteins. PTPa homophilic binding has 
only been assessed using systems in which full-length protein is rare (Haj et al., 1999). In 
these systems, as most of the PTPa protein is soluble, even if individual molecules interact 
they will not be detected as binding to cells, therefore they show very litde binding of PTPa 
soluble extracellular domain to PTPa expressing cells. Whilst these models replicate the in 
vivo situation it means that they cannot give a clear answer as to whether cleaved soluble 
and full-length PTPa interact in trans. PTPa has been shown above to form rif-dimers 
when expressed in the same cell, and some evidence exists that solublised PTPa proteins 
can interact in solution (Figure 5.4). Therefore, the formation of trans-dimers by PTPa 
expressed on different cells was assessed using two methods. Firsdy, the method previously 
used by this laboratory was repeated using cells that expressed significant levels of 
uncleaved protein. In addition, PTPa homophilic binding was assessed using the same 
techniques previously used to demonstrate homophilic adhesion in the related type lib 
RPTPs.
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Figure 7.2: Analysis of homophilic binding with the RAP assay
HEK 293T cells were cultured on coverslips, transfected (A-C: Green fluorescent protein 
GFP; D-I: 3xFLAG-PTPa-HA) and incubated with conditioned media (A-C. G-I: PTPa- 
EC-AP; D-F: media from GFP-transfected cells). Coverslips were then washed, fixed and 
detected with anti-FLAG antibody and the AP colourigenic substrate NBT/BCIP. GFP 
was detected using its intrinsic epifluorescence in the FITC channel.
The control supernatant from cells expressing intracellular GFP lacked any detectable 
fluorescence in the GFP channel (Data not shown).
233PTPa-expressing cells may bind soluble PTPa. When HEK-293T cells were heat- 
treated to inactivate cellular alkaline phosphatase, some background, endogenous cell- 
associated alkaline phosphatase signal remained (Figure 7.2 D). To avoid denaturation of 
possible PTPa ligands, heat inactivation was carried out after incubation of cells with 
alkaline phosphatase (AP) probe and crosslinking of bound probe with parafomaldehyde.
As the PTPa-AP fusion exhibits resistance to heat inactivation, it is relatively unaffected by 
this treatment (Flanagan and Cheng, 2000; Flanagan et al., 2000). When cells expressing a 
control protein (GFP) were incubated with a PTPa extracellular domain-alkaline fusion 
probe, there was very little increase in this background signal (Figure 7.2 A). However, 
when cells expressing PTPa were incubated in conditioned media containing a soluble 
PTPa extracellular domain-AP fusion, pilot experiments suggested that the proportion of 
cells showing AP activity increased. (Figure 7.2 G-I). However, a significant proportion of 
this increase in probe binding was in cells that did not themselves express PTPa (Figure 7.2 
C,F).
The RAP assay on PTPa-transfected cells described above suggested that binding 
of soluble PTPa extracellular domains is higher in populations of cells in which some 
express PTPa than in cells that do not express significant levels of full-length protein. 
However, quantitative analysis of the effect was complicated by the requirements to 
normalise for transfection efficiency and background alkaline phosphatase activity. It 
remained unclear therefore whether PTPa exhibits homophilic binding. This question was 
addressed using a technique previously validated for the related PTPp (Cismasiu et al.,
2004). Briefly, cells were incubated with soluble PTPa extracellular domain in conditioned 
media, thoroughly washed and then processed for SDS-PAGE analysis. Bound PTPa 
extracellular domain should only be detectable in the lysates if it has bound to the cells.
The PTPa extracellular domain binds at a low level to the HEK-293T cell line and
this binding is unaffected by transfection of HEK-293T cells with full-length PTPa (Figure
7.3 C6-7). Soluble PTPa extracellular domain-alkaline phosphatase fusions were produced
in conditioned media as previously described (Figure 7.3 A, Bl). Following incubation of
control or PTPa-transfected cells with conditioned media there was no detectable change
in the level of PTPa-AP fusion protein in the conditioned media (Figure 7.3 Bl, B3-4).
Similarly, although PTPa-AP probe bound at low levels to HEK-293T cells, the amount of
probe binding to HEK-293T cells was low and was unaffected by transfection with full-
length PTPa (Figure 7.3 C6-7). Together these suggest that quantitatively very little binding
of PTPa-AP probe to either control or PTPa-transfected cells occurs. However, the rate of
234PTPa extracellular domain shedding by full-length PTPa-transfected HEK-293T cells was 
notable. Conditioned media containing the AP fusion proteins or the soluble extracellular 
domain cleavage fragment was collected 3 days after transfection. As previously described, 
this is the time point for maximal recovery of these fusion proteins (Aricescu, 2002).
Similar amounts of soluble protein were found in both kinds of conditioned media at this 
time point. However, in media recollected after incubation with PTPa-transfected cells for 
8 hours, the amount of PTPa shed by the cells was suprisingly high (Figure 7.3 B4).
7.1.3: His-tagged extracellular domain deletion series
A series of PTPa extracellular domain-alkaline phosphatase fusions were previously 
characterised and shown to affect the ability of PTPa extracellular domains to bind the 
retinal HSPG ligand in a periodic manner (Chilton, 2000). However, the AP fusion 
constructs cannot be used to probe PTPa dimerisation, as enzymatically active alkaline 
phosphatase is an obligate dimer. Therefore, a series of PTPa ectodomain deletions were 
designed with His tags replacing the AP moiety to allow large-scale purification of the 
PTPa extracellular domains (pHL-PTPa-FNA3 provided by Dr R. Aricescu). These 
constructs were designed to assist the identification of PTPa ligands and for subsequent 
use in biochemical experiments. These experiments will include dynamic light scattering 
and crystallographic approaches to determine the structure of PTPa and characterise the 
minimum domain requirements for PTPa dimerisation.
Expression and secretion of enzymatically active protein (where appropriate) was 
confirmed by SDS-PAGE analysis and phosphatase activity assay using medium 
conditioned by cells transfected with the His-tagged PTPa constructs. All of the 
recombinant proteins were expressed at their expected molecular weights (SAP.His —  His- 
tagged soluble alkaline phosphatase (56.1 kDa —  data not shown), PTPa-FNA2.His (55.8 
kDa), PTPa-FNA3.His (66.3 kDa), PTPa-FNA4.His (77.5 kDa), PTPa-FNA3-AP.His 
(120.6 kDa)) by transfected HEK-293T cells (Figure 7.4 A, B, C).
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236Figure 7.3: Analysis of homophilic binding by SDS-PAGE
A. The phosphatase activities of FLAG tagged and untagged PTPa extracellular domain- 
alkaline phosphatase fusions were compared using a colourigenic substrate (p- 
Nitrophenylphosphate (pNPP)).
Conditioned media was harvested after three days from cells expressing FLAG-tagged (A) 
or untagged (B) PTPa-AP probes or GFP (C). Media was passed through a 0.22pm filter to 
remove cells and debris and analysed by SDS-PAGE. In addition, cells transfected with 
GFP- or full length PTPa were incubated with this conditioned media for eight hours.
After eight hours, the media was re-collected and the cells were washed and lysed for SDS- 
PAGE analysis as before. PTPa proteins were detected with the IG2 antibody.
B. Conditioned media before and after incubation with cells expressing GFP or full length 
PTPa.
1.  Conditioned media collected after three days from cells expressing PTPa-AP 
probes (A —  FLAG-tagged; B —  untagged) or GFP (C).
2.  Conditioned media collected after 3 days from mock-transfected (M) or PTPa- 
expressing (S) cells.
3.  Conditioned media from 1  (above) recollected after an 8 hour incubation with 
GFP-expressing cells.
4.  Conditioned media from 1  (above) recollected after an 8 hour incubation with 
PTPa-expressing cells.
C. Lysates from cells expressing GFP or full length PTPa after incubation with conditoned 
media.
5.  Conditioned media as shown in Bl  (above).
6.  Lysates from GFP-expressing cells after an 8 hour incubation with control (C) or 
PTPa-AP containing conditioned media (FLAG-tagged (A/B as above)
7.  Lysates from full length PTPa-expressing cells after an 8 hour incubation with 
control (C) or PTPa-AP containing conditioned media (A/B as above).
237PTPa-His tagged proteins form higher order oligomers in solution (Figure 7.4 B).
In addition to the expected bands, lysates from FNA2.His-, FNA3.His-, FNA4.His- and 
FNA3AP.His-transfected cells showed small amounts of a higher molecular weight protein. 
In FNA2.His- and FNA3.His-transfected lysates, this protein ran at about 150 kDa and 180 
kDa respectively, commensurate with trimers of these two proteins. In contrast,
FNA4.His- and FNA3AP.His transfected cells migrate at 150 kDa and >200 kDa 
respectively, commensurate with dimers of these two proteins. The FNA3AP.His protein 
was expected to form dimers (~240kDa) due to its incorporation of the AP moiety, which 
is an obligate dimer. However, the nature of these species in the other samples was not 
clear. Although higher molecular weight species were not detected from cells expressing 
the original FNA3AP protein from the series designed by John Chilton, this protein 
expressed at much lower levels than the His-tagged proteins (Figure 7.4 B).
7.2: Intracellular domain interactions
Whilst it has been difficult to identify ligands for RPTPs, it has also been difficult 
to identify proteins that interact with the intracellular domain including any candidate 
phosphotyrosine substrates. Cysteine-based PTPs exhibit high basal levels of activity and 
show broad substrate specificity in vitro (Zhang, 2002). Therefore, it is difficult to determine 
whether proteins identified in vitro as substrates are physiological substrates or merely 
artefacts of the cell type or expression system used. To date, there are no known PTPa 
substrates and the only known interacting partners for the PTPa intracellular domain are 
the intracellular domains of RPTPs including those of PTPa itself (Wallace et al., 1998; 
Blanchetot and den Hertog, 2000b; Blanchetot et al., 2002b). To characterise the 
intracellular domain interactions of PTPa, the co-immunoprecipitation method that was 
used with good effect above to show PTPa dimerisation was used to co-immunoprecipitate 
proteins that interact with PTPa.
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239Figure 7.4: Expression of soluble 6xHis-tagged PTPa extracellular domain deletion
proteins
A.  Schematic diagram of PTPa extracellular domain deletion proteins showing their 
domain organisation and location of 6xHis and alkaline phosphatase moieties.
B.  Reducing SDS-PAGE analysis of conditioned media from HEK-293T cells transfected 
with the indicated PTPa extracellular domain deletions or soluble alkaline phosphatase. 
* - High molecular weight species
C.  Graph showing alkaline phosphatase activity of conditioned media from HEK-293T 
cells transfected with the indicated PTPa extracellular domain deletions or soluble 
alkaline phosphatase.
2407.2.1: Co-immunoprecipitation of mid-type PTPa
Co-immunoprecipitation experiments using full-length wild type PTPa failed to 
isolate any identifiable PTPa binding proteins. Robust levels of PTPa expression were 
obtained and following immunoprecipitation, purified PTPa could be identified on SDS- 
PAGE gels detected with silver or brilliant blue stains to show total protein (Figure 7.5 A). 
However, it was not possible to identify any other co-purifying bands due to the high 
background level of bands that co-immunoprecipitated with the anti-FLAG or anti-HA 
antibodies under these conditions. Immunoblot analysis of immunoprecipitates confirmed 
robust immunoprecipitation of PTPa. Moreover, both extracellular domain cleavage 
fragments (E90/81) immunoprecipitated with antibodies directed against the carboxy- 
terminal tag and both intracellular domain cleavage fragments (P8 5/75 ) immunoprecipitated 
with antibodies directed against the amino-terminal tag (Figure 7.5 C, D). Significandy, 
more full-length than cleaved protein immunoprecipitated in these experiments.
7.2.2: Co-immunoprecipitation of substrate trapping mutant PTPa
The aim of the immunoprecipitation experiments described above was first and 
foremost to identify PTPa substrates and only then to investigate other PTPa-interacting 
proteins. However, many protein-protein interactions are transient, occurring only for 
short periods of time or only under specific conditions which may themselves only be of 
brief duration. This is especially likely to be true of tyrosine phosphatase-substrate 
interactions. The tyrosine phosphate group is one of the major determinants of substrate 
binding. A part of the tyrosine phosphatase catalytic mechanism, this phosphate group is 
transferred to an enzyme thio-phosphate intermediate. As tyrosine phosphatases exhibit 
high levels of activity at rest, a major part of the substrate binding mechanism is likely to be 
lost soon after substrate binding (Streuli et al., 1989; Guan et al., 1990). This is likely to 
make substrate-enzyme interactions very brief.
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A.  Immunoprecipitation of PTPa using antibodies directed against the extracellular 
FLAG or intracellular HA tag. Immunoprecipitates were analysed under reducing 
conditions using SDS-PAGE (12.5% total acrylamide gel). Gels were stained for total 
protein using a non-ammoniacal silver stain.
B.  Schematic diagram of PTPa cleavage products showing epitope tag locations
C.  Immunoprecipitation of P85/75 subunits with antibody directed against the 
extracellular domain FLAG tag.
D.  Immunoprecipitation of E90/81 subunits with antibody directed against the 
intracellular domain HA tag.
PTPa and immunoglobulin species are labelled. Control immunoprecipitates were carried 
out on lysates from cells expressing a non-HA/FLAG tagged form of PTPa.
243Cellular phosphotyrosine levels are maintained at relatively low levels compared for 
example to serine or threonine phosphate due to the tightly regulated activity of tyrosine 
kinases and the high basal activity level of cellular tyrosine phosphatases (Hunter and 
Sefton, 1980; Streuli et al., 1989; Guan et al., 1990). Several strategies exist to boost cellular 
phosphotyrosine levels to increase the likelihood of the phosphatase substrate being 
present in its phosphorylated form at a sufficient level for purification and subsequent 
identification. Briefly, cells may be treated with substances that increase tyrosine kinase 
activity or they may be treated with tyrosine phosphatase inhibitors. Stimulants of tyrosine 
kinase activity are generally pathway specific agents such as growth factors whose use 
results in significant increases in cellular phosphotyrosine level that are concentrated in a 
small number of proteins. The choice of a suitable agent therefore requires some degree of 
thought and a measure of luck if it is to stimulate the phosphorylation of the appropriate 
substrate proteins. On the other hand, most tyrosine phosphatase inhibitors are not 
targeted but inhibit all cellular tyrosine phosphatases, resulting in significant increases in 
cellular phosphotyrosine spread across a large range of proteins. This effect is believed to 
be due both to the inhibition of substrate dephosphorylation and to the inactivation of 
those phosphatases that are responsible for dephosphorylating the activation loop tyrosine 
in tyrosine kinases, so increasing kinase activity in a general manner at the same time as 
decreasing phosphatase activity in a pan-cellular manner.
Tyrosine phosphatase enzymes can be altered by site-directed mutagenesis to forms 
that bind substrate but are unable to catalyse hydrolysis of the tyrosine phosphatase bond. 
Such mutations are known as “substrate-trapping” mutations or simply as trapping 
mutations. A number of tyrosine phosphatase trapping mutations exist (Blanchetot et al.,
2005). These mutations may be divided into mutations that perturb the catalytic cysteine, 
mutations that affect the WPD loop and mutations that affect the chelation of an essential 
water molecule required for phosphatase function. The characteristics of these mutants and 
the theoretical differences in the effects of tyrosine phosphatase inhibitors on wild type and 
trapping mutant enzymes were described above (1.1.3).
Expression of wild type or substrate trapping PTPa did not alter the cellular 
phosphotyrosine level. Wild type PTPa and PTPa containing each of four D1 trapping 
mutations and one D2 trapping mutation were expressed in HEK-293T cells (Figure 7.6A). 
As previously described, phosphotyrosine levels in HEK-293T cells were undetectable in 
the absence of a phosphotyrosine inhibitor. Following phosphatase inhibitor (pervanadate) 
treatment although phosphotyrosine levels were detectable, no significant difference could
244be detected between control cells and cells transfected with wild type or substrate trapping 
PTPa (Figure 7.6B).
Immunoprecipitation of substrate trapping PTPa detected several phosphotyrosine 
positive putative substrates but did not allow their identification. Immunoprecipitation of 
wild type or substrate trapping PTPa in the absence of tyrosine phosphatase inhibition 
failed to immunoprecipitate any tyrosine phosphorylated bands. However, following 
pervanadate treatment, immunoprecipitates from both wild type and substrate trapping 
PTPa contained three major phosphotyrosine positive bands. These species corresponded 
to the expected size of full-length PTPa and the PTPa intracellular domain cleavage 
fragments (Figure 7.7A, B). It is notable that the phosphotyrosine content of these bands 
was significandy higher in immunoprecipitates from substrate trapping PTPa-expressing 
cells than in immunoprecipitates from wild type PTPa-expressing cells. As previously 
described above (6.2), the intracellular cleavage fragments of both wild type and now 
substrate trapping PTPa were seen to exhibit higher levels of tyrosine phosphorylation 
than full-length protein. In addition to these PTPa bands, small amounts of tyrosine 
phosphorylated protein could also be seen in some of the samples containing substrate 
trapping PTPa that migrated at approximately 40 kilodaltons (D181A) and at 
approximately 60 kilodaltons (D181A, C215S Dl) (Figure 1.1 A). A band that 
immunoprecipitates with the D181A trapping mutations has previously been detected but 
not identified (Aricescu, 2002). Several other faint bands could be seen ranging from 25 to 
50 kilodaltons; note the generally increased signal density and the presence of some specific 
bands in the 25-50kDa region (Figure 7.7A lane 5-8 when compared to lanes 1-4).
Analysis of these gels using a non-ammoniacal silver stain to detect total protein 
revealed a very large number of proteins in both control and PTPa immunoprecipitates 
(Figure 7.8A, B). This hindered the identification of the phosphotyrosine positive bands 
and their subsequent excision and identification by mass spectrometry. Although a 40 
kilodalton species can be identified in pervanadate treated D181A/Q262A and C215D Dl 
immunoprecipitates (Figure 7.8B lanes 1, 3), it did not prove possible to excise sufficient 
amounts of pure protein to identify this species. In addition, small amounts of this peptide 
could be seen in C215S D2 immunoprecipitates (Figure 7.8B lane 5).
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246Figure 7.6: Expression of “substrate trapping” PTPa proteins
HEK 293T cells were transfected with expression vectors containing either GFP or PTPa 
(Wild type, D181A, C215S D l, D181A/Q262A, C215D Dl  or C215S D2)
A.  Expression of PTPa wild type and substrate trapping proteins
Cells were lysed and analysed by SDS-PAGE. Western blots were detected with an 
antibody (M2) directed against the amino-terminal FLAG tag.
B.  Phosphotyrosine content of cells transfected with control protein (GFP), wild type 
PTPa or substrate trapping PTPa.
Following incubation with pervanadate, cells were lysed and analysed by SDS-PAGE. 
Western blots were detected with the 4G10 anti-phosphotyrosine antibody.
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248Figure 7.7: Immunoprecipitation of substrate trapping PTPa 1 —  Phosphotyrosine 
detection
A.  Anti-HA immunoprecipitates from WT-Myc, WT-HA , D181A-HA and C215S 
Dl-HA expressing HEK-293T cells
Smaller panel shows shorter exposure of lanes 5-8. Red asterisk (*) indicates 
phosphotyrosine positive putative substrate (Mw~ 40kDa) in pervanadate treated D181A 
sample. Red dagger (j*) indicates phosphotyrosine positive putative substrate (Mw~60kDa) 
in pervanadate treated D181A and C215S Dl  samples.
B.  Anti-HA immunoprecipitates from D181A/Q262A-HA, C215D Dl-HA and 
C215S D2-HA expressing HEK-293T cells.
Treatment with or without lOpM pervanadate is indicated below each major figure. PTPa 
full-length protein (FL1 6 6 ) and PTPa cleavage fragments (E/P subunits) are indicated. 
Antibody heavy (IgH , Mw~50kDa) and light (IgL, Mw~25kDa) bands are marked. In lane 4, 
the small amount of phosphotyrosine-positive PTPa E /P subunits at 80-90kDa is partially 
masked by a defect on the gel.
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250Figure 7.8: Immunoprecipitation of substrate trapping PTPa 2 —  Silver stain
A.  Anti-HA immunoprecipitates from WT-Myc, WT-HA , D181A-HA and C215S 
Dl-HA expressing HEK-293T cells
B.  Anti-HA immunoprecipitates from D181A/Q262A-HA, C215D Dl-HA and 
C215S D2-HA expressing HEK-293T cells.
Treatment with or without 10p.M pervanadate is indicated below each major figure. The 
size of the PTPa full-length protein (FL166) and PTPa cleavage fragments (E/P subunits) 
are indicated. Antibody heavy (IgH , Mw~50kDa) and light (IgL , Mw~25kDa) bands are 
marked.
Red asterisk (*) indicates putative PTPa interacting protein (Mw~ 40kDa) in pervanadate 
treated D181A/Q262A, C215D D1 and C215S D2 samples.
2517.2.3: Construction of GST-PTPafusion proteins
Co-immunoprecipitation of substrate trapping mutant PTPa did not yield sufficient 
amounts of the putative substrate-trapped interacting proteins to allow their identification. 
It was important therefore to increase the scale and stringency of the 
immunoprecipitations. A range of alternative methods of high-level recombinant protein 
production such as yeast and bacterial expression systems exist together with several large- 
scale purification techniques. One of the most widely used systems, which combines both 
high-level recombinant protein production and easy purification is the glutathione-S- 
transferase pull-down technique. This commonly uses elements from the lac operon to 
allow the induction of recombinant protein expression by addition of a lactose analogue 
(e.g. Isopropyl-1 -thio-(3-D-galactoside —  IPTG) to the culture medium. The recombinant 
protein is commonly fused with a GST moiety. GST binds strongly to glutathione and 
glutathione immobilised on beads can be used to purify the protein of interest from 
induced bacterial cell lysates. This results in columns of immobilised GST -PTPa protein, 
down which lysates from mammalian cells can be passed. Several PTPa constructs were 
generated that allowed the inducible expression of wild type and substrate trapping 
(D181A, Q262A, Dbl, C215S, C215D) PTPa. These constructs contained the entire PTPa 
intracellular domain (bp: 2743-4701; a.a.: 928-1499) located behind a single GST moiety 
(Figure 7.9 A). The expected molecular weights of GST and the GST-PTPa fusions are 
~27.5 kDA and ~98.4kDa, respectively.
It did not prove possible to derive conditions allowing the expression of all of the
GST-PTPa fusion proteins. Evaluation of the GST-PTPa fusion proteins was carried out
in collaboration with Dr Clare Faux (Neural Development unit, ICH). It was only possible
to obtain expression of two of the GST-PTPa fusion proteins, those containing the C215S
and C215D mutations. In the absence of IPTG, only low-level “leaky” expression of GST,
GST-PTPa C215S D1 and GST-PTPa C215D D1  fusion protein was detected (Figure 7.9
D). In contrast, following incubation with inducing concentrations of IPTG, robust
expression of the GST, GST-PTPa C215S D1 and GST-PTPa C215D D1  fusion proteins
was detected (Figure 7.9 B). Indeed expression levels were high enough to allow the GST
and GST-PTPa fusion proteins to be identified on SDS-PAGE gels using Brilliant Blue
staining (Figure 7.9 B). Although significant amounts of the C215S GST-PTPa fusion
protein were produced following induction at 37°C, at this temperature the C215D GST
fusion protein was insoluble. Soluble GST-PTPa C215D expression was only possible
following induction at 25-28°C. It did not prove possible to derive suitable conditions for
252the expression of the wild type, D181A or D181A/Q262A GST-PTPa fusion proteins (Dr 
Clare Faux; Personal communication). Further analysis of these fusion proteins and their 
potential use to “pull-down” PTPa interacting proteins is being continued by Dr Clare 
Faux.
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A.  Schematic diagram of PTPa-GST fusion proteins
The PTPa intracellular domain (a.a. 928-1499) was cloned into the pGEX-KT vector 
between the BamHI and EcoRI sites, 3’ to the glutathione-S-transferase (GST) moiety.
B.  GST-PTPa fusion protein expression 1: Brilliant Blue stain
D.  GST-PTPa fusion protein expression 2: Anti-GST detection
Bacterial cells were transformed with the appropriate GST expression vector and lysed with 
or without induction for 4 hours with O.lmM Isopropyl-1 -thio-(TD-galactoside (IPTG). 
Lysates were analysed using SDS-PAGE. Gels were stained using Brilliant Blue G-250 (B) 
or blotted to PVDF membranes and detected using an anti-GST antibody (D). GST alone, 
GST-PTPac215S and GST-PTPa215D are shown.
C.  GST fusion protein column purification. Brilliant Blue stain
Glutathione-bead purification of GST and GST-PTPa C215S fusion protein. Column 
purification was kindly carried out by Dr Clare Faux (Neural Development Unit, ICH). 
Bacterial cell lysates were processed using glutathione beads and the resulting eluates 
concentrated as described above. Concentrated protein samples produce in this manner 
were analysed by SDS-PAGE. Gels were stained with Brilliant Blue G-250.
The expected sizes of the GST (27.5 kDa) and GST-PTPa fusions (98.4 kDa) are indicated 
to the right of the gels.
2557.3: Discussion
This chapter describes attempts to identify PTPa-interacting proteins.
Unfortunately, it was not possible to identify any proteins that interacted with PTPa; 
however, a number of experimental tools were produced that may in the future increase 
our understanding of PTPa function. The approaches used may be divided into those that 
looked at the interactions of the PTPa extracellular domain and those that looked at the 
interactions of the intracellular domain.
PTPa ligands were located using fusions of the PTPa extracellular domain with 
alkaline phosphatase (AP) (Haj et al., 1999; Sajnani-Perez et al., 2003). However, only 
dimeric AP is enzymatically active (Holmgren et al., 1977). Therefore, it is not yet known 
whether the orientation of the PTPa-AP fusions is determined by the AP or the PTPa 
components, which has obvious significance for the authenticity of ligands identified in this 
manner. However, only dimeric PTPa extracellular domains recognise the basement 
membrane ligand (Lee et al., 2006a). Although fusion of the AP moiety with PTPa did not 
interfere with PTPa ligand recognition, this may depend on the site of fusion (Chilton, 
2000). Such a phenomenon might explain the difficulties many researchers have had using 
fusions of RPTPs other than PTPa with AP. The PTPa-AP fusions may have been 
serendipitously designed such that they form ligand-binding sites whereas other researchers 
may not have had the same luck when they designed their AP fusion proteins. The 
basement membrane ligands bound by the PTPa-AP probes are also recognised by a VSV- 
tagged PTPa extracellular domain probe, which would not suffer from the same structural 
constraints (Rashid-Doubell et al., 2002). However, although VSV-tagged PTPa was readily 
detectable in solid phase binding assays, it proved difficult to detect following long term in 
vivo expression (Aricescu et al., 2002; Rashid-Doubell et al., 2002). This might reflect the 
expression level of the probe or the accessibility of the tag. In order to further optimise tag 
detection, the 3xFLAG tag was used, which is larger, containing three repeats of the tag 
sequence, and more polar than many other epitope tags.
The addition of a 3xFLAG tag to the extreme amino-terminus of the mature PTPa 
protein did not interfere with ligand binding (Figure 7.1) (Aricescu et al., 2002; Sajnani- 
Perez et al., 2003). These data suggest that tags located at the extreme amino-terminal end 
of the PTPa protein have only minimal effects on the binding of known PTPa ligands and 
are a useful adjunct to AP fusion proteins for identifying and characterising PTPa ligands. 
In particular, analysis of the binding pattern of epitope-tagged PTPa extracellular domain
256probes that lack the AP moiety will determine several important questions. As it has 
recendy been shown that only dimeric PTPa is able to bind basement membrane ligands, if 
epitope-tagged PTPa extracellular domains also bind ligand then it may be concluded that 
PTPa extracellular domains form dimers in solution (Lee et al., 2006a). Unfortunately, it 
may continue to prove difficult to detect these dimers directly. Secondly, if the hypothesis 
that the binding properties of truncated PTPa-AP fusions are due to the constraining effect 
of the AP dimer interface is correct, then ligand binding assays using epitope-tagged PTPa 
extracellular domains and no AP component might fail to detect a difference in binding 
specificity between FNA5 and FNA6, for example. Importantly, this experiment would also 
determine whether there is a real difference in ligand binding between the two major PTPa 
isoforms, PTPal and PTPa2.
In addition, epitope tagged PTPa was used to reassess whether PTPa exhibits 
homophilic binding using cells expressing high levels of full length PTPa at the cell 
membrane. This thesis has previously shown that PTPa forms dimers on the cell surface. 
However, it was not possible to determine whether these dimers represented the 
interaction of PTPa molecules expressed on the same cell (in as) or the interaction of PTPa 
molecules expressed on neighbouring cells (in trans). Trans-interactions of this kind are 
known as homophilic adhesion and are a common feature of many adhesion molecules 
including several other RPTPs (Brady-Kalnay et al., 1993; Gebbink et al., 1993b; Brady- 
Kalnay and Tonks, 1994; Sap et al., 1994; Zondag et al., 1995; Wang and Bixby, 1999;
Baker et al., 2000b; Yang et al., 2003; Cismasiu et al., 2004; Yang et al., 2005; Aricescu et al., 
2006). However, previous work has found little evidence that PTPa exhibits homophilic 
binding. This may be related to the absence of the LASE-c/meC alternatively spliced 
exons, which may be important for PTP8/LAR homophilic adhesion, in the PTPa proteins 
assayed (O'Grady et al., 1994; Pulido et al., 1995a; Yang et al., 2003; Yang et al., 2005). 
Indeed, careful examination of previous studies might suggest that PTPa-AP probe binding 
decreases when cells are transfected with PTPa (Haj et al., 1999). In this thesis, a PTPa-AP 
probe was shown to bind to HEK-293T cells and binding was seen to increase following 
transfection of the HEK-293T cells with full-length PTPa. Interestingly, PTPa-AP probe 
binding appeared to increase following transfection with PTPa not only in PTPa- 
expressing cells but also in neighbouring cells. This may be related to the recent finding 
that PTPa can act as a ligand as well as a receptor (Sajnani et al., 2005) and suggests that a 
possible candidate for the PTPa ligand present on HEK-293T cells might be bound PTPa 
extracellular domain shed by the transfected cells. Unfortunately, if this pattern of binding
257both to cells transfected with PTPa and to neighbouring untransfected cells is correct, this 
may make the detection and interpretation of probe binding significandy more difficult to 
investigate using conventional methods. Probe binding would then require transfection of 
the cell population with PTPa but might also be inhibited by excessive transfection 
efficiencies. In addition, the AP probe method did not lend itself to straightforward 
quantitation of PTPa-AP probe binding. There was both background AP activity, despite 
heat inactivation and a significant level of background probe binding to the cell line. In 
addition, there was significant inter-experimental variation in PTPa expression level.
The role of homophilic binding in other RPTPs was not established using probe 
binding methods. Classically, techniques such as differential adhesion have been used to 
demonstrate homophilic adhesion (Brady-Kalnay et al., 1993; Gebbink et al., 1993b; Brady- 
Kalnay and Tonks, 1994; Sap et al., 1994; Zondag et al., 1995; Wang and Bixby, 1999;
Baker et al., 2000b; Yang et al., 2003; Cismasiu et al., 2004; Yang et al., 2005; Aricescu et al.,
2006). Experience suggested that the establishment of two stably transfected cell lines 
expressing distincdy tagged PTPa proteins was a difficult proposition (A. Stoker, 
unpublished results). However, recent work on PTPp has used an alternative method to 
assess homophilic adhesion (Cismasiu et al., 2004). Analysis of homophilic binding by 
PTPa using SDS-PAGE confirmed that PTPa extracellular domains bind to HEK-293T 
cells. This method was more easily quantifiable than the immunohistochemical method 
outlined above. However, in this case there was no evidence for a decrease or increase in 
PTP-AP probe binding following transfection with PTPa. However, it may be that SDS- 
PAGE is an inappropriate method to use in this case. The method by definition takes an 
average of the probe binding across the whole plate. This would indeed be more sensitive 
to low levels of probe binding in the absence of any background binding. However, given 
that significant amounts of probe bind to untransfected cells, it would require a 
significandy greater level of probe binding following transfection to detect any change.
The experiments described in this thesis and those published previously do not
therefore support a role for homophilic adhesion in PTPa function (Haj et al., 1999).
However, several interesting points can be made about these experiments. Firsdy, it may be
possible to obtain large amounts of the PTPa-interacting protein present on HEK-293T
cells and thus to potentially identify a novel PTPa ligand. Although it is not clear whether
HEK-293T cells express PTPa (Stoker, 1994) and so whether this target could reflect a
physiological PTPa ligand, it would represent the first PTPa ligand to be identified from a
direct interaction in living cells. In addition, experiments in two cell lines seem to show that
258the level of PTPa-AP probe binding is affected by PTPa transfection. Whilst the 
limitations of the AP-probe method are well known, this might suggest that either shed or 
cell membrane PTPa interferes with PTPa-AP probe binding. It is likely to become 
necessary to conduct differential adhesion experiments as used on those members of the 
RPTP family known to show homophilic adhesion. These experiments will probably 
require the use of PTPa mutants that cannot undergo proteolysis and shedding from the 
cell membrane.
The shedding rate of PTPa extracellular domains was serendipitously noted during 
the SDS-PAGE homophilic binding experiments. It appeared that the ectodomain 
shedding rate was significandy greater from cells expressing full-length PTPa compared to 
the PTPa-EC-AP or FNA3-AP constructs. Accumulation of satisfactory amounts of the 
AP fusion proteins required several days (Aricescu, 2002). After short incubations in 
conditioned media, a striking amount of shed PTPa extracellular domain was detected 
(Figure 7.3 B). Despite this though the overall level of soluble protein was comparable at 3- 
4 days (Data not shown). Therefore, it is possible that shed PTPa does not accumulate in 
conditioned media at the same rate at which it is shed, but that a significant proportion is 
lost from the media via degradation, binding to cells or the extracellular matrix or by 
endocytosis into cells. Interestingly, endocytosis would explain the unexplained portion of 
extracellular domain PTPa protein that is protected from limited trypsin digestion. In 
addition, this high rate of shedding may suggest that expression of a tagged full-length 
PTPa may be a more efficient method to produce soluble probe than expression of a 
truncated secreted protein such as the AP probe. Finally, although a significant proportion 
of PTPa is detectable as the full-length form following expression in HEK-293T cells, in 
tissues PTPa and other type Ila RPTPs are predominandy found in the form of the 
extracellular cleavage fragments (Stoker et al., 1995a; Stoker et al., 1995b). If PTPa 
secretion from the cell does occur as rapidly as suggested by this data and previous pulse 
chase experiments on LAR, then much of the PTPa detected in vivo may not be in the 
form of the E81/P 85 complex previously reported. Instead, large amounts of cleaved E8 1  
protein may represent shed protein that, following shedding, has re-bound to an unknown 
receptor on the cell membrane or in the extracellular compartment (Yu et al., 1992; Streuli 
et al., 1992).
SDS-PAGE analysis of the His-tagged PTPa extracellular domain deletion series 
revealed a number of unexpected high molecular weight bands (Figure 7.4 B). A number of 
possible explanations exist for these bands. Firsdy, they may represent aggregates or
259complexes of the His-tagged proteins. Such aggregates may be artefactual due to their high 
expression level (Di Fiore et al., 1987; Di Marco et al., 1990; Maru et al., 1990; Brandt-Rauf 
et al., 1990). However, similar species are not clearly seen with the endogenous full-length 
soluble extracellular domain protein although they would be similar in size to the full- 
length protein. Bands of approximately this size were seen occasionally in conditioned 
media samples from cells transfected with wild-type PTPa (Data not shown). However, 
such samples were routinely discarded, as it was believed that these bands reflected 
contamination of the conditioned media with cell-membrane associated full-length protein. 
Alternatively, these bands may represent complexes of PTPa with another protein. In this 
case, it is likely that the low level of these bands reflects a high affinity interaction that is 
not completely dissociated under the conditions employed for lysis and SDS-PAGE 
analysis. However, the size of the high molecular weight bands does not increase in 
proportion to the increasing size of the corresponding His-tagged PTPa peptide.
Therefore, if these proteins represent complexes of another protein with PTPa, then one 
of two situations must exist. Either different proteins interact with each deletion mutant or 
the valency of the interaction must vary from one deletion mutant to the next. This raises a 
final possibility for the nature of the high molecular weight species. They may represent 
PTPa homo-oligomers with different valencies. Since AP fusions are believed to form 
dimers, it is of note that the high molecular weight species seen with PTPa-FNA3-AP.His 
is of the expected size for a PTPa-FNA3-AP.His dimer. However, the His-tagged proteins 
that do not contain the AP moiety would not be constrained to dimer formation. The 
approximate sizes of the deletion series, the corresponding high molecular weight band and 
the suggested valency of the PTPa homo-oligomer are as follows:
1.  PTPa-FNA2.His  (55.8  kDa)  -  150 kDa  -  -Trimer
2.  PTPa-FNA3.His  (66.3 kDa)  -  180kDa  -  -Trimer
3.  PTPa-FNA4.His  (77.5 kDa)  -  150kDa  -  -Dimer
4.  PTPa-FNA3-AP.His (120.6 kDa)  -  >200kDa  -  — Dimer
The nature of these homo-oligomeric complexes may be revealed as part of the ongoing 
biochemical characterisation of these proteins
Attempts were made to identify PTPa substrates using wild type and substrate 
trapping forms of PTPa. No interacting proteins could be identified using wild type PTPa 
or substrate trapping PTPa in the absence of phosphatase inhibitors but a number of 
interacting bands were visible following the immunoprecipitation of substrate trapping
260PTPa from tyrosine phosphatase inhibited lysates. Unfortunately, it did not prove possible 
to detect these coimmunoprecipitating bands above background on gels stained with silver 
or Brilliant Blue and so, it was not possible to identify these bands. During these 
experiments it was confirmed that PTPa is preferentially tyrosine phosphorylated in the 
cleaved form rather than the FL form (Chapter 6). In addition, the level of tyrosine 
phosphorylation of PTPa was increased by substrate trapping mutations, confirming that 
PTPa, like other RPTPs, is able to auto-dephosphorylate itself (den Hertog et al., 1994; 
Tsujikawa et al., 2001; Aricescu, 2002). As this effect occurred in the presence of an 
irreversible phosphatase inhibitor in the lysis buffer, tyrosine dephosphorylation is likely to 
have occurred in the cell rather than to represent an artefactual post lysis effect. Finally, it is 
possible that the incorporation of non-native sequence (i.e. epitope tags) interferes with 
PTPa protein-protein interactions. Recent work has identified an interaction of wild type 
PTPa with certain growth factor receptors (Faux et al, manuscript in preparation).
Several factors were identified that might be responsible for the failure of the 
substrate trapping/immunprecipitation approach to produce sufficient amounts of PTPa 
interacting proteins to permit their identification. Firstly, the level of PTPa expression 
achieved was inadequate. Secondly, the specificity of the immunoprecipitation requires 
optimisation. In addition, although tyrosine phosphatase inhibition appeared to be required 
to generate sufficient phosphotyrosine substrate, it may block substrate binding by the 
trapping mutants. Attempts to minimise this effect by separating overexpressed PTPa and 
the tyrosine phosphatase treatment in different cell cultures were not successful (Data not 
shown). Although some trapping mutations may be relatively immune to the 
conformational effects of catalytic cysteine oxidation, substitution at both catalytic site 
cysteines may be required for complete immunity. Alternative strategies might include 
overexpressing an active tyrosine kinase rather than using a phosphatase inhibitor to boost 
phosphotyrosine levels. A further problem with the substrate trapping mutations is that 
they are likely themselves to alter the conformation of the active site and so potentially 
interfere with substrate binding (Scapin et al., 2001). However, the substrate trapping 
mutations are an unfortunate necessity for substrate co-immunoprecipitation. In their 
absence, the substrate phosphotyrosine is rapidly hydrolysed and the substrate is ejected 
from the active site, preventing its co-immunoprecipitation (Guan and Dixon, 1991). A 
solution to this Catch-22 situation is not immediately apparent and it is worth noting that 
although substrate trapping mutants have been extremely successful with non-receptor 
PTPs, they have been much less useful with RPTPs and there have been few successful
261attempts to initially identify RPTP substrates using full length proteins expressed in 
cultured cells.
The substrate trapping approach was pursued using bacterially expressed GST- 
fusion proteins to avoid many of the problems outlined above. Several GST-PTPa fusion 
proteins were designed for expression in E.coli; however, it proved difficult to obtain 
efficient expression of most of the GST-PTPa fusion proteins. It was only possible to 
induce expression of two of the five GST-PTPa fusion proteins (C215S, C215D) and 
experiments using these proteins are ongoing (C. Faux, unpublished data). Recent work 
optimising the expression of PTPa proteins in E.coli may guide the production of other 
GST-PTPa fusions (Lee et al., 2006b). It is of note that both of the proteins that were 
successfully expressed (C215S, C215D) lacked the DI or membrane proximal catalytic 
cysteine (C215). Moreover, the C215D mutation, which is perceived to be less structurally 
disruptive than the C215S mutation, was more difficult to obtain, requiring lower 
temperatures for successful expression. Therefore, it is possible that an intact DI  catalytic 
cysteine is for some reason detrimental to efficient expression in this bacterial expression 
system. Unfortunately, the immunoprecipitation experiment suggested that the D181A 
mutant might be the most useful of the trapping mutants. If it proves necessary to use the 
catalytic cysteine retaining PTPa substrate trapping mutations, it may prove necessary to 
change to an alternative expression system. However, the most likely explanation for the 
difficulties experienced in GST-PTPa fusion protein expression is that the size of the 2- 
domain fusion (~98.4 kDa) is close to the upper limit of what is possible using this kind of 
bacterial expression system. Alternative approaches might include using smaller GST 
fusions containing only the membrane proximal phosphatase domains or alternative 
expression systems. However, this would potentially be at the expense of losing some 
physiological accuracy if, as has been suggested, the D2 domain participates in some way in 
the regulation of DI  (Streuli et al., 1990; Wang and Pallen, 1991; Johnson et al., 1992; 
Debant et al., 1996; Wu et al., 1997; Kashio et al., 1998; Felberg and Johnson, 1998; Buist 
et al., 2000; Felberg and Johnson, 2000; Tsujikawa et al., 2001; Krueger et al., 2003; Persson 
et al., 2004; Wang and Johnson, 2005).
In this chapter, attempts were made to isolate proteins that interact with PTPa. 
Although it was not possible to identify any PTPa interacting proteins, pilot experiments 
proved the concept that immunoaffinity purification methods could be used to obtain 
PTPa interacting proteins. Future work will optimise the use of the tools generated in this 
chapter to identify these proteins. In addition, the role of homophilic interactions in PTPa
262function was revisited. Although it was not possible to demonstrate homophilic adhesion 
with PTPa extracellular domains, data suggested that this area might fruitfully be probed in 
greater detail. Lasdy, the PTPa extracellular domain binds to a ligand on HEK-293T cells. 
Given the difficulty in identifying PTPa interacting proteins, these cells represent an 
abundant source of a potential PTPa ligand that should be followed up. If proven, this 
interaction would represent the first example of a PTPa interacting protein demonstrated 
in living cells. In conclusion, the identification of PTPa interacting proteins remains a key 
goal in developing our understanding of the function of this poorly understood protein and 
indeed of the large family of RPTPs, about which still little is understood.
263Chapter 8: Cloning of chicken LAR(RPTPf)
In vertebrates, the type Ha family of RPTPs has three members: PTP8, LAR 
(PTPf) and PTPa. The phenotype produced by deletion of any one of these genes in mice 
is relatively mild with only PTPa knockouts exhibiting significant neonatal mortality 
(Skames et al., 1995; Schaapveld et al., 1997; Elchebly et al., 1999; Wallace et al., 1999; 
Uetani et al., 2000). However, disruption of PTPa and PTP8 together has a synergistic 
effect (Stepanek et al., 2005; Uetani et al., 2006). Drosophila melanogaster has six RPTPs of 
which four are selectively expressed in neurons (DLAR, DPTP69D, DPTP99A, 
DPTP10D), and a fifth (DPTP52F) is expressed only in neurons after formation of the 
ventral nerve cord (Streuli et al., 1989; Tian et al., 1991; Yang et al., 1991; Hariharan et al., 
1991; Oon et al., 1993; Desai et al., 1994; Sun et al., 2000a; Schindelholz et al., 2001). Of 
these “neural” RPTPs, DLAR and arguably DPTP69D are structurally similar to type II 
RPTPs and as such are thought to share a common lineage with the vertebrate type Ha and 
lib RPTPs (Schindelholz et al., 2001). Disruption of any one of the Drosophila neural 
RPTPs tends to produce only a mild, partially penetrant defect in neuronal development 
whereas the combined disruption of two or more fly RPTPs produces more striking 
defects (Desai et al., 1996; Krueger et al., 1996; Desai et al., 1997a; Garrity et al., 1999; 
Newsome et al., 2000a; Sun et al., 2000a; Sun et al., 2001; Schindelholz et al., 2001; Maurel- 
Zaffran et al., 2001; Clandinin et al., 2001; Kaufmann et al., 2002; Desai and Purdy, 2003). 
On the other hand, the functional relationship between fly RPTPs varies between 
developmental pathways such that in some systems, certain Drosophila RPTP mutations 
partially rescue the phenotype of mutations in other RPTPs. Therefore, it has been 
postulated that the fly RPTPs cooperate and oppose each other at multiple decision points 
in axon outgrowth (Desai et al., 1997a; Sun et al., 2001). The expression patterns of the 
vertebrate type II RPTPs overlap (1.2.1.2). Therefore, it is possible that as in Drosophila, 
vertebrate RPTPs act together to regulate axon guidance at choice points. This would 
potentially allow intact RPTPs to partially compensate for the disruption of a single RPTP 
gene such as PTPa. Only recently have the first combined disruption studies been 
published using vertebrate models (Stepanek et al., 2005; Uetani et al., 2006). Together with 
the previously identified PTPa and PTP8, the isolation of the last remaining uncloned 
chick type Ha RPTP, LAR, will allow the potentially overlapping roles of type II RPTPs in 
axon guidance to be analysed.
264Several different methods were used to isolate chick LAR. Degenerate PCR and 
library screening with PTPa fragments were unsuccessful and only PTPa sequences were 
obtained in this way. The isolation of the chick homologue of LAR was made possible by 
the concurrent development of several publicly available chicken EST databases. These 
contain a number of small LAR fragments, which allowed the design of LAR specific 
primers and subsequent successful RT-PCR. Two clones were obtained from independent 
experiments and sequenced. The clones encoded LAR isoform 1 with three 
immunoglobulin domains, seven (see below) fibronectin type III domains and two 
intracellular tyrosine phosphatase domains. The chick LAR clones were almost full-length 
and lacked only small regions at the 5’ and 3’ end of the coding sequence. These gaps were 
filled by in silico cloning from the EST databases to obtain a predicted sequence for the 
entire chick LAR protein.
8.1: Cloning
8.1.1: Ubraiy screen
Using a previously constructed library containing cDNA from day 7 chick embryos 
(Aricescu, 2002), plates were prepared and probed with a chick LAR EST probe. The 
probe was obtained by a Basic Local Alignment Search Tool (BLAST) search of a chick 
bursal EST database (DKFZ clone: dkfz426_27il0rl) (Altschul et al., 1990; 
Abdrakhmanov et al., 2000). The EST was a close match to the 3’ untranslated region 
(UTR) of human LAR. The 3’ EST was not conserved between type Ha RPTP subfamilies 
(i.e. PTPa vs PTP8 vs LAR) but was highly conserved between species orthologues (i.e. 
mouse LAR vs human LAR; Data not shown). Thus, the probe was highly specific for 
LAR orthologues. However, library screening using replica plates was unsuccessful. Only 
chick PTPa was isolated in these experiments. (Figure 8.1).
8.1.2: Degenerate PCR
Following the failure of the colony screening, the same chick library was probed 
using RTPCR with degenerate oligonucleotides. Primers were designed which had the best 
possible combination of low degeneracy with specificity for LAR orthologues over other 
type Ha RPTPs. Following a process of optimisation, a number of PCR products were 
generated. However, following cloning and sequence analysis, these all proved to be chick 
PTPa (Figure 8.2).
265Figure 8.1: cDNA library screening using colony hybridisation with a LAR 3’ EST probe
Filter replicas were taken from agar plates plated with E.coli transformed with the chick 
cDNA library (R. Aricescu, unpublished data). The nylon filters were probed with a chick 
LAR 3’EST probe and a chemiluminescent detection system. Three representative filters 
are shown with positive colonies highlighted with a red circle. These colonies were 
identified on the original plates and subjected to DNA sequence analysis. All positive 
colonies analysed contained chick PTPa. The black orientation markings at the edges of the 
plates and the filter grid system can also be seen.
2668.1.3: Ijong-range PCR
During the course of this thesis, several chick genome and chick EST projects were 
established that gradually provided chick sequence data (Boardman et al., 2002; Carre et al., 
2006). Several ESTs were identified using the BLAST tool that corresponded to chick LAR 
(Altschul et al., 1990). Using these sequences to design PCR primers, PCR was attempted 
on the library described above and on fresh chick cDNA. It was not possible to generate 
LAR product using the chick library. However, optimisation of the PCR conditions using 
chick cDNA (Wayne bames, Personal communication) to optimise for the recovery of 
long, accurately replicated PCR products generated a single LAR specific band (Figure 8.3). 
This was cloned and sequenced using conventional methods. To allow accurate 
determination of the chicken LAR DNA sequence and to reveal errors introduced during 
the reverse transcription or PCR steps, a second LAR clone was generated in a completely 
independent experiment and the two sequences were compared.
8.2: Sequence analysis 
8.2.1: DNy4 sequence
Using RT-PCR as described above, two independent clones of chicken LAR were 
isolated. The cDNA sequences are included in the appendix to this work (Appendix 1: 
cLAR DNA sequences). Slighdy different primer sets were used for the two cloning 
experiments with the result that the two sequences differ slighdy in length. The longer, 
clone 1, is 5381  base pairs long whereas the shorter, clone 2, contains a shorter region of 
5243 base pairs entirely located within the boundaries of clone 1. The difference in size is 
largely accounted for by a single area of 5’ sequence, present in clone 1 that is lacking in 
clone 2. Although the 5’ primers used to amplify clones 1 and 2 were to all intents identical, 
clone 2 begins 131 base pairs after this shared primer site and lacks any primer-derived 
sequence at its 5’ end. The reason for this difference is unclear.
267A.
Codehop LAR 1  
xLAR  550  c  gtg
mJ*AR 150  g  gtg
IF  c  gtg
V
gcc tct ttt gtg 
gcc tcc ttc gtg 
gcc tcc ttc gtg 
A  S  F  V
tgc caa gca ac 
tgc caa get  ac 
tgy car gen ac 
C  Q  A
Codehop LAR  1R  (Reverse  complement)
XI-AR  1130  gaa gtg  atg  cct  ggg  ggc a
mLAR 730  gag gtg  atg  ccg  ggc  ggc a
1R  gar gtn atg  ccc  ggc  ggc a
E  V  M   P  G  G
1500
1000
1500
1000
400
268Figure 8.2: cDNA library screening using degenerate primers
A chicken cDNA library (Aricescu, 2002) was amplified using degenerate primers designed 
using the Consensus Degenerate Hybrid Oligonucleotide Primer (Codehop) system 
(http://bioinformatics.weizmann.ac.il/blocks/codehop.html) (Rose et al., 1998; Rose et al., 
2003).
A. Illustrative alignments are shown of Codehop LAR 1  forward and reverse primers with 
'Kenopus laevis (Accession number AF197945) and Mus musculus (AF300943) LAR to 
demonstrate the principle of the Codehop system.
B.& C. Agarose gels showing the pattern of bands amplified by each set of Codehop 
primers using denaturation temperature of 50°C (B) or 45°C (C). Lanes 1, 2, etc =
Codehop primer set 1F=1R, 2F+2R etc. L= Hyperladder 1  (Bioline) —  molecular weights 
as indicated.
269The two clones were sequenced bidirectionally and only two sequence variations 
were found between the two clones. Sequence variation one results in the replacement of a 
serine (Codon: teg) residue with a proline (Codon: ccg) residue. The relevant nucleotide 
difference is LAR clone 1 thymine 2054  LAR clone 2 cytosine 1923 (See appendix 1). 
Xenopus LAR has a serine (Codons: tea) at this site and human, mouse and rat 
homologues all have an alanine (Codons: gen human gcc, mouse get, rat get) at this site. 
Sequence variation two results in a silent change in a proline codon (Codons: cca-ccg). 
Unfortunately, unlike sequence variation one, this residue is not conserved in all species 
and so it more difficult to predict which sequence is correct. For example, Xenopus LAR 
has an alanine at this site (Codon: gca)\Takifugu rubripes (Pugu) LAR has a cysteine at this site 
(Codon tgt); rat (Codon: cct), mouse (Codon: cca) and dog (Codon: ccg) have a proline at 
this site and human LAR has a leucine (Codon: ttg). The relevant nucleotide difference is 
LAR clone 1 adenine 2452  LAR clone 2 guanine 2321  (See appendix 1). In addition to 
comparison of the chicken LAR clone sequences at the sequence variation sites with LAR 
orthologues from other species, publicly available chick EST databases were examined for 
LAR EST clones that might be informative. ESTs were identified that covered the regions 
of interest; the EST sequences agreed with the LAR clone 1  sequence at both sites 
(Variation 1  (Codon teg) —  Genbank accession number XM_422408; Varation 2 (Codon 
cca) —  ChEST101jl3). Lastly, a short region at either end of each clone was derived from 
the PCR primers and as such remains to be verified empirically. However, several chick 
ESTs isolated independently from those used to design the oligonucleotide primers 
confirm that this sequence is correct.
8.2.2: Protein sequence
Domain analysis of the translation of the chicken LAR cDNA revealed that the 
clones encode the full-length isoform of chick LAR containing three Ig domains, seven 
(see below) fibronectin type 3 domains and two intracellular tyrosine phosphatase domains 
(Figure 8.4A). However, neither clone contains the full-length chicken LAR cDNA. By 
comparison to full-length LAR orthologues found in other species, clone 1 is missing 
approximately 70-80 amino acids (~220 base pairs) at its amino terminus. The carboxy- 
terminal end is missing about 20-30 amino acids (~75 base pairs).
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Figure 8.3: Long and accurate PCR (LA-PCR) cloning of chicken LAR
Using independendy generated reagents, chicken LAR was cloned using long and accurate 
PCR on cDNA reverse transcribed from RNA derived from chick embryos.
A. RT-PCR cloning of chicken LAR clone 1
B. RT-PCR cloning of chicken LAR clone 2
2718.2.3: Sequence extrapolation using ESTs  front public databases
The LAR clone sequences did not contain the full-length chicken LAR cDNA. 
During the course of this thesis, significant amounts of chicken sequence data has been 
made publicly available as part of the work of two chicken EST sequencing consortia 
(Biotechnology and Biological Sciences Research Council/University of Manchester 
database —  http://chick.umist.ac.uk/  (Boardman et al., 2002; Hubbard et al., 2005); 
University of Delaware —  http://www.chickest.udel.edu/). Therefore, the available data 
was examined to determine whether it was possible to obtain the rest of the chicken LAR 
cDNA in this way.
Several cDNAs were identified that extended the chicken LAR clones at the 5’ and 
3’ ends to complete the coding sequence. Firsdy, at the 5’ end, BLAST (Altschul et al.,
1990) was used to probe the UMIST chick EST database with the LAR clone 1  sequence 
and two EST clones were retrieved (Umist database ref. nos. ChEST35h5, ChEST35p7 —  
Stage 20-21 whole embryo) that aligned with the extreme 5’ end of clone 1. Translation of 
the consensus sequence of these 2 ESTs extended the LAR sequence to include the 
predicted ATG and Kozak consensus sequence. Similarly, at the 3’ end a BLAST search of 
the UMIST database retrieved two independendy derived EST clones (ChEST371m20 —  
Stage 36 limbs, ChEST958o6 —  adult pancreas) that extended the 3’ end of clone 1. 
Translation of the resulting consensus sequence extended the LAR sequence to include the 
termination codon.
8.2.4: Analysis
The completed chicken LAR protein sequence (Derived from LAR clone 1  + EST 
clones as described above) was analysed using standard bioinformatic techniques. The 
identity of chicken LAR as the chicken LAR homologue was confirmed in a number of 
ways. Firsdy, domain prediction using CD-Search (Marchler-Bauer and Bryant, 2004; 
Marchler-Bauer et al., 2005) confirmed that chicken LAR has the characteristic architecture 
of a type Ha RPTP. That is, chicken LAR contains three amino-terminal extracellular 
Immunoglobulin (Ig) domains followed by a number of fibronectin type III (FNIII) 
domains and paired, carboxy-terminal intracellular tyrosine phosphatase domains (Figure 
8.4A). Interestingly it was noted that CD-search only identified 7 FNIII repeats in chicken 
LAR. A similar number were identified in LAR orthologues from other species, whereas 
type 1 isoform PTPa and PTP8 clones were shown to have the expected 8 FNIII domains.
272It is also interesting to note that PTPa and PTP8 show significant conservation in the 
region between FNIII domain 7 and the transmembrane domain, which in these proteins 
contains an additional FNIII domain. In contrast, this region in LAR proteins shows 
substantial differences from the PTPa/8 consensus (Figure 8.5). Some domain analysis 
prediction algorithms predicted an eighth FNII domain in this region of LAR but with 
significant differences from the model FNIII domain (Data not shown).
Analysis of the completed chicken LAR cDNA revealed that with respect to 
previously reported type Ha RPTP alternatively spliced exons it is LASE-a/b/d negative, 
LASE-c/meC positive, meA/B negative (Zhang and Longo, 1995; Pulido et al., 1995a).
Secondly, phylogenetic comparison of the DNA sequence of the membrane 
proximal tyrosine phosphatase domain confirmed that chicken LAR was more closely 
related to LAR family members and particularly Fugu LAR than PTPa/8 family members 
(Figure 8.4B). The membrane proximal or sole tyrosine phosphatase domain was identified 
by comparison to the conserved domain database (Marchler-Bauer et al., 2005) tyrosine 
phosphatase consensus domain (CD00047.3/28929).
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274Figure 8.4: Domain and phylogenetic analysis of chick LARI
A.  The domain structure of chick LARI was predicted using CD-Search, which predicts 
domains in submitted proteins by comparison to protein domain databases. Each row 
indicates the results obtained using a different protein domain database. Blue boxes 
indicate type 2 Ig domains, green boxes indicate FN3 domains and the red boxes 
indicate cysteine-based PTP domains. The grey box indicates regions of low similarity 
to specific known domains. The orange-brown box indicates a low level of homology 
to a DSP type PTP domain.
B.  Phlyogenetic analysis of type II and related RPTPs based upon an alignment of 
membrane proximal or unique tyrosine phosphatase catalytic domains. Tyrosine 
phosphatase catalytic domains were defined according to the conserved domain 
database (CD00047.3). Alignment was performed using ClustalW (Thompson et al., 
1994) and phylogenetic trees drawn using Phylip and Treedraw. Scale bar represents 0.1 
substitutions per site. Chicken LAR is highlighted with a red arrow. PTP sequences 
used were as follows (Genbank accession numbers):
1.  LAR (Homo sapiens —  NM_002840, Mus musculus —  NM_011213.1, Rattus norvegicus —  
NM_019249, Danio rerio —  XM_684112, Xenopus laevis —  AF197945, Takifugu mbripes —  
NEWSINFRUG00000161578)
2.  PTP8 (H.sapiens —  NM_130391, M. musculus —  NM_001014288, R  Norvegicus —  
XM_233065, D. rerio XM_685632, G. gallus-XM_429156, X .laevis-AF197944
3.  PTPa (H.sapiens —  NM_002850, M. musculus —  NM_011218, JLnorvegicus —  LI 1587, G. 
gallus- NM_205407, X. laevis- AF198450, T. rubripes- NEWSINFRUG00000143678, 
D. rerio —  XM_695020
4.  Selected invertebrate RPTPs
a.  Stronglocentrotuspurpuratus unique type II RPTP -  XM_780807)
b.  C.  elegans PTP3 -  AF316539, CLR-1 -  AF047880
c.  Drosophila LAR -  AH006566, PTP52F -  NM_137249, DPTP69D -  
NM_176324
d.  Hirudo medicinalis HmLARl —  AF017084, HmLAR2 —  AF017083
275Lastly, the complete chicken LAR protein sequence was aligned with those of 
human PTPa, PTPS and LAR proteins (Figure 8.5). This confirmed that chicken LAR was 
indeed the chick LAR orthologue rather than a PTPa or PTPS family member. Previous 
work on different members of the type Ha family has identified several important sequence 
motifs. The identity of these residues in chicken LAR was analysed using an alignment 
(ClustalW) of the completed LAR sequence with the human type II RPTP paralogues. 
Firstly, a number of basic residues located in the first and second Ig domains of chick 
PTPa are important for binding to the only known type Ila ligand, heparan sulphate 
proteoglycans (Aricescu et al., 2002). These residues are absolutely conserved in chick LAR 
(Figure 8.5, red asterisks). Secondly, two arginine residues within a penta-arginine motif are 
essential for amino-terminal cleavage of human LAR (Serra-Pages et al., 1994). These 
residues are also present in chicken LAR (Figure 8.5, green asterisks, green arrow indicates 
cleavage site). However, the site at which human PTPa undergoes amino-terminal cleavage 
(Aicher et al., 1997) is not conserved in human or chicken LAR (Figure 8.5, blue arrow 
indicates cleavage site). Lastly, as mentioned above, the transmembrane cysteine seen in all 
PTPa or PTPS proteins, but which is absent in all LAR proteins is indeed lacking in 
chicken LAR (Figure 8.5, red text).
Although this gene has been named chicken LAR in accordance with current 
practice, it is acknowledged that it might now be more appropriate to rename these genes 
according to the system used for all other RPTPs. This was originally proposed in the 
paper that set forward the type 1-5 (now 8) classification for RPTPs, but was not acted 
upon (Fischer et al., 1991). In addition to simplifying the classification of PTPs, it is 
probably no longer appropriate to describe this gene by virtue of its similarity to the 
leucocyte common antigen or CD45. This analogy was initially made on the basis of the 
shared tandem phosphatase domains (Streuli et al., 1988). However, it is now apparent that 
as judged by this criterion, most RPTPs are at least as equally closely related to CD45 as is 
LAR. Thus, it may be argued that LAR genes should be renamed PTPf or RPTPf in 
accordance with the nomenclature used in the genome projects.
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280Figure 8.5 Alignment of chicken LAR translation with human type Ha RPTPs (Type I 
isoforms)
The translation of the complete, extrapolated chicken LAR coding sequence (clone 1  + 
ChEST-derived sequences) was compared to its human orthologue (Human LARI —  
Accession number: AAH48768.1) and type Ha paralogues (hRPTPal —  NP 002841.2; 
hRPTPSl —  NP 002830.1) using the ClustalW program (Thompson et al., 1994). The site 
of the transmembrane cysteine that is conserved in LAR orthologues (Chick LARI  1273) 
but which is replaced with isoleucine or leucine in all PTPa or PTPS orthologues is 
highlighted in BJ. The basic sites (Human RPTPal  K68, K69, K71, K72; R97, R100) 
required for chick PTPa binding to heparan sulphate proteoglycans (Aricescu et al., 2002) 
are marked by red asterisks (*) above the sequence. The arginine residues (Chick LARI 
R1166, R1169) required for amino-terminal cleavage are marked by green asterisks (*) and 
the amino-terminal cleavage site (Chick LARI  R1169/Q1170) is marked with a green 
arrow (^) (Serra-Pages et al., 1994). Finally, the site at which human PTPa (Human 
RPTPal  P I275/11276) undergoes carboxy-terminal cleavage site (Aicher et al., 1997) is 
marked with a blue arrow (^).
Known alternatively spliced exons present in type Ha RPTPs are marked as follows: 
meA e.g. human PTPS aa: 181-189 (Pulido et al., 1995a). 
meB e.g. human PTPS aa: 227-230 (Pulido et al., 1995a).
LASE-a e.g. human PTPa aa: 1351-1366 (Zhang and Longo, 1995).
LASE-b e.g. human PTPa aa: 1310-1313 (Zhang and Longo, 1995).
2818.3: Discussion
This chapter describes the cloning of the third member of the chick type Ha RPTP 
subfamily, chick LAR (RPTPf). Several unsuccessful attempts to clone the chick LAR 
cDNA were described, with the cDNA finally being obtained using long and accurate RT- 
PCR. Two independent clones were obtained to allow the accurate determination of the 
chick LAR sequence. Two sequence variations were identified between the two clones but 
comparison to EST databases suggested that these represented amplification errors in 
clone 2 rather than genuine polymorphisms. The LAR clones encode the full-length or type 
1 LAR isoform containing three extracellular amino-terminal immunoglobulin domains and 
7 fibronectin type III repeats followed by the intracellular tandem tyrosine phosphatase 
domains. Phylogenetic analysis of the chick LAR gene confirmed that it was a member of 
the LAR sub-family, being most closely related to the Takifugu rubripes LAR protein. The 
LAR clones isolated are not complete and EST clones that will allow their completion are 
listed in the text.
As mentioned above, the cloning of LAR was problematic. Several possible 
explanations present themselves. Initial experiments were carried out using an existing 
cDNA library. The probe used for the initial library screen did not prove on final analysis 
to come from the chicken LAR gene. However, it did not prove possible to isolate LAR 
from the library even using the primers that were finally successful in cloning LAR. This 
suggests either that LAR was not expressed at a high enough level in the tissue of origin of 
the library or that the cDNAs were not long enough to span the 5 kilobase gap between 
the primer binding sites. As the library has previously been used to clone PTPa and other 
similarly large genes, it is likely that LAR was not present in the library (Personal 
communication, R. Aricescu). The high degree of similarity between PTPa and LAR 
probably explains why on low stringency screens, PTPa was cloned with LAR specific 
primers. Although, LAR expression data is not available in the chick, analysis of data in 
other species suggests that many tissues express a combination of the type Ha RPTPs. 
However, in many tissues the expression level of PTPa in particular is significandy higher 
than that of LAR. It is notable that the original cloning strategy used to isolate 
CRYPa/chick PTPa used a LAR probe. Thus, the difference in expression level between 
PTPa and LAR in chick embryos has previously resulted in the preferential isolation of 
PTPa rather than LAR cDNAs (Stoker, 1994).
282As described above, previous work on different members of the type Ha family has 
identified several important sequence motifs (Figure 8.5). Firsdy, the binding site that is 
responsible in chick PTPa for heparan sulphate proteoglycan binding is conserved 
(Aricescu et al., 2002). This suggests that chick LAR is able to bind heparin sulphate and 
therefore is likely to utilise the same (or closely related) physiological ligands as PTPa. The 
ability of chicken LAR to bind HSPGs is easily assessable using the Receptor Affinity 
Probe system previously used to identify chick PTPa as an HSPG-binding protein. It will 
be interesting to determine whether chick LAR, PTPa and PTPS bind the same ligands or 
have distinct specificities for different HSPGs.
Secondly, the furin-like amino-terminal proteolytic site (Serra-Pages et al., 1994) in 
LAR proteins is conserved suggesting that like other type II RPTPs, chick LAR will be 
subject to this kind of cleavage event. However, the region containing the carboxy-terminal 
metalloprotease type site in human PTPa (Aicher et al., 1997) whilst highly conserved in all 
PTPa and PTPS proteins is not conserved in human or chick LARI. Human LAR protein 
undergoes shedding in an analogous manner to that of human PTPa (Streuli et al., 1992). It 
is may therefore be suggested that LAR carboxy-terminal cleavage is mediated by different 
mechanisms than that of PTPa or PTPS. However, the metalloproteases responsible for 
cleavage at this site do not have canonical cleavage sites and indeed do not always cleave at 
a specific site. Their specificity seems to be directed at a set distance from the plasma 
membrane rather than an amino acid sequence. Therefore, LAR cleavage may utilise the 
same enzymes despite the significant sequence variations.
Lastly, the transmembrane cysteine seen in all PTPa or PTPS proteins, but which is 
absent in all LAR proteins is indeed lacking in chick LARI. Although mutational analysis of 
this residue in chick PTPa did not show a role for this residue in the formation of high 
molecular weight species by wild type PTPa, its striking pattern of conservation merits 
further study when the mechanism of type Ha RPTP dimerisation is better understood.
The sequence of chicken LAR, together with those of the previously determined 
chick PTPS and PTPa proteins will be important in the development of the understanding 
of the combinatorial role of the type II RPTPs. It has so far been very difficult to 
determine the role PTPs play in axon guidance. In different projections, they may play 
opposing roles and disruption of individual family members often has very little effect. The 
chick retinotectal projection is a well-known model for axon guidance. The ability to
283manipulate all 3 members of an RPTP subfamily in an accessible system may help clarify 
the type of role PTPs play in cell signaling.
284Chapter 9; Final discussion
The work in this thesis may be divided into three main categories. It was shown for 
the first time that a type Ha RPTP forms dimers in cell membranes (Lee et al., 2006a). In 
addition, the processing and quaternary structure of PTPa was investigated. These data 
raised a number of interesting possibilities and suggested a new model for type Ha RPTP 
function. Secondly, a number of pilot experiments were conducted to identify the 
biochemical pathways with which PTPa interacts. Unfortunately, no PTPa-interacting 
proteins were identified. However, in agreement with studies on the type IV RPTP, PTPa, 
PTPa was shown to form high molecular weight species in response to H20 2  treatment. It 
may be possible to adapt this finding to produce a useful assay that can in turn be used to 
follow the effects of other manipulations on PTPa. In addition, the final member of the 
chick type Ha RPTP family was cloned to permit future experiments where members of 
the type Ha RPTP family are perturbed individually or in combination.
A large proportion of PTPa was shown to be dimeric using the disulphide 
crosslinking technique (4.3). Although this may reflect a dominant effect of the ectopic 
cysteine residues, the finding that wild type PTPa co-immunoprecipitates in the absence of 
any cellular treatments suggests that dimerisation is an important part of PTPa function 
(Chapter 5). However, it has proven difficult to discover what effect dimerisation has on 
PTPa function or indeed, whether mature PTPa is constitutively dimeric. Preliminary 
experiments suggested that heparin sulphate, a putative PTPa ligand that binds to the 
PTPa extracellular domain, does not affect the degree of PTPa dimerisation (6.5). 
However, it has recently been shown that heparin sulphate ligands only bind to the dimeric 
form of PTPa. Therefore, it is possible that some PTPa ligands do not affect PTPa 
dimerisation per se but rather have allosteric effects on the conformation of receptor dimers 
or perhaps facilitate the presentation of an as yet unidentified ligand to the PTPa dimer.
This thesis also presented some interesting findings with regard to type Ha RPTP 
cleavage. Firstly, in agreement with other studies, amino-terminal cleavage was shown to be 
dispensible for subsequent carboxyl-terminal cleavage or ectodomain shedding. In addition, 
carboxyl-terminal cleavage alone was shown to be insufficient for ectodomain shedding. 
This suggests that either an additional cleavage event or a conformational change is 
required for ectodomain shedding. It is of note that y-secretase cleavage has recently been 
shown to play a role in PTPk processing, although not in PTPk ectodomain shedding
285(Anders et al., 2006). It may prove possible using PTPa mutants to dissect the molecular 
determinants and mechanism of RPTP ectodomain shedding.
The sensitivity of PTPa species to extracellular trypsin suggested that a significant 
proportion of the E8 1  species, which is produced by amino-terminal cleavage, is located 
inside the cell. In contrast, most of the E^ species and the full length PTPa appeared to be 
located at the cell surface, whether in the monomeric or dimeric form (4.2.2, 3.2.2). The 
PTPa dimers described above contained exclusively either full-length PTPa or 
proteolytically cleaved forms and full-length/cleaved heterodimers were not seen. 
Therefore, either PTPa cleavage must affect both dimer subunits essentially simultaneously 
or only monomeric PTPa is susceptible to cleavage, with the cleaved subunits retaining the 
potential of the parent molecule to form dimers.
These data suggest a model where full length PTPa (FL1 6 6 ) is expressed on the cell 
surface where it exists in an equilibrium between a dimeric and monomeric form, the 
balance of which may be determined by factors including ligand binding. In response to an 
undefined stimulus, FL166 is internalised in association with the amino-terminal cleavage 
event producing E8 1  and P85. This may occur either immediately before internalisation, 
possibly stimulating PTPa internalisation or may be an intracellular event. A significant 
proportion of E8t is retained in an intracellular site. Separately, PTPa is subject to carboxyl- 
terminal cleavage to generate E(X ) and P75. This occurs at the cell surface and is associated 
with ectodomain shedding but is not alone sufficient for this process. It remains unclear 
whether molecules initially cleaved at one site are secondarily subject to cleavage at the 
other, although this is likely.
Lastly, it will be of interest to fully characterise the alternatively spliced isoforms 
and the expression pattern of chick LAR. Indeed, it would also be of value to complete the 
isoform specific expression pattern studies of chick PTPa and PTPS. At the current time, 
despite their multiple isoforms that may have distinct functional properties, studies 
generally only consider a single or at most two species. The chicken LAR clone 1 cDNA 
was submitted directly to Genbank as Gallus gallus receptor  protein tyrosine phosphatase L A R  
mRsNA,partialcds (Accession number pending).
Several future lines of work are suggested by this thesis. Firstly, the significance of 
PTPa processing should not be underestimated. Therefore, PTPa cleavage and 
dimerisation need further characterisation, with particular emphasis on the effects of ligand
286PTPa. It may be that simple assays such as formation of high molecular weight species may 
provide some insight into the effects of empirical manipulation on PTPa dimerisation or 
conformation. Secondly, it will be important to identify the substrates and pathways with 
which PTPa interacts. This will also facilitate the study of the effects of dimerisation or 
ligand binding on PTPa function. Current approaches modelled on the functional 
behaviour of tyrosine kinases have only been of limited value. It may be that alternative 
approaches are needed to identify the function of PTPa.
The work described in this thesis was presented in a recent publication that 
addressed one of the fundamental issues in the RPTP field —  how ligand binding is affected 
by RPTP dimerisation. This paper included the disulphide crosslinking and co- 
immunoprecipitation analysis of PTPa dimerisation presented in this thesis. In addition, 
data from other researchers was used to refine the dimer interface to the transmembrane 
domain and to demonstrate the effects of dimerisation on the PTPa-ligand interaction. In 
this paper, it was reported for the first time that PTPa exists in a dimeric state within cells. 
In addition, it was shown that only dimeric PTPa is able to bind the heterophilic basement 
membrane and muscle ligands, and that the ligand binding specificities of the short PTPal 
and longer PTPa2 isoforms are not due to a straightforward relationship between ligand 
binding and domain structure. Instead, it was proposed that the different patterns of type 
II RPTP ligand binding might reflect different rotational conformations of the dimerised 
extracellular domains (Lee et al., 2006a). This model of rotational conformers was first 
proposed in a previous PhD thesis (Chilton, 2000).
287Appendix 1: cLAR DNA sequences
LAR clone 1 —  p289 
LAR clone 2 —  p296
The two sequence variations between LAR clone 1  (bp 2054, 2452) and LAR clone 2 (bp 
1923, 2321) are highlighted in red. The region of the LAR clones derived from the 
oligonucleotide primers is in italics and underlined.
5’ EST clone -  p302
Sequence derived from chick EST (ChEST35h5) in publicly available UMIST/BBSRC 
database to extend 5’ end of LAR clone 1  to include initiation codon, which is highlighted 
in red.
3’ EST clone - p302
Sequence derived from chick EST (ChEST371m20) in publicly available UMIST/BBSRC 
database to extend 3’ end of LAR clone 1  to include stop codon, which is highlighted in
red.
288LAR Clone 1
10  20  30  40  50
GTTTGATGAT  GGGTCGGGAT  CTGTTCTGCG  GATACAGCCG  CTGCGTGTCC 
60  70  80  90  100
ATCGAGACGA  AGCCATCTAC  GAGTGCACGG  CCACCAACAG  CGTTGGGGAG 
110  120  130  140  150
ATAAACACAA  GTGCCAAATT  AACAGTGTTA  GAAGAAGACC  ACCTCCCAGC 
160  170  180  190  200
TGGCTTCCCA  ACCATTGATA  TGGGCCCGCA  GCTGAAGGTG  GTGGAGAAGG 
210  220  230  240  250
CCCGCACAGC  CACGATGCTC  TGTGCTGCCA  GTGGTAACCC  CGATCCCGAA 
260  270  280  290  300
ATCTCCTGGT  TCAAGGACTT  CCTGCCTGTt  GACACTGCAA  CTAGCAATGG 
310  320  330  340  350
GAGAATCAAG  CAGCTCCGCT  CGGGAGCTCT  GCAAATAGAG  AACAGCGAGG 
360  370  380  390  400
AGTCGGACCA  AGGCAAATAT  GAATGTGTTG  CAACCAACAG  CGCAGGAACC 
410  420  430  440  450
CGTTATTCTG  CCCCGGCGAA  CCTGTATGTT  CGAGTGCGGC  GTGTTGCTCC 
460  470  480  490  500
TCGATTCTCA  ATCCCTCCGA  GCAACCACGA  GGTGATGCCT  GGAGGGAGCG 
510  520  530  540  550
TGAACCTCAC  GTgCGTgGCA  GTAGGTGCCC  CCATGCCCTA  CGTGAAGTGG 
560  570  580  590  600
ATGGCTGGTG  TGGAGGAGCT  GACCAAAGAG  GATGAGATGC  CCGTCGGCCG 
610  620  630  640  650
GAACgTGCTg  GAGCTGAACA  ACATCATGCA  GTCCGCCGAC  TACACCTGTG 
660  670  680  690  700
TGGCCATCTC  TTCCCTCGGC  ATGATCGAAG  CAACGGCCCA  GATCACTATC 
710  720  730  740  750
AAAGCGCTGC  CAAAACCTCC  AACAGAGCCA  TTAGTGACTG  AAACGACAGC 
760  770  780  790  800
TACCAGCGTG  ACCCTCACCT  GGGATTCAGG  CAACTCCGAC  CCCATTTCAT
289LAR  C lon e  1  (ctd )
810  820  830  840  850
ATTACGTCAT  CCAGTACAAG  CCCAAATCCT  TGGAGGGTCA  GTTCCAGGAG 
-   860  870  880  890  900
GTGGACGGTG  TGGCGACAAC  CCGTTATAGC  ATAGGTGGGC  TCAGCCCCTT 
910  920  930  940  950
CTCGGAGTAC  GAGTTCCGGG  TCATTGCAGT  CAATAACATT  GGCAGGGGCC
960  970  980  990  1000
CCCCCAGCGA  GCTGGTCGAG  GCCCGGACAG  GAGAGCAAGC  TCCTTCAAGT
1010  1020  1030  1040  1050
CCACCCCTCA  AAGTCCAGGC  GCGGATGCTG  AGTGCCAGCA  CCATGCTGGT
1060  1070  1080  1090  1100
CCAGTGGGAG  CAGCCAGAGG  AGCCAAATGG  ACAGATCCGA  GGGTACCGCG
1110  1120  1130  1140  1150
TTTACTACAC  CACCGACTCG  CATCTGCCTT  CGAGCATGTG  GCAAAAACAC
1160  1170  1180  1190  1200
AACACCGACG  ACAGCCATCT  CACCACTGTT  GGGAGCCTCA  TCACAGGGAC
1210  1220  1230  1240  1250
CACATACAGC  ATCCGTGTCC  TGGCCTTCAC  TTCGGTGGGC  GACGGGCCGC
1260  1270  1280  1290  1300
CCTCGGACAT  CATCCAGGTC  AAAACGCAGC  AAGGAGTTCC  TGCCCAGCCA
1310  1320  1330  1340  1350
GCTGACTTCC  AGGCAGAGGC  AGAGTCTGAT  ACCCGCATCC  TGCTGACGTG
1360  1370  1380  1390  1400
GCTGCCTGCC  TCTCAGGAAC  GCATTACCAA  ATATGAGCTG  CTGTACTGGG
1410  1420  1430  1440  1450
AAGGAGAGGA  CGGTGTTCAG  CAAAAAGTGG  AGTTTGACCC  AACCTCCTCG
1460  1470  1480  1490  1500
TATGCTGTGG  AAGGTCTCGA  ACCAGACACG  CTGTACAAGT  TCCGGCTGGG
1510  1520  1530  1540  1550
TGCCCACTCT  GAGCTGGGGG  TAGGAGTCTA  CACCCCAACT  GTGGAAGCCA
1560  1570  1580  1590  1600
GAACTGCCCA  ATCCACCCCT  TCTGCCCCAC  CCCAAGAAGT  CGAGTGTGTA
1610  1620  1630  1640  1650
AGCACCAGCT  CCACTACCAT  CCGGGTAAGT  TGGGTGCCAC  CGCCTGCACA
290LAR  C lon e  1  (ctd )
1660  1670  1680  1690  1700
GAGCCGCAAT  GGGGTCATCA  CCCAGTACTC  CATTGCGTAC  CAGGCAGTGG
1710  1720  1730  1740  1750
AAGGAGATGA  CAGCACCAAG  CATGTGGTGG  ATGGCATTGG  ACGGGAGCAC
1760  1770  1780  1790  1800
TCCAGCTGGG  AGATCAAGGA  CCTGGAGAAA  TGGACCGAGT  ACAAGGTGTG
1810  1820  1830  1840  1850
GGTAAGGGCT  CACACCGATG  TGGGGCCAGG  ACCGGAGAGC  ATCCCCGTGC
1860  1870  1880  1890  1900
ACGTGCGCAC  TGATGAGGAT  GTGCCCAGTG  CCCCACCACG  AAAGGTGGAG
1910  1920  1930  1940  1950
GTGGAGTCCG  TGAATTCAAC  AGCCATCCGG  GTGAGCTGGA  AGCTGCCCAT
1960  1970  1980  1990  2000
CTCCAACAAG  CAGCATGGGC  AGATCCGGGG  CTACCAGGTG  ACCTACGTGA
2010  2020  2030  2040  2050
AGCTGGAAAA  CAACGAGCCC  CGCGGGCAGC  CCGTCATCAA  GGACGTCATG
2060  2070  2080  2090  2100
CTGTCGGAAG  CACAGTGGAG  AGCTGAGGAC  TCCGTCGACC  ATGAGACGGT
2110  2120  2130  2140  2150
CATTGGAGGC  CTGCTGCCGG  AAACCACCTA  CTCCGTCACA  GTCGCTGCCT
2160  2170  2180  2190  2200
ACACAACCAA  GGGAGATGGT  GCCCGCAGCA  AGCCCAAGGT  CATCACCACC
2210  2220  2230  2240  2250
ACAGGGGCAG  TCCCGGGGAA  GCCCACCATG  ATGATTAGCA  CGACAGCCAT
2260  2270  2280  2290  2300
GAACACAGCC  CTCATCCAGT  GGCACCCACC  CAAGGAGATG  GTAGGGGAGC
2310  2320  2330  2340  2350
TGCTGGGTTA  CCGGCTGCAG  TACAGACGTC  TTGATGAgGA  AAAGATGAAC
2360  2370  2380  2390  2400
ACGATAGACT  TCGGGAAGAG  AGACCATCAC  TACACTGTGA  CCAACTTGCA
2410  2420  2430  2440  2450
CAAGGGGGCC  ACGTACCTCT  TCAGACTGTC  TGCCAAGAAC  AGAGCTGGTC
2460  2470  2480  2490  2500
CAGGAGAGGA  GTTTGAGAAG  GAGATCACTA  CCGCAGAAGA  CGTGCCGAGT
291LAR  C lon e  1  (ctd )
2510  2520  2530  2540  2550
GGATTCCCAC  AGAACCTGCG  CGTGGTGGGC  CTCACCACTT  CCACCACAGA
2560  2570  2580  2590  2600
GGTTGCATGG  GACCCCCCAG  TCTTGGCGGA  AAGAAACGGC  AAGATTGTCA
2610  2620  2630  2640  2650
ACTACACAGT  GGTATACAGA  GACATAAATA  GCCAGCAGGA  CCTGGTTAAC
2660  2670  2680  2690  2700
ATCACCAAGG  ACACAAGTAT  CACTTTGACG  AATTTGAAGC  CTGATACCAC
2710  2720  2730  2740  2750
TTATGACATC  AAAGTGAGGG  CCCGCACCAA  TAAGGGGGTT  GGGCCGCTCA
2760  2770  2780  2790  2800
GCCCCAGCAT  CCAGTCCCGG  ACCATGCCTG  TTGAGCAAGT  GTTTGCTAAG
2810  2820  2830  2840  2850
AACTTCCGTG  TCAACGCCGT  CATGAAAACA  TCCGTGTTGC  TGAGCTGGGA
2860  2870  2880  2890  2900
AGTGCCTGAC  TCCTATAAAT  CTGCAGTGCC  TTTTAAGATT  CTGTACAACA
2910  2920  2930  2940  2950
GCCAGAGTGT  GGAGGTGGAC  GGCTACTCCA  TGAAGAAGCT  CATAAGTGAC
2960  2970  2980  2990  3000
CTCCAGCCAG  ACACGGACTA  CTCTTTTGTG  CTCATGAACC  GTGGGAACAG
3010  3020  3030  3040  3050
TGCTGGGGGG  CTCCAGCACC  TCGTCTCCAT  CCGCACTGCG  CCTGACGTCT
3060  3070  3080  3090  3100
TGCAAAGCAA  ACCCATTGCC  ACCAACAAGT  ATATCCAGGA  AGGAAAGTTC
3110  3120  3130  3140  3150
ACGCTTACCC  TTCCCAAAGT  GCAGACCACT  GTGCCAGTTC  GGTGGTACTA
3160  3170  3180  3190  3200
CATTGTGGTC  GTGCCGGCAG  AGCAGAGCCC  CAGCAGCCCG  ACAGCGCGGT
3210  3220  3230  3240  3250
GGCGGACGCC  TGATGAGATG  GAGCTGGACC  AGCTGCTGGA  GGCCATAAGC
3260  3270  3280  3290  3300
CAGGGCAGTC  AGAGCAGGCG  CCAGAGACGC  CAAGCAGACA  GACTCAAGCC
3310  3320  3330  3340  3350
CTACATTGCT  GCCCAAGTGG  ACGTGCTGCC  CGAGACCTTC  ACCCTGGGGG
292LAR  C lon e  1  (ctd )
3360  3370  3380  3390  3400
ACGAGAAGAA  CTACAAGGGT  TTCTACAACA  AGCCCCTCTC  TCAGGACCTG
3410  3420  3430  3440  3450
AGCTACCGCT  GCTTCGTGCT  GGCCTCGCTG  GAGGATGGGG  ACACGAAGAG
3460  3470  3480  3490  3500
ATACGCAGCC  AGCCCCTACT  CAGATGAGAT  TGTGATGGAA  TTGGCTTCAG
3510  3520  3530  3540  3550
CAAAGCAGCA  GGATGAGCCA  GAGATGCTGT  GGGTGATGGG  ACCTGTCCTG
3560  3570  3580  3590  3600
GCTGTGATAT  TAATCATCAT  CATCGTCATC  GCTATACTCC  TCTTCAAAAG
3610  3620  3630  3640  3650
GAAAAGAGCA  CACTCCCCCT  CTTCCAAAGA  TGAGCACTCT  ATTGGCCTGA
3660  3670  3680  3690  3700
AGGACTCGCT  CTTGGCCCAC  TCCTCTGACC  CGGTTGAGAT  GAGGCGGCTC
3710  3720  3730  3740  3750
AACTACCAGA  CTCCAGGCAT  GCGGGACCAC  CCGCCCATCC  CCGTGACCGA
3760  3770  3780  3790  3800
CCTCGCCGAC  AACATCGACC  GGCTGAAGGC  CAACGATGGC  CTCAAGTTCT
3810  3820  3830  3840  3850
CCCAGGAGTA  CGAGTCCATC  GATCCCGGGC  AGCAGTTCAC  GTGGGAGAAC
3860  3870  3880  3890  3900
TCCAACCTGG  AAGTAAACAA  ACCGAAAAAC  CGCTATGCAA  ACGTGATCGC
3910  3920  3930  3940  3950
CTACGATCAC  TCCCGCGTCA  TCCTGACCTC  CATCGATGGG  GCCCCAGGCA
3960  3970  3980  3990  4000
GCGATTACAT  CAACGCCAAT  TACATCGACG  GCTATAGGAA  GCAGAACGCC
4010  4020  4030  4040  4050
TACATCGCGA  CGCAGGGACC  TCTGCCTGAA  ACCCTCAGTG  ACTTCTGGAG
4060  4070  4080  4090  4100
AATGGTGTGG  GAGCAGAGAA  CAGCAACGAT  CGTCATGATG  ACCAGGCTGG
4110  4120  4130  4140  4150
AGGAGAAGTC  CAGGGTGAAG  TGTGACCAGT  ACTGGCCGAG  CCGGGGTACA
4160  4170  4180  4190  4200
GAAACCTACG  GGATGATCCA  GGTTACACTG  CTGGACACCG  TTGAGCTGGC
293LAR  C lon e  1  (ctd )
4210  4220  4230  4240  4250
GACCTACACA  GTCCGAACCT  TTGCCCTGTA  CAAGAACGGC  TCCAGCGAGA
4260  4270  4280  4290  4300
AGCGAGAGCT  GCGACAGTTC  CAGTTCATGG  CATGGCCTGA  TCACGGGGTC
4310  4320  4330  4340  4350
CCAGAATACC  CCACCCCAAT  CCTCGCTTTC  CTGCGGCGGG  TCAAGGCCTG
4360  4370  4380  4390  4400
CAACCCACCC  GATGCTGGGC  CCATGGTTGT  CCATTGCAGT  GCTGGCGTGG
4410  4420  4430  4440  4450
GCCGAACTGG  TTGCTTCATT  GTCATTGATG  CCATGCTGGA  GAGGATGAAG
4460  4470  4480  4490  4500
CATGAGAAGA  CCGTGGACAT  CTACGGGCAC  GTGACGTGCA  TGCGCTCGCA
4510  4520  4530  4540  4550
GCGCAACTAC  ATGGTGCAGA  CAGAGGACCA  GTACATCTTC  ATCCACGAGG
4560  4570  4580  4590  4600
CCCTGCTGGA  GGCAGCCACG  TGCGGCAATA  CCGAGGTGCC  TGCACGCAAC
4610  4620  4630  4640  4650
CTCTTCGCTC  ACATCCAGAA  ACTGACCCAG  GTGCCTCCAG  GAGAGAGCGT
4660  4670  4680  4690  4700
CACTGCGATG  GAGCTGGAAT  TCAAGCTGCT  GGCCAACTCT  AAAGCACATA
4710  4720  4730  4740  4750
CCTCACGTTT  CATCAGTGCC  AACCTCCCAT  GCAACAAATT  CAAGAACCGC
4760  4770  4780  4790  4800
CTCGTGAACA  TCATGCCATA  CGAGCTGACA  AGAGTCTGCC  TGCAGCCCAT
4810  4820  4830  4840  4850
CCGGGGTGTT  GAGGGCTCTG  ATTACATCAA  TGCCAGCTTC  ATTGATGGGT
4860  4870  4880  4890  4900
ACAGGCAGCA  GAAGGCCTAC  ATTGCCACGC  AGGGACCACT  GGCCGAGACC
4910  4920  4930  4940  4950
ACAGAAGATT  TCTGGCGAAT  GCTCTGGGAG  CACAACTCCA  CCATTGTGGT
4960  4970  4980  4990  5000
GATGTTGACA  AAGCTGCGTG  AGATGGGCCG  GGAGAAGTGC  CATCAGTACT
5010  5020  5030  5040  5050
GGCCTGCGGA  GCGCTCTGCC  CGTTACCAGT  ACTTCGTGGT  GGACCCCATG
294LAR  C lon e  1  (ctd )
5060  5070  5080  5090  5100
GCAGAGTACA  ACATGCCGCA  GTACATCCTC  CGGGAGTTCA  AAGTCACAGA
5110  5120  5130  5140  5150
TGCCAGGGAC  GGCCAGTCAC  GGACCATCCG  CCAGTTCCAG  TTCACAGACT
5160  5170  5180  5190  5200
GGCCTGAGCA  GGGAGTGCCA  AAGACGGGAG  AGGGCTTCAT  CGACTTCATT
5210  5220  5230  5240  5250
GGGCAGGTGC  ACAAGACCAA  GGAGCAGTTT  GGTCAGGACG  GGCCCATCAC
5260  5270  5280  5290  5300
GGTGCACTGC  AGCGCTGGGG  TCGGGCGCAC  GGGCGTGTTC  ATCACACTGA
5310  5320  5330  5340  5350
GCATCGTGCT  GGAGAGGATG  CGCTACGAGG  GGGTGGTGGA  CATGTTCCAG 
5360  5370  5380
A C G G TG A A G A   CTTTGCGGAC  GCAGCGGCCGG
295LAR Clone 2
10  20  30  40  50
AAGAAGACCA  CCTCCCAGCT  GGCTTCCCAA  CCATTGATAT  GGGCCCGCAG 
60  70  80  90  100
CTGAAGGTGG  TGGAGAAGGC  CCGCACAGCC  ACGATGCTCT  GTGCTGCCAG 
110  120  130  140  150
TGGTAACCCC  GATCCCGAAA  TCTCCTGGTT  CAAGGACTTC  CTGCCTGTTG 
160  170  180  190  200
ACACTGCAAC  TAGCAATGGG  AGAATCAAGC  AGCTCCGCTC  GGGAGCTCTG 
210  220  230  240  250
CAAATAGAGA  ACAGCGAGGA  GTCGGACCAA  GGCAAATATG  AATGTGTTGC 
260  270  280  290  300
AACCAACAGC  GCAGGAACCC  GTTATTCTGC  CCCGGCGAAC  CTGTATGTTC 
310  320  330  340  350
GAGTGCGGCG  TGTTGCTCCT  CGATTCTCAA.TCCCTCCGAG  CAACCACGAG 
360  370  380  390  400
GTGATGCCTG  GAGGGAGCGT  GAACCTCACG  TGCGTGGCAG  TAGGTGCCCC 
410  420  430  440  450
CATGCCCTAC  GTGAAGTGGA  TGGCTGGTGT  GGAGGAGCTG  ACCAAAGAGG 
460  470  480  490  500
ATGAGATGCC  CGTCGGCCGG  AACGTGCTGG  AGCTGAACAA  CATCATGCAG 
510  520  530  540  550
TCCGCCGACT  ACACCTGTGT  GGCCATCTCT  TCCCTCGGCA  TGATCGAAGC 
560  570  580  590  600
AACGGCCCAG  ATCACTATCA  AAGCGCTGCC  AAAACCTCCA  ACAGAGCCAT 
610  620  630  640  650
TAGTGACTGA  AACGACAGCT  ACCAGCGTGA  CCCTCACCTG  GGATTCAGGC 
660  670  680  690  700
AACTCCGACC  CCATTTCATA  TTACGTCATC  CAGTACAAGC  CCAAATCCTT 
710  720  730  740  750
GGAGGGTCAG  TTCCAGGAGG  TGGACGGTGT  GGCGACAACC  CGTTATAGCA 
760  770  780  790  800
TAGGTGGGCT  CAGCCCCTTC  TCGGAGTACG  AGTTCCGGGT  CATTGCAGTC
296LAR  C lon e  2  (Ctd)
810  820  830  840  850
AATAACATTG  GCAGGGGCCC  CCCCAGCGAG  CTGGTCGAGG  CCCGGACAGG 
860  870  880  890  900
AGAGCAAGCT  CCTTCAAGTC  CACCCCTCAA  AGTCCAGGCG  CGGATGCTGA 
910  920  930  940  950
GTGCCAGCAC  CATGCTGGTC  CAGTGGGAGC  AGCCAGAGGA  GCCAAATGGA
960  970  980  990  1000
CAGATCCGAG  GGTACCGCGT  TTACTACACC  ACCGACTCGC  ATCTGCCTTC
1010  1020  1030  1040  1050
GAGCATGTGG  CAAAAACACA  ACACCGACGA  CAGCCATCTC  ACCACTGTTG
1060  1070  1080  1090  1100
GGAGCCTCAT  CACAGGGACC  ACATACAGCA  TCCGTGTCCT  GGCCTTCACT
1110  1120  1130  1140  1150
TCGGTGGGCG  ACGGGCCGCC  CTCGGACATC  ATCCAGGTCA  AAACGCAGCA
1160  1170  1180  1190  1200
AGGAGTTCCT  GCCCAGCCAG  CTGACTTCCA  GGCAGAGGCA  GAGTCTGATA
1210  1220  1230  1240  1250
CCCGCATCCT  GCTGACGTGG  CTGCCTGCCT  CTCAGGAACG  CATTACCAAA
1260  1270  1280  1290  1300
TATGAGCTGC  TGTACTGGGA  AGGAGAGGAC  GGTGTTCAGC  AAAAAGTGGA
1310  1320  1330  1340  1350
GTTTGACCCA  ACCTCCTCGT  ATGCTGTGGA  AGGTCTCGAA  CCAGACACGC
1360  1370  1380  1390  1400
TGTACAAGTT  CCGGCTGGGT  GCCCACTCTG  AGCTGGGGGT  AGGAGTCTAC
1410  1420  1430  1440  1450
ACCCCAACTG  TGGAAGCCAG  AACTGCCCAA  TCCACCCCTT  CTGCCCCACC
1460  1470  1480  1490  1500
CCAAGAAGTC  GAGTGTGTAA  GCACCAGCTC  CACTACCATC  CGGGTAAGTT
1510  1520  1530  1540  1550
GGGTGCCACC  GCCTGCACAG  AGCCGCAATG  GGGTCATCAC  CCAGTACTCC
1560  1570  1580  1590  1600
ATTGCGTACC  AGGCAGTGGA  AGGAGATGAC  AGCACCAAGC  ATGTGGTGGA
1610  1620  1630  1640  1650
TGGCATTGGA  CGGGAGCACT  CCAGCTGGGA  GATCAAGGAC  CTGGAGAAAT
297LAR  C lon e  2  (Ctd)
1660  1670  1680  1690  1700
GGACCGAGTA  CAAGGTGTGG  GTAAGGGCTC  ACACCGATGT  GGGGCCAGGA
1710  1720  1730  1740  1750
CCGGAGAGCA  TCCCCGTGCA  CGTGCGCACT  GATGAGGATG  TGCCCAGTGC
1760  1770  1780  1790  1800
CCCACCACGA  AAGGTGGAGG  TGGAGTCCGT  GAATTCAACA  GCCATCCGGG
1810  1820  1830  1840  1850
TGAGCTGGAA  GCTGCCCATC  TCCAACAAGC  AGCATGGGCA  GATCCGGGGC
1860  1870  1880  1890  1900
TACCAGGTGA  CCTACGTGAA  GCTGGAAAAC  AACGAGCCCC  GCGGGCAGCC
1910  1920  1930  1940  1950
CGTCATCAAG  GACGTCATGC  TGCCGGAAGC  ACAGTGGAGA  GCTGAGGACT
1960  1970  1980  1990  2000
CCGTCGACCA  TGAGACGGTC  ATTGGAGGCC  TGCTGCCGGA  AACCACCTAC
2010  2020  2030  2040  2050
TCCGTCACAG  TCGCTGCCTA  CACAACCAAG  GGAGATGGTG  CCCGCAGCAA
2060  2070  2080  2090  2100
GCCCAAGGTC  ATCACCACCA  CAGGGGCAGT  CCCGGGGAAG  CCCACCATGA
2110  2120  2130  2140  2150
TGATTAGCAC  GACAGCCATG  AACACAGCCC  TCATCCAGTG  GCACCCACCC
2160  2170  2180  2190  2200
AAGGAGATGG  TAGGGGAGCT  GCTGGGTTAC  CGGCTGCAGT  ACAGACGTCT
2210  2220  2230  2240  2250
TGATGAGGAA  AAGATGAACA  CGATAGACTT  CGGGAAGAGA  GACCATCACT
2260  2270  2280  2290  2300
ACACTGTGAC  CAACTTGCAC  AAGGGGGCCA  CGTACCTCTT  CAGACTGTCT
2310  2320  2330  2340  2350
GCCAAGAACA  GAGCTGGTCC  GGGAGAGGAG  TTTGAGAAGG  AGATCACTAC
2360  2370  2380  2390  2400
CGCAGAAGAC  GTGCCGAGTG  GATTCCCACA  GAACCTGCGC  GTGGTGGGCC
2410  2420  2430  2440  2450
TCACCACTTC  CACCACAGAG  GTTGCATGGG  ACCCCCCAGT  CTTGGCGGAA
2460  2470  2480  2490  2500
AGAAACGGCA  AGATTGTCAA  CTACACAGTG  GTATACAGAG  ACATAAATAG
298LAR  C lon e  2  (Ctd)
2510  2520  2530  2540  2550
CCAGCAGGAC  CTGGTTAACA  TCACCAAGGA  CACAAGTATC  ACTTTGACGA
2560  2570  2580  2590  2600
ATTTGAAGCC  TGATACCACT  TATGACATCA  AAGTGAGGGC  CCGCACCAAT
2610  2620  2630  2640  2650
AAGGGGGTTG  GGCCGCTCAG  CCCCAGCATC  CAGTCCCGGA  CCATGCCTGT
2660  2670  2680  2690  2700
TGAGCAAGTG  TTTGCTAAGA  ACTTCCGTGT  CAACGCCGTC  ATGAAAACAT
2710  2720  2730  2740  2750
CCGTGTTGCT  GAGCTGGGAA  GTGCCTGACT  CCTATAAATC  TGCAGTGCCT
2760  2770  2780  2790  2800
TTTAAGATTC  TGTACAACAG  CCAGAGTGTG  GAGGTGGACG  GCTACTCCAT
2810  2820  2830  2840  2850
GAAGAAGCTC  ATAAGTGACC  TCCAGCCAGA  CACGGACTAC  TCTTTTGTGC
2860  2870  2880  2890  2900
TCATGAACCG  TGGGAACAGT  GCTGGGGGGC  TCCAGCACCT  CGTCTCCATC
2910  2920  2930  2940  2950
CGCACTGCGC  CTGACGTCTT  GCAAAGCAAA  CCCATTGCCA  CCAACAAGTA
2960  2970  2980  2990  3000
TATCCAGGAA  GGAAAGTTCA  CGCTTACCCT  TCCCAAAGTG  CAGACCACTG
3010  3020  3030  3040  3050
TGCCAGTTCG  GTGGTACTAC  ATTGTGGTCG  TGCCGGCAGA  GCAGAACCCC
3060  3070  3080  3090  3100
AGCAGCCCGA  CAGCGCGGTG  GCGGACGCCT  GATGAGATGG  AGCTGGACCA
3110  3120  3130  3140  3150
GCTGCTGGAG  GCCATAAGCC  AGGGCAGTCA  GAGCAGGCGC  CAGAGACGCC
3160  3170  3180  3190  3200
AAGCAGACAG  ACTCAAGCCC  TACATTGCTG  CCCAAGTGGA  CGTGCTGCCC
3210  3220  3230  3240  3250
GAGACCTTCA  CCCTGGGGGA  CGAGAAGAAC  TACAAGGGTT  TCTACAACAA
3260  3270  3280  3290  3300
GCCCCTCTCT  CAGGACCTGA  GCTACCGCTG  CTTCGTGCTG  GCCTCGCTGG
3310  3320  3330  3340  3350
AGGATGGGGA  CACGAAGAGA  TACGCAGCCA  GCCCCTACTC  AGATGAGATT
299LAR  C lon e  2  (Ctd)
3360  3370  3380  3390  3400
GTGATGGAAT  TGGCTTCAGC  AAAGCAGCAG  GATGAGCCAG  AGATGCTGTG
3410  3420  3430  3440  3450
GGTGATGGGA  CCTGTCCTGG  CTGTGATATT  AATCATCATC  ATCGTCATCG
3460  3470  3480  3490  3500
CTATACTCCT  CTTCAAAAGG  AAAAGAGCAC  ACTCCCCCTC  TTCCAAAGAT
3510  3520  3530  3540  3550
GAGCACTCTA  TTGGCCTGAA  GGACTCGCTC  TTGGCCCACT  CCTCTGACCC
3560  3570  3580  3590  3600
GGTTGAGATG  AGGCGGCTCA  ACTACCAGAC  TCCAGGCATG  CGGGACCACC
3610  3620  3630  3640  3650
CGCCCATCCC  CGTGACCGAC  CTCGCCGACA  ACATCGACCG  GCTGAAGGCC
3660  3670  3680  3690  3700
AACGATGGCC  TCAAGTTCTC  CCAGGAGTAC  GAGTCCATCG  ATCCCGGGCA
3710  3720  3730  3740  3750
GCAGTTCACG  TGGGAGAACT  CCAACCTGGA  AGTAAACAAA  CCGAAAAACC
3760  3770  3780  3790  3800
GCTATGCAAA  CGTGATCGCC  TACGATCACT  CCCGCGTCAT  CCTGACCTCC
3810  3820  3830  3840  3850
ATCGATGGGG  CCCCAGGCAG  CGATTACATC  AACGCCAATT  ACATCGACGG
3860  3870  3880  3890  3900
CTATAGGAAG  CAGAACGCCT  ACATCGCGAC  GCAGGGACCT  CTGCCTGAAA
3910  3920  3930  3940  3950
CCCTCAGTGA  CTTCTGGAGA  ATGGTGTGGG  AGCAGAGAAC  AGCAACGATC
3960  3970  3980  3990  4000
GTCATGATGA  CCAGGCTGGA  GGAGAAGTCC  AGGGTGAAGT  GTGACCAGTA
4010  4020  4030  4040  4050
CTGGCCGAGC  CGGGGTACAG  AAACCTACGG  GATGATCCAG  GTTACACTGC
4060  4070  4080  4090  4100
TGGACACCGT  TGAGCTGGCG  ACCTACACAG  TCCGAACCTT  TGCCCTGTAC
4110  4120  4130  4140  4150
AAGAACGGCT  CCAGCGAGAA  GCGAGAGCTG  CGACAGTTCC  AGTTCATGG-C
4160  4170  4180  4190  4200
ATGGCCTGAT  CACGGGGTCC  CAGAATACCC  CACCCCAATC  CTCGCTTTCC
300LAR  C lon e  2  (Ctd)
4210  4220  4230  4240  4250
TGCGGCGGGT  CAAGGCCTGC  AACCCACCCG  ATGCTGGGCC  CATGGTTGTC
4260  4270  4280  4290  4300
CATTGCAGTG  CTGGCGTGGG  CCGAACTGGT  TGCTTCATTG  TCATTGATGC
4310  4320  4330  4340  4350
CATGCTGGAG  AGGATGAAGC  ATGAGAAGAC  CGTGGACATC  TACGGGCACG
4360  4370  4380  4390  4400
TGACGTGCAT  GCGCTCGCAG  CGCAACTACA  TGGTGCAGAC  AGAGGACCAG
4410  4420  4430  4440  4450
TACATCTTCA  TCCACGAGGC  CCTGCTGGAG  GCAGCCACGT  GCGGCAATAC
4460  4470  4480  4490  4500
CGAGGTGCCT  GCACGCAACC  TCTTCGCTCA  CATCCAGAAA  CTGACCCAGG
4510  4520  4530  4540  4550
TGCCTCCAGG  AGAGAGCGTC  ACTGCGATGG  AGCTGGAATT  CAAGCTGCTG
4560  4570  4580  4590  4600
GCCAACTCTA  AAGCACATAC  CTCACGTTTC  ATCAGTGCCA  ACCTCCCATG
4610  4620  4630  4640  4650
CAACAAATTC  AAGAACCGCC  TCGTGAACAT  CATGCCATAC  GAGCTGACAA
4660  4670  4680  4690  4700
GAGTCTGCCT  GCAGCCCATC  CGGGGTGTTG  AGGGCTCTGA  TTACATCAAT
4710  4720  4730  4740  4750
GCCAGCTTCA  TTGATGGGTA  CAGGCAGCAG  AAGGCCTACA  TTGCCACGCA
4760  4770  4780  4790  4800
GGGACCACTG  GCCGAGACCA  CAGAAGATTT  CTGGCGAATG  CTCTGGGAGC
4810  4820  4830  4840  4850
ACAACTCCAC  CATTGTGGTG  ATGTTGACAA  AGCTGCGTGA  GATGGGCCGG
4860  4870  4880  4890  4900
GAGAAGTGCC  ATCAGTACTG  GCCTGCGGAG  CGCTCTGCCC  GTTACCAGTA
4910  4920  4930  4940  4950
CTTCGTGGTG  GACCCCATGG  CAGAGTACAA  CATGCCGCAG  TACATCCTCC
4960  4970  4980  4990  5000
GGGAGTTCAA  AGTCACAGAT  GCCAGGGACG  GCCAGTCACG  GACCATCCGC
5010  5020  5030  5040  5050
CAGTTCCAGT  TCACAGACTG  GCCTGAGCAG  GGAGTGCCAA  AGACGGGAGA
301LAR  C lone  2  (Ctd)
5060  5070  5080  5090  5100
GGGCTTCATC  GACTTCATTG  GGCAGGTGCA  CAAGACCAAG  GAGCAGTTTG
5110  5120  5130  5140  5150
GTCAGGACGG  GCCCATCACG  GTGCACTGCA  GCGCTGGGGT  TGGGCGCACG
5160  5170  5180  5190  5200
GGCGTGTTCA  TCACACTGAG  CATCGTGCTG  GAGAGGATGC  GCTACGAGGG 
5210  5220  5230  5240
GGTGGTGGAC  ATGTTCCAGA  CGGTGAAGAC  TTTGCGGACG  CAG
5’ chicken LAR EST (ChEST35h5) sequence
10  20  30  40  50
GTAACGCTGG  ATGTGCTGAC  CACTTGCCTC  AGACTGAAGA  GGACTTGCTC
60  70  80  90  100
TGCTTTGGAA  TATGGTGCCT  AACTTCTGTG  TCTCAGTACT  CACTGTGCCA
110  120  130  140  150
GCAGTCATTC  TGTGCTGCTT  GATGCTGCCT  GATCCTGCTA  AAGCAGGAGC
160  170  180  190  200
CGAAAGCAAA  CCAACATTTA  TGAAAGCTCC  TGAAGATCAG  ATTGGGATTT
210  220  230  240  250
CGGGAGGAGT  GGCCTCTTTT  GTGTGTCAGG  CAACAGGAGA  GCCCAAGCCT 
CGAATCACGT  GGATGAAGAA  GGGGAAGAAA  GTCAGTTCTC  AGCGGTTTGA
260
GGTGATCGAG
3’ chicken LAR EST (ChEST371m20) sequence
10  20  30  40  50
GCCATGGTGC  AGACAGAGGA  CCAGTACCAG  CTGTGCTACA  GAGCGGCACT
60  70  80  90  100
GGAGTATCTC  GGCAGCTTTG  ACCACTATGC  AACGTAACTA  GTGCTTTCCT
C
302Appendix 2: Plasmid vector maps
Details of vector backbone structure can be obtained from the original supplier/creator 
(2.3). Vector maps were generated using the freeware program pDRAW32 
(http://www.acaclone.com/). The following colour legend was used:
Red —  cDNA inserts.
Green —  Other open reading frames (Arrow indicates orientation).
Blue —  Promoter, polyA signal or untranslated region.
Open boxes —  Plasmid origins of replication.
T7 Poly - 6508 
EcoRl - 6435 
Kpnl - 6425 
Smal - 6420 
BamHI -6415 
Xbal - 6410
Sail - 8876 
Hindlll - 8856 
lacZa - 8836 
T3 Poly - 8827 BamHI-215 
BspEI - 482 
Sail-718
Xbal - 1
pCRYPalphal
Bglll -1352
Stul - 1904
Hindlll - 2357
Pvul -3167 
BstBI - 3457
Hindlll -4195 
Kpnl - 4260 
EcoRI -4318
303Nrul - 208
SspI - 9302 Mlul - 228 
Spe I - 249 Seal - 8978 
Pvul - 8868  ^
SbJI - 905
PmlI - 1807
BstZ 171 - 7226
pBGA1 
9421  bp
SV40 ori - 5959
Sadi -4013
Xhol - 4946
BsrGl - 233 
I   Spe I - 289
I   /   AWd - 524 
/   I  SwaBI- 630
/   /  /  ScoICRI - 856
SacI - 858 
Preprotrypsin leader - 901 
/   3xFLAG - 943 
/   HindlU - 1007
p3xFLAG-CMV25-Myc 
6406 bp
pBR322 ori - 4572
£y<?RI - 2066
M fll - 2645
SV40PA-3555  " /   I  |  '& ,BI- 2930
Mfe\- 3552  /  ArwI-3103
Afel - 3360
304Seal - 7946
pBR322 ori - 7067
Hpal - 6059 
SV40 PA - 6050 
AfeI - 5854
p3xFLAG-CMV25-PTPs-EC _ 
8857 bp  I
RsrGI - 276 
Spe I - 332 
NdeI - 567 
SnaBl - 673
Preprotrypsin leader - 945 
3xFLAG - 987 
Notl - 1057 
Sacll - 1063 
BspEl - 1264
Pm/I- 1867 
Bglll - 2134
Stul - 2686
Nrul - 5597 
Ps/BI - 5424
fe5HII-5139
Xbal - 3552 
BbvCl - 3881 
Agel - 4143
Seal-9412
pBR322 ori - 8533
//pal - 7525 
SV40 PA-7516 
Afe  I - 7320
Nrul - 7063 
&s/BI - 6890
RsrGI - 276
Spe I - 332
Preprotrypsin leader - 945 
3xFLAG - 987 
Notl - 1057 
RspOMI - 1395 
Apal - 1399
Pm/I - 1867
p3xFLAG-CMV25-PTPs-EC-AP 
10323 bp
Avrll - 3758
Age  I - 5609
BbvCl - 5347 AT joI - 5006 
A&al - 5018
305pBR322 ori - 10843
Hpal - 9835 
SV40 PA - 9826
BssHII - 8915
BsrGI - 126
Spel- 182
Preprotrypsin leader - 795 
3xFLAG - 837 
Notl - 907 
SacII -913 
BspEI- 1114 
Bglll - 1984
StuI - 2536
p3xFLAG-CMV25-PTPs-UTR 
12800 bp
AgeI-7919 
BbvCl - 7657
Xbal - 7327
BmgBI - 4346
Acc65I - 4888 
Kpnl - 4892 
EcoRI - 4950
pBR322 ori - 8843
Hpal - 7835 
SV40 PA - 7826 
Afe  I - 7630
BssHll -6915
&s/*GI-126
Spel- 182
Preprotrypsin leader - 795 
3xFLAG - 837 
Notl - 907 
— n  SacII - 913
BspYLl -  1114
Bglll - 1984
StuI - 2536 p3xFLAG-CMV25-PTPs-Myc 
10783 bp
Age  1-5919
BbvCl - 5657
BmgBI - 4346 
Acc65l - 4888 
Kpnl - 4892 
EcoKl - 4950 
Myc - 5328 
Xbal - 5328
306pBR322 ori - 8801
BsrGl - 49
Spel- 105
Xhol - 678
Preprotrypsin leader - 734 
3xFLAG -116 
Notl - 847 
Sadi - 853 
BamHI - 1042 
BspEl - 1054
Bglll - 1924
StuI - 2476
Hpal - 7794 
SV40 PA - 7784 
Afel - 7589
SssHII - 6874
p3xFLAG-CMv-25-PTPs-Myc-5'+3' Xhol 
10819 bp
BmgEl - 4286 
^cc65I - 4828 
Kpnl - 4832
Age I - 5878
BbvC 1-5616
EcoRl - 4890 
Xbal - 5271 
Myc - 5276 
Xhol - 5318
pBR322 ori - 8726
Hpal - 7719 
SV40 PA - 7709 
Afel - 7514
fiwHII - 6799
Spel - 10849 
&S/-GI - 10793
Preprotrypsin leader - 610 
3XFLAG - 655 
Notl -125 
S ad i-731 
BspEl - 932
Bglll -  1802
StuI - 2354
p3xFLAG-CMV25-PTPs-3xMyc 
10849 bp
Age I - 5803
Acc65l - 4706 
Kpnl - 4710 
£coRI - 4768 
3xMyc - 5146 
Xbal - 5146
307Notl -  10805 
3xFLAG -  10734 
Preprotrypsin leader -  10692 
Xhol - 10636 
Spe I - 10063 
5srGI- 10007
Sadi - 6
BamHI - 195 
BspEl - 207
Bglll - 1077
pBR322 ori - 7940
Hpal - 6933 
SV40 PA - 6923 
Afel - 6728
p3xFLAG-CMV25-PTPs-HA 
10805 bp
StuI - 1629
RwHII -6013
/lcc65I -3981 
Kpnl - 3985 
£coRI - 4043 
HA-4421 
Xbal - 4421 
Xhol - 4457 
BbvCl - 4755 
Agel - 5017
Xbal- 10111 
Mlul -  10099 
Xhol - 10088 
Bmtl -  10086 
Nhel - 10082 
/15/SI - 9661 
Spe 1-9149 
RsrGI - 9093
BspEl - 395 
5(3/1 - 631
PA - 6846 
RmHII-6513 
Bbel - 6119 
Sfol - 6117 
Narl - 6116 
KosI-6115 
Avrll - 5922 
SV40 ori- 5841
pCI-Neo-PTPs-HA 
10121  bp
Pcil - 2174 
Zfr/EII - 2196
Arwl- 4115 
Bell - 4593
HA - 4609 
Xbal - 4609 
//pal - 4822
308Kpnl - 6061 
Acc65\ - 6057 
StuI - 5748 
Bbsl - 5663
AvrU - 5186
BamHI - 4747 
Pvull - 4740
Sphl - 4541 
EcoKl -4517 
Xbal - 4400
Aar  I - 4001
A  pal - 3640 
PspOMI - 3636
6xHis tag - 5 
Bell - 26 
Xhol - 32 
Nrul - 47 
Bglll - 131
Clal - 783 
Sapl - 850
FspI-2081
Pvul - 2229 
Seal - 2339
SraBI-3136
Sspl - 2663 
Sail - 2778
Pw/I - 5441 
Sacl - 5411 
£coICRI - 5409
Kpnl - 6071 
Acc65l - 6067
\
6xHis tag - 5 
Bell - 26 
Xhol - 32 
Nrul- 47
BspEl - 4838 
Mfel - 4790
SbJI - 4539 
5/?/zI - 4533 
£coRI - 4517
pHL-FND2 
6071  bp
Sodl - 3807
Clal - 783 
Sapl - 850
Fspl - 2081
Pvul - 2229 
Seal - 2339
SwaBI -3136
Sspl - 2663
309Pmll - 5421
BspEl -4818 
Mfel - 4770
£coRI - 4517 
Xbal - 4400
Kpnl - 63306xHis tag
Acc65l - 6326 
Bbsl - 6256 
StuI - 6240
Bell - 26 
Xhol - 32 
Nrul - 47
pHL FND3 
6330 bp
SacI! - 3807
Clal - 783 
Sapl - 850
Fspl - 2081
Pvul - 2229 
Seal - 2339
Sspl - 2663
SaaBI- 3136
Acc65l - 6652 
£coRV - 6531 
Ajlll - 6514 
Notl - 6430 
Bbsl - 6276 
Stwl - 6260
' 66566xHis tag - 5
Bell - 26 
Xhol - 32 
Nrul - 47
Pmll - 5441
SspEI - 4838 
A^el - 4790
Sbjl - 4539 
Sphl - 4533 
£eoRl -4517
pHL FND4 
6656 bp
SacII - 3807
Clal - 783 
Sapl - 850
Fspl - 2081
Pvul - 2229 
Seal - 2339
Sspl - 2663
SaaBI - 3136
310Nrul - 7751 
Xhol - 7736 
Bell - 7730 
6xHis tag - 7709
Avrll - 6829
Clal - 684 
Sapl - 751
Pmll - 5322
PHL-FND3-AP 
7803 bp
Fspl -  1982
Pvul - 2130 
Seal - 2240
Sspl - 2564
BspEl -4719 
Mfe1-4671 
£coRI - 4418
Aftal - 4301
SraBI - 3037
Xmal - 5
- 68531
Ncol - 6434 
Kpnl - 6414 
Acc65l - 6410
Smal -1
pGEX3 primer - 99 
Zral - 301 
Aatll - 303
Nrul - 6356 
Hindlll - 6349 
Nde 1-6156 
SraBI - 5996 
BmgQl - 5868 
Mfel - 5759
BamHI - 4978 
pGEX5 primer - 4896
ShyzI - 4712
M13R primer - 4251 
tac promoter - 421
pGEXKT-PTPsDI +D2 
6853 bp
M13F primer - 3632 
M13R primer-3571
Mlul - 2726 
£coRV - 3176 
Hpal - 3232 
Kasl - 3365 
Narl - 3366 
Sfol - 3367 
Bbel - 3369
311Acc651 - 7302
Spe I - 5 
EcoR\ -  11 
/N otl- 18 
// Nde  I - 38 
Mwl - 55 
P6 poly - 80
rimer - 138
£coRI - 6482
p GEMT-Easy-LAR1 
8398 bp
Narl - 5128 
Kasl - 5127
Notl - 2999 
£coRI - 3008
£coRI - 3727 
5c/I - 4106
SpeI - 5
£coRI - 11 
Notl - 18 
f  Nde I - 38 
^   Mlul - 55
SP6 poly - 80 
- ^ ^ 4 J 3 R  primer - 138 
342
EcoRl - 7553
p GEMT-Easy-LAR2 
8260 bp
•  Notl - 2999 
EcoRl - 3008
BbvCl - 4959 
£coRl - 4798
Acc65l - 3978
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